wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	S-1,	2003,	2003,	Isatoribine (ANA245),	Phase I,	 RiboproteomicsTM GATETM and RIBObaseTM,	23,	,	,	,	,	,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	S-1,	2003,	2003,	Oral Prodrug of Isatoribine (ANA971),	Preclinical,	 RiboproteomicsTM GATETM and RIBObaseTM,	23,	,	,	,	,	,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	S-1,	2003,	2003,	ANA97X,	Preclinical,	 RiboproteomicsTM GATETM and RIBObaseTM,	23,	,	,	,	2006,	-1,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	S-1,	2003,	2003,	ANA246,	Preclinical,	 RiboproteomicsTM GATETM and RIBObaseTM,	23,	,	,	,	,	,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	S-1,	2003,	2003,	AN 025-1,	Discovery,	 RiboproteomicsTM GATETM and RIBObaseTM,	23,	,	,	,	,	,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	S-1,	2003,	2003,	Bacterial Ribosomal Translation Inhibitors,	Discovery,	 RiboproteomicsTM GATETM and RIBObaseTM,	23,	,	,	,	2008,	-1,	Antibacterials,	,	bacterial infections,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	424,	2003,	2004,	Isatoribine (ANA245),	Phase I,	 RiboproteomicsTM GATETM and RIBObaseTM,	23,	,	,	,	2009,	-0.772,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	424,	2003,	2004,	Oral Prodrug of Isatoribine (ANA971),	Preclinical,	 RiboproteomicsTM GATETM and RIBObaseTM,	23,	,	,	,	2006,	-0.9741,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	424,	2003,	2004,	ANA97X,	Preclinical,	 RiboproteomicsTM GATETM and RIBObaseTM,	23,	,	,	,	2006,	-1,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	424,	2003,	2004,	ANA246,	Preclinical,	 RiboproteomicsTM GATETM and RIBObaseTM,	23,	,	,	,	,	,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	424,	2003,	2004,	AN 025-1,	Preclinical,	 RiboproteomicsTM GATETM and RIBObaseTM,	23,	,	,	,	,	,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	424,	2003,	2004,	  LB80380,	Preclinical,	 RiboproteomicsTM GATETM and RIBObaseTM,	23,	,	,	,	,	,	Viral Infections,	,	HBV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	424,	2003,	2004,	Bacterial Ribosomal Translation Inhibitors,	Discovery,	 RiboproteomicsTM GATETM and RIBObaseTM,	23,	,	,	,	2008,	-1,	Antibacterials,	,	bacterial infections,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2005,	ANA975,	Phase I,	TLR-Based Small-Molecule ,	23,	,	,	Isatoribine (ANA245),	2009,	-0.772,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2005,	ANA975,	 IND,	TLR-Based Small-Molecule ,	23,	,	,	,	,	,	Viral Infections,	,	HBV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2005,	TLR-7 Agonists,	Discovery,	TLR-Based Small-Molecule ,	23,	,	,	,	2008,	-1,	Viral Infections,	,	Viral Applications,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2005,	AN 025-1,	Preclinical,	TLR-Based Small-Molecule ,	23,	,	,	,	,	,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2005,	Isatoribine,	Phase I,	TLR-Based Small-Molecule ,	23,	,	,	,	2007,	-0.6787,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2005,	ANA380,	Phase II,	TLR-Based Small-Molecule ,	23,	,	,	  LB80380,	2009,	-0.8796,	Viral Infections,	,	HBV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2005,	Bacterial Ribosomal Translation Inhibitors,	Discovery,	TLR-Based Small-Molecule ,	23,	,	,	,	2008,	-1,	Antibacterials,	,	bacterial infections,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2006,	ANA975,	Phase I,	TLR-Based Small-Molecule ,	23,	,	,	,	2009,	-0.772,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2006,	ANA975,	Phase I,	TLR-Based Small-Molecule ,	23,	,	,	,	,	,	Viral Infections,	,	HBV,	,	IND,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2006,	ANA380,	Phase II,	TLR-Based Small-Molecule ,	23,	,	,	,	2009,	-0.8796,	Viral Infections,	,	HBV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2006,	ANA773,	Preclinical,	TLR-Based Small-Molecule ,	22,	,	,	,	,	,	Cancer,	,	Cancer,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2006,	AN 025-1,	Preclinical,	TLR-Based Small-Molecule ,	23,	,	,	,	,	,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2006,	Bacterial Ribosomal Translation Inhibitors,	Discovery,	TLR-Based Small-Molecule ,	23,	,	,	,	2008,	-1,	Antibacterials,	,	bacterial infections,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2006,	 AN 033-1,	Discovery,	TLR-Based Small-Molecule ,	23,	,	,	TLR-7 Agonists,	,	,	Viral Infections,	,	Viral Applications,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2006,	TLR-7 Agonists,	Discovery,	TLR-Based Small-Molecule ,	23,	,	,	,	2008,	-0.9774,	Viral Infections,	,	Viral Applications,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2007,	ANA975,	Phase I,	TLR-Based Small-Molecule ,	23,	,	,	,	2009,	-0.8009,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2007,	ANA59X,	Preclinical,	Structure-Based Drug Design & Medicinal Chemistry,	23,	,	,	AN 025-1,	,	,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2007,	ANA380,	Phase II,	Structure-Based Drug Design & Medicinal Chemistry,	23,	,	,	,	2009,	-0.9412,	Viral Infections,	,	HBV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2007,	ANA975,	 IND,	TLR-Based Small-Molecule ,	23,	,	,	,	,	,	Viral Infections,	,	HBV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2007,	ANA773,	Preclinical,	TLR-Based Small-Molecule ,	22,	,	,	,	,	,	Cancer,	,	Cancer,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2008,	ANA773,	Phase I ,	TLR-Based Small-Molecule ,	22,	,	,	,	,	,	Cancer,	,	Cancer,	,	yes,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2008,	ANA598,	early stage clinical trials,	 non-nucleoside inhibitor,	23,	,	,	ANA59X,	,	,	Viral Infections,	,	HCV,	,	yes,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2009,	ANA773,	Phase II ,	TLR-Based Small-Molecule ,	22,	,	,	,	,	,	Cancer,	,	Cancer,	,	yes,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2009,	ANA598,	Phase Ib ,	 non-nucleoside inhibitor,	23,	,	,	,	,	,	Viral Infections,	,	HCV,	,	yes,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2009,	ANA773,	early stage clinical trials,	TLR-Based Small-Molecule ,	23,	,	,	,	,	,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2010,	ANA773,	Phase II ,	TLR-Based Small-Molecule ,	22,	,	,	,	,	,	Cancer,	,	Cancer,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2010,	ANA598,	Phase II,	 non-nucleoside inhibitor,	23,	,	,	,	,	,	Viral Infections,	,	HCV,	,	yes,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2010,	ANA773,	early stage clinical trials,	TLR-Based Small-Molecule ,	23,	,	,	,	,	,	Viral Infections,	,	HCV,	,	,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2011,	ANA598,	Phase IIa,	 non-nucleoside inhibitor,	23,	,	,	,	,	,	Viral Infections,	,	HCV,	,	yes,
wvcs20040001128495,	ANADYS PHARMACEUTICALS INC,	10-K,	2003,	2011,	ANA773,	early stage clinical trials,	TLR-Based Small-Molecule ,	23,	,	,	,	,	,	Viral Infections,	,	HCV,	,	,
nvcs19970000907654,	HYSEQ INC,	S-1,	1997,	1997,	Therapuetic Product,	Research,	"HyX Platform, which utilizes the Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,	21,	,	,	,	2002,	-0.3077,	pharmaceuticals,	,	"cell receptors and certain
central nervous system, cardiovascular and infectious diseases,"	,	,
nvcs19970000907654,	HYSEQ INC,	S-1,	1997,	1997,	Diagnostic Product,	Research,	"HyX Platform, which utilizes the Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,	21,	,	,	,	2000,	-0.3462,	pharmaceuticals,	,	"cell receptors and certain
central nervous system, cardiovascular and infectious diseases,"	,	,
nvcs19970000907654,	HYSEQ INC,	424,	1997,	1997,	Therapuetic Product,	Research,	"HyX Platform, which utilizes the Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,	,	,	,	,	2002,	-0.3077,	,	,	,	,	,
nvcs19970000907654,	HYSEQ INC,	424,	1997,	1997,	Diagnostic Product,	Research,	"HyX Platform, which utilizes the Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,	,	,	,	,	2000,	-0.3462,	,	,	,	,	,
nvcs19970000907654,	HYSEQ INC,	10-K,	1997,	1998,	Therapuetic Product,	Research,	"HyX Platform, which utilizes the Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,	21,	,	,	,	2002,	-0.3077,	pharmaceuticals,	,	"cell receptors and certain
central nervous system, cardiovascular and infectious diseases,"	,	,
nvcs19970000907654,	HYSEQ INC,	10-K,	1997,	1998,	Diagnostic Product,	Research,	"HyX Platform, which utilizes the Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,	21,	,	,	,	2000,	0.3077,	pharmaceuticals,	,	"cell receptors and certain
central nervous system, cardiovascular and infectious diseases,"	,	,
nvcs19970000907654,	HYSEQ INC,	10-K,	1997,	1999,	IL-1Hy2,	Research,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	,	,	,	Therapuetic Product,	2002,	-0.3077,	pharmaceuticals,	,	.  Inflammatory Diseases,	"cell receptors and certain
central nervous system, cardiovascular and infectious diseases,"	,
nvcs19970000907654,	HYSEQ INC,	10-K,	1997,	1999,	CD39L4,	Pre Clinical,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	,	,	,	,	2011,	-0.68,	pharmaceuticals,	,	.  Inflammatory Diseases,	"cell receptors and certain
central nervous system, cardiovascular and infectious diseases,"	,
nvcs19970000907654,	HYSEQ INC,	10-K,	1997,	1999,	IL-1Hy1,	Pre Clinical,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	21,	,	,	,	2002,	-0.3333,	pharmaceuticals,	,	Heart Disease,	"cell receptors and certain
central nervous system, cardiovascular and infectious diseases,"	,
nvcs19970000907654,	HYSEQ INC,	10-K,	1997,	2000,	IL-1Hy2,	Research,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	,	,	,	,	2002,	-0.25,	pharmaceuticals,	,	.  Inflammatory Diseases,	,	,
nvcs19970000907654,	HYSEQ INC,	10-K,	1997,	2000,	CD39L4,	Pre Clinical,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	,	,	,	,	2011,	-0.68,	pharmaceuticals,	,	.  Inflammatory Diseases,	,	,
nvcs19970000907654,	HYSEQ INC,	10-K,	1997,	2000,	IL-1Hy1,	Pre Clinical,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	21,	,	,	,	2002,	-0.68,	pharmaceuticals,	,	Heart Disease,	,	,
nvcs19970000907654,	HYSEQ INC,	10-K,	1997,	2001,	Alfimeprase,	Phase 1,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	9,	21,	,	CD39L4,	2011,	-0.68,	acute cardiovascular,	,	Alfimeprase in Acute Peripheral Arterial Occlusion (PAO),	,	Yes,
nvcs19970000907654,	HYSEQ INC,	10-K,	1997,	2002,	Alfimeprase,	Phase 1,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	9,	21,	,	,	2011,	-0.68,	acute cardiovascular,	,	1.Alfimeprase in Acute Peripheral Arterial Occlusion (PAO) 2.  Alfimeprase in catheter occlusion,	Alfimeprase in Acute Peripheral Arterial Occlusion (PAO),	Yes,
nvcs19970000907654,	HYSEQ INC,	10-K,	1997,	2002,	rNAPc2,	Phase 2,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	9,	21,	,	,	2010,	-0.8298,	acute cardiovascular,	,	acute coronary syndromes (ACS),	,	,
nvcs19970000907654,	HYSEQ INC,	10-K,	1997,	2002,	ARC183,,	Pre Clinical,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	9,	21,	,	,	,	,	acute cardiovascular,	,	acute cardiac surgical procedures,	,	,
nvcs19970000907654,	HYSEQ INC,	10-K,	1997,	2003,	Alfimeprase,	Phase 2,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	9,	21,	,	,	2011,	-0.68,	acute cardiovascular,	,	1.Alfimeprase in Acute Peripheral Arterial Occlusion (PAO) 2.  Alfimeprase in catheter occlusion,	,	Yes,
nvcs19970000907654,	HYSEQ INC,	10-K,	1997,	2003,	rNAPc2,	Phase 2,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	9,	21,	,	,	2010,	-0.8298,	acute cardiovascular,	,	acute coronary syndromes (ACS),	,	yes,
nvcs19970000907654,	HYSEQ INC,	10-K,	1997,	2003,	ARC183,,	Pre Clinical,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	9,	21,	,	,	,	,	acute cardiovascular  therapies,	,	acute cardiac surgical procedures,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2004,	Alfimeprase,	Phase 3,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	9,	21,	,	,	2011,	-0.68,	acute cardiovascular  therapies,	,	1.Alfimeprase in Acute Peripheral Arterial Occlusion (PAO) 2.  Alfimeprase in catheter occlusion,	,	Yes,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2004,	rNAPc2,	Phase 2a,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	9,	21,	,	,	2010,	-0.8298,	acute cardiovascular,	,	acute coronary syndromes (ACS),	,	yes,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2004,	ARC183,	Pre Clinical,	"biochip technology, Company's
proprietary sequencing by hybridization (""SBH"") technology as its foundation,,"	9,	21,	,	,	,	,	acute cardiovascular,	,	acute cardiac surgical procedures,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2005,	Alfimeprase,	Phase 3,	 direct-acting fibrinolytic (rDAF),	9,	21,	,	,	2011,	-0.68,	acute cardiovascular,	,	1.Alfimeprase in Acute Peripheral Arterial Occlusion (PAO) ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2005,	Alfimeprase,	Phase 3,	 direct-acting fibrinolytic (rDAF),	9,	21,	,	,	,	,	acute cardiovascular,	,	Alfimeprase in catheter occlusion,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2005,	Alfimeprase,	Phase I,	 direct-acting fibrinolytic (rDAF),	9,	21,	40,	,	,	,	acute cardiovascular,	,	Stroke ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2005,	Alfimeprase,	Pre clinical,	 direct-acting fibrinolytic (rDAF),	9,	21,	,	,	,	,	acute cardiovascular,	,	DVT (Deep Vein Thombosis,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2005,	rNAPc2,	Phase 2a,	Tissue Factor Inhibitor,	9,	21,	,	,	2010,	0.6,	acute cardiovascular,	,	acute coronary syndromes (ACS),	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2005,	ARC183,	Pre Clinical,	Thrombin Inhibitor,	9,	21,	,	,	,	,	acute cardiovascular,	,	acute cardiac surgical procedures,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2005,	NU206,	Pre Clinical,	GI signaling Pathway modulator,	22,	,	,	,	2011,	-0.6,	cancer therapies,	,	mucositis ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2005,	rNAPc2,	Pre Clinical,	Tissue Factor Inhibitor,	22,	,	,	,	,	,	cancer therapies,	,	 variety of cancers. ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2006,	Alfimeprase,	Phase 3,	 direct-acting fibrinolytic (rDAF),	9,	21,	,	,	2011,	-0.68,	acute cardiovascular,	,	1.Alfimeprase in Acute Peripheral Arterial Occlusion (PAO) ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2006,	Alfimeprase,	Phase 3,	 direct-acting fibrinolytic (rDAF),	9,	21,	,	,	,	,	acute cardiovascular,	,	Alfimeprase in catheter occlusion,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2006,	Alfimeprase,	Phase I,	 direct-acting fibrinolytic (rDAF),	9,	21,	40,	,	,	,	acute cardiovascular,	,	Stroke ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2006,	Alfimeprase,	Pre clinical,	 direct-acting fibrinolytic (rDAF),	9,	21,	,	,	,	,	acute cardiovascular,	,	DVT (Deep Vein Thombosis,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2006,	rNAPc2,	Phase 2a,	Tissue Factor Inhibitor,	9,	21,	,	,	2010,	0.6,	acute cardiovascular,	,	acute coronary syndromes (ACS),	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2006,	ARC183,	Pre Clinical,	Thrombin Inhibitor,	9,	21,	,	,	,	,	acute cardiovascular,	,	acute cardiac surgical procedures,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2006,	NU206,	Pre Clinical,	GI signaling Pathway modulator,	22,	,	,	,	2011,	-0.6,	cancer therapies,	,	mucositis ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2006,	rNAPc2,	Pre Clinical,	Tissue Factor Inhibitor,	22,	,	,	,	,	,	cancer therapies,	,	 variety of cancers. ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2007,	Alfimeprase,	Phase 3,	 direct-acting fibrinolytic (rDAF),	9,	21,	,	,	2011,	-0.68,	acute cardiovascular,	,	1.Alfimeprase in Acute Peripheral Arterial Occlusion (PAO) ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2007,	Alfimeprase,	Phase 3,	 direct-acting fibrinolytic (rDAF),	9,	21,	,	,	,	,	acute cardiovascular,	,	Alfimeprase in catheter occlusion,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2007,	Alfimeprase,	Phase II,	 direct-acting fibrinolytic (rDAF),	9,	21,	40,	,	,	,	acute cardiovascular,	,	Stroke ,	,	Phase I,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2007,	rNAPc2,	Phase 2a,	Tissue Factor Inhibitor,	9,	21,	,	,	2010,	0,	acute cardiovascular,	,	acute coronary syndromes (ACS),	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2007,	NU 172,	Pre Clinical,	Thrombin Inhibitor,	9,	21,	,	ARC183,	,	,	acute cardiovascular,	,	acute cardiac surgical procedures,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2007,	rNAPc2,	Phase 2,	 anticoagulant protein,	22,	,	,	,	,	,	cancer therapies,	,	Colorectal Cancer,	,	preclinical,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2007,	NU206,	Pre Clinical,	GI signaling Pathway modulator,	22,	,	,	,	2011,	-0.6,	cancer therapies,	,	mucositis ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2008,	Alfimeprase,	Phase II,	 direct-acting fibrinolytic (rDAF),	9,	21,	,	,	2011,	-0.68,	acute cardiovascular,	,	Alfimeprase in catheter occlusion,	,	Phase 3,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2008,	Alfimeprase,	Phase II,	 direct-acting fibrinolytic (rDAF),	9,	21,	40,	,	,	,	acute cardiovascular,	,	Stroke ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2008,	NU 172,	Pre Clinical,	Thrombin Inhibitor,	9,	21,	,	,	,	,	acute cardiovascular,	,	acute cardiac surgical procedures,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2008,	rNAPc2,	Phase 2a,	Tissue Factor Inhibitor,	9,	21,	,	,	2010,	0,	acute cardiovascular,	,	acute coronary syndromes (ACS),	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2008,	NU206,	Pre Clinical,	GI signaling Pathway modulator,	22,	,	,	,	2011,	-0.6,	cancer therapies,	,	mucositis ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2008,	Leukemia Therapeutic Antibody Program,	Pre Clinical,	monoclonal antibody (mAbs) ,	22,	27,	,	,	2011,	0,	cancer therapies,	,	Leukemia,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2008,	Wnt Therapeutics Program,	Pre Clinical,	Wnt signaling pathway ,	26,	,	,	,	2011,	0,	gastrointestinal disease,	,	Inflammatory Bowel Disease (IBD),	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2008,	Wnt Therapeutics Program,	Pre Clinical,	Wnt signaling pathway ,	26,	,	,	,	,	,	gastrointestinal disease,	,	 peptic ulcers,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2008,	Wnt Therapeutics Program,	Pre Clinical,	Wnt signaling pathway ,	20,	,	,	,	,	,	bone disorders,	,	bone disorders,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2008,	Wnt Therapeutics Program,	Pre Clinical,	Wnt signaling pathway ,	22,	,	,	,	,	,	cancer,	,	steolytic lesions ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2009,	Alfimeprase,	Phase II,	 direct-acting fibrinolytic (rDAF),	9,	21,	,	,	2011,	0,	acute cardiovascular,	,	Alfimeprase in catheter occlusion,	,	Phase 3,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2009,	Alfimeprase,	Phase II,	 direct-acting fibrinolytic (rDAF),	9,	21,	40,	,	,	,	acute cardiovascular,	,	Stroke ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2009,	NU 172,	Pre Clinical,	Thrombin Inhibitor,	9,	21,	,	,	,	,	acute cardiovascular,	,	acute cardiac surgical procedures,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2009,	NU206,	Pre Clinical,	GI signaling Pathway modulator,	22,	,	,	,	2011,	0,	cancer therapies,	,	mucositis ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2009,	Leukemia Therapeutic Antibody Program,	Pre Clinical,	monoclonal antibody (mAbs) ,	22,	27,	,	,	2011,	0,	cancer therapies,	,	Leukemia,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2009,	Wnt Therapeutics Program,	Pre Clinical,	Wnt signaling pathway ,	26,	,	,	,	2011,	0,	gastrointestinal disease,	,	Inflammatory Bowel Disease (IBD),	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2009,	Wnt Therapeutics Program,	Pre Clinical,	Wnt signaling pathway ,	26,	,	,	,	,	,	gastrointestinal disease,	,	 peptic ulcers,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2009,	Wnt Therapeutics Program,	Pre Clinical,	Wnt signaling pathway ,	20,	,	,	,	,	,	bone disorders,	,	bone disorders,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2009,	Wnt Therapeutics Program,	Pre Clinical,	Wnt signaling pathway ,	22,	,	,	,	,	,	cancer,	,	steolytic lesions ,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2010,	GencaroTM,	Phase III ,	beta-blocker and mild vasodilator,,	9,	21,	,	,	,	,	Acute Cardiovascular,	,	chronic heart failure,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2010,	NU 172,	Pre Clinical,	Thrombin Inhibitor,	9,	21,	,	,	,	,	acute cardiovascular,	,	acute cardiac surgical procedures,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2010,	rNAPc2,	Phase 2a,	Tissue Factor Inhibitor,	9,	21,	,	,	,	,	acute cardiovascular,	,	acute coronary syndromes (ACS),	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2011,	GencaroTM,	Phase III ,	beta-blocker and mild vasodilator,,	9,	21,	,	,	,	,	Acute Cardiovascular,	,	chronic heart failure,	,	,
nvcs19970000907654,	ARCA biopharma, Inc.,	10-K,	1997,	2011,	rNAPc2,	Phase 2a,	Tissue Factor Inhibitor,	9,	21,	,	,	,	,	acute cardiovascular,	,	acute coronary syndromes (ACS),	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	S-1,	1997,	1997,	Primsol trimethoprim solution,	 marketing approval,	Taste masking  ,	9,	23,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 Acute middle ear Infection   ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	S-1,	1997,	1997,	Prednisolone sodium phosphate syrup,	 marketing approval,	Taste masking  ,	5,	29,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Inflammation,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	S-1,	1997,	1997,	 Pediatemp acetaminophen beads,	Phase III,	Controlled-release  ,	62,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 Pain and fever,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	S-1,	1997,	1997,	Cromolyn sodium cream,	Phase I,	Transdermal delivery    ,	8,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Dermatitis,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	S-1,	1997,	1997,	 Cromolyn sodium nasal spray,	Preclinical,	Bioadhesion       ,	,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Nasal allergies  ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	S-1,	1997,	1997,	Pediamist nasal saline spray,	Marketed,	 Intranasal delivery device   ,	,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 Nasal dryness  ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	S-1,	1997,	1997,	 Feverall   ,	Marketed,	"Upsher-Smith's Feverall line of over-the-counter acetaminophen rectal
suppositories,"	62,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Pain and fever,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	S-1,	1997,	1997,	Pediavent albuterol,	Phase I,	Controlled-release    ,	5,	29,	,	,	1999,	-0.2857,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Asthma,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	424,	1997,	1997,	Primsol trimethoprim solution,	 marketing approval,	Taste masking  ,	9,	23,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 Acute middle ear Infection   ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	424,	1997,	1997,	Prednisolone sodium phosphate syrup,	 marketing approval,	Taste masking  ,	5,	29,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Inflammation,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	424,	1997,	1997,	 Pediatemp acetaminophen beads,	Phase III,	Controlled-release  ,	62,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 Pain and fever,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	424,	1997,	1997,	Cromolyn sodium cream,	Phase I,	Transdermal delivery    ,	8,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Dermatitis,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	424,	1997,	1997,	 Cromolyn sodium nasal spray,	Preclinical,	Bioadhesion       ,	,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Nasal allergies  ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	424,	1997,	1997,	Pediamist nasal saline spray,	Marketed,	 Intranasal delivery device   ,	,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 Nasal dryness  ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	424,	1997,	1997,	 Feverall   ,	Marketed,	"Upsher-Smith's Feverall line of over-the-counter acetaminophen rectal
suppositories,"	62,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Pain and fever,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	424,	1997,	1997,	Pediavent albuterol,	Phase I,	Controlled-release    ,	5,	29,	,	,	1999,	-0.2857,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Asthma,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1998,	Primsol trimethoprim solution,	NDA,	Taste masking  ,	9,	23,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 Acute middle ear Infection   ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1998,	Orapred syrup    ,	ANDA,	Taste masking  ,	5,	29,	,	Prednisolone sodium phosphate syrup,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Inflammation,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1998,	 Pediatemp acetaminophen beads,	Phase III,	Controlled-release  ,	62,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 Pain and fever,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1998,	Cromolyn sodium cream,	NDA,	Transdermal delivery    ,	8,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Dermatitis,	,	yes,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1998,	 Cromolyn sodium nasal spray,	NDA,	Bioadhesion       ,	,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Nasal allergies  ,	,	yes,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1998,	Pediamist nasal saline spray,	Marketed,	 Intranasal delivery device   ,	,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 Nasal dryness  ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1998,	Feverall(R) acetaminophen rectal ,	Marketed,	"Upsher-Smith's Feverall line of over-the-counter acetaminophen rectal
suppositories,"	62,	,	,	Feverall,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Pain and fever,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1998,	Duricef(R) oral suspension,	Marketed,	cephalosporin oral suspension,	23,	29,	3,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Upper respiratory, urinary tract infections ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1998,	Feverall(R) controlled-release  beads  ,	Phase III,	Controlled-release,	62,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 pain and fever,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1999,	Primsol trimethoprim solution,	NDA,	Taste masking  ,	9,	23,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 Acute middle ear Infection   ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1999,	Orapred syrup    ,	ANDA,	Taste masking  ,	5,	29,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Inflammation,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1999,	Cromolyn sodium cream,	NDA,	Transdermal delivery    ,	8,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Dermatitis,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1999,	 Cromolyn sodium nasal spray,	NDA,	Bioadhesion       ,	,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Nasal allergies  ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1999,	Pediamist nasal saline spray,	Marketed,	 Intranasal delivery device   ,	,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 Nasal dryness  ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1999,	Feverall(R) acetaminophen rectal ,	Marketed,	"Upsher-Smith's Feverall line of over-the-counter acetaminophen rectal
suppositories,"	62,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Pain and fever,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1999,	Omnicef(R) (Cefdinir) Oral Suspension and Capsules,	Marketed,	cephalosporin oral suspension,	23,	29,	3,	Duricef(R) oral suspension,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Upper respiratory, urinary tract infections ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1999,	Feverall(R) controlled-releaseS Sprinkles,	NDA,	Controlled-release,	62,	,	,	Feverall(R) controlled-release  beads  ,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 pain and fever,	,	yes,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	1999,	Pediavent albuterol    ,	Phase III,	Controlled-release,	5,	29,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Asthma,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	2000,	Primsol trimethoprim solution,	NDA,	Taste masking  ,	9,	23,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 Acute middle ear Infection   ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	2000,	Orapred syrup    ,	ANDA,	Taste masking  ,	5,	29,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Inflammation,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	2000,	Cromolyn sodium cream,	NDA,	Transdermal delivery    ,	8,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Dermatitis,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	2000,	 Cromolyn sodium nasal spray,	NDA,	Bioadhesion       ,	,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Nasal allergies  ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	2000,	Pediamist nasal saline spray,	Marketed,	 Intranasal delivery device   ,	,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 Nasal dryness  ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	2000,	Feverall(R) acetaminophen rectal ,	Marketed,	"Upsher-Smith's Feverall line of over-the-counter acetaminophen rectal
suppositories,"	62,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Pain and fever,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	2000,	Omnicef(R) (Cefdinir) Oral Suspension and Capsules,	Marketed,	cephalosporin oral suspension,	23,	29,	3,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Upper respiratory, urinary tract infections ,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	2000,	Feverall(R) controlled-releaseS Sprinkles,	NDA,	Controlled-release,	62,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	 pain and fever,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	2000,	Pediavent albuterol    ,	Phase III,	Controlled-release,	5,	29,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	Asthma,	,	,
wvcs19970001019731,	ASCENT PEDIATRICS INC,	10-K,	1997,	2000,	 Pediotic,	,	corticosteroid/antibiotic,	23,	,	,	,	,	,	PEDIATRIC PHARMACEUTICAL INDUSTRY,	,	outer ear infection,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	S-1,	2004,	2004,	Testim,	Marketed,	testosterone gel ,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Hypogonadism,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	S-1,	2004,	2004,	Androgen Replacement Film,	 Preclinical,	 androgen replacement film,	3,	,	,	,	2007,	0.6,	urologic and sexual health disorders,	,	 hypogonadism ,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	S-1,	2004,	2004,	Transmucosal Film Technology Platform,	 Preclinical,	transmucosal film technology.,	3,	,	,	,	2007,	1.2,	urologic and sexual health disorders,	,	overactive bladder. ,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	S-1,	2004,	2004,	Overactive Bladder Film,	 Preclinical,	Transmucosal Film Technology Platform,	3,	,	,	,	2012,	-0.7778,	urologic and sexual health disorders,	,	overactive bladder. ,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	424,	2004,	2004,	Testim,	Marketed,	testosterone gel ,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Hypogonadism,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	424,	2004,	2004,	Androgen Replacement Film,	 Preclinical,	 androgen replacement film,	3,	,	,	,	2007,	0.6,	urologic and sexual health disorders,	,	 hypogonadism ,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	424,	2004,	2004,	Transmucosal Film Technology Platform,	 Preclinical,	transmucosal film technology.,	3,	,	,	,	2007,	1.2,	urologic and sexual health disorders,	,	overactive bladder. ,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	424,	2004,	2004,	Overactive Bladder Film,	 Preclinical,	Transmucosal Film Technology Platform,	3,	,	,	,	2012,	-0.7778,	urologic and sexual health disorders,	,	overactive bladder. ,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2005,	Testim,	Marketed,	testosterone gel ,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Hypogonadism,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2005,	AA4500,	 Phase II ,	 injectable enzyme,	3,	,	,	,	2009,	-0.968,	urologic and sexual health disorders,	,	Dupuytren’s Disease,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2005,	AA4500,	 Phase II ,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Peyronie’s Disease ,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2005,	Androgen Replacement Film,	Phase I,	 androgen replacement film,	,	,	,	,	2007,	-0.936,	,	,	 hypogonadism ,	,	yes,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2005,	Transmucosal Film Technology Platform,	 Preclinical,	transmucosal film technology.,	3,	,	,	,	2007,	-0.912,	urologic and sexual health disorders,	,	overactive bladder. ,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2005,	Overactive Bladder Film,	Phase I,	Transmucosal Film Technology Platform,	3,	,	,	,	2012,	-0.7778,	urologic and sexual health disorders,	,	overactive bladder. ,	,	yes,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2006,	Testim,	Marketed,	testosterone gel ,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Hypogonadism,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2006,	AA4500,	 Phase II ,	 injectable enzyme,	3,	,	,	,	2009,	-0.968,	urologic and sexual health disorders,	,	Dupuytren’s Disease,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2006,	AA4500,	 Phase II ,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Peyronie’s Disease ,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2006,	AA4500,	 Phase II ,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Frozen Shoulder Syndrome,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2006,	A2600,	Phase II,	Transmucosal Film Technology,	3,	,	,	Testosterone Replacement Film,	2008,	-0.992,	urologic and sexual health disorders,	,	 hypogonadism,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2006,	AA4010,	 Phase I,	Transmucosal Film Technology,	3,	,	,	Overactive Bladder Film,	2012,	-0.7778,	urologic and sexual health disorders,	,	overactive bladder,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2006,	Pain Film,	Phase I,	Transmucosal Film Technology,	62,	3,	,	,	2012,	-0.5556,	urologic and sexual health disorders,	,	chronic pain,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2007,	Testim,	Marketed,	testosterone gel ,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Hypogonadism,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2007,	AA4500,	Phase III,	 injectable enzyme,	3,	,	,	,	2009,	-0.9864,	urologic and sexual health disorders,	,	Dupuytren’s Disease,	,	yes,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2007,	AA4500,	 Phase II ,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Peyronie’s Disease ,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2007,	AA4500,	 Phase II ,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Frozen Shoulder Syndrome,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2007,	AA4010,	 Phase I,	Transmucosal Film Technology,	3,	,	,	,	2012,	-0.7778,	urologic and sexual health disorders,	,	overactive bladder,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2007,	Pain Product,	Phase I,	Transmucosal Film Technology,	62,	3,	,	Pain Film,	2012,	-0.5556,	urologic and sexual health disorders,	,	chronic pain,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2008,	Testim,	Marketed,	testosterone gel ,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Hypogonadism,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2008,	XIAFLEX™,	Phase III,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Dupuytren’s Disease,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2008,	XIAFLEX™,	 Phase II ,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Peyronie’s Disease ,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2008,	XIAFLEX™,	 Phase II ,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Frozen Shoulder Syndrome,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2008,	AA4010,	 Phase I,	Transmucosal Film Technology,	3,	,	,	,	2012,	-0.7778,	urologic and sexual health disorders,	,	overactive bladder,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2008,	Pain product,	Phase I,	Transmucosal Film Technology,	62,	3,	,	,	2012,	-0.5556,	urologic and sexual health disorders,	,	chronic pain,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2009,	Testim,	Marketed,	testosterone gel ,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Hypogonadism,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2009,	XIAFLEX™,	Phase III,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Dupuytren’s Disease,	Frozen Shoulder Syndrome,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2009,	XIAFLEX™,	 Phase II ,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Peyronie’s Disease ,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2009,	XIAFLEX™,	 Phase II ,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Adhesive Capsulitis,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2009,	AA4010,	 Phase I,	Transmucosal Film Technology,	3,	,	,	,	2012,	-0.7778,	urologic and sexual health disorders,	,	overactive bladder,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2009,	Pain product,	Phase I,	Transmucosal Film Technology,	62,	3,	,	,	2012,	-0.5556,	urologic and sexual health disorders,	,	chronic pain,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2010,	Testim,	Marketed,	testosterone gel ,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Hypogonadism,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2010,	XIAFLEX™,	Marketed,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Dupuytren’s Disease,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2010,	XIAFLEX™,	Phase II,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Peyronie’s Disease ,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2010,	XIAFLEX™,	 Phase II ,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Adhesive Capsulitis,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2010,	AA4010,	 Phase I,	Transmucosal Film Technology,	3,	,	,	,	2012,	-0.9949,	urologic and sexual health disorders,	,	overactive bladder,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2010,	Pain product,	Phase I,	Transmucosal Film Technology,	62,	3,	,	,	2012,	-0.9897,	urologic and sexual health disorders,	,	chronic pain,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2011,	Testim,	Marketed,	testosterone gel ,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Hypogonadism,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2011,	XIAFLEX™,	Marketed,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Dupuytren’s Disease,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2011,	XIAFLEX™,	Phase III,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Peyronie’s Disease ,	,	yes,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2011,	XIAFLEX™,	 Phase II ,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Adhesive Capsulitis,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2012,	Testim,	Marketed,	testosterone gel ,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Hypogonadism,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2012,	XIAFLEX™,	Marketed,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Dupuytren’s Disease,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2012,	XIAFLEX™,	Phase III,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Peyronie’s Disease ,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2012,	XIAFLEX™,	 Phase II ,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	Adhesive Capsulitis,	,	,
wvcs20040001182129,	AUXILIUM PHARMACEUTICALS INC,	10-K,	2004,	2012,	XIAFLEX™,	Phase I,	 injectable enzyme,	3,	,	,	,	,	,	urologic and sexual health disorders,	,	cellulite,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	S-1,	2004,	2004,	Sebazole,	Phase III,	ketoconazole,	8,	,	,	,	,	,	dermatology,	,	seborrheic dermatitis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	S-1,	2004,	2004,	  Zimycan,	Phase III,	miconazole,	8,	,	,	,	,	,	dermatology,	,	"Candida-associated
 diaper dermatiti,"	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	S-1,	2004,	2004,	Hyphanox,	Phase III,	itraconazole,	8,	70,	,	,	,	,	dermatology,	,	vaginal candidiasis tinea pedis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	S-1,	2004,	2004,	Liarozole,	Phase III,	RAMBA class,	8,	,	,	,	2008,	-0.5918,	dermatology,	,	congenital ichthyosis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	S-1,	2004,	2004,	Rambazole,	Phase I,	RAMBA class,	8,	,	,	,	,	,	dermatology,	,	"severe acne
psoriasis,"	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	S-1,	2004,	2004,	Azoline,	Phase I,	triazole antifungal,	8,	23,	,	,	,	,	dermatology,	,	fungal infections,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	S-1,	2004,	2004,	 Hivenyl,	Phase I,	H1 antihistamine,	8,	,	,	,	,	,	dermatology,	,	dermatological allergies,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	S-1,	2004,	2004,	Atopik,	Development,	PDE4 inhibitor,	8,	,	,	,	2008,	-0.5,	dermatology,	,	atopic dermatitis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	S-1,	2004,	2004,	 Ecalcidene,	Preclinical,	vitamin D 3 derivative,	8,	,	,	,	,	,	dermatology,	,	psoriasis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	424,	2004,	2004,	Sebazole,	Phase III,	ketoconazole,	8,	,	,	,	,	,	dermatology,	,	seborrheic dermatitis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	424,	2004,	2004,	  Zimycan,	Phase III,	miconazole,	8,	,	,	,	,	,	dermatology,	,	"Candida-associated
 diaper dermatiti,"	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	424,	2004,	2004,	Hyphanox,	Phase III,	itraconazole,	8,	70,	,	,	,	,	dermatology,	,	vaginal candidiasis tinea pedis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	424,	2004,	2004,	Liarozole,	Phase III,	RAMBA class,	8,	,	,	,	2008,	-0.5918,	dermatology,	,	congenital ichthyosis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	424,	2004,	2004,	Rambazole,	Phase I,	RAMBA class,	8,	,	,	,	,	,	dermatology,	,	"severe acne
psoriasis,"	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	424,	2004,	2004,	Azoline,	Phase I,	triazole antifungal,	8,	23,	,	,	,	,	dermatology,	,	fungal infections,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	424,	2004,	2004,	 Hivenyl,	Phase I,	H1 antihistamine,	8,	,	,	,	,	,	dermatology,	,	dermatological allergies,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	424,	2004,	2004,	Atopik,	Development,	PDE4 inhibitor,	8,	,	,	,	2008,	-0.5,	dermatology,	,	atopic dermatitis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	424,	2004,	2004,	 Ecalcidene,	Preclinical,	vitamin D 3 derivative,	8,	,	,	,	,	,	dermatology,	,	psoriasis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2005,	Zimycan,	NDA ,	miconazole,	8,	,	,	,	,	,	dermatology,	,	"Candida-associated
 diaper dermatiti,"	,	yes,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2005,	Sebazole,	Phase III,	ketoconazole,	8,	,	,	,	,	,	dermatology,	,	seborrheic dermatitis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2005,	Hyphanox,	Phase III,	itraconazole,	8,	70,	,	,	,	,	dermatology,	,	vaginal candidiasis tinea pedis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2005,	Liarozole,	Phase III,	RAMBA class,	8,	,	,	,	2008,	-0.5918,	dermatology,	,	congenital ichthyosis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2005,	Rambazole,	Phase 2,	RAMBA class,	8,	,	,	,	,	,	dermatology,	,	"severe acne
psoriasis,"	,	yes,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2005,	Azoline,	Phase 2,	triazole antifungal,	8,	23,	,	,	,	,	dermatology,	,	fungal infections,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2005,	 Hivenyl,	Phase 2,	H1 antihistamine,	8,	,	,	,	,	,	dermatology,	,	dermatological allergies,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2005,	Atopik,	Development,	PDE4 inhibitor,	8,	,	,	,	2008,	-0.5,	dermatology,	,	atopic dermatitis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2005,	Ketanserin,	Preclinical,	 serotonin 2 ,	8,	,	,	,	2008,	-0.5,	dermatology,	,	diabetic and arterial ulcers,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2006,	Vusion™,	Marketed,	miconazole,	8,	,	,	  Zimycan,	,	,	dermatology,	,	"Candida-associated
 diaper dermatiti,"	,	yes,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2006,	Solagé,	Marketed,	mequinol,	8,	,	,	,	,	,	dermatology,	,	solar lentigines,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2006,	VANIQA®,	Marketed,	eflornithine HCI,	8,	,	,	,	,	,	dermatology,	,	slowing the growth of unwanted facial hair in women,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2006,	Sebazole,	NDA,	ketoconazole,	8,	,	,	,	,	,	dermatology,	,	seborrheic dermatitis,	,	yes,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2006,	Hyphanox,	Phase III,	itraconazole,	8,	70,	,	,	,	,	dermatology,	,	vaginal candidiasis tinea pedis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2006,	Liarozole,	Phase III,	RAMBA class,	8,	,	,	,	2008,	-0.6154,	dermatology,	,	congenital ichthyosis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2006,	Rambazole,	Phase 2,	RAMBA class,	8,	,	,	,	,	,	dermatology,	,	"severe acne
psoriasis,"	,	yes,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2006,	Azoline,	Phase 2,	triazole antifungal,	8,	23,	,	,	,	,	dermatology,	,	fungal infections,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2006,	 Hivenyl,	Phase 2,	H1 antihistamine,	8,	,	,	,	,	,	dermatology,	,	dermatological allergies,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2006,	Atopik,	Development,	PDE4 inhibitor,	8,	,	,	,	2008,	-0.9167,	dermatology,	,	atopic dermatitis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2006,	Ketanserin,	Preclinical,	 serotonin 2 ,	8,	,	,	,	2008,	-0.7917,	dermatology,	,	diabetic and arterial ulcers,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2007,	Vusion™,	Marketed,	miconazole,	8,	,	,	  Zimycan,	,	,	dermatology,	,	"Candida-associated
 diaper dermatiti,"	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2007,	Solagé,	Marketed,	mequinol,	8,	,	,	,	,	,	dermatology,	,	solar lentigines,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2007,	VANIQA®,	Marketed,	eflornithine HCI,	8,	,	,	,	,	,	dermatology,	,	slowing the growth of unwanted facial hair in women,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2007,	Xolegel™ ,	Marketed,	ketoconazole,	8,	2,	,	Sebazole,	,	,	dermatology,	,	seborrheic dermatitis,	,	yes,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2007,	Denavir® ,	Marketed,	penciclovir cream,	8,	,	,	,	,	,	dermatology,	,	 herpes labialis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2007,	Hyphanox,	Phase III,	itraconazole,	8,	70,	,	,	,	,	dermatology,	,	vaginal candidiasis tinea pedis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2007,	Azoline,	Phase 2,	triazole antifungal,	8,	23,	,	,	,	,	dermatology,	,	fungal infections,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2007,	Rambazole,	Phase 2,	RAMBA class,	8,	,	,	,	,	,	dermatology,	,	"severe acne
psoriasis,"	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2007,	 Hivenyl,	Phase 2,	H1 antihistamine,	8,	,	,	,	,	,	dermatology,	,	dermatological allergies,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2008,	Vusion™,	Marketed,	miconazole,	8,	,	,	  Zimycan,	,	,	dermatology,	,	"Candida-associated
 diaper dermatiti,"	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2008,	Solagé,	Marketed,	mequinol,	8,	,	,	,	,	,	dermatology,	,	solar lentigines,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2008,	Xolegel™ ,	Marketed,	ketoconazole,	8,	2,	,	Sebazole,	,	,	dermatology,	,	seborrheic dermatitis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2008,	Hyphanox,	Phase III,	itraconazole,	8,	70,	,	,	,	,	dermatology,	,	vaginal candidiasis tinea pedis,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2008,	Pramiconazole,	Phase II,	pramiconazole,	8,	,	,	,	,	,	dermatology,	,	tinea versicolor,	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2008,	Rambazole,	Phase 2,	RAMBA class,	8,	,	,	,	,	,	dermatology,	,	"severe acne
psoriasis,"	,	,
wvcs20040001173657,	BARRIER THERAPEUTICS INC,	10-K,	2004,	2008,	 Hivenyl,	Phase 2,	H1 antihistamine,	8,	,	,	,	,	,	dermatology,	,	dermatological allergies,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	S-1,	1997,	1997,	Lisofylline,	Phase III,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	,	2001,	-0.8867,	ONCOLOGY,	,	ONCOLOGY,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	S-1,	1997,	1997,	CT-2584,	Phase I,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	,	2003,	-0.9189,	ONCOLOGY,	,	ONCOLOGY,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	S-1,	1997,	1997,	Lisofylline,	Phase II,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	5,	9,	25,	,	,	,	INFLAMMATION,	,	INFLAMMATION,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	S-1,	1997,	1997,	CT-3578,	Research,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	5,	,	,	,	2000,	-0.6,	IMMUNOLOGY,	,	IMMUNOLOGY,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	424,	1997,	1997,	Lisofylline,	Phase III,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	,	2001,	-0.8867,	ONCOLOGY,	,	ONCOLOGY,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	424,	1997,	1997,	CT-2584,	Phase I,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	,	2003,	-0.9189,	ONCOLOGY,	,	ONCOLOGY,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	424,	1997,	1997,	Lisofylline,	Phase II,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	5,	9,	25,	,	,	,	INFLAMMATION,	,	INFLAMMATION,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	424,	1997,	1997,	CT-3578,	Research,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	5,	,	,	,	2000,	-0.6,	IMMUNOLOGY,	,	IMMUNOLOGY,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	1998,	Lisofylline,	Phase III,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	,	2001,	-0.8867,	ONCOLOGY,	,	ONCOLOGY,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	1998,	CT-2584,	Phase I,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	,	2003,	-0.9189,	ONCOLOGY,	,	ONCOLOGY,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	1998,	Lisofylline,	Phase II/III,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	5,	9,	25,	,	,	,	INFLAMMATION,	,	INFLAMMATION,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	1998,	CT-3578,	Research,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	5,	,	,	,	2000,	-0.9867,	IMMUNOLOGY,	,	IMMUNOLOGY,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	1999,	LSF™,	Phase III,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	Lisofylline,	2001,	-0.8867,	ONCOLOGY,	,	ONCOLOGY,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	1999,	APRA(TM),	Phase I,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	CT-2584,	2003,	-0.9189,	ONCOLOGY,	,	"Hormone refractory prostate cancer                  
                2.Soft tissue sarcoma,"	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	1999,	PG-TXL(TM),	Phase I,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	,	2009,	-0.9717,	ONCOLOGY,	,	Breast, lung and ovarian cancers,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	1999,	PG-CAMPTOTHECIN,	Pre Clinical,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	,	,	,	ONCOLOGY,	,	Colon cancer,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	1999,	PG-ETOPOSIDE,	Research,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	,	2003,	-0.9189,	ONCOLOGY,	,	Lung cancer,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	1999,	LSF,	Phase II/III,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	5,	9,	25,	,	2001,	-0.5405,	INFLAMMATION,	,	INFLAMMATION,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2000,	"ATO (arsenic                                                          
   trioxide),"	Phase II,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	27,	,	,	,	,	ONCOLOGY,	,	Hodgkin's lymphoma , leukemia, cervical cancer,  ALL,	yes,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2000,	PG-TXL(TM),	Phase I,	PG-TXL’s polymer technolog,	22,	,	,	,	2009,	-0.9717,	ONCOLOGY,	,	1. HEMATOLOGIC MALIGNANCIES 2. SOLID TUMORS,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2000,	PG-CAMPTOTHECIN,	Pre Clinical,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	,	,	,	ONCOLOGY,	,	Colon cancer,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2000,	APRA(TM),	Phase II,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	PG-ETOPOSIDE,	2003,	-0.9189,	ONCOLOGY,	,	"Hormone refractory prostate cancer                  
                2.Soft tissue sarcoma,"	,	yes,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2001,	TRISENOX,	Phase III,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	"ATO (arsenic                                                          
   trioxide),"	2007,	-0.2318,	ONCOLOGY,	,	HEMATOLOGIC MALIGNANCIES,	Hodgkin's lymphoma , leukemia, cervical cancer,  ALL,	yes,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2001,	TRISENOX,	Phase III,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	"ATO (arsenic                                                          
   trioxide),"	,	,	ONCOLOGY,	,	. SOLID TUMORS,	Hodgkin's lymphoma , leukemia, cervical cancer,  ALL,	yes,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2001,	PG-TXL(TM),	Phase I,	PG-TXL’s polymer technolog,	22,	,	,	,	2009,	-0.9717,	ONCOLOGY,	,	Breast, lung and ovarian cancers,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2001,	PG-CAMPTOTHECIN,	Pre Clinical,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	,	,	,	ONCOLOGY,	,	Colon cancer,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2001,	CT-2584,	Phase II,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	APRA(TM),	2003,	-0.9829,	ONCOLOGY,	,	Hormone refractory prostate cancer,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2002,	TRISENOX,	Marketing,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	,	2007,	-0.2318,	ONCOLOGY,	,	HEMATOLOGIC MALIGNANCIES,	,	yes,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2002,	PG-TXL(TM),	Phase I,	PG-TXL’s polymer technology,	22,	,	,	,	2009,	-0.9717,	ONCOLOGY,	,	Breast, lung and ovarian cancers,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2002,	PG-CPT,	Phase I,	"i) technology for quantitative measuring of specific species of
lipids and phospholipids; (ii) cloning of critical lipid regulatory enzymes;
and (iii) using the cloned enzymes to validate targets and to develop high
throughput screens capable of analyzing large chemical libraries,"	22,	,	,	PG-CAMPTOTHECIN,	,	,	ONCOLOGY,	,	Colon cancer,	,	yes,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2003,	TRISENOX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	2007,	-0.2318,	ONCOLOGY,	,	Multiple Myeloma (MM),	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2003,	TRISENOX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Myelodysplastic Syndromes (MDS),	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2003,	TRISENOX,	Marketed,	Polyglutamate Drug Delivery Technology,	9,	22,	27,	,	,	,	ONCOLOGY,	,	Acute Promyelocytic Leukemia (APL),	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2003,	TRISENOX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	27,	,	,	,	,	ONCOLOGY,	,	Chronic Myeloid Leukemia (CML),	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2003,	TRISENOX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	SOLID TUMORS,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2003,	XYOTAX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	PG-TXL(TM),	2009,	-0.9717,	ONCOLOGY,	,	NSCLC ,	Breast, lung and ovarian cancers,	yes,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2003,	XYOTAX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	PG-TXL(TM),	,	,	ONCOLOGY,	,	Breast, lung and ovarian cancers,	,	yes,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2003,	PG-CPT,	Phase I,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Colon cancer,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2004,	TRISENOX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	2007,	-0.2318,	ONCOLOGY,	,	Multiple Myeloma (MM),	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2004,	TRISENOX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Myelodysplastic Syndromes (MDS),	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2004,	TRISENOX,	Marketed,	Polyglutamate Drug Delivery Technology,	9,	22,	27,	,	,	,	ONCOLOGY,	,	Acute Promyelocytic Leukemia (APL),	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2004,	TRISENOX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	27,	,	,	,	,	ONCOLOGY,	,	Chronic Myeloid Leukemia (CML),	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2004,	TRISENOX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	SOLID TUMORS,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2004,	XYOTAX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	2009,	-0.9717,	ONCOLOGY,	,	NSCLC ,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2004,	XYOTAX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Breast, lung and ovarian cancers,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2004,	Pixantrone,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	PG-CPT,	,	,	ONCOLOGY,	,	Aggressive NHL,,	yes,	yes,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2004,	CT-2106,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	2009,	-0.6667,	ONCOLOGY,	,	 colorectal cancer ,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2005,	TRISENOX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	2007,	6.7333,	ONCOLOGY,	,	Multiple Myeloma (MM),	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2005,	TRISENOX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Myelodysplastic Syndromes (MDS),	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2005,	TRISENOX,	Marketed,	Polyglutamate Drug Delivery Technology,	9,	22,	27,	,	,	,	ONCOLOGY,	,	Acute Promyelocytic Leukemia (APL),	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2005,	TRISENOX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	27,	,	,	,	,	ONCOLOGY,	,	Chronic Myeloid Leukemia (CML),	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2005,	TRISENOX,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	SOLID TUMORS,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2005,	XYOTAX,	,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	2009,	-0.9717,	ONCOLOGY,	,	NSCLC ,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2005,	XYOTAX,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Breast, lung and ovarian cancers,	,	yes,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2005,	Pixantrone,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	 colorectal cancer ,	,	yes,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2005,	CT-2106,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	2009,	-0.6667,	ONCOLOGY,	,	ovarian cancer,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2006,	XYOTAX,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	2009,	-0.9717,	ONCOLOGY,	,	NSCLC ,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2006,	XYOTAX,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Breast, lung and ovarian cancers,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2006,	Pixantrone,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Aggressive NHL,,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2006,	CT-2106,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	2009,	-0.6667,	ONCOLOGY,	,	 colorectal cancer ,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2007,	XYOTAX,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	2009,	-0.8,	ONCOLOGY,	,	NSCLC ,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2007,	XYOTAX,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Breast, lung and ovarian cancers,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2007,	XYOTAX,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Breast, lung and ovarian cancers,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2007,	Pixantrone,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Aggressive NHL,,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2007,	CT-2106,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	2009,	-0.9714,	ONCOLOGY,	,	 colorectal cancer ,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2008,	Pixantrone,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Aggressive NHL,,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2008,	Zevalin,	Phase III,	radioimmunotherapeutic agent ,	22,	,	,	,	2011,	-0.2463,	ONCOLOGY,	,	NHL,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2008,	Paclitaxel,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	2010,	-0.709,	ONCOLOGY,	,	NSCLC,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2008,	PaclitaxelPoliglumex(CT-2103),	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Ovarian Cancer,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2008,	Brostallicin,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	soft tissue sarcoma ,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2008,	PaclitaxelPoliglumex(CT-2103),	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	NSCLC,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2009,	Pixantrone,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Aggressive NHL,,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2009,	OPAXIO (CT-2103),	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	"Paclitaxel

Poliglumex

(CT-2103),"	,	,	ONCOLOGY,	,	NSCLC,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2009,	OPAXIO (CT-2103),	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	"Paclitaxel

Poliglumex

(CT-2103),"	,	,	ONCOLOGY,	,	Ovarian Cancer,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2009,	Brostallicin,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	soft tissue sarcoma ,	,	Phase II,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2009,	Brostallicin,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Myxoid liposarcoma ,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2009,	Zevalin,	Phase III,	radioimmunotherapeutic agent ,	22,	,	,	,	2011,	0.8364,	ONCOLOGY,	,	NHL,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2010,	Pixantrone,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Aggressive NHL,,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2010,	OPAXIO (CT-2103),	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	NSCLC,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2010,	OPAXIO (CT-2103),	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Ovarian Cancer,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2010,	OPAXIO (CT-2103),	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Ovarian Cancer,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2010,	Brostallicin,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	soft tissue sarcoma ,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2010,	Brostallicin,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Myxoid liposarcoma ,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2010,	Brostallicin,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Breast or Ovarian Cancer,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2011,	Pixuvri,	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	Pixantrone,	,	,	ONCOLOGY,	,	Aggressive NHL,,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2011,	OPAXIO (CT-2103),	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	NSCLC,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2011,	OPAXIO (CT-2103),	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Ovarian Cancer,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2011,	OPAXIO (CT-2103),	Phase III,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Ovarian Cancer,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2011,	OPAXIO (CT-2103),	Phase II,	Polyglutamate Drug Delivery Technology,	22,	40,	,	,	,	,	ONCOLOGY,	,	Metastatic brain cancer ,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2011,	OPAXIO (CT-2103),	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Esophageal cancer,	,	,
wvcs19970000891293,	CELL THERAPEUTICS INC,	10-K,	1997,	2011,	Brostallicin,	Phase II,	Polyglutamate Drug Delivery Technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Metastatic triple-negative breast cancer ,	Breast or Ovarian Cancer,	,
wvcs19970001020214,	CERUS CORP,	S-1,	1996,	1996,	Platelet   Photochemical Treatment  System,	Phase I,	Platelet Pathogen Inactivation System.,	27,	,	,	,	2006,	0.75,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	S-1,	1996,	1996,	Platelet   Photochemical Treatment  System,	Phase I,	Platelet Pathogen Inactivation System.,	27,	,	,	,	,	,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	S-1,	1996,	1996,	FFP  Photochemical Treatment System,	Preclinical,	FFP Pathogen Inactivation System,	27,	,	,	,	2006,	4.25,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	S-1,	1996,	1996,	FFP  Photochemical Treatment System,	Preclinical,	FFP Pathogen Inactivation System,	27,	,	,	,	,	,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	S-1,	1996,	1996,	Red Cell ALE  Treatment System,	Preclinical,	Red Cell ALE Treatment System.,	27,	,	,	,	2003,	0.32,	Blood Transfusion,	,	anemia,	,	,
wvcs19970001020214,	CERUS CORP,	S-1,	1996,	1996,	Red Cell ALE  Treatment System,	Preclinical,	Red Cell ALE Treatment System.,	27,	,	,	,	,	,	Blood Transfusion,	,	anemia,	,	,
wvcs19970001020214,	CERUS CORP,	424,	1996,	1997,	Platelet   Photochemical Treatment  System,	Phase I,	Platelet Pathogen Inactivation System.,	27,	,	,	,	2006,	0.75,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	424,	1996,	1997,	Platelet   Photochemical Treatment  System,	Phase I,	Platelet Pathogen Inactivation System.,	27,	,	,	,	,	,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	424,	1996,	1997,	FFP  Photochemical Treatment System,	Preclinical,	FFP Pathogen Inactivation System,	27,	,	,	,	2006,	4.25,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	424,	1996,	1997,	FFP  Photochemical Treatment System,	Preclinical,	FFP Pathogen Inactivation System,	27,	,	,	,	,	,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	424,	1996,	1997,	Red Cell ALE  Treatment System,	Preclinical,	Red Cell ALE Treatment System.,	27,	,	,	,	2003,	0.32,	Blood Transfusion,	,	anemia,	,	,
wvcs19970001020214,	CERUS CORP,	424,	1996,	1997,	Red Cell ALE  Treatment System,	Preclinical,	Red Cell ALE Treatment System.,	27,	,	,	,	,	,	Blood Transfusion,	,	anemia,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	1998,	Platelet   Photochemical Treatment  System,	Phase II,	Platelet Pathogen Inactivation System.,	27,	,	,	,	2006,	0.75,	Blood Transfusion,	,	Surgery,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	1998,	Platelet   Photochemical Treatment  System,	Phase II,	Platelet Pathogen Inactivation System.,	22,	27,	,	,	,	,	Blood Transfusion,	,	cancer chemotherapy,	Surgery,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	1998,	FFP  Photochemical Treatment System,	Preclinical,	FFP Pathogen Inactivation System,	27,	,	,	,	2006,	4.25,	Blood Transfusion,	,	Bleeding Disorders,	Surgery,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	1998,	FFP  Photochemical Treatment System,	Preclinical,	FFP Pathogen Inactivation System,	27,	,	,	,	,	,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	1998,	Red Cell ALE  Treatment System,	Preclinical,	Red Cell ALE Treatment System.,	27,	,	,	,	2003,	0.32,	Blood Transfusion,	,	Transplantation,	Surgery,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	1998,	Red Cell ALE  Treatment System,	Preclinical,	Red Cell ALE Treatment System.,	27,	,	,	,	,	,	Blood Transfusion,	,	anemia,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	1999,	Platelet   Photochemical Treatment  System,	Phaes III,	Platelet Pathogen Inactivation System.,	27,	,	,	,	2006,	0.75,	Blood Transfusion,	,	Surgery,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	1999,	Platelet   Photochemical Treatment  System,	Phaes III,	Platelet Pathogen Inactivation System.,	22,	27,	,	,	,	,	Blood Transfusion,	,	cancer chemotherapy,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	1999,	FFP  Photochemical Treatment System,	Phase I/III,	FFP Pathogen Inactivation System,	27,	,	,	,	2006,	4.25,	Blood Transfusion,	,	Surgery,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	1999,	FFP  Photochemical Treatment System,	Phase I/III,	FFP Pathogen Inactivation System,	27,	,	,	,	,	,	Blood Transfusion,	,	Bleeding Disorders,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	1999,	Red Cell ALE  Treatment System,	Phase I,	Red Cell ALE Treatment System.,	27,	,	,	,	2003,	0.32,	Blood Transfusion,	,	Transplantation,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	1999,	Red Cell ALE  Treatment System,	Phase I,	Red Cell ALE Treatment System.,	27,	,	,	,	,	,	Blood Transfusion,	,	anemia,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	1999,	Plasma for  Fractionation,	Preclinical,	FFP Pathogen Inactivation System,	27,	20,	,	,	2002,	0,	Blood Disease,	,	Allogeneic bone marrow transplant,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2000,	INTERCEPT Platelet System,	Phaes III,	Platelet Pathogen Inactivation System.,	27,	,	,	Platelet   Photochemical Treatment  System,	2006,	0.75,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2000,	INTERCEPT Platelet System,	Phaes III,	Platelet Pathogen Inactivation System.,	22,	27,	,	Platelet   Photochemical Treatment  System,	,	,	Blood Transfusion,	,	cancer chemotherapy,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2000,	INTERCEPT Plasma System,	Phase I/III,	FFP Pathogen Inactivation System,	27,	,	,	FFP  Photochemical Treatment System,	2006,	4.25,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2000,	INTERCEPT Plasma System,	Phase I/III,	FFP Pathogen Inactivation System,	27,	,	,	FFP  Photochemical Treatment System,	,	,	Blood Transfusion,	,	Bleeding Disorders,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2000,	INTERCEPT Red Blood Cell System,	Phase I,	Red Cell ALE Treatment System.,	27,	,	,	Red Cell ALE  Treatment System,	2003,	0.32,	Blood Transfusion,	,	Transplantation,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2000,	INTERCEPT Red Blood Cell System,	Phase I,	Red Cell ALE Treatment System.,	27,	,	,	Red Cell ALE  Treatment System,	,	,	Blood Transfusion,	,	anemia,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2000,	Allogeneic Cellular Immunotherapies  (ACIT),	Phase I,	Donor Leukocyte Treatment System.,	22,	27,	20,	,	2004,	-0.0833,	ONCOLOGY,	,	Allogeneic bone marrow transplant,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2000,	Plasma for  Fractionation,	Preclinical,	FFP Pathogen Inactivation System,	27,	,	,	,	2002,	-0.5833,	Blood Disease,	,	1.immunoglobulin deficiencies,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2001,	INTERCEPT Platelet System,	Phaes III,	Helinx technology,	27,	,	,	,	2006,	0.75,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2001,	INTERCEPT Platelet System,	Phaes III,	Helinx technology,	22,	27,	,	,	,	,	Blood Transfusion,	,	cancer chemotherapy,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2001,	INTERCEPT Plasma System,	Phase III,	Helinx technology,	27,	,	,	,	2006,	4.25,	Blood Transfusion,	,	Surgery,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2001,	INTERCEPT Plasma System,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Transfusion,	,	Bleeding Disorders,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2001,	INTERCEPT Red Blood Cell System,	Phase II,	Helinx technology,	27,	,	,	,	2003,	7.25,	Blood Transfusion,	,	anemia,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2001,	INTERCEPT Red Blood Cell System,	Phase II,	Helinx technology,	27,	,	,	,	,	,	Blood Transfusion,	,	Transplantation,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2001,	Allogeneic Cellular Immunotherapies  (ACIT),	Phase I,	Helinx technology,	27,	20,	,	,	2004,	-0.0833,	Blood Transfusion,	,	Allogeneic bone marrow transplant,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2002,	INTERCEPT Platelet System,	Phase III,	Helinx technology,	27,	,	,	,	2006,	0.75,	Blood Transfusion,	,	Surgery,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2002,	INTERCEPT Platelet System,	Phase III,	Helinx technology,	22,	27,	,	,	,	,	Blood Transfusion,	,	cancer chemotherapy,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2002,	INTERCEPT Plasma System,	Phase III,	Helinx technology,	27,	,	,	,	2006,	4.25,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2002,	INTERCEPT Plasma System,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Transfusion,	,	Bleeding Disorders,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2002,	Red Cell ALE  Treatment System,	Phase III,	Helinx technology,	27,	,	,	,	2006,	-1,	Blood Transfusion,	,	anemia,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2002,	Red Cell ALE  Treatment System,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Transfusion,	,	Transplantation,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2002,	Allogeneic Cellular Immunotherapies  (ACIT),	Phase I,	Helinx technology,	27,	20,	,	,	2004,	10,	Blood Transfusion,	,	Allogeneic bone marrow transplant,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2002,	Epstein-Barr Virus (EBV) Vaccine,	Phase I,	Helinx technology,	25,	,	,	,	2004,	2,	Organ Transplantation,	,	 organ transplant recipients ,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2003,	INTERCEPT Platelet System,	Phase III,	Helinx technology,	27,	,	,	,	2006,	0.75,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2003,	INTERCEPT Platelet System,	Phase III,	Helinx technology,	22,	27,	,	,	,	,	Blood Transfusion,	,	cancer chemotherapy,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2003,	INTERCEPT Plasma System,	Phase III,	Helinx technology,	27,	,	,	,	2006,	4.25,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2003,	INTERCEPT Plasma System,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Transfusion,	,	Bleeding Disorders,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2003,	Red Cell ALE  Treatment System,	Phase III,	Helinx technology,	27,	,	,	,	2006,	-1,	Blood Transfusion,	,	anemia,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2003,	Red Cell ALE  Treatment System,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Transfusion,	,	Transplantation,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2003,	Broad platform using attenuatedListeria strains to stimulate immune response,	Research,	 bacterium Listeria monocytogenes,	22,	27,	,	,	2006,	-0.75,	ONCOLOGY,	,	Cancer,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2004,	INTERCEPT Platelet System,	Phase III,	Helinx technology,	27,	,	,	,	2006,	1.625,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2004,	INTERCEPT Platelet System,	Phase III,	Helinx technology,	22,	27,	,	,	,	,	Blood Transfusion,	,	cancer chemotherapy,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2004,	INTERCEPT Plasma System,	Phase III,	Helinx technology,	27,	,	,	,	2006,	1.625,	Blood Transfusion,	,	Surgery,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2004,	INTERCEPT Plasma System,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Transfusion,	,	Bleeding Disorders,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2004,	Red Cell ALE  Treatment System,	Phase III,	Helinx technology,	27,	,	,	,	2006,	-1,	Blood Transfusion,	,	anemia,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2004,	Red Cell ALE  Treatment System,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Transfusion,	,	Transplantation,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2004,	Broad platform using attenuatedListeria strains to stimulate immune response,	Preclinical,	 bacterium Listeria monocytogenes,	22,	23,	,	,	2006,	-0.75,	ONCOLOGY,	,	Cancer, infectious diseases,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2005,	CRS-100,	Preclinical,	 bacterium Listeria monocytogenes,	22,	28,	,	,	2009,	-0.75,	ONCOLOGY,	,	Liver Cancer,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2005,	CRS-207,	Preclinical,	 bacterium Listeria monocytogenes,	22,	,	,	,	2009,	-0.125,	ONCOLOGY,	,	" 
Pancreatic and ovarian cancer,"	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2005,	MEDI-543 (EphA2),	Preclinical,	 bacterium Listeria monocytogenes,	22,	,	,	,	2009,	-1,	ONCOLOGY,	,	Breast Cancer,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2005,	MEDI-543 (EphA2),	Preclinical,	 bacterium Listeria monocytogenes,	22,	,	,	,	,	,	ONCOLOGY,	,	Prostate Cancer,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2005,	MEDI-543 (EphA2),	Preclinical,	 bacterium Listeria monocytogenes,	22,	,	,	,	,	,	ONCOLOGY,	,	Colon Cancer,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2005,	Anthrax Vaccine,	Preclinical,	KBMA Platform,	23,	,	,	,	2009,	-1,	Infectious Diseases,	,	Anthrax vaccine,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2005,	Tularemia Vaccine,	Preclinical,	KBMA Platform,	23,	,	,	,	2009,	-1,	Infectious Diseases,	,	Tularemia Vaccine,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2005,	INTERCEPT Blood System for platelets,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	Blood Tranfusion,	Inactivation of pathogens for Transfusion,	cancer chemotherapy,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2005,	INTERCEPT Blood System for plasma,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	Blood Tranfusion,	Inactivation of pathogens for Transfusion,	Bleeding Disorders,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2005,	INTERCEPT Blood System for red blood cells,	Phase I,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	Blood Tranfusion,	Inactivation of pathogens for Transfusion,	anemia,	yes-Phase III,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2006,	CRS-100,	Phase I,	 bacterium Listeria monocytogenes,	22,	28,	,	,	2009,	-0.75,	ONCOLOGY,	,	Liver Cancer,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2006,	CRS-207,	Preclinical,	 bacterium Listeria monocytogenes,	22,	,	,	,	2009,	-0.125,	ONCOLOGY,	,	" 
Pancreatic and ovarian cancer,"	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2006,	MEDI-543 (EphA2),	Preclinical,	 bacterium Listeria monocytogenes,	22,	,	,	,	2009,	-1,	ONCOLOGY,	,	Breast Cancer,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2006,	MEDI-543 (EphA2),	Preclinical,	 bacterium Listeria monocytogenes,	22,	,	,	,	,	,	ONCOLOGY,	,	Prostate Cancer,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2006,	MEDI-543 (EphA2),	Preclinical,	 bacterium Listeria monocytogenes,	22,	,	,	,	,	,	ONCOLOGY,	,	Colon Cancer,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2006,	Anthrax Vaccine,	Preclinical,	KBMA Platform,	23,	,	,	,	2009,	-1,	Infectious Diseases,	,	Anthrax vaccine,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2006,	Tularemia Vaccine,	Preclinical,	KBMA Platform,	23,	,	,	,	2009,	-1,	Infectious Diseases,	,	Tularemia Vaccine,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2006,	INTERCEPT Blood System for platelets,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Inactivation of pathogens for Transfusion,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2006,	INTERCEPT Blood System for plasma,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Inactivation of pathogens for Transfusion,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2006,	INTERCEPT Blood System for red blood cells,	Phase I,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Inactivation of pathogens for Transfusion,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2006,	HIV Vaccine,	Pre clinical,	KBMA Platform,	23,	,	,	,	2009,	-1,	Infectious Diseases,	,	Therapeutic vaccine against HIV,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2006,	Hepatitis C Vaccine,	Pre clinical,	KBMA Platform,	23,	,	,	,	2008,	3,	Infectious Diseases,	,	Therapeutic vaccine against hepatitis C virus,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2007,	INTERCEPT Blood System for platelets,	Marketed,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Inactivation of pathogens for Transfusion,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2007,	INTERCEPT Blood System for plasma,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Inactivation of pathogens for Transfusion,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2007,	INTERCEPT Blood System for red blood cells,	Phase I,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Inactivation of pathogens for Transfusion,	,	yes,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2007,	CRS-100,	Phase I,	 bacterium Listeria monocytogenes,	22,	,	,	,	2009,	-0.6154,	Oncology,	,	Colorectal cancer ,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2007,	CRS-207,	Preclinical,	 bacterium Listeria monocytogenes,	22,	,	,	,	2009,	-0.4615,	Oncology,	,	" 
Pancreatic and ovarian cancer,"	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2007,	MEDI-543 (EphA2),	Preclinical,	 bacterium Listeria monocytogenes,	22,	,	,	,	2009,	-1,	Oncology,	,	Breast, prostate and colon cancers and metastatic melanoma,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2007,	Anthrax Vaccine,	Preclinical,	KBMA Platform,	23,	,	,	,	2009,	-1,	INFECTIOUS DISEASE,	,	Anthrax vaccine,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2007,	Tularemia Vaccine,	Preclinical,	KBMA Platform,	23,	,	,	,	2009,	-1,	INFECTIOUS DISEASE,	,	Prophylactic vaccine against tularemia,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2007,	HIV Vaccine,	Preclinical,	KBMA Platform,	23,	,	,	,	2009,	-1,	INFECTIOUS DISEASE,	,	HIV,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2008,	INTERCEPT Blood System for platelets,	Marketed,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Surgery, transplantation, bleeding disorders,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2008,	INTERCEPT Blood System for plasma,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Surgery, transplantation, bleeding disorders,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2008,	INTERCEPT Blood System for red blood cells,	Phase I,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Surgery, transplantation, bleeding disorders,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2009,	INTERCEPT Blood System for platelets,	Marketed,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Surgery, transplantation, bleeding disorders,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2009,	INTERCEPT Blood System for plasma,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Surgery, transplantation, bleeding disorders,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2009,	INTERCEPT Blood System for red blood cells,	Phase I,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Surgery, transplantation, bleeding disorders,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2010,	INTERCEPT Blood System for platelets,	Marketed,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Surgery, transplantation, bleeding disorders,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2010,	INTERCEPT Blood System for plasma,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Surgery, transplantation, bleeding disorders,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2010,	INTERCEPT Blood System for red blood cells,	Phase I,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Surgery, transplantation, bleeding disorders,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2011,	INTERCEPT Blood System for platelets,	Marketed,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Surgery, transplantation, bleeding disorders,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2011,	INTERCEPT Blood System for plasma,	Phase III,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Surgery, transplantation, bleeding disorders,	,	,
wvcs19970001020214,	CERUS CORP,	10-K,	1996,	2011,	INTERCEPT Blood System for red blood cells,	Phase I,	Helinx technology,	27,	,	,	,	,	,	Blood Safety,	,	Surgery, transplantation, bleeding disorders,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	S-1,	2004,	2004,	CORLUX,	Phase III,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	 PMD,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	S-1,	2004,	2004,	CORLUX,	 IND,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Alzheimer’s Disease,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	424,	2004,	2004,	CORLUX,	Phase III,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	 PMD,	,	Phase III,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	424,	2004,	2004,	CORLUX,	Clinical Trial,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Alzheimer’s Disease,	,	IND,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2005,	CORLUX,	Phase III,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	 PMD,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2005,	CORLUX,	Clinical Trial,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Alzheimer’s Disease,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2006,	CORLUX,	Phase III,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	 PMD,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2006,	CORLUX,	Clinical Trial,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Alzheimer’s Disease,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2006,	CORLUX,	Pre Clinical,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	 antipsychotic medication induced weight gain.,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2007,	CORLUX,	Phase III,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	 PMD,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2007,	CORLUX,	Clinical Trial,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Alzheimer’s Disease,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2007,	CORLUX,	Pre Clinical,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	 antipsychotic medication induced weight gain.,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2008,	CORLUX,	Phase III,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Psychotic depression,	 PMD,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2008,	CORLUX,	Pre Clinical,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Antipsychotic-induced Weight Gain Mitigation.    ,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2008,	CORLUX,	Pre Clinical,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Cushing’s Syndrome,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2009,	CORLUX,	Phase III,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Psychotic depression,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2009,	CORLUX,	Pre clinical,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Antipsychotic-induced Weight Gain Mitigation.    ,	,	yes,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2009,	CORLUX,	Phase III,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Cushing’s Syndrome,	,	yes,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2010,	CORLUX,	Phase III,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Psychotic depression,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2010,	CORLUX,	Pre clinical,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Antipsychotic-induced Weight Gain Mitigation.    ,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2010,	CORLUX,	IND,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Cushing’s Syndrome,	,	yes,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2011,	CORLUX,	Phase III,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Psychotic depression,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2011,	CORLUX,	Pre clinical,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Antipsychotic-induced Weight Gain Mitigation.    ,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2011,	CORLUX,	IND,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Cushing’s Syndrome,	,	,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2011,	CORT 108297 ,	Phase I,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Antipsychotic-induced Weight Gain Mitigation.    ,	,	yes,
wvcs20040001088856,	CORCEPT THERAPEUTICS INC,	10-K,	2004,	2011,	CORT 113083,	 preclinical studies ,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	Antipsychotic-induced Weight Gain Mitigation.    ,	,	,
wvcs19970001042561,	CORIXA CORP,	S-1,	1997,	1997,	VACCINES,	Research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	2003,	3.5,	Oncology,	,	Breast/Prostate Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	S-1,	1997,	1997,	VACCINES,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	,	,	Oncology,	,	"Her-2/neu Peptide Vaccines for  P
                  Breast and Ovarian Cancer ,"	,	,
wvcs19970001042561,	CORIXA CORP,	S-1,	1997,	1997,	VACCINES,	Research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	27,	,	,	,	,	Oncology,	,	Lung Cancer, Lymphoma,	,	,
wvcs19970001042561,	CORIXA CORP,	S-1,	1997,	1997,	VACCINES,	Pre Clinincal,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	Tuberculosis Vaccines   ,	,	,
wvcs19970001042561,	CORIXA CORP,	S-1,	1997,	1997,	ADJUVANTS,	Pre Clinincal,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	2000,	0.3333,	infectious diseases,	,	Infectious Disease,	,	,
wvcs19970001042561,	CORIXA CORP,	S-1,	1997,	1997,	DIAGNOSTICS,	Development,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	2001,	6.25,	infectious diseases,	,	Trypanosoma cruzi,	,	,
wvcs19970001042561,	CORIXA CORP,	S-1,	1997,	1997,	DIAGNOSTICS,	Development,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	 Tuberculosis ,	,	,
wvcs19970001042561,	CORIXA CORP,	S-1,	1997,	1997,	DIAGNOSTICS,	Marketed,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	Leishmaniasis  ,	,	,
wvcs19970001042561,	CORIXA CORP,	S-1,	1997,	1997,	DIAGNOSTICS,	Preclinical,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	Tick-Borne Diseases  ,	,	,
wvcs19970001042561,	CORIXA CORP,	S-1,	1997,	1997,	 Adoptive Immunotherapy,	Preclinical,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	 Adoptive Immunotherapy,	,	,
wvcs19970001042561,	CORIXA CORP,	S-1,	1997,	1997,	 Companion Animal Health,	Development,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	 Companion Animal Health,	,	,
wvcs19970001042561,	CORIXA CORP,	424,	1997,	1997,	VACCINES,	Research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	2003,	3.5,	Oncology,	,	Breast/Prostate Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	424,	1997,	1997,	VACCINES,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	,	,	Oncology,	,	"Her-2/neu Peptide Vaccines for  P
                  Breast and Ovarian Cancer ,"	,	,
wvcs19970001042561,	CORIXA CORP,	424,	1997,	1997,	VACCINES,	Research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	27,	,	,	,	,	Oncology,	,	Lung Cancer, Lymphoma,	,	,
wvcs19970001042561,	CORIXA CORP,	424,	1997,	1997,	VACCINES,	Pre Clinincal,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	Tuberculosis Vaccines   ,	,	,
wvcs19970001042561,	CORIXA CORP,	424,	1997,	1997,	ADJUVANTS,	Pre Clinincal,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	2000,	0.3333,	infectious diseases,	,	Infectious Disease,	,	,
wvcs19970001042561,	CORIXA CORP,	424,	1997,	1997,	DIAGNOSTICS,	Development,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	2001,	6.25,	infectious diseases,	,	Trypanosoma cruzi,	,	,
wvcs19970001042561,	CORIXA CORP,	424,	1997,	1997,	DIAGNOSTICS,	Development,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	 Tuberculosis ,	,	,
wvcs19970001042561,	CORIXA CORP,	424,	1997,	1997,	DIAGNOSTICS,	Marketed,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	Leishmaniasis  ,	,	,
wvcs19970001042561,	CORIXA CORP,	424,	1997,	1997,	DIAGNOSTICS,	Preclinical,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	Tick-Borne Diseases  ,	,	,
wvcs19970001042561,	CORIXA CORP,	424,	1997,	1997,	 Adoptive Immunotherapy,	Preclinical,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	,	,	Oncology,	,	 Adoptive Immunotherapy,	,	,
wvcs19970001042561,	CORIXA CORP,	424,	1997,	1997,	 Companion Animal Health,	Development,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	 Companion Animal Health,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1998,	VACCINES,	Research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	2003,	3.5,	Oncology,	,	Breast/Prostate Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1998,	VACCINES,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	,	,	Oncology,	,	"Her-2/neu Peptide Vaccines for  P
                  Breast and Ovarian Cancer ,"	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1998,	VACCINES,	Research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	27,	,	,	,	,	Oncology,	,	Lung Cancer, Lymphoma,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1998,	VACCINES,	Pre Clinincal,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	Tuberculosis Vaccines   ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1998,	ADJUVANTS,	Pre Clinincal,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	2000,	6,	infectious diseases,	,	Infectious Disease,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1998,	DIAGNOSTICS,	Development,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	2001,	6.25,	infectious diseases,	,	Trypanosoma cruzi,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1998,	DIAGNOSTICS,	Development,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	 Tuberculosis ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1998,	DIAGNOSTICS,	Marketed,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	 Tuberculosis ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1998,	DIAGNOSTICS,	Marketed,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	Leishmaniasis  ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1998,	DIAGNOSTICS,	Preclinical,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	Tick-Borne Diseases  ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1998,	 Adoptive Immunotherapy,	Preclinical,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	,	,	Oncology,	,	 Adoptive Immunotherapy,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1998,	 Companion Animal Health,	Development,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	 Companion Animal Health,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	AnergiX.RA(TM) complex,	Phase II,	AnergiX.RA(TM) complex,	5,	20,	,	Vaccines,	2003,	3.5,	Autoimmune,	,	rheumatoid arthritis,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	Breast cancer vaccine,	Research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	Vaccines,	2001,	0.25,	Oncology,	,	Breast Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	 Chlamydia Pneumoniae vaccine,	Research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	29,	,	Vaccines,	,	,	infectious diseases,	,	Chlamydia trachomitis ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	Colon cancer vaccine,	Research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	2003,	0,	Oncology,	,	Colon Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	 Her2/neu vaccine,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	Vaccines,	,	,	Oncology,	,	breast and ovarian cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	 Mammaglobin vaccine,	research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	,	,	Oncology,	,	Breast Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	Ovarian cancer vaccine,	research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	2001,	1,	Oncology,	,	Ovarian Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	Tuberculosis Vaccines   ,	Pre Clinincal,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	Vaccines,	2005,	-0.1667,	infectious diseases,	,	Tuberculosis ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	 Diagnostic for canine leishmaniasis ,	Marketed,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	Diagnostics,	,	,	infectious diseases,	,	Leishmaniasis  ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	Diagnostic for Chagas' Disease,	 development ,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	29,	,	,	2003,	-0.1,	infectious diseases,	,	Chagas' Disease ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	Diagnostic for  tuberculosis   ,	Marketed,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	29,	,	Diagnostics,	2003,	-0.1,	infectious diseases,	,	Tuberculosis ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	Reference diagnostic tick-borne diseases,	Preclinical,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	Diagnostics,	2001,	0.0667,	infectious diseases,	,	Tick-Borne Diseases  ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	 Companion Animal Health,	Development,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	 Companion Animal Health,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	 AnergiX.MG(TM) complex, for myasthenia gravis,	Preclinical,	AnergiX.MG(TM) complex,	5,	,	,	,	,	,	Autoimmune Disease,	,	myasthenia gravis,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	AnergiX.MS(TM) complex, for multiple sclerosis,	Phase I,	AnergiX.MG(TM) complex,	5,	,	,	,	,	,	Autoimmune Disease,	,	multiple sclerosis,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	AnervaX.DB(TM) peptide vaccine, for diabetes,	Preclinical,	AnervaX.DB(TM),	5,	24,	,	,	,	,	Autoimmune Disease,	,	Diabetes,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	 Herpes Virus vaccine,	 research  ,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	29,	,	,	,	,	Infectious Diseases,	,	Herpes,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	 Leukemia/lymphoma vaccine,	 research  ,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	27,	,	,	,	,	Oncology,	,	Leukemia/lymphoma,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	Lung cancer vaccine,	research ,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	2001,	0.25,	Oncology,	,	Lung Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	Muc-1 peptide vaccine,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	2002,	-1,	Oncology,	,	epithelial tumors,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	 Adoptive Immunotherapy,	Preclinical,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	,	,	Oncology,	,	 Adoptive Immunotherapy,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	1999,	PVAC(TM) compound,	Phase II,	PVAC(TM),	5,	,	,	,	2004,	-1,	Autoimmune Diseases,	,	psoriasis  ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	AnergiX.RA(TM) complex,	Phase II,	AnergiX.RA(TM) complex,	5,	20,	,	,	2003,	3.5,	Autoimmune,	,	rheumatoid arthritis,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	AnergiX.MS(TM) complex, for multiple sclerosis,	Phase II,	AnergiX.MG(TM) complex,	5,	,	,	,	,	,	Autoimmune Disease,	,	multiple sclerosis,	,	Phase I ,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	BEXXAR(TM) therapy    ,	BLA review ,	monoclonal antibody,	22,	,	,	,	2005,	0.1801,	Oncology,	,	NHL,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	PVAC(TM) compound,	Phase II,	PVAC(TM),	5,	,	,	,	2004,	-1,	Autoimmune Diseases,	,	psoriasis  ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	Melacine(R) vaccine,	Phase III,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	2004,	-0.5581,	Oncology,	,	Melanoma,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	 Detox(TM) adjuvant,	Phase III,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	,	,	Oncology,	,	Breast Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	 Her2/neu vaccine,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	,	,	Oncology,	,	breast and ovarian cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	Muc-1 peptide vaccine,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	2002,	-1,	Oncology,	,	pancreatic cancer,	epithelial tumors,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	Diagnostic for  tuberculosis   ,	Marketed,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	29,	,	Diagnostics,	2003,	-0.1,	infectious diseases,	,	Tuberculosis ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	 Novel cancer vaccines,	Research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	Breast Cancer Vaccines,	,	,	Oncology,	,	Breast Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	 Novel cancer vaccines,	Research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	Colon cancer vaccine,	,	,	Oncology,	,	Colon Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	Novel infectious disease Vaccinesq,	Research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	29,	,	 Chlamydia Pneumoniae vaccine,	2003,	0,	infectious diseases,	,	Chlamydia trachomitis ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	 Diagnostic for leishmaniasis ,	Marketed,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	 Diagnostic for canine leishmaniasis ,	,	,	infectious diseases,	,	Leishmaniasis  ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	Diagnostic for Chagas' Disease,	 development ,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	29,	,	,	2003,	-0.1,	infectious diseases,	,	Chagas' Disease ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	 Novel infectious disease vaccine,	Pre Clinincal,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	Tuberculosis Vaccines   ,	,	,	infectious diseases,	,	Tuberculosis ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	 Novel infectious disease vaccine,	 research  ,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	29,	,	 Herpes Virus vaccine,	,	,	Infectious Diseases,	,	Herpes,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	 Companion Animal Health,	Commercialized,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	 Companion Animal Health,	,	Development,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	 Adoptive Immunotherapy,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	,	,	Oncology,	,	Multiple Cancers,	 Adoptive Immunotherapy,	Preclinical,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2000,	RC-552,	Preclinical,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	21,	,	,	,	2003,	-0.9231,	Cardiovascular Disease,	,	Ischemia-reperfusion,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	AnergiX.RA(TM) complex,	Phase II,	AnergiX.RA(TM) complex,	5,	20,	,	,	2003,	0.3846,	Autoimmune,	,	rheumatoid arthritis,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	AnergiX.MS(TM) complex, for multiple sclerosis,	Phase II,	AnergiX.MG(TM) complex,	5,	,	,	,	,	,	Autoimmune Disease,	,	multiple sclerosis,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	BEXXAR(TM) therapy    ,	BLA review ,	monoclonal antibody,	22,	,	,	,	2005,	0.1801,	Oncology,	,	NHL,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	PVAC(TM) compound,	Phase II,	PVAC(TM),	5,	,	,	,	2004,	-1,	Autoimmune Diseases,	,	psoriasis  ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	Melacine(R) vaccine,	Phase III,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	2004,	-0.5581,	Oncology,	,	Melanoma,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	ENHANZYN(TM) adjuvant ,	Phase III,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	 Detox(TM) adjuvant,	2004,	-0.1429,	Oncology,	,	Breast Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	 Her2/neu vaccine,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	,	,	Oncology,	,	breast and ovarian cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	 Novel cancer vaccines,	Research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	,	,	Oncology,	,	Breast Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	 Novel cancer vaccines,	Research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	Colon cancer vaccine,	,	,	Oncology,	,	Colon Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	WT-1 vaccine      ,	Preclinical,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	27,	,	,	2003,	-0.8333,	Oncology,	,	Leukemia,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	Mammaglobin vaccine ,	Preclinical,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	2003,	-0.3333,	Oncology,	,	Breast Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	CPI-0004         ,	Preclinical,	TAP pro-drug  ,	22,	,	,	,	2003,	-0.1667,	Oncology,	,	solid tumor cancers,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	Diagnostic for  tuberculosis   ,	Marketed,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	29,	,	,	2003,	3.5,	infectious diseases,	,	Tuberculosis ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	Novel infectious disease Vaccinesq,	Research,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	29,	,	,	2003,	-0.3333,	infectious diseases,	,	Chlamydia trachomitis ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	 Diagnostic for leishmaniasis ,	Marketed,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	Leishmaniasis  ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	Diagnostic for Chagas' Disease,	Marketed,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	29,	,	,	2003,	3.5,	infectious diseases,	,	Chagas' Disease ,	,	Development,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	 Novel infectious disease vaccine,	Pre Clinincal,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	Tuberculosis ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	 Novel infectious disease vaccine,	 research  ,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	29,	,	,	,	,	Infectious Diseases,	,	Herpes,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	Novel infectious disease Vaccine,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	2005,	-0.1667,	Infectious Diseases,	,	Leishmaniasis  ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	 Companion Animal Health,	Commercialized,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	 Companion Animal Health,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	 Adoptive Immunotherapy,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	,	,	Oncology,	,	Multiple Cancers,	 Adoptive Immunotherapy,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2001,	RC-552,	Preclinical,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	21,	,	,	,	2003,	-0.8333,	Cardiovascular Disease,	,	Ischemia-reperfusion,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2002,	BEXXAR(TM) therapy    ,	BLA review ,	monoclonal antibody,	22,	,	,	,	2005,	0.1801,	Oncology,	,	NHL,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2002,	PVAC(TM) compound,	Phase II,	PVAC(TM),	5,	,	,	,	2004,	-1,	Autoimmune Diseases,	,	psoriasis  ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2002,	Melacine(R) vaccine,	Phase III,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	2004,	-0.882,	Oncology,	,	Melanoma,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2002,	ENHANZYN(TM) adjuvant ,	Phase III,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	2004,	-0.9255,	Oncology,	,	Breast Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2002,	 Her2/neu vaccine,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	,	,	Oncology,	,	breast and ovarian cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2002,	 Novel infectious disease vaccine,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	,	,	infectious diseases,	,	Tuberculosis ,	,	Preclinical,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2002,	Novel infectious disease Vaccine,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	,	2005,	-0.1667,	Infectious Diseases,	,	Leishmaniasis  ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2002,	PVAC treatment,	Phase I,	PVAC(TM),	5,	20,	2,	,	2004,	5,	Autoimmune Diseases,	,	Scleroderma,		,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2003,	BEXXAR(TM) therapy    ,	Marketed,	monoclonal antibody,	22,	,	,	,	2005,	30.6667,	Oncology,	,	NHL,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2003,	 Her2/neu vaccine,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	22,	,	,	,	,	,	Oncology,	,	Breast Cancer,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2003,	Tuberculosis vaccine,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	 Novel infectious disease vaccine,	2005,	-0.3333,	infectious diseases,	,	Tuberculosis ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2003,	Leishmaniasis vaccine,	Phase I,	"microsphere delivery systems that specifically activate
appropriate T cell responses; (ii) adjuvants that specifically enhance
appropriate T cell responses; and (iii) disease-specific antigens,"	23,	,	,	Novel infectious disease Vaccine,	2005,	-0.1667,	Infectious Diseases,	,	Leishmaniasis  ,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2003,	CRX-675 TLR4 agonist,	Phase I,	TLR4 Agonists and Antagonists,	5,	,	,	,	,	,	immunotherapeutic agents,	,	Seasonal Allergic,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2004,	CRX-675 TLR4 agonist,	Phase I,	TLR4 Agonists and Antagonists,	5,	,	,	,	,	,	immunotherapeutic agents,	,	Seasonal Allergic,	,	,
wvcs19970001042561,	CORIXA CORP,	10-K,	1997,	2004,	CRX-527 TLR4 agonist,	U.S. IND,	TLR4 Agonists and Antagonists,	5,	23,	,	,	,	,	immunotherapeutic agents,	,	Infection prevention,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	S-1,	2004,	2004,	Zyflo®: The Immediate-Release Formulation of Zileuton,	 NDA,	Immediate-Release Formulation of Zileuton,	5,	25,	29,	,	2010,	-1,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	S-1,	2004,	2004,	Zyflo®: The Immediate-Release Formulation of Zileuton,	Phase I,	Immediate-Release Formulation of Zileuton,	5,	25,	29,	,	,	,	chronic respiratory disease,	,	COPD,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	S-1,	2004,	2004,	Controlled-Release Formulation of Zileuton,	 NDA,	controlled-release formulation of zileuton,	5,	25,	29,	,	,	,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	S-1,	2004,	2004,	Intravenous Formulation of Zileuton,	Research,	Intravenous formulation of Zileuton,	5,	25,	29,	,	2010,	1.75,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	S-1,	2004,	2004,	 CTI-01 program,	Phase I,	inflammatory signaling pathways,	25,	,	,	,	,	,	organ failures ,	,	organ damage,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	S-1,	2004,	2004,	HMGB1 program,	Preclinical,	inflammatory signaling pathways,	25,	,	,	,	2010,	-0.6364,	organ failures ,	,	organ failure,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	S-1,	2004,	2004,	cholinergic anti-inflammatory program,	Research,	inflammatory signaling pathways,	25,	20,	,	,	2007,	0.4,	organ failures ,	,	 acute inflammatory disease,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	424,	2004,	2004,	Zyflo®: The Immediate-Release Formulation of Zileuton,	 NDA,	Immediate-Release Formulation of Zileuton,	5,	25,	29,	,	2010,	-1,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	424,	2004,	2004,	Zyflo®: The Immediate-Release Formulation of Zileuton,	Phase I,	Immediate-Release Formulation of Zileuton,	5,	25,	29,	,	,	,	chronic respiratory disease,	,	COPD,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	424,	2004,	2004,	Controlled-Release Formulation of Zileuton,	 NDA,	controlled-release formulation of zileuton,	5,	25,	29,	,	,	,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	424,	2004,	2004,	Intravenous Formulation of Zileuton,	Research,	Intravenous formulation of Zileuton,	5,	25,	29,	,	2010,	1.75,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	424,	2004,	2004,	 CTI-01 program,	Phase I,	inflammatory signaling pathways,	25,	,	,	,	,	,	organ failures ,	,	organ damage,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	424,	2004,	2004,	HMGB1 program,	Preclinical,	inflammatory signaling pathways,	25,	,	,	,	2010,	-0.6364,	organ failures ,	,	organ failure,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	424,	2004,	2004,	cholinergic anti-inflammatory program,	Research,	inflammatory signaling pathways,	25,	20,	,	,	2007,	0.4,	organ failures ,	,	 acute inflammatory disease,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2005,	ZYFLO: The Tablet Formulation of Zileuton,	Marketed,	Immediate-Release Formulation of Zileuton,	5,	25,	29,	Zyflo®: The Immediate-Release Formulation of Zileuton,	2010,	-1,	chronic respiratory disease,	,	asthma,	,	yes,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2005,	ZYFLO: The Tablet Formulation of Zileuton,	Phase II,	Immediate-Release Formulation of Zileuton,	5,	25,	29,	Zyflo®: The Immediate-Release Formulation of Zileuton,	,	,	chronic respiratory disease,	,	COPD,	,	yes,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2005,	ZYFLO: The Tablet Formulation of Zileuton,	Phase II,	Immediate-Release Formulation of Zileuton,	5,	25,	29,	,	,	,	chronic respiratory disease,	,	Acne,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2005,	Controlled-Release Formulation of Zileuton,	 NDA,	controlled-release formulation of zileuton,	5,	25,	29,	,	,	,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2005,	Intravenous Formulation of Zileuton,	Preclinical,	Intravenous formulation of Zileuton,	5,	25,	29,	,	2010,	1.75,	chronic respiratory disease,	,	asthma,	,	yes,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2005,	 CTI-01 program,	Phase II,	inflammatory signaling pathways,	5,	,	,	,	,	,	inflammation-mediated diseases,	organ failures ,	organ damage,	,	yes,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2005,	 CTI-01 program,	Preclinical,	inflammatory signaling pathways,	5,	,	,	,	,	,	inflammation-mediated diseases,	organ failures ,	post-operative ileus,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2005,	HMGB1 program,	Preclinical,	inflammatory signaling pathways,	5,	,	,	,	2010,	-0.6364,	inflammation-mediated diseases,	organ failures ,	Chron's Disease,	organ failure,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2005,	HMGB1 program,	Preclinical,	inflammatory signaling pathways,	5,	20,	,	,	,	,	inflammation-mediated diseases,	organ failures ,	rheumatoid arthritis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2005,	HMGB1 program,	Preclinical,	inflammatory signaling pathways,	5,	,	,	,	,	,	inflammation-mediated diseases,	organ failures ,	  Sepsis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2005,	cholinergic anti-inflammatory program,	Preclinical,	inflammatory signaling pathways,	5,	9,	20,	,	2007,	-0.3636,	inflammation-mediated diseases,	organ failures ,	 acute inflammatory disease,	,	yes,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2006,	ZYFLO: The Tablet Formulation of Zileuton,	Marketed,	Immediate-Release Formulation of Zileuton,	5,	25,	29,	,	2010,	-1,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2006,	ZYFLO: The Tablet Formulation of Zileuton,	Phase II,	Immediate-Release Formulation of Zileuton,	5,	25,	29,	,	,	,	chronic respiratory disease,	,	COPD,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2006,	ZYFLO: The Tablet Formulation of Zileuton,	Phase II,	Immediate-Release Formulation of Zileuton,	5,	25,	29,	,	,	,	chronic respiratory disease,	,	nasal polyposis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2006,	Controlled-Release Formulation of Zileuton,	 NDA,	controlled-release formulation of zileuton,	5,	25,	29,	,	,	,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2006,	Intravenous Formulation of Zileuton,	Phase II,	Intravenous formulation of Zileuton,	5,	25,	29,	,	2010,	1.75,	chronic respiratory disease,	,	asthma,	,	yes,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2006,	 CTI-01 program,	Phase II,	inflammatory signaling pathways,	5,	,	,	,	,	,	inflammation-mediated diseases,	,	organ damage,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2006,	 CTI-01 program,	Phase I,	inflammatory signaling pathways,	5,	,	,	,	,	,	inflammation-mediated diseases,	,	post-operative ileus,	,	yes,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2006,	Alpha-7 Receptor Program,	Preclinical,	inflammatory signaling pathways,	5,	9,	20,	,	2010,	-0.5556,	inflammation-mediated diseases,	,	Inflammation,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2006,	HMGB1 program,	Preclinical,	inflammatory signaling pathways,	5,	20,	,	,	2010,	-0.6364,	inflammation-mediated diseases,	,	rheumatoid arthritis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2006,	HMGB1 program,	Preclinical,	inflammatory signaling pathways,	5,	,	,	,	,	,	inflammation-mediated diseases,	,	  Sepsis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2007,	ZYFLO: The Tablet Formulation of Zileuton,	Marketed,	Immediate-Release Formulation of Zileuton,	5,	25,	29,	,	2010,	-1,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2007,	Controlled-Release Formulation of Zileuton,	 NDA,	controlled-release formulation of zileuton,	5,	25,	29,	,	,	,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2007,	Intravenous Formulation of Zileuton,	Phase II,	Intravenous formulation of Zileuton,	5,	25,	29,	,	2010,	1.75,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2007,	Life-Cycle Extension,	Preclinical,	5-lipoxygenase inhibitory profiles,	5,	29,	,	,	2010,	0.3333,	chronic respiratory disease,	,	 asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2007,	HMGB1 program,	Preclinical,	inflammatory signaling pathways,	5,	20,	,	,	2010,	-0.6364,	inflammation-mediated diseases,	,	rheumatoid arthritis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2007,	HMGB1 program,	Preclinical,	inflammatory signaling pathways,	5,	,	,	,	,	,	inflammation-mediated diseases,	,	  Sepsis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2007,	Alpha-7 Receptor Program,	Preclinical,	inflammatory signaling pathways,	5,	9,	20,	,	2010,	-0.5556,	inflammation-mediated diseases,	,	Inflammation,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2008,	ZYFLO: The Tablet Formulation of Zileuton,	Marketed,	Immediate-Release Formulation of Zileuton,	5,	25,	29,	,	2010,	-1,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2008,	ZYFLO CR: The Extended-Release Formulation of Zileuton,	Marketed,	controlled-release formulation of zileuton,	5,	25,	29,	Controlled-Release Formulation of Zileuton,	,	,	chronic respiratory disease,	,	asthma,	,	yes,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2008,	Injectable Formulation of Zileuton,	Phase II,	Intravenous formulation of Zileuton,	5,	25,	29,	Intravenous Formulation of Zileuton,	2010,	-0.8608,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2008,	R(+) Isomer of Zileuton,	Phase I,	5-lipoxygenase inhibitory profiles,	5,	29,	,	Life-Cycle Extension,	2010,	-0.9494,	chronic respiratory disease,	,	 asthma,	,	yes,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2008,	Alpha-7 Receptor Program,	Preclinical,	inflammatory signaling pathways,	5,	9,	20,	,	2010,	-0.9494,	inflammation-mediated diseases,	,	Inflammation,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2008,	HMGB1 program,	Preclinical,	inflammatory signaling pathways,	5,	20,	,	,	2010,	-0.9494,	inflammation-mediated diseases,	,	rheumatoid arthritis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2008,	HMGB1 program,	Preclinical,	inflammatory signaling pathways,	5,	,	,	,	,	,	inflammation-mediated diseases,	,	  Sepsis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2009,	ZYFLO CR: The Extended-Release Formulation of Zileuton,	Marketed,	controlled-release formulation of zileuton,	5,	25,	29,	,	,	,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2009,	SPECTRACEF,	Marketed,	cefditoren pivoxil,,	9,	23,	29,	,	,	,	infections in adults and adolescents,	,	respiratory tract infections,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2009,	SPECTRACEF,	Marketed,	cefditoren pivoxil,,	23,	29,	,	,	,	,	infections in adults and adolescents,	,	chronic bronchitis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2009,	ALLERX,	Marketed,	antihistamine chlorpheniramine,	5,	,	,	,	,	,	Allergy,	,	 allergic rhinitis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2009,	SPECTRACEF,	NDA,	cefditoren pivoxil,,	9,	23,	29,	,	,	,	infections in adults and adolescents,	,	Acute bacterial exacerbations of chronic bronchitis with COPD,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2009,	SPECTRACEF Suspension,	NDA,	cefditoren pivoxil,,	23,	,	,	,	2011,	-0.1714,	infections in adults and adolescents,	,	Pharyngitis and tonsillitis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2009,	CRTX 058,	NDA,	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ,	5,	,	,	,	,	,	Allergy,	,	 allergic rhinitis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2009,	CRTX 067,	NDA,	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ,	23,	,	,	,	,	,	infections in adults and adolescents,	,	Cough/Cold,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2009,	CRTX 069,	NDA,	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ,	23,	,	,	,	,	,	infections in adults and adolescents,	,	Cough/Cold,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2010,	ZYFLO CR: The Extended-Release Formulation of Zileuton,	Marketed,	controlled-release formulation of zileuton,	5,	25,	29,	,	,	,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2010,	SPECTRACEF,	Marketed,	cefditoren pivoxil,,	9,	23,	29,	,	,	,	infections in adults and adolescents,	,	respiratory tract infections,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2010,	SPECTRACEF,	Marketed,	cefditoren pivoxil,,	23,	29,	,	,	,	,	infections in adults and adolescents,	,	chronic bronchitis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2010,	ALLERX,	Marketed,	antihistamine chlorpheniramine,	5,	,	,	,	,	,	Allergy,	,	 allergic rhinitis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2010,	CUROSURF,	Marketed,	 porcine-derived natural lung surfactant,	29,	,	,	,	,	,	Respiratory Sydromes,	,	 RDS,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2010,	 FACTIVE,	Marketed,	gemifloxacin mesylate,	23,	29,	,	,	,	,	infections in adults and adolescents,	,	chronic bronchitis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2010,	HYOMAX,	Marketed,	 hyoscyamine sulfate,	26,	3,	,	,	,	,	intestinal disorders,	,	ysenteries, diverticulitis, urinary incontinence and IBS,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2010,	CRTX 067,	Preclinical,	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ,	23,	,	,	,	,	,	infections in adults and adolescents,	,	Cough/Cold,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2010,	CRTX 069,	Preclinical,	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ,	23,	,	,	,	,	,	infections in adults and adolescents,	,	Cough/Cold,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2010,	CRTX 058,	Preclinical,	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ,	5,	,	,	,	,	,	Allergy,	,	 allergic rhinitis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2010,	CRTX 070,	Preclinical,	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ,	5,	,	,	,	,	,	Allergy,	,	 allergic rhinitis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2010,	CRTX 073,	Preclinical,	,	5,	29,	,	,	,	,	chronic respiratory disease,	,	Anti-Asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2011,	ZYFLO CR: The Extended-Release Formulation of Zileuton,	Marketed,	controlled-release formulation of zileuton,	5,	25,	29,	,	,	,	chronic respiratory disease,	,	asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2011,	SPECTRACEF,	Marketed,	cefditoren pivoxil,,	9,	23,	29,	,	,	,	infections in adults and adolescents,	,	respiratory tract infections,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2011,	SPECTRACEF,	Marketed,	cefditoren pivoxil,,	23,	29,	,	,	,	,	infections in adults and adolescents,	,	chronic bronchitis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2011,	ALLERX,	Marketed,	antihistamine chlorpheniramine,	5,	,	,	,	,	,	Allergy,	,	 allergic rhinitis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2011,	CUROSURF,	Marketed,	 porcine-derived natural lung surfactant,	29,	,	,	,	,	,	Respiratory Sydromes,	,	 RDS,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2011,	 FACTIVE,	Marketed,	gemifloxacin mesylate,	23,	29,	,	,	,	,	infections in adults and adolescents,	,	chronic bronchitis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2011,	HYOMAX,	Marketed,	 hyoscyamine sulfate,	26,	3,	,	,	,	,	intestinal disorders,	,	ysenteries, diverticulitis, urinary incontinence and IBS,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2011,	CRTX 067,	Under FDA Review,	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ,	23,	,	,	,	,	,	infections in adults and adolescents,	,	Cough/Cold,	,	yes,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2011,	CRTX 069,	Preclinical,	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ,	23,	,	,	,	,	,	infections in adults and adolescents,	,	Cough/Cold,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2011,	CRTX 058,	Preclinical,	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ,	5,	,	,	,	,	,	Allergy,	,	 allergic rhinitis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2011,	CRTX 070,	Preclinical,	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ,	5,	,	,	,	,	,	Allergy,	,	 allergic rhinitis,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2011,	CRTX 073,	Preclinical,	controlled-release formulation of zileuton,	5,	29,	,	,	,	,	chronic respiratory disease,	,	Anti-Asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2011,	CRTX 809,	Preclinical,	controlled-release formulation of zileuton,	5,	29,	,	,	,	,	chronic respiratory disease,	,	Anti-Asthma,	,	,
wvcs20040001145404,	CORNERSTONE THERAPEUTICS INC,	10-K,	2004,	2011,	CRTX 072,	Preclinical,	Neos’s Dynamic Variable Release technology and Dynamic Time Release Suspension® technology ,	23,	,	,	,	,	,	infections in adults and adolescents,	,	Cough/Cold,	,	,
wvcs20040001138812,	COTHERIX INC,	S-1,	2004,	2004,	Ventavis,	 NDA ,	 inhaled prostacyclin analogue,	21,	29,	,	,	,	,	cardiopulmonary and infectious diseases,	,	Pulmonary arterial hypertension,	,	,
wvcs20040001138812,	COTHERIX INC,	S-1,	2004,	2004,	Ventavis,	Phase II ,	 inhaled prostacyclin analogue,	21,	29,	,	,	,	,	cardiopulmonary and infectious diseases,	,	Pulmonary arterial hypertension associated with idiopathic pulmonary fibrosis,	,	,
wvcs20040001138812,	COTHERIX INC,	S-1,	2004,	2004,	CTX-100,	Phase I,	 proprietary hyaluronic acid solution ,	21,	29,	,	,	2006,	0.2,	cardiopulmonary and infectious diseases,	,	Emphysema,	,	,
wvcs20040001138812,	COTHERIX INC,	S-1,	2004,	2004,	CTX-100,	Phase I,	 proprietary hyaluronic acid solution ,	21,	29,	30,	,	,	,	cardiopulmonary and infectious diseases,	,	Genetic emphysema,	,	,
wvcs20040001138812,	COTHERIX INC,	424,	2004,	2004,	Ventavis,	 NDA ,	 inhaled prostacyclin analogue,	21,	29,	,	,	,	,	cardiopulmonary and infectious diseases,	,	Pulmonary arterial hypertension,	,	,
wvcs20040001138812,	COTHERIX INC,	424,	2004,	2004,	Ventavis,	Phase II ,	 inhaled prostacyclin analogue,	21,	29,	,	,	,	,	cardiopulmonary and infectious diseases,	,	Pulmonary arterial hypertension associated with idiopathic pulmonary fibrosis,	,	,
wvcs20040001138812,	COTHERIX INC,	424,	2004,	2004,	CTX-100,	Phase I,	 proprietary hyaluronic acid solution ,	21,	29,	,	,	2006,	-0.9745,	cardiopulmonary and infectious diseases,	,	Emphysema,	,	,
wvcs20040001138812,	COTHERIX INC,	424,	2004,	2004,	CTX-100,	Phase I,	 proprietary hyaluronic acid solution ,	21,	29,	30,	,	,	,	cardiopulmonary and infectious diseases,	,	Genetic emphysema,	,	,
wvcs20040001138812,	COTHERIX INC,	10-K,	2004,	2004,	Ventavis,	Markted,	 inhaled prostacyclin analogue,	21,	29,	,	,	,	,	cardiopulmonary and infectious diseases,	,	Pulmonary arterial hypertension,	,	yes,
wvcs20040001138812,	COTHERIX INC,	10-K,	2004,	2004,	Ventavis,	Phase II ,	 inhaled prostacyclin analogue,	21,	29,	,	,	,	,	cardiopulmonary and infectious diseases,	,	Pulmonary arterial hypertension associated with idiopathic pulmonary fibrosis,	,	,
wvcs20040001138812,	COTHERIX INC,	10-K,	2004,	2005,	Ventavis,	Markted,	 inhaled prostacyclin analogue,	21,	29,	,	,	,	,	cardiopulmonary and infectious diseases,	,	Pulmonary arterial hypertension,	,	yes,
wvcs20040001138812,	COTHERIX INC,	10-K,	2004,	2005,	Ventavis,	Phase II ,	 inhaled prostacyclin analogue,	21,	29,	,	,	,	,	cardiopulmonary and infectious diseases,	,	Pulmonary arterial hypertension associated with idiopathic pulmonary fibrosis,	,	,
wvcs20040001138812,	COTHERIX INC,	10-K,	2004,	2006,	Ventavis,	Markted,	 inhaled prostacyclin analogue,	21,	29,	,	,	,	,	cardiopulmonary and infectious diseases,	,	Pulmonary arterial hypertension,	,	,
wvcs20040001138812,	COTHERIX INC,	10-K,	2004,	2006,	Ventavis,	Phase II ,	 inhaled prostacyclin analogue,	21,	29,	,	,	,	,	cardiopulmonary and infectious diseases,	,	Pulmonary arterial hypertension associated with idiopathic pulmonary fibrosis,	,	,
wvcs19970000942416,	COULTER PHARMACEUTICALS INC,	S-1,	1996,	1996,	B-1 Therapy,	Phase I/II,	conjugated antibodies ,	22,	27,	,	,	,	,	Cancer,	,	NON-HODGKIN'S LYMPHOMA,	,	,
wvcs19970000942416,	COULTER PHARMACEUTICALS INC,	S-1,	1996,	1996,	Super-Leu-Dox,	Preclinical,	tumor-activated peptide pro-drugs.,	22,	,	,	,	,	,	Cancer,	,	Solid Tumours,	,	,
wvcs19970000942416,	COULTER PHARMACEUTICALS INC,	424,	1996,	1997,	B-1 Therapy,	Phase I/II,	conjugated antibodies ,	22,	27,	,	,	,	,	Cancer,	,	NON-HODGKIN'S LYMPHOMA,	,	,
wvcs19970000942416,	COULTER PHARMACEUTICALS INC,	424,	1996,	1997,	Super-Leu-Dox,	Preclinical,	tumor-activated peptide pro-drugs.,	22,	,	,	,	,	,	Cancer,	,	Solid Tumours,	,	,
wvcs19970000942416,	COULTER PHARMACEUTICALS INC,	424,	1996,	1997,	B-1 Therapy,	Phase I/II,	conjugated antibodies ,	22,	27,	,	,	,	,	Cancer,	,	NON-HODGKIN'S LYMPHOMA,	,	,
wvcs19970000942416,	COULTER PHARMACEUTICALS INC,	424,	1996,	1997,	Super-Leu-Dox,	Preclinical,	tumor-activated peptide pro-drugs.,	22,	,	,	,	,	,	Cancer,	,	Solid Tumours,	,	,
wvcs19970000942416,	COULTER PHARMACEUTICALS INC,	10-K,	1996,	1998,	BEXXAR,	Phase III,	conjugated antibodies ,	22,	27,	,	B-1 Therapy,	,	,	Cancer,	,	NON-HODGKIN'S LYMPHOMA,	,	yes,
wvcs19970000942416,	COULTER PHARMACEUTICALS INC,	10-K,	1996,	1998,	Super-Leu-Dox,	Preclinical,	tumor-activated peptide pro-drugs.,	22,	,	,	,	,	,	Cancer,	,	Solid Tumours,	,	,
wvcs19970000942416,	COULTER PHARMACEUTICALS INC,	10-K,	1996,	1999,	BEXXAR,	Phase III,	conjugated antibodies ,	22,	27,	,	,	,	,	Cancer,	,	NON-HODGKIN'S LYMPHOMA,	,	,
wvcs19970000942416,	COULTER PHARMACEUTICALS INC,	10-K,	1996,	1999,	Super-Leu-Dox,	IND,	tumor-activated peptide pro-drugs.,	22,	,	,	,	,	,	Cancer,	,	Solid Tumours,	,	yes,
wvcs19970000942416,	COULTER PHARMACEUTICALS INC,	10-K,	1996,	1999,	BEXXAR,	Phase III,	conjugated antibodies ,	22,	27,	,	,	,	,	Cancer,	,	NON-HODGKIN'S LYMPHOMA,	,	,
wvcs19970000942416,	COULTER PHARMACEUTICALS INC,	10-K,	1996,	1999,	Super-Leu-Dox,	IND,	tumor-activated peptide pro-drugs.,	22,	,	,	,	,	,	Cancer,	,	Solid Tumours,	,	,
wvcs19970000942416,	COULTER PHARMACEUTICALS INC,	10-K,	1996,	1999,	Bexxar,	Phase I,	conjugated antibodies ,	22,	27,	,	,	,	,	Cancer,	,	 B-cell chronic lymphocytic leukemia.,	,	,
wvcs19970000942416,	COULTER PHARMACEUTICALS INC,	10-K,	1996,	1999,	64G12,	Preclinical,	64G12 antibody,	5,	,	,	,	,	,	Autoimmune Disease,	,	autoimmune diseases,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2003,	2003,	Chronic lymphocytic leukemia, or CLL,	Phase I/II ,	Xcellerate Technology,	5,	,	,	,	,	,	Immunology,	,	CLL,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2003,	2003,	Multiple myeloma.,	Phase I/II,	Xcellerate Technology,	5,	,	,	,	,	,	Immunology,	,	Multiple myeloma.  ,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2003,	2003,	Non-Hodgkin’s lymphoma.,	clinical trial,	Xcellerate Technology,	5,	27,	,	,	,	,	Immunology,	,	Non-Hodgkin’s lymphoma.,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2003,	2003,	Kidney cancer,	Phase I,	Xcellerate Technology,	5,	22,	,	,	,	,	Immunology,	,	Kidney cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2003,	2003,	Prostate cancer,	 Phase I/II ,	Xcellerate Technology,	5,	22,	,	,	,	,	Immunology,	,	Prostate cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2003,	2003,	HIV.,	Preclinical,	Xcellerate Technology,	5,	,	,	,	,	,	Immunology,	,	HIV.,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	424,	2003,	2004,	Chronic lymphocytic leukemia, or CLL,	Phase I/II ,	Xcellerate Technology,	5,	,	,	,	,	,	Immunology,	,	CLL,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	424,	2003,	2004,	Multiple myeloma.,	Phase I/II,	Xcellerate Technology,	5,	,	,	,	,	,	Immunology,	,	Multiple myeloma.  ,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	424,	2003,	2004,	Non-Hodgkin’s lymphoma.,	clinical trial,	Xcellerate Technology,	5,	27,	,	,	,	,	Immunology,	,	Non-Hodgkin’s lymphoma.,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	424,	2003,	2004,	Kidney cancer,	Phase I,	Xcellerate Technology,	5,	22,	,	,	,	,	Immunology,	,	Kidney cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	424,	2003,	2004,	Prostate cancer,	 Phase I/II ,	Xcellerate Technology,	5,	22,	,	,	,	,	Immunology,	,	Prostate cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	424,	2003,	2004,	HIV.,	Preclinical,	Xcellerate Technology,	5,	,	,	,	,	,	Immunology,	,	HIV.,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2005,	Chronic lymphocytic leukemia, or CLL,	Phase I/II ,	Xcellerate Technology,	5,	,	,	,	,	,	Immunology,	,	CLL,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2005,	Multiple myeloma.,	Phase I/II,	Xcellerate Technology,	5,	,	,	,	,	,	Immunology,	,	Multiple myeloma.  ,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2005,	Non-Hodgkin’s lymphoma.,	Phase I,	Xcellerate Technology,	5,	27,	,	,	,	,	Immunology,	,	Non-Hodgkin’s lymphoma.,	,	yes,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2005,	HIV.,	Phase I,	Xcellerate Technology,	5,	,	,	,	,	,	Immunology,	,	HIV.,	,	yes,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2005,	Kidney cancer,	Phase II,	Xcellerate Technology,	5,	22,	,	,	,	,	Immunology,	,	Kidney cancer,	,	yes,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2005,	Prostate cancer,	 Phase I/II ,	Xcellerate Technology,	5,	22,	,	,	,	,	Immunology,	,	Prostate cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2006,	Chronic lymphocytic leukemia, or CLL,	Phase I/II ,	Xcellerate Technology,	5,	,	,	,	,	,	Immunology,	,	CLL,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2006,	Multiple myeloma.,	Phase I/II,	Xcellerate Technology,	5,	,	,	,	,	,	Immunology,	,	Multiple myeloma.  ,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2006,	Non-Hodgkin’s lymphoma.,	Phase I,	Xcellerate Technology,	5,	27,	,	,	,	,	Immunology,	,	Non-Hodgkin’s lymphoma.,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2006,	HIV.,	Phase I,	Xcellerate Technology,	5,	,	,	,	,	,	Immunology,	,	HIV.,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2006,	Kidney cancer,	Phase II,	Xcellerate Technology,	5,	22,	,	,	,	,	Immunology,	,	Kidney cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2006,	Prostate cancer,	 Phase I/II ,	Xcellerate Technology,	5,	22,	,	,	,	,	Immunology,	,	Prostate cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2007,	Seliciclib, (CYC202),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Non-small cell lung cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2007,	Seliciclib, (CYC202),	Phase I ,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Nasopharyngeal carcinoma,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2007,	Sapacitabine, (CYC682),	Phase I,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2007,	CYC116,	IND,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2007,	CDK Inhibitors, Second Generation,	Preclinical,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2007,	Clotrimazole Analogs,	Preclinical,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2007,	Plk Inhibitors,	Preclinical,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2007,	GSK-3 Inhibitors,	Preclinical,	genomic technology,	24,	,	,	,	,	,	,	,	Type 2 Diabetes,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2007,	Cell Cycle Inhibitors,	Preclinical,	genomic technology,	5,	,	,	,	,	,	Immunology,	,	HIV/AIDS,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2007,	Cell Cycle Inhibitors,	Preclinical,	genomic technology,	5,	,	,	,	,	,	,	,	Inflammatory Kidney Diseases,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2008,	Seliciclib, (CYC202),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Non-small cell lung cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2008,	Seliciclib, (CYC202),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Nasopharyngeal carcinoma,	,	yes,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2008,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Elderly AML,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2008,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	CTCL,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2008,	Sapacitabine, (CYC682),	Phase I ,	genomic technology,	22,	27,	,	,	,	,	Oncology ,	,	Advanced leukemias and MDS,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2008,	CYC116,	Phase I,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	yes,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2008,	CDK Inhibitors, Second Generation,	Preclinical,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2008,	Clotrimazole Analogs,	Preclinical,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2008,	Plk Inhibitors,	Preclinical,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2008,	GSK-3 Inhibitors,	Preclinical,	genomic technology,	24,	,	,	,	,	,	Diabetes,	,	Type 2 Diabetes,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2008,	Cell Cycle Inhibitors,	Preclinical,	genomic technology,	5,	,	,	,	,	,	Immunology,	,	HIV/AIDS,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2008,	Cell Cycle Inhibitors,	Phase I,	genomic technology,	5,	,	,	,	,	,	Immunology,	,	Inflammatory Kidney Diseases,	,	yes,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2009,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Elderly AML,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2009,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	CTCL,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2009,	Sapacitabine, (CYC682),	Phase I ,	genomic technology,	22,	27,	,	,	,	,	Oncology ,	,	Advanced leukemias and MDS,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2009,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	NSCLC,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2009,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	MDS,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2009,	Seliciclib, (CYC202),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Non-small cell lung cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2009,	Seliciclib, (CYC202),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Nasopharyngeal carcinoma,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2009,	CYC116,	Phase I,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2009,	CDK Inhibitors, Second Generation,	Preclinical,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2009,	Cell Cycle Inhibitors,	Phase I,	genomic technology,	5,	,	,	,	,	,	Immunology,	,	Inflammatory Kidney Diseases,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2010,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Elderly AML,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2010,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	CTCL,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2010,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	NSCLC,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2010,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	MDS,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2010,	Seliciclib, (CYC202),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Non-small cell lung cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2010,	Seliciclib, (CYC202),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Nasopharyngeal carcinoma,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2010,	CYC116,	Phase I,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2010,	CDK Inhibitors, Second Generation,	Preclinical,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2010,	Cell Cycle Inhibitors,	Phase I,	genomic technology,	5,	,	,	,	,	,	Immunology,	,	Inflammatory Kidney Diseases,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2011,	Sapacitabine, (CYC682),	Phase III,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Elderly AML,	,	yes,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2011,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	CTCL,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2011,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	NSCLC,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2011,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	MDS,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2011,	Seliciclib, (CYC202),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Non-small cell lung cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2011,	Seliciclib, (CYC202),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Nasopharyngeal carcinoma,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2011,	CYC116,	Phase I,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2011,	CDK Inhibitors, Second Generation,	Preclinical,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2011,	Cell Cycle Inhibitors,	Phase I,	genomic technology,	5,	,	,	,	,	,	Immunology,	,	Autoimmune Inflammatory Diseases,	Inflammatory Kidney Diseases,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2012,	Sapacitabine, (CYC682),	Phase III,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Elderly AML,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2012,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	CTCL,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2012,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	NSCLC,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2012,	Sapacitabine, (CYC682),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	MDS,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2012,	Seliciclib, (CYC202),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Non-small cell lung cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2012,	Seliciclib, (CYC202),	Phase II,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Nasopharyngeal carcinoma,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2012,	Seliciclib, CYC065,	Preclinical,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001130166,	Cyclacel Pharmaceuticals, Inc.,	10-K,	2003,	2012,	Plk1 Inhibitors,	Preclinical,	genomic technology,	22,	,	,	,	,	,	Oncology ,	,	Cancer,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	S-1,	2004,	2004,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	,	2010,	-0.5622,	Cancer,	,	Lung Cancer,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	S-1,	2004,	2004,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Colorectal,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	S-1,	2004,	2004,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Breast,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	S-1,	2004,	2004,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Ovarian,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	S-1,	2004,	2004,	cardiac myosin activator,	Phase I,	cardiac myosin activators,	9,	21,	,	,	2008,	0,	Cardiac Disease,	,	Acute Heart Failure,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	424,	2004,	2004,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	,	2010,	-0.5622,	Cancer,	,	Lung Cancer,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	424,	2004,	2004,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Colorectal,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	424,	2004,	2004,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Breast,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	424,	2004,	2004,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Ovarian,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	424,	2004,	2004,	cardiac myosin activator,	Phase I,	cardiac myosin activators,	9,	21,	,	,	2008,	0,	Cardiac Disease,	,	Acute Heart Failure,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2005,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	,	2010,	-0.5622,	Cancer,	,	Lung Cancer,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2005,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Colorectal,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2005,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Breast,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2005,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Ovarian,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2005,	cardiac myosin activator,	Phase I,	cardiac myosin activators,	9,	21,	,	,	2008,	0,	Cardiac Disease,	,	Acute Heart Failure,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2005,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	2,	,	,	,	,	Cancer,	,	Head and Neck,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2005,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2005,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	melanoma,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2005,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Hepatocellular,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2005,	SB-715992,	Phase II,	Cytometrix technologies PUMA system,	22,	28,	,	,	,	,	Cancer,	,	Renal Cell,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2005,	SB-715992,	Phase I,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Hematoglogical,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2005,	SB-715992,	Phase I,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Solid Tumor,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2005,	 SB-743921 ,	Phase I,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Multiple Tumor Types,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2006,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	2010,	-0.5622,	Cancer,	,	Lung Cancer,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2006,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Colorectal,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2006,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Breast,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2006,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Ovarian,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2006,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	2,	,	SB-715992,	,	,	Cancer,	,	Head and Neck,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2006,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2006,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	melanoma,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2006,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Hepatocellular,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2006,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	28,	,	SB-715992,	,	,	Cancer,	,	Renal Cell,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2006,	Ispinesib,	Phase I,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Hematoglogical,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2006,	Ispinesib,	Phase I,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Solid Tumor,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2006,	 SB-743921 ,	Phase I,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Multiple Tumor Types,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2006,	 SB-743921 ,	Phase I,	Cytometrix technologies PUMA system,	22,	27,	,	,	,	,	Cancer,	,	Non-Hodgkin's lymphoma,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2006,	CK-1213296,	Phase II,	cardiac myosin activators,	9,	21,	,	cardiac myosin activator,	2008,	-1,	Cardiac Disease,	,	Acute Heart Failure,	,	yes,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	2010,	-0.5622,	Cancer,	,	Lung Cancer,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Colorectal,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Breast,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Ovarian,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	2,	,	SB-715992,	,	,	Cancer,	,	Head and Neck,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	melanoma,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Hepatocellular,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	Ispinesib,	Phase II,	Cytometrix technologies PUMA system,	22,	28,	,	SB-715992,	,	,	Cancer,	,	Renal Cell,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	Ispinesib,	Phase I,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Hematoglogical,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	Ispinesib,	Phase I,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Solid Tumor,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	Ispinesib,	Phase I,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Pediatric Solid Tumors,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	 SB-743921 ,	Phase I,	Cytometrix technologies PUMA system,	22,	,	,	,	,	,	Cancer,	,	Multiple Tumor Types,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	 SB-743921 ,	Phase I,	Cytometrix technologies PUMA system,	22,	27,	,	,	,	,	Cancer,	,	Non-Hodgkin's lymphoma,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	 CK-1827452,	Phase II,	cardiac myosin activators,	9,	21,	,	cardiac myosin activator,	,	,	Cardiac Disease,	,	Acute Heart Failure,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2007,	GSK-923295,	Phase I,	Cytometrix technologies PUMA system,	22,	,	,	,	2010,	-0.2574,	Cancer,	,	Multiple Tumor Types,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2008,	Ispinesib,	Phase I,	Cytometrix technologies PUMA system,	22,	27,	,	,	2010,	-0.0594,	Cancer,	,	Leukemia,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2008,	Ispinesib,	Phase I,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Pediatric Solid Tumors,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2008,	Ispinesib,	Phase I,	Cytometrix technologies PUMA system,	22,	,	,	SB-715992,	,	,	Cancer,	,	Breast,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2008,	 SB-743921 ,	Phase I,	Cytometrix technologies PUMA system,	22,	27,	,	,	2010,	-0.3267,	Cancer,	,	Non-Hodgkin's lymphoma,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2008,	GSK-923295,	Phase I,	Cytometrix technologies PUMA system,	22,	,	,	,	2010,	-0.2574,	Cancer,	,	Advanced Soild Tumors,	Multiple Tumor Types,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2008,	 CK-1827452,	Phase II,	cardiac myosin activators,	,	,	,	,	2010,	0.495,	,	,	,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2008,	 CK-1827452,	Phase II,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2009,	,	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2010,	,	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2011,	,	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs20040001061983,	CYTOKINETICS INC,	10-K,	2004,	2012,	,	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	S-1,	1996,	1996,	MS-325,	Phase I,	proprietary biophysics technology platform.,	21,	60,	,	`,	,	,	Cardiovascular Disease,	,	CAD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	S-1,	1996,	1996,	MS-325,	Phase I,	proprietary biophysics technology platform.,	21,	60,	,	`,	,	,	Cardiovascular Disease,	,	. PVD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	S-1,	1996,	1996,	MS-325,	Phase I,	proprietary biophysics technology platform.,	21,	60,	,	`,	,	,	Cardiovascular Disease,	,	CAD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	S-1,	1996,	1996,	MS-325,	Phase I,	proprietary biophysics technology platform.,	21,	60,	,	`,	,	,	Cardiovascular Disease,	,	. PVD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	S-1,	1996,	1996,	MS-325,	Phase I,	proprietary biophysics technology platform.,	21,	60,	,	`,	,	,	healthcare-Diagnostics,	,	CAD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	S-1,	1996,	1996,	MS-325,	Phase I,	proprietary biophysics technology platform.,	21,	60,	,	`,	,	,	Cardiovascular Disease,	,	. PVD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	1998,	MS-325,	Phase II,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	CAD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	1998,	MS-325,	Phase III,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	PVD,	,	yes,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	1998,	MS-325,	Phase III,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	PVD,	,	yes,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	1998,	MS-325,	Phase II,	proprietary biophysics technology platform.,	22,	60,	,	,	,	,	Oncology,	,	BREAST CANCER,	,	yes,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	1999,	AngioMARK,	Phase II,	proprietary biophysics technology platform.,	21,	60,	,	MS-325,	,	,	Cardiovascular Disease,	,	CAD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	1999,	AngioMARK,	Phase III,	proprietary biophysics technology platform.,	21,	60,	,	MS-325,	,	,	Cardiovascular Disease,	,	PVD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	1999,	AngioMARK,	Phase III,	proprietary biophysics technology platform.,	21,	60,	,	MS-325,	,	,	Cardiovascular Disease,	,	PVD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	1999,	AngioMARK,	Phase II,	proprietary biophysics technology platform.,	22,	60,	,	MS-325,	,	,	Oncology,	,	BREAST CANCER,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2000,	MS-325,	Phase II,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	CAD,	,	yes,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2000,	MS-325,	Phase III,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	PVD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2000,	MS-325,	Phase III,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	PVD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2000,	MS-325,	Phase II,	proprietary biophysics technology platform.,	22,	60,	,	,	,	,	Oncology,	,	BREAST CANCER,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2001,	MS-325,	Phase II,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	CAD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2001,	MS-325,	Phase III,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	PVD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2001,	MS-325,	Phase III,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	PVD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2001,	MS-325,	Phase II,	proprietary biophysics technology platform.,	22,	60,	,	,	,	,	Oncology,	,	BREAST CANCER,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2001,	MS-325,	Pre Clinical,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	DVT,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2001,	MS-325,	Phase II ,	proprietary biophysics technology platform.,	23,	60,	70,	,	,	,	Sexual Arousal,	,	Female Sexual Arousal Dysfunction,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2002,	MS-325,	Phase II,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	CAD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2002,	MS-325,	Phase III,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	PVD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2002,	MS-325,	Phase III,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	PVD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2002,	MS-325,	Phase II,	proprietary biophysics technology platform.,	22,	60,	,	,	,	,	Oncology,	,	BREAST CANCER,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2002,	MS-325,	Pre Clinical,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	DVT,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2002,	MS-325,	Phase II ,	proprietary biophysics technology platform.,	23,	60,	70,	,	,	,	Sexual Arousal,	,	Female Sexual Arousal Dysfunction,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2003,	MS-325,	Phase II,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	CAD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2003,	MS-325,	Phase III,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	PVD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2003,	MS-325,	Phase III,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	PVD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2003,	MS-325,	Phase II,	proprietary biophysics technology platform.,	22,	60,	,	,	,	,	Oncology,	,	BREAST CANCER,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2003,	MS-325,	Pre Clinical,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	DVT,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2003,	MS-325,	Phase II ,	proprietary biophysics technology platform.,	23,	60,	70,	,	,	,	Sexual Arousal,	,	Female Sexual Arousal Dysfunction,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2004,	MS-325,	Phase II,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	healthcare-Diagnostics,	,	CAD,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2004,	MS-325,	NDA,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	healthcare-Diagnostics,	,	PVD,	,	YES,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2004,	MS-325,	Phase II,	proprietary biophysics technology platform.,	22,	60,	,	,	,	,	healthcare-Diagnostics,	,	BREAST CANCER,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2004,	MS-325,	Phase II ,	proprietary biophysics technology platform.,	23,	60,	70,	,	,	,	healthcare-Diagnostics,	,	Female Sexual Arousal Dysfunction,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2004,	MS-325,	Phase II ,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	healthcare-Diagnostics,	,	Myocardial Perfusion,	,	,
wvcs19970001027702,	EPIX MEDICAL INC,	10-K,	1996,	2004,	EP-2104R,	Pre Clinical,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	healthcare-Diagnostics,	,	DVT,	,	,
wvcs19970001027702,	EPIX Pharmaceuticals, Inc.,	10-K,	1996,	2005,	MS-325,	Phase II,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	healthcare-Diagnostics,	,	CAD,	,	,
wvcs19970001027702,	EPIX Pharmaceuticals, Inc.,	10-K,	1996,	2005,	MS-325,	MARKETED,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	healthcare-Diagnostics,	,	PVD,	,	,
wvcs19970001027702,	EPIX Pharmaceuticals, Inc.,	10-K,	1996,	2005,	MS-325,	Phase II,	proprietary biophysics technology platform.,	22,	60,	,	,	,	,	healthcare-Diagnostics,	,	BREAST CANCER,	,	,
wvcs19970001027702,	EPIX Pharmaceuticals, Inc.,	10-K,	1996,	2005,	MS-325,	Phase II ,	proprietary biophysics technology platform.,	23,	60,	70,	,	,	,	healthcare-Diagnostics,	,	Female Sexual Arousal Dysfunction,	,	,
wvcs19970001027702,	EPIX Pharmaceuticals, Inc.,	10-K,	1996,	2005,	MS-325,	Phase II ,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	healthcare-Diagnostics,	,	Myocardial Perfusion,	,	,
wvcs19970001027702,	EPIX Pharmaceuticals, Inc.,	10-K,	1996,	2005,	EP-2104R,	Phase I,	proprietary biophysics technology platform.,	21,	60,	,	,	,	,	healthcare-Diagnostics,	,	DVT,	,	yes,
wvcs19970001027702,	EPIX Pharmaceuticals, Inc.,	10-K,	1996,	2006,	AngioMARK,	Phase III,	 Target Visualization Technologytm,	21,	60,	,	,	,	,	healthcare-Diagnostics,	,	CAD,	,	,
wvcs19970001027702,	EPIX Pharmaceuticals, Inc.,	10-K,	1996,	2006,	AngioMARK,	MARKETED,	 Target Visualization Technologytm,	21,	60,	,	,	,	,	healthcare-Diagnostics,	,	PVD,	,	,
wvcs19970001027702,	EPIX Pharmaceuticals, Inc.,	10-K,	1996,	2006,	AngioMARK,	Phase II,	 Target Visualization Technologytm,	22,	60,	,	,	,	,	healthcare-Diagnostics,	,	BREAST CANCER,	,	,
wvcs19970001027702,	EPIX Pharmaceuticals, Inc.,	10-K,	1996,	2006,	AngioMARK,	Phase II ,	 Target Visualization Technologytm,	23,	60,	70,	,	,	,	healthcare-Diagnostics,	,	Female Sexual Arousal Dysfunction,	,	,
wvcs19970001027702,	EPIX Pharmaceuticals, Inc.,	10-K,	1996,	2006,	AngioMARK,	Phase II ,	 Target Visualization Technologytm,	21,	60,	,	,	,	,	healthcare-Diagnostics,	,	Myocardial Perfusion,	,	,
wvcs19970001027702,	EPIX Pharmaceuticals, Inc.,	10-K,	1996,	2006,	EP-2104R,	Phase I,	 Target Visualization Technologytm,	21,	60,	,	,	,	,	healthcare-Diagnostics,	,	Thrombus Imaging,	,	,
wvcs19970001027702,	EPIX Pharmaceuticals, Inc.,	10-K,	1996,	2007,	Downsized No product line,	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs19970001027702,	EPIX Pharmaceuticals, Inc.,	10-K,	1996,	2008,	Downsized No product line,	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs19970001027702,	EPIX Pharmaceuticals, Inc.,	10-K,	1996,	2009,	Downsized No product line,	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs20040001115285,	EYETECH PHARMACEUTICALS INC,	S-1,	2003,	2003,	Macugen,	 Phase 2/3,	synthesized aptamer,	1,	,	,	,	,	,	Eye Disease,	,	AMD,	,	,
wvcs20040001115285,	EYETECH PHARMACEUTICALS INC,	S-1,	2003,	2003,	Macugen,	Phase 2 ,	synthesized aptamer,	1,	,	,	,	,	,	Eye Disease,	,	DME,	,	,
wvcs20040001115285,	EYETECH PHARMACEUTICALS INC,	S-1,	2003,	2003,	Macugen,	Phase 2,	synthesized aptamer,	1,	,	,	,	,	,	Eye Disease,	,	Retinal Vein Occlusion,	,	,
wvcs20040001115285,	EYETECH PHARMACEUTICALS INC,	424,	2003,	2004,	Macugen,	 Phase 2/3,	synthesized aptamer,	1,	,	,	,	,	,	Eye Disease,	,	AMD,	,	,
wvcs20040001115285,	EYETECH PHARMACEUTICALS INC,	424,	2003,	2004,	Macugen,	Phase 2 ,	synthesized aptamer,	1,	,	,	,	,	,	Eye Disease,	,	DME,	,	,
wvcs20040001115285,	EYETECH PHARMACEUTICALS INC,	424,	2003,	2004,	Macugen,	Phase 2,	synthesized aptamer,	1,	,	,	,	,	,	Eye Disease,	,	Retinal Vein Occlusion,	,	,
wvcs20040001115285,	EYETECH PHARMACEUTICALS INC,	10-K,	2003,	2004,	Macugen,	 Phase 2/3,	synthesized aptamer,	1,	,	,	,	,	,	Eye Disease,	,	AMD,	,	,
wvcs20040001115285,	EYETECH PHARMACEUTICALS INC,	10-K,	2003,	2004,	Macugen,	Phase 2 ,	synthesized aptamer,	1,	,	,	,	,	,	Eye Disease,	,	DME,	,	,
wvcs20040001115285,	EYETECH PHARMACEUTICALS INC,	10-K,	2003,	2004,	Macugen,	Phase 2,	synthesized aptamer,	1,	,	,	,	,	,	Eye Disease,	,	Retinal Vein Occlusion,	,	,
wvcs20040001115285,	EYETECH PHARMACEUTICALS INC,	10-K,	2003,	2005,	Macugen,	 Phase 2/3,	synthesized aptamer,	1,	,	,	,	,	,	Eye Disease,	,	AMD,	,	,
wvcs20040001115285,	EYETECH PHARMACEUTICALS INC,	10-K,	2003,	2005,	Macugen,	Phase 2 ,	synthesized aptamer,	1,	,	,	,	,	,	Eye Disease,	,	DME,	,	,
wvcs20040001115285,	EYETECH PHARMACEUTICALS INC,	10-K,	2003,	2005,	Macugen,	Phase 2,	synthesized aptamer,	1,	,	,	,	,	,	Eye Disease,	,	Retinal Vein Occlusion,	,	,
wvcs20040001260990,	GTX INC ,	S-1,	2003,	2003,	Acapodene,	Phase II,	 SERM,	22,	,	,	,	,	,	Oncology,	,	prostate cancer,	,	,
wvcs20040001260990,	GTX INC,	S-1,	2003,	2003,	Acapodene,	Phase  III ,	 SERM,	22,	,	,	,	,	,	Oncology,	,	androgen deprivation,	,	,
wvcs20040001260990,	GTX INC,	S-1,	2003,	2003,	Andarine,	Phase I,	 SERM,	22,	,	,	,	2010,	-1,	Oncology,	,	Cancer Cachexia,	,	,
wvcs20040001260990,	GTX INC,	S-1,	2003,	2003,	Prostarine,	Preclinical,	 SERM,	22,	,	,	,	2010,	-0.6923,	Oncology,	,	BPH,	,	,
wvcs20040001260990,	GTX INC,	S-1,	2003,	2003,	Ostarine,	Preclinical,	SARM,	20,	,	,	,	,	,	osteoporosis,	,	Male osteoporosis,	,	,
wvcs20040001260990,	GTX INC,	S-1,	2003,	2003,	Andromustine,	Preclinical,	SARM,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer,	,	,
wvcs20040001260990,	GTX INC,	424,	2003,	2004,	Acapodene,	Phase II,	 SERM,	22,	,	,	,	,	,	Oncology,	,	prostate cancer,	,	,
wvcs20040001260990,	GTX INC,	424,	2003,	2004,	Acapodene,	Phase  III ,	 SERM,	22,	,	,	,	,	,	Oncology,	,	androgen deprivation,	,	,
wvcs20040001260990,	GTX INC,	424,	2003,	2004,	Andarine,	Phase I,	 SERM,	22,	,	,	,	2010,	-1,	Oncology,	,	Cancer Cachexia,	,	,
wvcs20040001260990,	GTX INC,	424,	2003,	2004,	Prostarine,	Preclinical,	SARM,	22,	,	,	,	2010,	-0.6923,	Oncology,	,	BPH,	,	,
wvcs20040001260990,	GTX INC,	424,	2003,	2004,	Ostarine,	Preclinical,	SARM,	20,	,	,	,	,	,	osteoporosis,	,	Male osteoporosis,	,	,
wvcs20040001260990,	GTX INC,	424,	2003,	2004,	Andromustine,	Preclinical,	SARM,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2004,	Acapodene,	PhaseII,	 SERM,	22,	,	,	,	,	,	Oncology,	men’s health ,	prostate cancer,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2004,	Acapodene,	Phase  III ,	 SERM,	22,	,	,	,	,	,	Oncology,	men’s health ,	androgen deprivation,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2004,	Andarine,	Phase I,	 SERM,	22,	,	,	,	2010,	-1,	Oncology,	men’s health ,	Cancer Cachexia,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2004,	Prostarine,	Preclinical,	SARM,	22,	,	,	,	2010,	-0.6923,	Oncology,	men’s health ,	BPH,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2004,	Ostarine,	Preclinical,	SARM,	20,	,	,	,	,	,	osteoporosis,	men’s health ,	Male osteoporosis,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2004,	Andromustine,	Preclinical,	SARM,	22,	,	,	,	,	,	Oncology,	men’s health ,	Prostate cancer,	androgen deprivation,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2005,	Acapodene,	Phase III,	 SERM,	22,	,	,	,	,	,	Oncology,	,	prostate cancer,	,	yes,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2005,	FARESTON®,	MARKETED,	 SERM,	22,	,	,	,	2009,	0.0274,	Oncology,	,	metastatic breast cancer ,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2005,	Acapodene,	Phase  III ,	 SERM,	22,	,	,	,	,	,	Oncology,	,	Side effects of ADT,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2005,	Andarine,	Phase I,	 SERM,	22,	,	,	,	2010,	-1,	Oncology,	,	Cancer Cachexia,	Male osteoporosis,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2005,	Prostarine,	Preclinical,	SARM,	22,	,	,	,	2010,	-0.6923,	Oncology,	,	BPH,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2005,	Ostarine,	Phase I,	SARM,	20,	,	,	,	,	,	osteoporosis,	,	Andropause and sarcopenia,	,	yes,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2005,	Andromustine,	Preclinical,	SARM,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2006,	Acapodene,	Phase III,	 SERM,	22,	,	,	,	,	,	Oncology,	,	prostate cancer,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2006,	FARESTON®,	MARKETED,	 SERM,	22,	,	,	,	2009,	0.0274,	Oncology,	,	metastatic breast cancer ,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2006,	Acapodene,	Phase  III ,	 SERM,	22,	,	,	,	,	,	Oncology,	,	Side effects of ADT,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2006,	Andarine,	Phase II,	 SERM,	22,	,	,	,	2010,	-1,	Oncology,	,	Cancer Cachexia,	Andropause and sarcopenia,	yes,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2006,	Prostarine,	Preclinical,	SARM,	22,	,	,	,	2010,	-0.6923,	Oncology,	,	BPH,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2006,	Ostarine,	Phase II,	SARM,	20,	,	,	,	,	,	osteoporosis,	,	Muscle wasting and bone loss,	,	yes,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2006,	Andromustine,	Preclinical,	SARM,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2007,	Acapodene,	Phase III,	 SERM,	22,	,	,	,	,	,	Oncology,	,	prostate cancer,	Cancer Cachexia,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2007,	FARESTON®,	MARKETED,	 SERM,	22,	,	,	,	2009,	-0.7973,	Oncology,	,	metastatic breast cancer ,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2007,	Acapodene,	Phase  III ,	 SERM,	22,	,	,	,	,	,	Oncology,	,	Side effects of ADT,	Muscle wasting and bone loss,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2007,	Andarine,	Phase I ,	 SERM,	22,	20,	,	,	2010,	-1,	Oncology,	,	 muscle wasting ,	,	yes,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2007,	Ostarine,	Phase II,	SARM,	22,	20,	,	,	,	,	Oncology,	,	CKD/ESRD,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2007,	Ostarine,	Phase II,	SARM,	20,	,	,	,	,	,	osteoporosis,	,	Osteoporosis and Frailty,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2007,	Ostarine,	Phase II,	SARM,	22,	,	,	,	,	,	Oncology,	,	Cancer cachexia,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2007,	Prostarine,	Preclinical,	SARM,	22,	,	,	,	2010,	-0.6923,	Oncology,	,	BPH,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2007,	Andromustine,	Preclinical,	SARM,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2008,	Acapodene,	Phase III,	 SERM,	22,	,	,	,	,	,	Oncology,	,	prostate cancer,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2008,	Acapodene,	Phase  III ,	 SERM,	22,	,	,	,	,	,	Oncology,	,	Side effects of ADT,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2008,	Ostarine,	Phase II,	SARM,	22,	,	,	,	,	,	Oncology,	,	Cancer cachexia,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2008,	GTx-838,	Preclinical,	SARM,	22,	20,	,	Andarine,	2010,	-1,	Oncology,	,	muscle wasting and/or bone loss.,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2008,	Ostarine,	Phase II,	SARM,	20,	,	,	,	,	,	osteoporosis,	,	Osteoporosis and Frailty,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2008,	GTx-758,	Preclinical,	LH inhibitor,	22,	,	,	Andromustine,	,	,	Oncology,	,	Advanced Prostate Cancer,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2008,	GTx-878,	Preclinical,	"Estrogen receptor 
beta agonist,"	22,	,	,	Prostarine,	2010,	-0.8571,	Oncology,	,	BPH,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2009,	Toremifene,	Phase III,	 SERM,	22,	,	,	Acapodene,	,	,	Oncology,	,	prostate cancer,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2009,	Toremifene,	FDA Review,	 SERM,	22,	,	,	Acapodene,	,	,	Oncology,	,	Side effects of ADT,	,	yes,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2009,	Ostarine,	Phase II,	SARM,	22,	,	,	,	,	,	Oncology,	,	Cancer cachexia,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2009,	MK-0773,	Phase II,	SARM,	20,	,	,	,	2011,	-1,	osteoporosis,	,	sarcopenia,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2009,	GTx-758,	Phase I,	LH inhibitor,	22,	,	,	Andromustine,	,	,	Oncology,	,	Advanced Prostate Cancer,	,	yes,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2009,	 FARESTON,	Marketed,	 SERM,	22,	,	,	,	,	,	Oncology,	,	metastatic breast cancer,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2010,	Toremifene,	Phase III,	 SERM,	22,	,	,	,	,	,	Oncology,	,	prostate cancer,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2010,	Toremifene,	FDA Review,	 SERM,	22,	,	,	,	,	,	Oncology,	,	Side effects of ADT,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2010,	Ostarine,	Phase II,	SARM,	22,	,	,	,	,	,	Oncology,	,	Cancer cachexia,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2010,	Ostarine,	Phase II,	SARM,	20,	,	,	,	,	,	osteoporosis,	,	chronic sarcopenia,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2010,	GTx-758,	Phase II ,	LH inhibitor,	22,	,	,	,	,	,	Oncology,	,	Advanced Prostate Cancer,	,	yes,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2010,	 FARESTON,	Marketed,	 SERM,	22,	,	,	,	,	,	Oncology,	,	metastatic breast cancer,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2011,	Toremifene,	FDA Review,	 SERM,	22,	,	,	,	,	,	Oncology,	,	prostate cancer,	,	yes,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2011,	Toremifene,	FDA Review,	 SERM,	22,	,	,	,	,	,	Oncology,	,	Side effects of ADT,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2011,	Ostarine,	Phase III,	SARM,	22,	,	,	,	,	,	Oncology,	,	Cancer cachexia,	,	yes,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2011,	Ostarine,	Phase III,	SARM,	20,	,	,	,	,	,	osteoporosis,	,	chronic sarcopenia,	,	yes,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2011,	CapesarisTM,	Phase II ,	"Selective ER
alpha agonist,"	22,	,	,	,	,	,	Oncology,	,	Side effects of ADT,	,	,
wvcs20040001260990,	GTX INC,	10-K,	2003,	2011,	 FARESTON,	Marketed,	alpha agonist,	22,	,	,	,	,	,	Oncology,	,	metastatic breast cancer,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	 Canine Allergy Diagnostic   ,	marketed,	enzyme-linked immunoassay,	8,	,	,	,	,	,	animal health products,	,	ALLERGY & DERMATOLOGY,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	 Feline Allergy Diagnostic ,	Marketed,	enzyme-linked immunoassay,	8,	,	,	,	,	,	animal health products,	,	ALLERGY & DERMATOLOGY,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	  Canine Allergy   Immunotherapeutic,	Marketed,	Antibodies,	8,	70,	,	,	,	,	animal health products,	,	ALLERGY & DERMATOLOGY,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	 Feline Allergy Immunotherapeutic,	IND,	Antibodies,	8,	70,	,	,	,	,	animal health products,	,	ALLERGY & DERMATOLOGY,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	Ancillary Dermatology Products,	Marketed,	x,	8,	,	,	,	,	,	animal health products,	,	ALLERGY & DERMATOLOGY,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	Canine Flea Bite Allergy Diagnostic,	Marketed,	enzyme-linked immunoassay,	,	,	,	,	,	,	animal health products,	,	FLEA BITE ALLERGY,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	 Feline Flea Bite Allergy Diagnostic,	Research,	enzyme-linked immunoassay,	,	,	,	,	,	,	animal health products,	,	FLEA BITE ALLERGY,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	Canine Flea Bite Allergy   Vaccine,	Research,	x,	70,	,	,	,	,	,	animal health products,	,	FLEA BITE ALLERGY,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	 Feline Flea Bite Allergy Vaccine,	Research,	x,	70,	,	,	,	,	,	animal health products,	,	FLEA BITE ALLERGY,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	Flea Control Vaccines,	Research,	x,	70,	,	,	,	,	,	animal health products,	,	 FLEA CONTROL,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	Environmental Flea Control ,	Research,	x,	,	,	,	,	,	,	animal health products,	,	 FLEA CONTROL,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	  Pharmaceutical Flea Control,	Research,	small molecule,	,	,	,	,	,	,	animal health products,	,	 FLEA CONTROL,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	 Feline Heartworm Diagnostic,	Marketed,	x,	21,	23,	,	,	,	,	animal health products,	,	HEARTWORM INFECTION,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	  Canine Heartworm Diagnostic,	Marketed,	x,	21,	23,	,	,	,	,	animal health products,	,	HEARTWORM INFECTION,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	Heartworm Vaccines,	Research,	Antibodies,	21,	23,	,	,	,	,	animal health products,	,	HEARTWORM INFECTION,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	  Canine Periodontal Disease   Therapeutic,	Marketed,	semi-solid implant,	70,	,	,	,	,	,	animal health products,	,	DENTISTRY,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	Canine Dental Hygiene Kits    ,	Marketed,	x,	,	,	,	,	,	,	animal health products,	,	DENTISTRY,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	 Feline Trivalent Viral Vaccine   ,	Marketed,	injectable vaccines,	23,	,	,	,	,	,	animal health products,	,	INFECTIOUS DISEASES,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	 Bartonellosis ,	NDA,	x,	23,	,	,	,	,	,	animal health products,	,	INFECTIOUS DISEASES,	,	,
1,	HESKA CORP,	S-1,	1997,	1997,	 Equine Influenza Vaccine        ,	NDA,	,	23,	,	,	,	,	,	animal health products,	,	INFECTIOUS DISEASES,	,	,
1,	HESKA CORP,	424,	1997,	1997,	 Canine Allergy Diagnostic   ,	marketed,	enzyme-linked immunoassay,	8,	,	,	,	,	,	animal health products,	,	ALLERGY & DERMATOLOGY,	,	,
1,	HESKA CORP,	424,	1997,	1997,	 Feline Allergy Diagnostic ,	Marketed,	enzyme-linked immunoassay,	8,	,	,	,	,	,	animal health products,	,	ALLERGY & DERMATOLOGY,	,	,
1,	HESKA CORP,	424,	1997,	1997,	  Canine Allergy   Immunotherapeutic,	Marketed,	Antibodies,	8,	70,	,	,	,	,	animal health products,	,	ALLERGY & DERMATOLOGY,	,	,
1,	HESKA CORP,	424,	1997,	1997,	 Feline Allergy Immunotherapeutic,	IND,	Antibodies,	8,	70,	,	,	,	,	animal health products,	,	ALLERGY & DERMATOLOGY,	,	,
1,	HESKA CORP,	424,	1997,	1997,	Ancillary Dermatology Products,	Marketed,	x,	8,	,	,	,	,	,	animal health products,	,	ALLERGY & DERMATOLOGY,	,	,
1,	HESKA CORP,	424,	1997,	1997,	Canine Flea Bite Allergy Diagnostic,	Marketed,	enzyme-linked immunoassay,	,	,	,	,	,	,	animal health products,	,	FLEA BITE ALLERGY,	,	,
1,	HESKA CORP,	424,	1997,	1997,	 Feline Flea Bite Allergy Diagnostic,	Research,	enzyme-linked immunoassay,	,	,	,	,	,	,	animal health products,	,	FLEA BITE ALLERGY,	,	,
1,	HESKA CORP,	424,	1997,	1997,	Canine Flea Bite Allergy   Vaccine,	Research,	x,	70,	,	,	,	,	,	animal health products,	,	FLEA BITE ALLERGY,	,	,
1,	HESKA CORP,	424,	1997,	1997,	 Feline Flea Bite Allergy Vaccine,	Research,	x,	70,	,	,	,	,	,	animal health products,	,	FLEA BITE ALLERGY,	,	,
1,	HESKA CORP,	424,	1997,	1997,	Flea Control Vaccines,	Research,	x,	70,	,	,	,	,	,	animal health products,	,	 FLEA CONTROL,	,	,
1,	HESKA CORP,	424,	1997,	1997,	Environmental Flea Control ,	Research,	x,	,	,	,	,	,	,	animal health products,	,	 FLEA CONTROL,	,	,
1,	HESKA CORP,	424,	1997,	1997,	  Pharmaceutical Flea Control,	Research,	small molecule,	,	,	,	,	,	,	animal health products,	,	 FLEA CONTROL,	,	,
1,	HESKA CORP,	424,	1997,	1997,	 Feline Heartworm Diagnostic,	Marketed,	x,	21,	23,	,	,	,	,	animal health products,	,	HEARTWORM INFECTION,	,	,
1,	HESKA CORP,	424,	1997,	1997,	  Canine Heartworm Diagnostic,	Marketed,	x,	21,	23,	,	,	,	,	animal health products,	,	HEARTWORM INFECTION,	,	,
1,	HESKA CORP,	424,	1997,	1997,	Heartworm Vaccines,	Research,	Antibodies,	21,	23,	,	,	,	,	animal health products,	,	HEARTWORM INFECTION,	,	,
1,	HESKA CORP,	424,	1997,	1997,	  Canine Periodontal Disease   Therapeutic,	Marketed,	semi-solid implant,	70,	,	,	,	,	,	animal health products,	,	DENTISTRY,	,	,
1,	HESKA CORP,	424,	1997,	1997,	Canine Dental Hygiene Kits    ,	Marketed,	x,	,	,	,	,	,	,	animal health products,	,	DENTISTRY,	,	,
1,	HESKA CORP,	424,	1997,	1997,	 Feline Trivalent Viral Vaccine   ,	Marketed,	injectable vaccines,	23,	,	,	,	,	,	animal health products,	,	INFECTIOUS DISEASES,	,	,
1,	HESKA CORP,	424,	1997,	1997,	 Bartonellosis ,	NDA,	x,	23,	,	,	,	,	,	animal health products,	,	INFECTIOUS DISEASES,	,	,
1,	HESKA CORP,	424,	1997,	1997,	 Equine Influenza Vaccine        ,	NDA,	x,	23,	,	,	,	,	,	animal health products,	,	INFECTIOUS DISEASES,	,	,
1,	HESKA CORP,	424,	1997,	1998,	 Canine Allergy Diagnostic   ,	marketed,	enzyme-linked immunoassay,	8,	,	,	,	,	,	animal health products,	,	ALLERGY & DERMATOLOGY,	,	,
1,	HESKA CORP,	424,	1997,	1998,	 Feline Allergy Diagnostic ,	Marketed,	enzyme-linked immunoassay,	8,	,	,	,	,	,	animal health products,	,	ALLERGY & DERMATOLOGY,	,	,
1,	HESKA CORP,	424,	1997,	1998,	  Canine Allergy   Immunotherapeutic,	Marketed,	Antibodies,	8,	70,	,	,	,	,	animal health products,	,	ALLERGY & DERMATOLOGY,	,	,
1,	HESKA CORP,	424,	1997,	1998,	 Feline Allergy Immunotherapeutic,	marketed,	Antibodies,	8,	70,	,	,	,	,	animal health products,	,	ALLERGY & DERMATOLOGY,	,	yes,
1,	HESKA CORP,	424,	1997,	1998,	Ancillary Dermatology Products,	Marketed,	x,	8,	,	,	,	,	,	animal health products,	,	ALLERGY & DERMATOLOGY,	,	,
1,	HESKA CORP,	424,	1997,	1998,	Canine Flea Bite Allergy Diagnostic,	Marketed,	enzyme-linked immunoassay,	,	,	,	,	,	,	animal health products,	,	FLEA BITE ALLERGY,	,	,
1,	HESKA CORP,	424,	1997,	1998,	 Feline Flea Bite Allergy Diagnostic,	Marketed,	enzyme-linked immunoassay,	,	,	,	,	,	,	animal health products,	,	FLEA BITE ALLERGY,	,	yes,
1,	HESKA CORP,	424,	1997,	1998,	Canine Flea Bite Allergy   Vaccine,	Research,	x,	70,	,	,	,	,	,	animal health products,	,	FLEA BITE ALLERGY,	,	,
1,	HESKA CORP,	424,	1997,	1998,	 Feline Flea Bite Allergy Vaccine,	Research,	x,	70,	,	,	,	,	,	animal health products,	,	FLEA BITE ALLERGY,	,	,
1,	HESKA CORP,	424,	1997,	1998,	Flea Control Vaccines,	Research,	x,	70,	,	,	,	,	,	animal health products,	,	 FLEA CONTROL,	,	,
1,	HESKA CORP,	424,	1997,	1998,	Environmental Flea Control ,	Research,	x,	,	,	,	,	,	,	animal health products,	,	 FLEA CONTROL,	,	,
1,	HESKA CORP,	424,	1997,	1998,	  Pharmaceutical Flea Control,	Research,	small molecule,	,	,	,	,	,	,	animal health products,	,	 FLEA CONTROL,	,	,
1,	HESKA CORP,	424,	1997,	1998,	 Feline Heartworm Diagnostic,	Marketed,	x,	21,	23,	,	,	,	,	animal health products,	,	HEARTWORM INFECTION,	,	,
1,	HESKA CORP,	424,	1997,	1998,	  Canine Heartworm Diagnostic,	Marketed,	x,	21,	23,	,	,	,	,	animal health products,	,	HEARTWORM INFECTION,	,	,
1,	HESKA CORP,	424,	1997,	1998,	Heartworm Vaccines,	Research,	Antibodies,	21,	23,	,	,	,	,	animal health products,	,	HEARTWORM INFECTION,	,	,
1,	HESKA CORP,	424,	1997,	1998,	  Canine Periodontal Disease   Therapeutic,	Marketed,	semi-solid implant,	70,	,	,	,	,	,	animal health products,	,	DENTISTRY,	,	,
1,	HESKA CORP,	424,	1997,	1998,	Canine Dental Hygiene Kits    ,	Marketed,	x,	,	,	,	,	,	,	animal health products,	,	DENTISTRY,	,	,
1,	HESKA CORP,	424,	1997,	1998,	 Feline Trivalent Viral Vaccine   ,	Marketed,	injectable vaccines,	23,	,	,	,	,	,	animal health products,	,	INFECTIOUS DISEASES,	,	,
1,	HESKA CORP,	424,	1997,	1998,	 Bartonellosis ,	Expected,	x,	23,	,	,	,	,	,	animal health products,	,	INFECTIOUS DISEASES,	,	,
1,	HESKA CORP,	424,	1997,	1998,	 Equine Influenza Vaccine        ,	Expected,	x,	23,	,	,	,	,	,	animal health products,	,	INFECTIOUS DISEASES,	,	,
1,	HESKA CORP,	424,	1997,	1998,	 Canine Thyroid Supplement        ,	Marketed,	x,	24,	,	,	,	,	,	animal health products,	,	METABOLIC DISEASES,	,	,
1,	HESKA CORP,	10-K,	1997,	1999,	 Canine Allergy Diagnostic   ,	marketed,	enzyme-linked immunoassay,	,,	,	,	,	,	,	animal health products,	,	DIAGNOSTICS        ,	yes,	,
1,	HESKA CORP,	10-K,	1997,	1999,	 Feline Allergy Diagnostic ,	Marketed,	enzyme-linked immunoassay,	,	,	,	,	,	,	animal health products,	,	DIAGNOSTICS        ,	yes,	,
1,	HESKA CORP,	10-K,	1997,	1999,	 Feline Heartworm Diagnostic,	Marketed,	monoclonal antibodies,	,	,	,	,	,	,	animal health products,	,	DIAGNOSTICS        ,	yes,	,
1,	HESKA CORP,	10-K,	1997,	1999,	  Canine Heartworm Diagnostic,	Marketed,	monoclonal antibodies,	,	,	,	,	,	,	animal health products,	,	DIAGNOSTICS        ,	yes,	,
1,	HESKA CORP,	10-K,	1997,	1999,	Canine Leishmaniosis Diagnostic    ,	Marketed,	enzyme-linked immunoassay,	,	,	,	,	,	,	animal health products,	,	DIAGNOSTICS        ,	,	,
1,	HESKA CORP,	10-K,	1997,	1999,	  Canine Allergy   Immunotherapeutic,	Marketed,	Antibodies,	70,	,	,	,	,	,	animal health products,	,	BIOLOGICS AND VACCINES ,	yes,	,
1,	HESKA CORP,	10-K,	1997,	1999,	 Feline Allergy Immunotherapeutic,	marketed,	Antibodies,	70,	,	,	,	,	,	animal health products,	,	BIOLOGICS AND VACCINES ,	yes,	,
1,	HESKA CORP,	10-K,	1997,	1999,	 Feline Trivalent Viral Vaccine   ,	Marketed,	injectable vaccines,	,	,	,	,	,	,	animal health products,	,	BIOLOGICS AND VACCINES ,	yes,	,
1,	HESKA CORP,	10-K,	1997,	1999,	  Canine Periodontal Disease   Therapeutic,	Marketed,	semi-solid implant,	70,	,	,	,	,	,	animal health products,	,	Pharmaceuticals,	yes,	,
1,	HESKA CORP,	10-K,	1997,	1999,	 Canine Thyroid Supplement        ,	Marketed,	x,	,	,	,	,	,	,	animal health products,	,	Pharmaceuticals,	yes,	,
1,	HESKA CORP,	10-K,	1997,	1999,	F.A. Granules, Dietary Supplement,	Marketed,	x,	,	,	,	,	,	,	animal health products,	,	NUTRITIONAL SUPPLEMENTS,	,	,
1,	HESKA CORP,	10-K,	1997,	1999,	VET/OX(R) 4400 ,	Marketed,	x,	,	,	,	,	,	,	animal health products,	,	Monitoring Equipment        ,	,	,
1,	HESKA CORP,	10-K,	1997,	1999,	i-STAT(R) Portable Clinical   Analyzer (1)    ,	Marketed,	x,	,	,	,	,	,	,	animal health products,	,	 Diagnostic Equipment   ,	,	,
1,	HESKA CORP,	10-K,	1997,	1999,	Vet ABC Hematology Analyzer ,	Marketed,	,	,	,	,	,	,	,	animal health products,	,	Other Equipment ,	,	,
1,	HESKA CORP,	10-K,	1997,	2000,	 Feline Heartworm Diagnostic,	Marketed,	monoclonal antibodies,	,	,	,	,	,	,	animal health products,	,	DIAGNOSTICS        ,	,	,
1,	HESKA CORP,	10-K,	1997,	2000,	  Canine Heartworm Diagnostic,	Marketed,	monoclonal antibodies,	,	,	,	,	,	,	animal health products,	,	DIAGNOSTICS        ,	,	,
1,	HESKA CORP,	10-K,	1997,	2000,	 HESKA(R) ALLERCEPT(TM) Detection System,	marketed,	enzyme-linked immunoassay,	,	,	,	 Canine Allergy Diagnostic   ,	,	,	animal health products,	,	DIAGNOSTICS        ,	,	,
1,	HESKA CORP,	10-K,	1997,	2000,	 HESKA(R) ALLERCEPT(TM) Detection System,	Marketed,	enzyme-linked immunoassay,	,	,	,	 Feline Allergy Diagnostic ,	,	,	animal health products,	,	DIAGNOSTICS        ,	,	,
1,	HESKA CORP,	10-K,	1997,	2000,	Flu Avert(TM) ,	Marketed,	Antibodies,	,	,	,	,	,	,	animal health products,	,	BIOLOGICS AND VACCINES ,	,	,
1,	HESKA CORP,	10-K,	1997,	2000,	  Canine Allergy   Immunotherapeutic,	Marketed,	Antibodies,	70,	,	,	,	,	,	animal health products,	,	BIOLOGICS AND VACCINES ,	,	,
1,	HESKA CORP,	10-K,	1997,	2000,	 Feline Allergy Immunotherapeutic,	marketed,	Antibodies,	70,	,	,	,	,	,	animal health products,	,	BIOLOGICS AND VACCINES ,	,	,
1,	HESKA CORP,	10-K,	1997,	2000,	 Feline Trivalent Viral Vaccine   ,	Marketed,	injectable vaccines,	,	,	,	,	,	,	animal health products,	,	BIOLOGICS AND VACCINES ,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	S-1,	2003,	2003,	telbivudine,	phase III,	L-nucleoside,	23,	,	,	,	,	,	antiviral therapies,	,	HBV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	S-1,	2003,	2003,	valtorcitabine,	phase I/II,	L-nucleoside,	23,	,	,	,	2010,	-0.4545,	antiviral therapies,	,	HBV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	S-1,	2003,	2003,	NM 283,	phase I/II,	Nucleoside analog,	23,	,	,	,	2011,	-0.2903,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	S-1,	2003,	2003,	NV-08B,	preclinical,	Nucleoside analog,	23,	,	,	,	2009,	0,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	S-1,	2003,	2003,	NV-05A,	preclinical,	NNRTI,	23,	,	,	,	,	,	antiviral therapies,	,	HIV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	424,	2003,	2004,	telbivudine,	phase III,	L-nucleoside,	23,	,	,	,	,	,	antiviral therapies,	,	HBV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	424,	2003,	2004,	valtorcitabine,	phase I/II,	L-nucleoside,	23,	,	,	,	2010,	-0.4545,	antiviral therapies,	,	HBV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	424,	2003,	2004,	NM 283,	phase I/II,	Nucleoside analog,	23,	,	,	,	2011,	-0.2903,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	424,	2003,	2004,	NV-08B,	preclinical,	Nucleoside analog,	23,	,	,	,	2009,	0,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	424,	2003,	2004,	NV-05A,	preclinical,	NNRTI,	23,	,	,	,	,	,	antiviral therapies,	,	HIV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2005,	telbivudine,	phase III,	L-nucleoside,	23,	,	,	,	,	,	antiviral therapies,	,	HBV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2005,	valtorcitabine,	phase I/II,	L-nucleoside,	23,	,	,	,	2010,	-0.4545,	antiviral therapies,	,	HBV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2005,	NM 283,	phase I/II,	Nucleoside analog,	23,	,	,	,	2011,	-0.2903,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2005,	NV-08B,	preclinical,	Nucleoside analog,	23,	,	,	,	2009,	0,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2005,	NV-05A,	preclinical,	NNRTI,	23,	,	,	,	,	,	antiviral therapies,	,	HIV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2006,	telbivudine,	Phaes III,	L-nucleoside,	23,	,	,	,	,	,	antiviral therapies,	,	HBV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2006,	valtorcitabine,	phase IIb ,	L-nucleoside,	23,	,	,	,	2010,	-0.4545,	antiviral therapies,	,	HBV,	,	yes,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2006,	NM 283,	phase III,	Nucleoside analog,	23,	,	,	,	2011,	-0.2903,	antiviral therapies,	,	HCV,	,	yes,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2006,	NV-08B,	preclinical,	Nucleoside analog,	23,	,	,	,	2009,	0,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2006,	NV-05A,	preclinical,	NNRTI,	23,	,	,	,	,	,	antiviral therapies,	,	HIV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2007,	Tyzeka®,	Phaes III,	L-nucleoside,	23,	,	,	telbivudine,	,	,	antiviral therapies,	,	HBV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2007,	valtorcitabine,	phase IIb ,	L-nucleoside,	23,	,	,	,	2010,	-0.4545,	antiviral therapies,	,	HBV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2007,	valopicitabine,	phase IIb,	 nucleoside/nucleotide polymerase inhibitors,	23,	,	,	NM 283,	2011,	-0.2903,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2007,	NV-08B,	preclinical,	 nucleoside/nucleotide polymerase inhibitors,	23,	,	,	,	2009,	-1,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2007,	IDX-899 ,	phase I/II ,	NNRTI,	23,	,	,	NV-05A,	,	,	antiviral therapies,	,	HIV,	,	yes,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2008,	Tyzeka®,	Marketed,	L-nucleoside,	23,	,	,	,	,	,	antiviral therapies,	,	HBV,	,	yes,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2008,	valtorcitabine,	phase IIb ,	L-nucleoside,	23,	,	,	,	2010,	-0.75,	antiviral therapies,	,	HBV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2008,	valopicitabine,	phase IIb,	 nucleoside/nucleotide polymerase inhibitors,	23,	,	,	,	2011,	-0.2903,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2008,	IDX102,	late stage preclinical ,	 nucleoside/nucleotide polymerase inhibitors,	23,	,	,	,	,	,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2008,	IDX184,	late stage preclinical ,	 nucleoside/nucleotide polymerase inhibitors,	23,	,	,	,	,	,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2008,	IDX-899 ,	phase I/II ,	NNRTI,	23,	,	,	,	,	,	antiviral therapies,	,	HIV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2009,	Tyzeka®,	Marketed,	L-nucleoside,	23,	,	,	,	,	,	antiviral therapies,	,	HBV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2009,	valopicitabine,	phase IIb,	 nucleoside/nucleotide polymerase inhibitors,	23,	,	,	,	2011,	-0.6944,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2009,	IDX102,	late stage preclinical ,	 nucleoside/nucleotide polymerase inhibitors,	23,	,	,	,	,	,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2009,	IDX184,	Phase I,	 nucleoside/nucleotide polymerase inhibitors,	23,	,	,	,	,	,	antiviral therapies,	,	HCV,	,	yes,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2009,	IDX375 ,	IND,	non-nucleoside HCV polymerase inhibitor,	23,	,	,	,	,	,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2009,	IDX136 ,	IND,	 protease inhibitor,	23,	,	,	,	2011,	-1,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2009,	IDX316,	IND,	 protease inhibitor,	23,	,	,	,	2011,	-1,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2009,	IDX-899 ,	Marketed,	NNRTI,	23,	,	,	,	,	,	antiviral therapies,	,	HIV,	,	yes,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2010,	Tyzeka®,	Marketed,	L-nucleoside,	23,	,	,	,	,	,	antiviral therapies,	,	HBV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2010,	IDX102,	late stage preclinical ,	 nucleoside/nucleotide polymerase inhibitors,	23,	,	,	,	,	,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2010,	IDX184,	Phase I,	 nucleoside/nucleotide polymerase inhibitors,	23,	,	,	,	,	,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2010,	IDX375 ,	 phase I ,	non-nucleoside HCV polymerase inhibitor,	23,	,	,	,	,	,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2010,	 NS5A,	Discovery,	NS5A Inhibitors,	23,	,	,	,	,	,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2010,	IDX-899 ,	Marketed,	NNRTI,	23,	,	,	,	,	,	antiviral therapies,	,	HIV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2011,	Tyzeka®,	Marketed,	L-nucleoside,	23,	,	,	,	,	,	antiviral therapies,	,	HBV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2011,	IDX102,	late stage preclinical ,	 nucleoside/nucleotide polymerase inhibitors,	23,	,	,	,	,	,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2011,	IDX184,	Phase I,	 nucleoside/nucleotide polymerase inhibitors,	23,	,	,	,	,	,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2011,	IDX375 ,	 phase I ,	non-nucleoside HCV polymerase inhibitor,	23,	,	,	,	,	,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2011,	 NS5A,	Discovery,	NS5A Inhibitors,	23,	,	,	,	,	,	antiviral therapies,	,	HCV,	,	,
wvcs20040001093649,	IDENIX PHARMACEUTICALS INC,	10-K,	2003,	2011,	IDX-899 ,	Marketed,	NNRTI,	23,	,	,	,	,	,	antiviral therapies,	,	HIV,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	S-1,	1996,	1996,	MGBG,	Phase II,	Research Expertise,	22,	27,	,	,	,	,	CANCER TREATMENT,	,	lymphoma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	S-1,	1996,	1996,	DFMO,	Phase III,	Research Expertise,	22,	40,	,	,	2005,	-0.6667,	CANCER TREATMENT,	,	1. Brain tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	S-1,	1996,	1996,	Piritrexim,	Phase II,	Research Expertise,	22,	,	,	,	2001,	-0.9333,	CANCER TREATMENT,	,	Kaposi's sarcoma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	S-1,	1996,	1996,	Crisnatol,	Phase III,	Research Expertise,	22,	,	,	,	2000,	-0.3636,	CANCER TREATMENT,	,	Glioblastoma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	S-1,	1996,	1996,	DHAC,	Phase II,	Research Expertise,	22,	,	,	,	2000,	-0.8889,	CANCER TREATMENT,	,	Mesothelioma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	S-1,	1996,	1996,	Oxypurinol,	Preclinical,	Research Expertise,	22,	,	,	,	2003,	-0.9167,	CANCER TREATMENT,	,	Hyperuricemia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	S-1,	1996,	1996,	Intoplicine Aminopterin,	Phase I/II,	Research Expertise,	22,	,	,	,	2001,	-0.3333,	CANCER TREATMENT,	,	Endometrial cancer,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	S-1,	1996,	1996,	DFMO,	Phase III,	Research Expertise,	22,	,	,	,	,	,	CHEMOPREVENTION,	,	cervical                           intraepithelial        neoplasia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	S-1,	1996,	1996,	ILX23-7553,	Preclinical,	Research Expertise,	22,	,	,	,	2003,	-1,	CHEMOPREVENTION,	,	cancer Prevention,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	424,	1996,	1997,	MGBG,	Phase II,	Research Expertise,	22,	27,	,	,	,	,	CANCER TREATMENT,	,	lymphoma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	424,	1996,	1997,	DFMO,	Phase III,	Research Expertise,	22,	40,	,	,	2005,	-0.6667,	CANCER TREATMENT,	,	1. Brain tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	424,	1996,	1997,	Piritrexim,	Phase II,	Research Expertise,	22,	,	,	,	2001,	-0.9333,	CANCER TREATMENT,	,	Malignant fibrous histiocytoma,	Kaposi's sarcoma,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	424,	1996,	1997,	Crisnatol,	Phase III,	Research Expertise,	22,	,	,	,	2000,	-0.3636,	CANCER TREATMENT,	,	Glioblastoma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	424,	1996,	1997,	DHAC,	Phase II,	Research Expertise,	22,	,	,	,	2000,	-0.8889,	CANCER TREATMENT,	,	Mesothelioma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	424,	1996,	1997,	Oxypurinol,	Preclinical,	Research Expertise,	22,	,	,	,	2003,	-0.9167,	CANCER TREATMENT,	,	Hyperuricemia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	424,	1996,	1997,	Intoplicine Aminopterin,	Phase I/II,	Research Expertise,	22,	,	,	,	2001,	-0.3333,	CANCER TREATMENT,	,	Endometrial cancer(,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	424,	1996,	1997,	DFMO,	Phase III,	Research Expertise,	22,	,	,	,	,	,	CHEMOPREVENTION,	,	cervical                           intraepithelial        neoplasia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	424,	1996,	1997,	ILX23-7553,	Preclinical,	Research Expertise,	22,	,	,	,	2003,	-1,	CHEMOPREVENTION,	,	cancer Prevention,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1998,	MGBG,	Phase II,	Research Expertise,	22,	27,	,	,	,	,	CANCER TREATMENT,	,	lymphoma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1998,	DFMO,	Phase III,	Research Expertise,	22,	40,	,	,	2005,	-0.6667,	CANCER TREATMENT,	,	1. Brain tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1998,	Piritrexim,	Phase II,	Research Expertise,	22,	,	,	,	2001,	-0.9333,	CANCER TREATMENT,	,	Malignant fibrous histiocytoma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1998,	Crisnatol,	Phase III,	Research Expertise,	22,	,	,	,	2000,	-0.5333,	CANCER TREATMENT,	,	Glioblastoma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1998,	DHAC,	Phase II,	Research Expertise,	22,	,	,	,	2000,	-0.8667,	CANCER TREATMENT,	,	Mesothelioma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1998,	Oxypurinol,	Preclinical,	Research Expertise,	22,	,	,	,	2003,	-0.9167,	CANCER TREATMENT,	,	Hyperuricemia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1998,	Intoplicine Aminopterin,	Phase I/II,	Research Expertise,	22,	,	,	,	2001,	-0.3333,	CANCER TREATMENT,	,	Solid tumors,	Endometrial cancer(,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1998,	DFMO,	Phase III,	Research Expertise,	22,	,	,	,	,	,	CHEMOPREVENTION,	,	cervical                           intraepithelial        neoplasia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1998,	ILX23-7553,	Preclinical,	Research Expertise,	22,	,	,	,	2003,	-1,	CHEMOPREVENTION,	,	cancer Prevention,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1999,	CAMPATH(R),	Phase II,	Research Expertise,	22,	27,	,	MGBG,	,	,	CANCER TREATMENT,	,	Chronic lymphocytic leukemia,	lymphoma,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1999,	Eflornithine (DFMO),	Phase III,	Research Expertise,	22,	3,	,	DFMO,	2005,	-0.6667,	CANCER TREATMENT,	CHEMOPREVENTION,	Superficial bladder cancer(3,	1. Brain tumors,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1999,	Oxypurinol,	Preclinical,	Research Expertise,	22,	,	,	,	2003,	-0.9167,	CANCER TREATMENT,	,	Symptomatic hyperuricemia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1999,	Aminopterin,	Phase I/II,	Research Expertise,	22,	,	,	"Intoplicine      
Aminopterin,"	2001,	-0.3333,	CANCER TREATMENT,	,	Endometrial cancer,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1999,	Piritrexim,	Phase II,	Research Expertise,	22,	,	,	,	2001,	-0.9167,	CANCER TREATMENT,	,	Malignant fibrous histiocytoma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1999,	ILX-295501,	Phase II,	Research Expertise,	22,	,	,	,	2003,	-1,	CANCER TREATMENT,	,	solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1999,	Intoplicine,	Phase I,	Research Expertise,	22,	,	,	,	2001,	-1,	CANCER TREATMENT,	,	Solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1999,	SR-45023A,	Phase I,	Research Expertise,	22,	,	,	,	2001,	4,	CANCER TREATMENT,	,	Solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	1999,	ILX23-7553,	Phase I,	Research Expertise,	22,	,	,	,	2003,	-1,	CANCER TREATMENT,	CHEMOPREVENTION,	Solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2000,	CAMPATH(R),	Phase II,	Research Expertise,	22,	27,	,	,	,	,	CANCER TREATMENT,	,	1.  Chronic lymphocytic leukemia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2000,	CAMPATH(R),	Phase II,	Research Expertise,	22,	27,	,	,	,	,	CANCER TREATMENT,	,	Non-Hodgkin's Lymphoma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2000,	Eflornithine (DFMO),	Phase III,	Research Expertise,	22,	3,	,	,	2005,	-0.6667,	CANCER TREATMENT,	,	Superficial bladder cancer(3,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2000,	OXYPRIM(TM)(oxypurinol),	Preclinical,	Research Expertise,	22,	,	,	Oxypurinol,	2003,	-0.9167,	CANCER TREATMENT,	,	Symptomatic hyperuricemia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2000,	ILX-295501,	Phase II,	Research Expertise,	22,	,	,	,	2003,	-1,	CANCER TREATMENT,	,	solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2000,	APOMINE™,	Phase II,	Research Expertise,	22,	,	,	,	,	,	CANCER TREATMENT,	,	solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2000,	ILX23-7553,	Phase I,	Research Expertise,	22,	,	,	,	2003,	-1,	CANCER TREATMENT,	,	Solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2001,	CAMPATH(R),	Phase II,	Research Expertise,	22,	27,	,	,	,	,	CANCER TREATMENT,	,	1.  Chronic lymphocytic leukemia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2000,	CAMPATH(R),	Phase II,	Research Expertise,	22,	27,	,	,	,	,	CANCER TREATMENT,	,	Non-Hodgkin's Lymphoma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2001,	Eflornithine (DFMO),	Phase III,	Research Expertise,	22,	3,	,	,	2005,	-0.6667,	CANCER TREATMENT,	,	1.Superficial bladder cancer,	yes,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2001,	OXYPRIM(TM)(oxypurinol),	Preclinical,	Research Expertise,	22,	,	,	,	2003,	-0.8889,	CANCER TREATMENT,	,	Symptomatic hyperuricemia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2001,	ILX-295501,	Phase II,	Research Expertise,	22,	,	,	,	2003,	-1,	CANCER TREATMENT,	,	solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2001,	APOMINE™,	Phase II,	Research Expertise,	22,	,	,	,	,	,	CANCER TREATMENT,	,	solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2001,	ILX23-7553,	Phase I,	Research Expertise,	22,	,	,	,	2003,	-1,	CANCER TREATMENT,	,	Solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2001,	Clofarabine,	Phase II,	Research Expertise,	9,	22,	27,	,	,	,	CANCER TREATMENT,	,	Acute lymphocytic leukemia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2001,	NM-3,	Phase I,	Research Expertise,	22,	,	,	,	,	,	CANCER TREATMENT,	,	Solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2002,	CAMPATH(R),	Marketed,	Research Expertise,	22,	27,	,	,	,	,	CANCER TREATMENT,	,	1.  Chronic lymphocytic leukemia,	,	yes,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2002,	CAMPATH(R),	Phase II,	Research Expertise,	22,	27,	,	,	,	,	CANCER TREATMENT,	,	Non-Hodgkin's Lymphoma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2002,	Eflornithine (DFMO),	Phase III,	Research Expertise,	22,	3,	,	,	2005,	-0.6667,	CANCER TREATMENT,	,	1.Superficial bladder cancer,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2002,	ILX-651,	Phase II,	Research Expertise,	22,	,	,	,	,	,	CANCER TREATMENT,	,	solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2002,	APOMINE™,	Phase II,	Research Expertise,	22,	,	,	,	,	,	CANCER TREATMENT,	,	solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2002,	CLOFAREX(TM),	Phase II,	Research Expertise,	9,	22,	27,	Clofarabine,	,	,	CANCER TREATMENT,	,	Acute lymphocytic leukemia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2002,	NM-3,	Phase I,	Research Expertise,	22,	,	,	,	,	,	CANCER TREATMENT,	,	Solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2003,	CAMPATH(R),	Marketed,	Research Expertise,	22,	27,	,	,	,	,	CANCER TREATMENT,	,	1.  Chronic lymphocytic leukemia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2003,	CAMPATH(R),	Phase II,	Research Expertise,	22,	27,	,	,	,	,	CANCER TREATMENT,	,	Non-Hodgkin's Lymphoma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2003,	Eflornithine (DFMO),	Phase III,	Research Expertise,	22,	3,	,	,	2005,	-0.9779,	CANCER TREATMENT,	,	1.Superficial bladder cancer,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2003,	ILX-651,	Phase II,	Research Expertise,	22,	,	,	,	,	,	CANCER TREATMENT,	,	solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2003,	APOMINE™,	Phase II,	Research Expertise,	22,	20,	,	,	,	,	CANCER TREATMENT,	,	Osteoporosis,	solid tumors,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2003,	CLOFAREX(TM),	Phase II,	Research Expertise,	9,	22,	27,	,	,	,	CANCER TREATMENT,	,	Acute lymphocytic leukemia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2003,	NM-3,	Phase I,	Research Expertise,	22,	,	,	,	,	,	CANCER TREATMENT,	,	Solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2003,	Signal Transduction Inhibitors,	Preclinical,	Research Expertise,	22,	,	,	,	,	,	CANCER TREATMENT,	,	Solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2003,	Angiogenesis inhibitors,	Preclinical,	Research Expertise,	22,	,	,	,	,	,	CANCER TREATMENT,	,	Solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2004,	CAMPATH(R),	Marketed,	Research Expertise,	22,	27,	,	,	,	,	CANCER TREATMENT,	,	1.  Chronic lymphocytic leukemia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2004,	CAMPATH(R),	Phase II,	Research Expertise,	22,	27,	,	,	,	,	CANCER TREATMENT,	,	Non-Hodgkin's Lymphoma,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2004,	ILX-651,	Phase II,	Research Expertise,	22,	,	,	,	,	,	CANCER TREATMENT,	,	solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2004,	APOMINE™,	Phase II,	Research Expertise,	22,	20,	,	,	,	,	CANCER TREATMENT,	,	Osteoporosis,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2004,	CLOFAREX(TM),	Phase II,	Research Expertise,	9,	22,	27,	,	,	,	CANCER TREATMENT,	,	Acute lymphocytic leukemia,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2004,	NM-3,	Phase I,	Research Expertise,	22,	,	,	,	,	,	CANCER TREATMENT,	,	Solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2004,	Signal Transduction Inhibitors,	Preclinical,	Research Expertise,	22,	,	,	,	,	,	CANCER TREATMENT,	,	Solid tumors,	,	,
wvcs19970001001915,	ILEX ONCOLOGY INC,	10-K,	1996,	2004,	Angiogenesis inhibitors,	Preclinical,	Research Expertise,	22,	,	,	,	,	,	CANCER TREATMENT,	,	Solid tumors,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	S-1,	2004,	2004,	Veronate,	Phase III,	 MSCRAMM proteins ,	23,	,	,	,	2008,	-0.8267,	Infectious Diseases,	,	. Infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	S-1,	2004,	2004,	Aurexis,	Phase II,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	bloodstream infections ,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	S-1,	2004,	2004,	Enterococcal monoclonal antibodies,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	2009,	-1,	Infectious Diseases,	,	infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	S-1,	2004,	2004,	Candida monoclonal antibodies,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	2009,	0.2247,	Infectious Diseases,	,	Candida infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	S-1,	2004,	2004,	Staphylococcal vaccine,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	424,	2004,	2004,	Veronate,	Phase III,	 MSCRAMM proteins ,	23,	,	,	,	2008,	-0.8267,	Infectious Diseases,	,	. Infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	424,	2004,	2004,	Aurexis,	Phase II,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	bloodstream infections ,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	424,	2004,	2004,	Enterococcal monoclonal antibodies,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	2009,	-1,	Infectious Diseases,	,	infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	424,	2004,	2004,	Candida monoclonal antibodies,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	2009,	0.2247,	Infectious Diseases,	,	Candida infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	424,	2004,	2004,	Staphylococcal vaccine,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	 staphylococcal infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2005,	Veronate,	Phase III,	 MSCRAMM proteins ,	23,	,	,	,	2008,	-0.8267,	Infectious Diseases,	,	. Infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2005,	Aurexis,	Phase II,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	bloodstream infections ,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2005,	Enterococcal monoclonal antibodies,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	2009,	-1,	Infectious Diseases,	,	infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2005,	Candida monoclonal antibodies,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	2009,	0.2247,	Infectious Diseases,	,	Candida infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2005,	Staphylococcal vaccine,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	 staphylococcal infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2006,	Veronate,	Phase III,	 MSCRAMM proteins ,	23,	,	,	,	2008,	7.75,	Infectious Diseases,	,	. Infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2006,	Aurexis,	Phase II,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	bloodstream infections ,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2006,	Enterococcal monoclonal antibodies,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	2009,	-1,	Infectious Diseases,	,	infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2006,	Candida monoclonal antibodies,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	2009,	0.2247,	Infectious Diseases,	,	Candida infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2006,	Staphylococcal vaccine,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	 staphylococcal infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2006,	Staphylococcus epidermidis monoclonal antibodies,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	2009,	2.8,	Infectious Diseases,	,	coagulase negative staphylococci (CoNS),	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2007,	Aurexis,	Phase II,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	bloodstream infections ,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2007,	Enterococcal monoclonal antibodies,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	2009,	-1,	Infectious Diseases,	,	infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2007,	Candida monoclonal antibodies,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	2009,	10.4737,	Infectious Diseases,	,	Candida infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2007,	Staphylococcal vaccine,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	 staphylococcal infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2007,	Staphylococcus epidermidis monoclonal antibodies,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	2009,	3.75,	Infectious Diseases,	,	coagulase negative staphylococci (CoNS),	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2007,	Diagnostic for bacterial and fungal pathogens,	Clinical,	 MSCRAMM proteins ,	23,	,	,	,	2010,	-0.5385,	Infectious Diseases,	,	Staphylococcal infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2008,	Aurexis,	Phase II,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	bloodstream infections ,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2008,	Staphylococcal vaccine,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	 staphylococcal infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2008,	Diagnostic for bacterial and fungal pathogens,	Pre market,	 MSCRAMM proteins ,	23,	,	,	,	2010,	0.5,	Infectious Diseases,	,	Staphylococcal infections,	,	yes,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2008,	FV-100,	Phase I ,	 antiviral development programs,	23,	,	,	,	,	,	Infectious Diseases,	,	"Herpes 
Zoster
(shingles,"	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2008,	HIV Integrase Inhibitors,	Preclinical,	 antiviral development programs,	23,	,	,	,	,	,	Infectious Diseases,	,	"HIV 
Infection,"	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2008,	HCV Polymerase Inhibitors,	Preclinical,	 antiviral development programs,	23,	,	,	,	,	,	Infectious Diseases,	,	 viral hepatitis,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2008,	HCMV,	Preclinical,	 antiviral development programs,	23,	,	,	,	2010,	-1,	Infectious Diseases,	,	HCMV infection,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2009,	FV-100,	Phase II,	nucleoside analogue prodrug,	23,	,	,	,	,	,	Infectious Diseases,	,	"Herpes 
Zoster
(shingles,"	,	yes,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2009,	HIV Integrase Inhibitors,	Preclinical,	nucleoside analogue prodrug,	23,	,	,	,	,	,	Infectious Diseases,	,	"HIV 
Infection,"	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2009,	HCV Polymerase Inhibitors,	Preclinical,	nucleoside analogue prodrug,	23,	,	,	,	,	,	Infectious Diseases,	,	 viral hepatitis,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2009,	Aurexis,	Phase II,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	bloodstream infections ,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2009,	Staphylococcal vaccine,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	 staphylococcal infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2010,	FV-100,	Phase II,	nucleoside analogue prodrug,	23,	,	,	,	,	,	Infectious Diseases,	,	"Herpes 
Zoster
(shingles,"	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2010,	HCV Polymerase Inhibitors,	Preclinical,	nucleoside analogue prodrug,	23,	,	,	,	,	,	Infectious Diseases,	,	 viral hepatitis,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2010,	Aurexis,	Phase II,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	bloodstream infections ,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2010,	Staphylococcal vaccine,	Preclinical,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	 staphylococcal infections,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2011,	FV-100,	Phase II,	nucleoside analogue prodrug,	23,	,	,	,	,	,	Infectious Diseases,	,	"Herpes 
Zoster
(shingles,"	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2011,	HCV Polymerase Inhibitors,	Preclinical,	nucleoside analogue prodrug,	23,	,	,	,	,	,	Infectious Diseases,	,	 viral hepatitis,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2011,	Aurexis,	Phase II,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	bloodstream infections ,	,	,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2011,	Staphylococcal vaccine,	Phase I,	 MSCRAMM proteins ,	23,	,	,	,	,	,	Infectious Diseases,	,	 staphylococcal infections,	,	yes,
wvcs20040001274913,	INHIBITEX, INC.,	10-K,	2004,	2011,	INX-189,	Phase I,	nucleoside analogue prodrug,	23,	,	,	,	,	,	Infectious Diseases,	,	Hepatitis C Infection,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	S-1,	1997,	1997,	Thallium-201,	pre clinical,	LINAC design,	22,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	S-1,	1997,	1997,	Indium-111,	pre clinical,	LINAC design,	22,	50,	60,	,	2000,	-1,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	S-1,	1997,	1997,	Iodine-123,	pre clinical,	LINAC design,	22,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	S-1,	1997,	1997,	Gallium-67,	pre clinical,	LINAC design,	22,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	S-1,	1997,	1997,	Cobalt-57,	pre clinical,	LINAC design,	22,	50,	60,	,	1999,	-1,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	S-1,	1997,	1997,	Strontium-82,	pre clinical,	LINAC design,	22,	50,	60,	,	1999,	-1,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	424,	1997,	1997,	Thallium-201,	pre clinical,	LINAC design,	22,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	424,	1997,	1997,	Indium-111,	pre clinical,	LINAC design,	22,	50,	60,	,	2000,	-1,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	424,	1997,	1997,	Iodine-123,	pre clinical,	LINAC design,	22,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	424,	1997,	1997,	Gallium-67,	pre clinical,	LINAC design,	22,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	424,	1997,	1997,	Cobalt-57,	pre clinical,	LINAC design,	22,	50,	60,	,	1999,	-1,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	424,	1997,	1997,	Strontium-82,	pre clinical,	LINAC design,	22,	50,	60,	,	1999,	-1,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1998,	Thallium-201,	pre clinical,	LINAC design,	22,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1998,	Indium-111,	pre clinical,	LINAC design,	22,	50,	60,	,	2000,	-1,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1998,	Iodine-123,	pre clinical,	LINAC design,	22,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1998,	Gallium-67,	pre clinical,	LINAC design,	22,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1998,	Brachytherapy Devices,	pre clinical,	LINAC design,	22,	,	,	,	,	,	radiation therapy ,	,	Prostrate Cancer,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1998,	Brachytherapy Devices,	pre clinical,	LINAC design,	22,	,	,	,	,	,	radiation therapy ,	,	Prostrate Cancer,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1998,	Paladium-103,	pre clinical,	LINAC design,	22,	50,	60,	,	2000,	-1,	diagnostic radiopharmaceuticals ,	,	radiation oncology,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1999,	Iodine-131,	marketed,	LINAC design,	22,	27,	,	,	,	,	radiation therapy ,	,	Non-Hodkins lymphoma therapy,	radiation oncology,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1999,	Iodine-123,	marketed,	LINAC design,	40,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	Parkinson's disease diagnosis,	radiation oncology,	yes,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1999,	Rhenium-188,	marketed,	LINAC design,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Prevention of coronary restenosis,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1999,	FDG/F-18    ,	marketed,	LINAC design,	22,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	  Cancer diagnosis      ,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1999,	Phosphorus-32,	marketed,	LINAC design,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Prevention of coronary restenosis,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1999,	Yttrium-90,	marketed,	LINAC design,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Prevention of coronary restenosis,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1999,	Iridium-192,	marketed,	LINAC design,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Prevention of coronary restenosis,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1999,	Holmium-166,	marketed,	LINAC design,	22,	,	,	,	,	,	radiation therapy ,	,	Multiple myeloma therapy,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1999,	Thallium-201,	pre clinical,	LINAC design,	21,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	Myocardial perfusion imaging,	radiation oncology,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1999,	Strontium-89,	pre clinical,	LINAC design,	62,	22,	20,	,	,	,	radiation therapy ,	,	Bone Pain Palliation,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1999,	Gallium-67,	pre clinical,	LINAC design,	22,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	Cancer and inflammation diagnosis,	radiation oncology,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1999,	Strontium-82,	pre clinical,	LINAC design,	21,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	Heart function diagnosis,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1999,	Brachytherapy Devices,	pre clinical,	LINAC design,	22,	,	,	,	,	,	radiation therapy ,	,	Prostrate Cancer,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1999,	Brachytherapy Devices,	pre clinical,	LINAC design,	22,	,	,	,	,	,	radiation therapy ,	,	Prostrate Cancer,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	1999,	Copper-64,	pre clinical,	LINAC design,	22,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	Imaging for cancer,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	Iodine-131,	marketed,	LINAC design,	22,	27,	,	,	,	,	radiation therapy ,	,	Non-Hodkins lymphoma therapy,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	Iodine-123,	marketed,	LINAC design,	40,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	Parkinson's disease diagnosis,	,	yes,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	Rhenium-188,	marketed,	LINAC design,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Prevention of coronary restenosis,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	FDG/F-18    ,	marketed,	LINAC design,	22,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	  Cancer diagnosis      ,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	Phosphorus-32,	marketed,	LINAC design,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Prevention of coronary restenosis,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	Yttrium-90,	marketed,	LINAC design,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Prevention of coronary restenosis,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	Iridium-192,	marketed,	LINAC design,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Prevention of coronary restenosis,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	Holmium-166,	marketed,	LINAC design,	22,	,	,	,	,	,	radiation therapy ,	,	Multiple myeloma therapy  ,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	Thallium-201,	marketed,	LINAC design,	21,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	Myocardial perfusion imaging,	,	yes,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	Strontium-89,	marketed,	LINAC design,	62,	22,	20,	,	,	,	radiation therapy ,	,	Bone Pain Palliation,	,	yes,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	Gallium-67,	marketed,	LINAC design,	22,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	Cancer and inflammation diagnosis,	,	yes,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	Strontium-82,	marketed,	LINAC design,	21,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	Heart function diagnosis,	,	yes,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	Copper-64,	marketed,	LINAC design,	22,	50,	60,	,	,	,	diagnostic radiopharmaceuticals ,	,	Imaging for cancer,	,	yes,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	Iodine -125,	pre clinical,	LINAC design,	22,	,	,	Brachytherapy Devices,	,	,	radiation therapy ,	,	Prostrate Cancer,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	Iodine -125,	pre clinical,	LINAC design,	22,	,	,	Brachytherapy Devices,	,	,	radiation therapy ,	,	Prostrate Cancer,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2000,	Cobalt-57,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	Gamma camera calibration source,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2001,	Reactor Produced Radioisotopes,	marketed,	LINAC design,	22,	50,	60,	grouped,	,	,	diagnostic radiopharmaceuticals ,	,	radiation therapy devices,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2001,	Flood Source Contract Manufacture,	marketed,	LINAC design,	21,	50,	60,	,	2005,	0.5,	diagnostic radiopharmaceuticals ,	,	cardiovascular imaging centers,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2001,	Gemstone Processing,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2002,	HSA Cobalt,	marketed,	LINAC design,	22,	,	,	,	,	,	radiation therapy ,	,	"vascular  deformities  and  non-malignant
tumors in the brain,"	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2002,	Reactor Produced Radioisotopes,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2002,	Gemstone Processing,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2002,	Flood Source Contract Manufacture,	marketed,	LINAC design,	21,	50,	60,	,	2005,	0.5,	diagnostic radiopharmaceuticals ,	,	nuclear  medicine and  cardiovascular  imaging  centers,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2003,	HSA Cobalt,	marketed,	LINAC design,	22,	,	,	,	,	,	radiation therapy ,	,	"vascular  deformities  and  non-malignant
tumors in the brain,"	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2003,	Reactor Produced Radioisotopes,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2003,	Gemstone Processing,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2003,	Nuclear medicine calibration and reference standards manufacturing ,	marketed,	LINAC design,	21,	50,	60,	Flood Source Contract Manufacture,	2005,	-0.25,	diagnostic radiopharmaceuticals ,	,	nuclear  medicine and  cardiovascular  imaging  centers,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2004,	HSA Cobalt,	marketed,	LINAC design,	22,	,	,	,	,	,	radiation therapy ,	,	"vascular  deformities  and  non-malignant
tumors in the brain,"	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2004,	Reactor Produced Radioisotopes,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2004,	Reactor Produced Radioisotopes,	Clinical Trials,	LINAC design,	22,	27,	20,	,	,	,	Oncology,	,	etastic  bone cancer,  Non-Hodgkin's  Lymphoma,  and lung cancer,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2004,	Iodine-131 ,	Marketed,	LINAC design,	24,	,	,	,	2007,	-1,	Thyroid Diseases,	,	"Graves  disease,  thyroid
cancer,  and  hyperthyroidism.,"	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2004,	Calibration and Reference Standards,	marketed,	LINAC design,	21,	50,	60,	,	2007,	-1,	diagnostic radiopharmaceuticals ,	,	nuclear  medicine and  cardiovascular  imaging  centers,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2004,	General Measurement and Radiological Services,	marketed,	LINAC design,	50,	60,	,	Gemstone Processing,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2004,	Fluorine products,	Pre clinical,	"The FEP patents and intellectual
property,"	,	,	,	,	,	,	 microelectronics,	,	silicon chip  manufacture.,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2005,	Cobalt Products,	marketed,	LINAC design,	22,	,	,	HSA Cobalt,	,	,	radiation therapy ,	,	"vascular  deformities  and  non-malignant
tumors in the brain,"	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2005,	Radiochemical Products,	marketed,	LINAC design,	50,	60,	,	Reactor Produced Radioisotopes,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2005,	Iodine-131 ,	Marketed,	LINAC design,	24,	,	,	,	2007,	-1,	Thyroid Diseases,	,	"Graves  disease,  thyroid
cancer,  and  hyperthyroidism.,"	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2005,	Calibration and Reference Standards,	marketed,	LINAC design,	21,	50,	60,	,	2007,	-1,	diagnostic radiopharmaceuticals ,	,	nuclear  medicine and  cardiovascular  imaging  centers,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2005,	General Measurement and Radiological Services,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2005,	Fluorine products,	Pre clinical,	"The FEP patents and intellectual
property,"	,	,	,	,	,	,	 microelectronics,	,	silicon chip  manufacture.,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2006,	Cobalt Products,	marketed,	LINAC design,	22,	,	,	,	,	,	radiation therapy ,	,	"vascular  deformities  and  non-malignant
tumors in the brain,"	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2006,	Radiochemical Products,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2006,	General Measurement and Radiological Services,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2006,	Fluorine products,	Pre clinical,	"The FEP patents and intellectual
property,"	,	,	,	,	,	,	 microelectronics,	,	silicon chip  manufacture.,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2007,	Cobalt Products,	marketed,	LINAC design,	22,	,	,	,	,	,	radiation therapy ,	,	"vascular  deformities  and  non-malignant
tumors in the brain,"	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2007,	Radiochemical Products,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2007,	General Measurement and Radiological Services,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2007,	Fluorine products,	Phase I,	"The FEP patents and intellectual
property,"	,	,	,	,	,	,	 microelectronics,	,	silicon chip  manufacture.,	,	Pre clinical,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2007,	Transportation Services,	marketed,	n/a,	,	,	,	,	,	,	transportation of hazardous, radioactive, materials,	,	Transportation,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2008,	Cobalt Products,	marketed,	LINAC design,	22,	,	,	,	,	,	radiation therapy ,	,	"vascular  deformities  and  non-malignant
tumors in the brain,"	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2008,	Radiochemical Products,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2008,	General Measurement and Radiological Services,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2008,	Fluorine products,	Phase II,	"The FEP patents and intellectual
property,"	,	,	,	,	,	,	 microelectronics,	,	silicon chip  manufacture.,	,	Phase I,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2008,	Transportation Services,	marketed,	n/a,	,	,	,	,	,	,	transportation of hazardous, radioactive, materials,	,	Transportation,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2009,	Cobalt Products,	marketed,	LINAC design,	22,	,	,	,	,	,	radiation therapy ,	,	"vascular  deformities  and  non-malignant
tumors in the brain,"	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2009,	Radiochemical Products,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2009,	General Measurement and Radiological Services,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2009,	Fluorine products,	Marketed,	"The FEP patents and intellectual
property,"	,	,	,	,	,	,	 microelectronics,	,	silicon chip  manufacture.,	,	Phase II,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2009,	Transportation Services,	marketed,	n/a,	,	,	,	,	,	,	transportation of hazardous, radioactive, materials,	,	Transportation,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2010,	Cobalt Products,	marketed,	LINAC design,	22,	,	,	,	,	,	radiation therapy ,	,	"vascular  deformities  and  non-malignant
tumors in the brain,"	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2010,	Radiochemical Products,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2010,	General Measurement and Radiological Services,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2010,	Fluorine products,	Marketed,	"The FEP patents and intellectual
property,"	,	,	,	,	,	,	 microelectronics,	,	silicon chip  manufacture.,	,	Phase II,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2010,	Transportation Services,	marketed,	n/a,	,	,	,	,	,	,	transportation of hazardous, radioactive, materials,	,	Transportation,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2011,	Cobalt Products,	marketed,	LINAC design,	22,	,	,	,	,	,	radiation therapy ,	,	"vascular  deformities  and  non-malignant
tumors in the brain,"	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2011,	Radiochemical Products,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2011,	General Measurement and Radiological Services,	marketed,	LINAC design,	50,	60,	,	,	,	,	diagnostic radiopharmaceuticals ,	,	radiopharmaceuticals,	,	,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2011,	Fluorine products,	Marketed,	"The FEP patents and intellectual
property,"	,	,	,	,	,	,	 microelectronics,	,	silicon chip  manufacture.,	,	Phase II,
nvcs19970001038277,	INTERNATIONAL ISOTOPES INC,	10-K,	1997,	2011,	Transportation Services,	marketed,	n/a,	,	,	,	,	,	,	transportation of hazardous, radioactive, materials,	,	Transportation,	,	,
wvcs19970000915320,	LEUKOSITE INC,	S-1,	1997,	1997,	LDP-03 (ANTI-CAMPATH MAB),	Phase II,	Leukocyte Antigens,	22,	27,	,	,	,	,	Cancer,	,	Chronic lymphocytic leukemia,	,	,
wvcs19970000915320,	LEUKOSITE INC,	S-1,	1997,	1997,	LDP-01 (ANTI-b2 MAB),	pre clinical,	Integrin/Adhesion Molecules,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Myocardial infarction  ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	S-1,	1997,	1997,	LDP-01 (ANTI-b2 MAB),	Phase II,	Integrin/Adhesion Molecules,	5,	,	,	,	,	,	inflammatory, autoimmune ,	,	Kidney transplant,	,	,
wvcs19970000915320,	LEUKOSITE INC,	S-1,	1997,	1997,	LDP-01 (ANTI-b2 MAB),	Phase II,	Integrin/Adhesion Molecules,	21,	40,	,	,	,	,	Cardiovascular Disease,	,	 Thrombotic stroke ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	S-1,	1997,	1997,	LDP-02 (ANTI-b7 MAB),	Pre Clinical,	Integrin/Adhesion Molecules,	5,	26,	,	,	,	,	inflammatory, autoimmune ,	,	Inflammatory bowel disease,	,	,
wvcs19970000915320,	LEUKOSITE INC,	S-1,	1997,	1997,	CCR3 ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	5,	29,	,	,	,	,	respiratory disease,	,	 Asthma Allergic   ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	S-1,	1997,	1997,	MCP-1 ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	5,	20,	,	,	,	,	inflammatory, autoimmune ,	,	 Rheumatoid  arthritis ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	S-1,	1997,	1997,	IL-8 ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	 Myocardial infarction,	,	,
wvcs19970000915320,	LEUKOSITE INC,	S-1,	1997,	1997,	CCR5 ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	5,	23,	,	,	,	,	Infectious Diseases,	,	HIV-1 infection,	,	,
wvcs19970000915320,	LEUKOSITE INC,	424,	1997,	1997,	LDP-03 (ANTI-CAMPATH MAB),	Phase II,	Leukocyte Antigens,	22,	27,	,	,	,	,	Cancer,	,	Chronic lymphocytic leukemia,	,	,
wvcs19970000915320,	LEUKOSITE INC,	424,	1997,	1997,	LDP-01 (ANTI-b2 MAB),	pre clinical,	Integrin/Adhesion Molecules,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Myocardial infarction  ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	424,	1997,	1997,	LDP-01 (ANTI-b2 MAB),	Phase II,	Integrin/Adhesion Molecules,	5,	,	,	,	,	,	inflammatory, autoimmune ,	,	Kidney transplant,	,	,
wvcs19970000915320,	LEUKOSITE INC,	424,	1997,	1997,	LDP-01 (ANTI-b2 MAB),	Phase II,	Integrin/Adhesion Molecules,	21,	40,	,	,	,	,	Cardiovascular Disease,	,	 Thrombotic stroke ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	424,	1997,	1997,	LDP-02 (ANTI-b7 MAB),	Pre Clinical,	Integrin/Adhesion Molecules,	5,	26,	,	,	,	,	inflammatory, autoimmune ,	,	Inflammatory bowel disease,	,	,
wvcs19970000915320,	LEUKOSITE INC,	424,	1997,	1997,	CCR3 ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	5,	29,	,	,	,	,	respiratory disease,	,	 Asthma Allergic   ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	424,	1997,	1997,	MCP-1 ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	5,	20,	,	,	,	,	inflammatory, autoimmune ,	,	 Rheumatoid  arthritis ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	424,	1997,	1997,	IL-8 ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	 Myocardial infarction,	,	,
wvcs19970000915320,	LEUKOSITE INC,	424,	1997,	1997,	CCR5 ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	5,	23,	,	,	,	,	Infectious Diseases,	,	HIV-1 infection,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1998,	LDP-03 (ANTI-CAMPATH MAB),	Phase II,	Leukocyte Antigens,	22,	27,	,	,	,	,	Cancer,	,	Chronic lymphocytic leukemia,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1998,	LDP-01 (ANTI-b2 MAB),	pre clinical,	Integrin/Adhesion Molecules,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Myocardial infarction  ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1998,	LDP-01 (ANTI-b2 MAB),	Phase II,	Integrin/Adhesion Molecules,	5,	,	,	,	,	,	inflammatory, autoimmune ,	,	Kidney transplant,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1998,	LDP-01 (ANTI-b2 MAB),	Phase II,	Integrin/Adhesion Molecules,	21,	40,	,	,	,	,	Cardiovascular Disease,	,	 Thrombotic stroke ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1998,	LDP-02 (ANTI-b7 MAB),	Pre Clinical,	Integrin/Adhesion Molecules,	5,	26,	,	,	,	,	inflammatory, autoimmune ,	,	Inflammatory bowel disease,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1998,	CCR3 ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	5,	29,	,	,	,	,	respiratory disease,	,	 Asthma Allergic   ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1998,	MCP-1 ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	5,	20,	,	,	,	,	inflammatory, autoimmune ,	,	 Rheumatoid  arthritis ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1998,	IL-8 ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	 Myocardial infarction,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1998,	CCR5 ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	5,	23,	,	,	,	,	Infectious Diseases,	,	HIV-1 infection,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1999,	CAMPATH,	Phase II,	Leukocyte Antigens,	22,	27,	,	LDP-03 (ANTI-CAMPATH MAB),	,	,	Cancer,	,	Chronic lymphocytic leukemia,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1999,	LDP-01 (ANTI-b2 MAB),	pre clinical,	Integrin/Adhesion Molecules,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Myocardial infarction  ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1999,	LDP-01 (ANTI-b2 MAB),	Phase II,	Integrin/Adhesion Molecules,	5,	,	,	,	,	,	inflammatory, autoimmune ,	,	Kidney transplant,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1999,	LDP-01 (ANTI-b2 MAB),	Phase II,	Integrin/Adhesion Molecules,	21,	40,	,	,	,	,	Cardiovascular Disease,	,	 Thrombotic stroke ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1999,	LDP-02 (ANTI-b7 MAB),	Pre Clinical,	Integrin/Adhesion Molecules,	5,	26,	,	,	,	,	inflammatory, autoimmune ,	,	Inflammatory bowel disease,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1999,	LDP-977,	Phase I,	Integrin/Adhesion Molecules,	5,	29,	20,	,	,	,	inflammatory lung disease,	,	Asthma,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1999,	CCR3 ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	5,	29,	,	,	,	,	respiratory disease,	,	 Asthma Allergic   ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1999,	CCR2 RECEPTOR ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	5,	20,	,	MCP-1 ANTAGONIST,	,	,	inflammatory, autoimmune ,	,	 Rheumatoid  arthritis ,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1999,	CXCR-1,2 RECEPTOR ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	21,	25,	,	IL-8 ANTAGONIST,	,	,	Cardiovascular Disease,	,	 Myocardial infarction,	,	,
wvcs19970000915320,	LEUKOSITE INC,	10-K,	1997,	1999,	CCR5 ANTAGONIST,	Discovery,	Chemokine/Chemokine Receptor,	5,	23,	,	,	,	,	Infectious Diseases,	,	HIV-1 infection,	,	,
wvcs20040000899460,	MANNKIND CORP,	S-1,	2004,	2004,	Technosphere Insulin System,	Phase II,	Technosphere formulation technology,	24,	,	,	,	,	,	?Endocrinology,	,	type 2 diabetes,	,	,
wvcs20040000899460,	MANNKIND CORP,	S-1,	2004,	2004,	Cancer immunotherapy,	Phase II,	tumor-associated antigens,	5,	22,	,	,	,	,	Oncology,	,	Melanoma,	,	,
wvcs20040000899460,	MANNKIND CORP,	424,	2004,	2004,	Technosphere Insulin System,	Phase II,	Technosphere formulation technology,	24,	,	,	,	,	,	?Endocrinology,	,	type 2 diabetes,	,	,
wvcs20040000899460,	MANNKIND CORP,	424,	2004,	2004,	Cancer immunotherapy,	Phase II,	tumor-associated antigens,	5,	22,	,	,	,	,	Oncology,	,	Melanoma,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2005,	Technosphere Insulin System,	Phase III,	Technosphere formulation technology,	24,	,	,	,	,	,	?Endocrinology,	,	type 2 diabetes,	,	Phase II,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2005,	Cancer immunotherapy,	Phase II,	tumor-associated antigens,	5,	22,	,	,	,	,	Oncology,	,	Melanoma,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2006,	Technosphere Insulin System,	Phase III,	Technosphere formulation technology,	24,	,	,	,	,	,	?Endocrinology,	,	type 2 diabetes,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2006,	MKC1106,	Phase II,	tumor-associated antigens,	5,	22,	,	Cancer immunotherapy,	,	,	Oncology,	,	Solid tumors,	Melanoma,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2007,	Technosphere Insulin System,	Phase III,	Technosphere formulation technology,	24,	,	,	,	,	,	?Endocrinology,	,	type 2 diabetes,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2007,	MKC1106,	Phase I,	tumor-associated antigens,	5,	22,	,	,	,	,	Oncology,	,	Solid tumors,	,	Phase II,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2008,	Technosphere Insulin System,	Phase III,	Technosphere formulation technology,	24,	,	,	,	,	,	?Endocrinology,	,	type 2 diabetes,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2008,	MKC1106,	Phase I,	tumor-associated antigens,	5,	22,	,	,	,	,	Oncology,	,	Solid tumors,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2008,	MKC1106-MT,	Phase II,	tumor-associated antigens,	22,	,	,	,	,	,	Oncology,	,	Melanoma,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2009,	AFRESA,	Phase III,	Technosphere formulation technology,	24,	,	,	Technosphere Insulin System,	,	,	Endocrinology,	,	type 2 diabetes,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2009,	MKC1106,	Phase I,	tumor-associated antigens,	5,	22,	,	,	,	,	Oncology,	,	Solid tumors,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2009,	MKC1106-MT,	Phase II,	tumor-associated antigens,	22,	,	,	,	,	,	Oncology,	,	Melanoma,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2010,	AFRESA,	NDA,	Technosphere formulation technology,	24,	,	,	,	,	,	?Endocrinology,	,	type 2 diabetes,	,	Phase III,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2010,	MKC253 (GLP-1),	Phase I,	Technosphere formulation technology,	24,	,	,	,	,	,	Endocrinology,	,	type 2 diabetes,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2010,	MKC180 (obesity compound),	Preclinical,	Technosphere formulation technology,	24,	,	,	,	,	,	Endocrinology,	,	type 2 diabetes,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2010,	MKC1106,	Phase I,	tumor-associated antigens,	5,	22,	,	,	,	,	Oncology,	,	Solid tumors,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2010,	MKC1106-MT,	Phase II,	tumor-associated antigens,	22,	,	,	,	,	,	Oncology,	,	Melanoma,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2010,	MKC204 (IRE-1 inhibitor),	Preclinical,	tumor-associated antigens,	22,	,	,	,	,	,	Oncology,	,	Multiple myeloma,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2011,	AFRESA,	NDA,	Technosphere formulation technology,	24,	,	,	,	,	,	?Endocrinology,	,	type 2 diabetes,	,	Phase III,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2011,	MKC253 (GLP-1),	Phase I,	Technosphere formulation technology,	24,	,	,	,	,	,	Endocrinology,	,	type 2 diabetes,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2011,	MKC180 (obesity compound),	Preclinical,	Technosphere formulation technology,	24,	,	,	,	,	,	Endocrinology,	,	type 2 diabetes,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2011,	MKC1106,	Phase I,	tumor-associated antigens,	5,	22,	,	,	,	,	Oncology,	,	Solid tumors,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2011,	MKC1106-MT,	Phase II,	tumor-associated antigens,	22,	,	,	,	,	,	Oncology,	,	Melanoma,	,	,
wvcs20040000899460,	MANNKIND CORP,	10-K,	2004,	2011,	MKC204 (IRE-1 inhibitor),	Preclinical,	tumor-associated antigens,	22,	,	,	,	,	,	Oncology,	,	Multiple myeloma,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	S-1,	2003,	2003,	MEM 1003,	Phase I,	"Neuronal L-type
calcium channel,"	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	S-1,	2003,	2003,	MEM 1414,	Phase I,	PDE4 inhibitor,	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	S-1,	2003,	2003,	MEM 3454,	Preclinical,	Nicotinic alpha-7,	40,	,	,	,	,	,	CNS conditions,	,	Schizophrenia,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	S-1,	2003,	2003,	MEM 1917,	Preclinical,	PDE4 inhibitor,	40,	,	,	,	,	,	CNS conditions,	,	Depression,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	424,	2003,	2004,	MEM 1003,	Phase I,	"Neuronal L-type
calcium channel,"	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	424,	2003,	2004,	MEM 1414,	Phase I,	PDE4 inhibitor,	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	424,	2003,	2004,	MEM 3454,	Preclinical,	Nicotinic alpha-7,	40,	,	,	,	,	,	CNS conditions,	,	Schizophrenia,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	424,	2003,	2004,	MEM 1917,	Preclinical,	PDE4 inhibitor,	40,	,	,	,	,	,	CNS conditions,	,	Depression,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2005,	MEM 1003,	Phase I,	"Neuronal L-type
calcium channel,"	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2005,	MEM 1414,	Phase I,	PDE4 inhibitor,	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2005,	MEM 3454,	Phase I,	Nicotinic alpha-7,	40,	,	,	,	,	,	CNS conditions,	,	Schizophrenia,	,	yes,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2005,	MEM 1917,	Preclinical,	PDE4 inhibitor,	40,	,	,	,	,	,	CNS conditions,	,	Depression,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2005,	MEM 63908,	Preclinical,	Nicotinic alpha-7 partial agonist,	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2006,	MEM 1003,	Phase II,	"Neuronal L-type
calcium channel,"	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	yes,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2006,	MEM 1003,	Phase II,	"Neuronal L-type
calcium channel,"	40,	,	,	,	,	,	CNS conditions,	,	Bipolar Disorder,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2006,	MEM 1414,	Phase I,	PDE4 inhibitor,	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2006,	MEM 3454,	Phase II,	Nicotinic alpha-7,	40,	,	,	,	,	,	CNS conditions,	,	Schizophrenia,	,	yes,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2006,	MEM 1917,	Preclinical,	PDE4 inhibitor,	40,	,	,	,	,	,	CNS conditions,	,	Depression,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2006,	MEM 63908,	Preclinical,	Nicotinic alpha-7 partial agonist,	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2007,	MEM 1003,	Phase II,	"Neuronal L-type
calcium channel,"	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2007,	MEM 1414,	Phase I,	PDE4 inhibitor,	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2007,	MEM 3454,	Phase II,	Nicotinic alpha-7,	40,	,	,	,	,	,	CNS conditions,	,	Schizophrenia,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2007,	MEM 3454,	Phase II,	Nicotinic alpha-7,	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2007,	MEM 1917,	Preclinical,	PDE4 inhibitor,	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2007,	MEM 1917,	Preclinical,	PDE4 inhibitor,	40,	,	,	,	,	,	CNS conditions,	,	Depression,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2007,	MEM 63908,	Preclinical,	Nicotinic alpha-7 partial agonist,	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2007,	MEM 63908,	Preclinical,	Nicotinic alpha-7 partial agonist,	40,	,	,	,	,	,	CNS conditions,	,	Schizophrenia,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2008,	MEM 1003,	Phase II,	"Neuronal L-type
calcium channel,"	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2008,	MEM 3454,	Phase II,	Nicotinic alpha-7,	40,	,	,	,	,	,	CNS conditions,	,	Schizophrenia,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2008,	MEM 3454,	Phase II,	Nicotinic alpha-7,	40,	,	,	,	,	,	CNS conditions,	,	CIAS,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2008,	R4996/MEM 63908 ,	Phase I,	Nicotinic alpha-7,	40,	,	,	,	,	,	CNS conditions,	,	CIAS,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2008,	R4996/MEM 63908 ,	Phase I,	Nicotinic alpha-7,	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer’s ,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2008,	MEM 1917,	Preclinical,	PDE4 inhibitor,	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2008,	MEM 1917,	Preclinical,	PDE4 inhibitor,	40,	,	,	,	,	,	CNS conditions,	,	Depression,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2008,	MEM 1414,	Phase I,	PDE4 inhibitor,	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2008,	PDE10 Inhibitor Program,	,	 PDE10 inhibitors,	40,	,	,	,	,	,	CNS conditions,	,	CNS,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2008,	5-HT6 Antagonist Program,	,	5-HT6 antagonists,	40,	,	,	,	,	,	CNS conditions,	,	Alzheimer's,	,	,
wvcs20040001062216,	MEMORY PHARMACEUTICALS CORP,	10-K,	2003,	2008,	5-HT6 Antagonist Program,	,	5-HT6 antagonists,	40,	,	,	,	,	,	CNS conditions,	,	CIAS,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	S-1,	2004,	2004,	M-Enoxaparin,	Development,	Momenta Technology,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Thrombosis,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	S-1,	2004,	2004,	M-Dalteparin,	Development,	Momenta Technology,	9,	21,	,	,	2009,	-1,	Acute Coronary Syndrome,	,	Thrombosis,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	S-1,	2004,	2004,	M118,	Preclinical,	Momenta Technology,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Cardiovascular Disease,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	S-1,	2004,	2004,	Pulmonary Insulin,	Preclinical,	Momenta Technology,	24,	,	,	,	2006,	0.7143,	Endocrinology,	,	Diabetes,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	S-1,	2004,	2004,	Pulmonary HGH,	Preclinical,	Momenta Technology,	24,	,	,	,	2006,	0.7143,	Endocrinology,	,	Growth Hormone Deficiency,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	S-1,	2004,	2004,	Pulmonary Interferon-beta,	Discovery,	Momenta Technology,	5,	,	,	,	2006,	0.7143,	autoimmune diseases,	,	Multiple Sclerosis,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	424,	2004,	2004,	M-Enoxaparin,	Development,	Momenta Technology,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Thrombosis,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	424,	2004,	2004,	M-Dalteparin,	Development,	Momenta Technology,	9,	21,	,	,	2009,	-1,	Acute Coronary Syndrome,	,	Thrombosis,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	424,	2004,	2004,	M118,	Preclinical,	Momenta Technology,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Cardiovascular Disease,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	424,	2004,	2004,	Pulmonary Insulin,	Preclinical,	Momenta Technology,	24,	,	,	,	2006,	0.7143,	Endocrinology,	,	Diabetes,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	424,	2004,	2004,	Pulmonary HGH,	Preclinical,	Momenta Technology,	24,	,	,	,	2006,	0.7143,	Endocrinology,	,	Growth Hormone Deficiency,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	424,	2004,	2004,	Pulmonary Interferon-beta,	Discovery,	Momenta Technology,	5,	,	,	,	2006,	0.7143,	autoimmune diseases,	,	Multiple Sclerosis,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2005,	M-Enoxaparin,	 ANDA,	Momenta Technology,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Thrombosis,	,	Development,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2005,	M-Dalteparin,	 ANDA,	Momenta Technology,	9,	21,	,	,	2009,	-1,	Acute Coronary Syndrome,	,	Thrombosis,	,	Development,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2005,	Glycoproteins,	Discovery ,	Momenta Technology,	24,	,	,	,	2011,	0.2,	Endocrinology,	,	Various,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2005,	Sugar Therapeutic,	Discovery,	Momenta Technology,	22,	,	,	,	2011,	-0.2727,	Oncology,	,	Oncology,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2005,	M118,	Preclinical,	Momenta Technology,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Cardiovascular Disease,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2006,	M-Enoxaparin,	 ANDA,	Momenta Technology,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Thrombosis,	,	Development,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2006,	M-Dalteparin,	 ANDA,	Momenta Technology,	9,	21,	,	,	2009,	-1,	Acute Coronary Syndrome,	,	Thrombosis,	,	Development,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2006,	Glycoproteins,	Discovery ,	Momenta Technology,	24,	,	,	,	2011,	0.2,	Endocrinology,	,	Various,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2006,	Sugar Therapeutic,	Discovery,	Momenta Technology,	22,	,	,	,	2011,	-0.2727,	Oncology,	,	Oncology,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2006,	M118,	Preclinical,	Momenta Technology,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Cardiovascular Disease,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2007,	M-Enoxaparin,	NDA,	Momenta Technology,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	DVT,	Thrombosis,	ANDA,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2007,	M-Dalteparin,	 ANDA,	Momenta Technology,	9,	21,	,	,	2009,	-1,	Acute Coronary Syndrome,	,	DVT,	Thrombosis,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2007,	M356,	ANDA,	Momenta Technology,	40,	,	,	,	,	,	CNS,	,	 Relapse-Remitting Multiple Sclerosis,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2007,	Sugar Therapeutic,	Discovery,	Momenta Technology,	22,	,	,	,	2011,	-0.2727,	Oncology,	,	Oncology,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2007,	M118,	IND,	Momenta Technology,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Cardiovascular Disease,	,	Preclinical,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2007,	M178,	Discovery,	Momenta Technology,	24,	,	,	Glycoproteins,	2011,	0.2,	Endocrinology,	,	Various,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2007,	M249,	Discovery,	Momenta Technology,	24,	,	,	Glycoproteins,	2010,	-0.25,	Endocrinology,	,	Various,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2008,	M-Enoxaparin,	NDA,	Momenta Technology,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	DVT,	Thrombosis,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2008,	M118,	IND,	Momenta Technology,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Cardiovascular Disease,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2008,	M356,	ANDA,	Momenta Technology,	40,	,	,	,	,	,	CNS,	,	 Relapse-Remitting Multiple Sclerosis,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2008,	M178,	Discovery,	Momenta Technology,	24,	,	,	,	2011,	0.2,	Endocrinology,	,	Various,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2008,	M249,	Discovery,	Momenta Technology,	24,	,	,	,	2010,	-0.4,	Endocrinology,	,	Various,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2008,	Sugar Therapeutic,	Discovery,	Momenta Technology,	22,	,	,	,	2011,	-0.2727,	Oncology,	,	Oncology,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2009,	M-Enoxaparin,	NDA,	Momenta Technology,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	DVT,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2009,	M118,	IND,	Momenta Technology,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Cardiovascular Disease,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2009,	M356,	ANDA,	Momenta Technology,	40,	,	,	,	,	,	CNS,	,	 Relapse-Remitting Multiple Sclerosis,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2009,	M178,	Discovery,	Momenta Technology,	24,	,	,	,	2011,	-0.9016,	Endocrinology,	,	Various,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2009,	Glycoproteins,	Discovery,	Momenta Technology,	22,	,	,	Sugar Therapeutic,	2011,	-0.8689,	Oncology,	,	Oncology,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2010,	M-Enoxaparin,	NDA,	"Heparin or
Heparan-Sulfate ProteoGlycan
(HSPG) Based,"	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	DVT,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2010,	M118,	IND,	"Heparin or
Heparan-Sulfate ProteoGlycan
(HSPG) Based,"	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Cardiovascular Disease,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2010,	  M402,	preclinical studies ,	"Heparin or
Heparan-Sulfate ProteoGlycan
(HSPG) Based,"	22,	,	,	,	,	,	Oncology,	,	Tumors,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2010,	M356,	ANDA,	Complex Polypeptide,	40,	,	,	,	,	,	CNS,	,	 Relapse-Remitting Multiple Sclerosis,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2010,	Follow-On Biologics (FOBs) Program,	Discovery,	Therapeutic Protein,	,	,	,	,	,	,	therapeutic proteins,	,	therapeutic proteins,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2011,	M-Enoxaparin,	NDA,	"Heparin or
Heparan-Sulfate ProteoGlycan
(HSPG) Based,"	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	DVT,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2011,	M118,	IND,	"Heparin or
Heparan-Sulfate ProteoGlycan
(HSPG) Based,"	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Cardiovascular Disease,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2011,	  M402,	preclinical studies ,	"Heparin or
Heparan-Sulfate ProteoGlycan
(HSPG) Based,"	22,	,	,	,	,	,	Oncology,	,	Tumors,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2011,	M356,	ANDA,	Complex Polypeptide,	40,	,	,	,	,	,	CNS,	,	 Relapse-Remitting Multiple Sclerosis,	,	,
wvcs20040001235010,	MOMENTA PHARMACEUTICALS INC,	10-K,	2004,	2011,	Follow-On Biologics (FOBs) Program,	Discovery,	Therapeutic Protein,	,	,	,	,	,	,	therapeutic proteins,	,	therapeutic proteins,	,	,
wvcs20040001288379,	NEW RIVER PHARMACEUTICALS INC,	S-1,	2004,	2004,	NRP104 ,	IND application,	Carrierwave technology ,	,	,	,	,	,	,	Amphetamine-based drugs,	,	ADHD,	,	,
wvcs20040001288379,	NEW RIVER PHARMACEUTICALS INC,	S-1,	2004,	2004,	NRP369 ,	research phase,	Carrierwave technology ,	62,	,	,	,	,	,	opioid-based prodrugs,	,	Chronic Pain,	,	,
wvcs20040001288379,	NEW RIVER PHARMACEUTICALS INC,	S-1,	2004,	2004,	NRP290,	IND application,	Carrierwave technology ,	62,	9,	,	,	,	,	opioid-based prodrugs,	,	Acute Pain,	,	,
wvcs20040001288379,	NEW RIVER PHARMACEUTICALS INC,	424,	2004,	2004,	NRP104 ,	IND application,	Carrierwave technology ,	,	,	,	,	,	,	Amphetamine-based drugs,	,	ADHD,	,	,
wvcs20040001288379,	NEW RIVER PHARMACEUTICALS INC,	424,	2004,	2004,	NRP369 ,	research phase,	Carrierwave technology ,	62,	,	,	,	,	,	opioid-based prodrugs,	,	Chronic Pain,	,	,
wvcs20040001288379,	NEW RIVER PHARMACEUTICALS INC,	424,	2004,	2004,	NRP290,	IND application,	Carrierwave technology ,	62,	9,	,	,	,	,	opioid-based prodrugs,	,	Acute Pain,	,	,
wvcs20040001288379,	NEW RIVER PHARMACEUTICALS INC,	10-K,	2004,	2005,	NRP104 ,	Phase 2,	Carrierwave technology ,	,	,	,	,	,	,	Amphetamine-based drugs,	,	ADHD,	,	,
wvcs20040001288379,	NEW RIVER PHARMACEUTICALS INC,	10-K,	2004,	2005,	NRP369 ,	IND,	Carrierwave technology ,	62,	,	,	,	,	,	opioid-based prodrugs,	,	Chronic Pain,	,	,
wvcs20040001288379,	NEW RIVER PHARMACEUTICALS INC,	10-K,	2004,	2005,	NRP290,	IND,	Carrierwave technology ,	62,	9,	,	,	,	,	opioid-based prodrugs,	,	Acute Pain,	,	,
wvcs20040001288379,	NEW RIVER PHARMACEUTICALS INC,	10-K,	2004,	2006,	NRP104 ,	Phase 2,	Carrierwave technology ,	,	,	,	,	,	,	Amphetamine-based drugs,	,	ADHD,	,	,
wvcs20040001288379,	NEW RIVER PHARMACEUTICALS INC,	10-K,	2004,	2006,	NRP369 ,	IND,	Carrierwave technology ,	62,	,	,	,	,	,	opioid-based prodrugs,	,	Chronic Pain,	,	,
wvcs20040001288379,	NEW RIVER PHARMACEUTICALS INC,	10-K,	2004,	2006,	NRP290,	IND,	Carrierwave technology ,	62,	9,	,	,	,	,	opioid-based prodrugs,	,	Acute Pain,	,	,
wvcs20040001288379,	NEW RIVER PHARMACEUTICALS INC,	10-K,	2004,	2007,	Vvyanse,	Marketed,	Carrierwave technology ,	,	,	,	NRP104 ,	,	,	Amphetamine-based drugs,	,	ADHD,	,	yes,
wvcs20040001288379,	NEW RIVER PHARMACEUTICALS INC,	10-K,	2004,	2007,	NRP290,	Phase III,	Carrierwave technology ,	62,	9,	,	,	,	,	opioid-based prodrugs,	,	Acute Pain,	,	yes,
wvcs20040001288379,	NEW RIVER PHARMACEUTICALS INC,	10-K,	2004,	2007,	NRP409,	Phase I,	Carrierwave technology ,	24,	,	,	,	,	,	opioid-based prodrugs,	,	 primary hypothyroidism,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	S-1,	2001,	2001,	DCVax,	Phase III,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	S-1,	2001,	2001,	DCVax,	Phase II,	dendritic cell-based,	22,	40,	,	,	,	,	Cancer,	,	Brain Cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	S-1,	2001,	2001,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Lung Cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	S-1,	2001,	2001,	DCVax,	Pre-clinical,	dendritic cell-based,	22,	28,	,	,	,	,	Cancer,	,	Renal Cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	S-1,	2001,	2001,	HuRx,	Phase I,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	S-1,	2001,	2001,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Small cell lung cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	S-1,	2001,	2001,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Breast cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	S-1,	2001,	2001,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	424,	2001,	2001,	DCVax,	Phase III,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	424,	2001,	2001,	DCVax,	Phase II,	dendritic cell-based,	22,	40,	,	,	,	,	Cancer,	,	Brain Cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	424,	2001,	2001,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Lung Cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	424,	2001,	2001,	DCVax,	Pre-clinical,	dendritic cell-based,	22,	28,	,	,	,	,	Cancer,	,	Renal Cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	424,	2001,	2001,	HuRx,	Phase I,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	424,	2001,	2001,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Small cell lung cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	424,	2001,	2001,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Breast cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	424,	2001,	2001,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2002,	DCVax,	Phase III,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2002,	DCVax,	Phase II,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	Brain Cancer,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2002,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Non-small cell lung cancer,	Lung Cancer,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2002,	HuRx,	Phase I,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2002,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Small cell lung cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2002,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Breast cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2002,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2002,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Colon cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2002,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Melanoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2002,	CXCR4,	Pre-clinical,	Gene Therapy,	22,	,	,	,	2005,	-1,	Cancer,	,	Breast Cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2002,	CX43,	Pre-clinical,	Gene Therapy,	22,	,	,	,	2005,	-1,	Cancer,	,	Breast cancer,,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2003,	DCVax,	Phase III,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2003,	DCVax,	Phase II,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2003,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Non-small cell lung cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2003,	HuRx,	Phase I,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2003,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Small cell lung cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2003,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Breast cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2003,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2003,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Colon cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2003,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Melanoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2003,	CXCR4,	Pre-clinical,	Gene Therapy,	22,	,	,	,	2005,	-1,	Cancer,	,	Breast Cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2003,	CX43,	Pre-clinical,	Gene Therapy,	22,	,	,	,	2005,	-1,	Cancer,	,	Breast cancer,,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2004,	DCVax,	Phase III,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2004,	DCVax,	Phase II,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2004,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Non-small cell lung cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2004,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Breast cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2004,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2004,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Colon cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2004,	HuRx,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Melanoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2005,	DCVax,	Phase III,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2005,	DCVax,	Phase II,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2005,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Non-small cell lung cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2005,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	HuRx,	,	,	Cancer,	,	Breast cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2005,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	HuRx,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2005,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	HuRx,	,	,	Cancer,	,	Colon cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2005,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	HuRx,	,	,	Cancer,	,	Melanoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2006,	DCVax,	Phase III,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2006,	DCVax,	Phase II,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2006,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Non-small cell lung cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2006,	CXCR4,	Pre-clinical,	Gene Therapy,	22,	,	,	,	,	,	Cancer,	,	Breast cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2006,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2006,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Colon cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2006,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Melanoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2007,	DCVax,	Phase III,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2007,	DCVax,	Phase II,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2007,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Non-small cell lung cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2007,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Resectable solid tumors,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2007,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Solid tumors,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2007,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Breast cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2007,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2007,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Colon cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2007,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Melanoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2008,	DCVax,	Phase III,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2008,	DCVax,	Phase II,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2008,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Non-small cell lung cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2008,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Resectable solid tumors,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2008,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Solid tumors,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2008,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Breast cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2008,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2008,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Colon cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2008,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Melanoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2008,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Lung Cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2009,	DCVax,	Phase III,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2009,	DCVax,	Phase II,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2009,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Non-small cell lung cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2009,	DCVax,	Phase II,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Resectable solid tumors,	,	yes,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2009,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Solid tumors,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2009,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Breast cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2009,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2009,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Colon cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2009,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Melanoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2009,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Lung Cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2010,	DCVax,	Phase III,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2010,	DCVax,	Phase II,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2010,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Non-small cell lung cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2010,	DCVax,	Phase II,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Resectable solid tumors,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2010,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Solid tumors,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2010,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Breast cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2010,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2010,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Colon cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2010,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Melanoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2010,	CXCR4,	Pre-clinical,	monoclonal antibody-based,	22,	,	,	,	,	,	Cancer,	,	Lung Cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2011,	DCVax,	Phase III,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Prostate cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2011,	DCVax,	Phase II,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Glioblastoma,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2011,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Non-small cell lung cancer,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2011,	DCVax,	Phase II,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Resectable solid tumors,	,	,
nvcs20010001072379,	NORTHWEST BIOTHERAPEUTICS INC,	10-K,	2001,	2011,	DCVax,	Phase I,	dendritic cell-based,	22,	,	,	,	,	,	Cancer,	,	Solid tumors,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	S-1,	1996,	1996,	GMK.,	Phase III,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2009,	-1,	Cancer,	,	Several Types of Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	S-1,	1996,	1996,	MGV,	Phase 1/2,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2004,	-0.52,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	S-1,	1996,	1996,	MGV,	Phase 1/2,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	,	,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	S-1,	1996,	1996,	PRO  367,	Phase 1/2,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	S-1,	1996,	1996,	PRO 5,	Phase 1/2,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	2007,	-0.9167,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	424,	1996,	1997,	GMK.,	Phase III,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2009,	-1,	Cancer,	,	Several Types of Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	424,	1996,	1997,	MGV,	Phase 1/2,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2004,	-0.52,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	424,	1996,	1997,	MGV,	Phase 1/2,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	,	,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	424,	1996,	1997,	PRO  367,	Phase 1/2,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	424,	1996,	1997,	PRO 5,	Phase 1/2,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	2007,	-0.9167,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	1998,	GMK.,	Phase III,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2009,	-1,	Cancer,	,	Several Types of Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	1998,	MGV,	Phase 1/2,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2004,	-0.52,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	1998,	PRO  367,	Phase 1/2,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	1998,	PRO 5,	Phase 1/2,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	2007,	-0.9167,	HIV therapy,	,	HIV Infected Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	1998,	 HIV Co-receptor/HIV therapy           ,	    Research   ,	"HIV  co-receptor  technology CCR5 and
CXCR4.,"	23,	,	,	,	2006,	-1,	HIV therapy,	,	 HIV therapy ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	1998,	   ProVax,	Research,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	2001,	-0.9467,	HIV Therapeutics,	,	 HIV vaccine ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	1998,	HIV Attachment Drug,	 Research    ,	HIV  co-receptor  technology: CD4  receptor ,	23,	,	,	,	2006,	-1,	HIV therapy,	,	 HIV therapy ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	1999,	GMK.,	Phase III,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2009,	-1,	Cancer,	,	Melonoma,	Several Types of Cancer,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	1999,	MGV,	Phase 1/2,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2004,	-0.52,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	1999,	PRO 542     ,	Phase 1/2,	HIV  co-receptor  technology: CD4  receptor ,	23,	,	,	Pro 5,	2007,	-0.9167,	HIV therapy,	,	HIV Infected Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	1999,	PRO  367,	Phase 1/2,	HIV  co-receptor  technology: CD4  receptor ,	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	1999,	  DHA   ,	 Preclinical,	dehydroascorbic acid,	40,	,	,	,	2001,	-1,	central nervous system diseases,	,	 Alzheimer's disease,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	1999,	 HIV Co-receptor/HIV therapy           ,	    Research   ,	"HIV  co-receptor  technology CCR5 and
CXCR4.,"	23,	,	,	,	2006,	-1,	HIV therapy,	,	 HIV therapy ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	1999,	   ProVax,	Research,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	2001,	3,	HIV Therapeutics,	,	 HIV vaccine ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	1999,	HIV Attachment Drug,	 Research    ,	HIV  co-receptor  technology: CD4  receptor ,	23,	,	,	,	2006,	-1,	HIV therapy,	,	 HIV therapy ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2000,	GMK.,	Phase III,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2009,	-1,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2000,	MGV,	Phase II,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2004,	-0.52,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2000,	PRO 542     ,	Phase 1/2,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	2007,	-0.9167,	HIV therapy,	,	HIV Infected Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2000,	PRO  367,	Phase 1/2,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2000,	PRO 140 ,	 Preclinical,	 monoclonal antibody,,	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2000,	  DHA   ,	 Preclinical,	dehydroascorbic acid,	40,	,	,	,	,	,	central nervous system diseases,	,	 Alzheimer's disease,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2000,	 HIV Co-receptor/HIV therapy           ,	    Research   ,	"HIV  co-receptor  technology CCR5 and
CXCR4.,"	23,	,	,	,	2006,	-1,	HIV therapy,	,	 HIV therapy ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2000,	HIV Attachment Drug,	 Research    ,	HIV  co-receptor  technology: CD4  receptor ,	23,	,	,	,	2006,	-1,	HIV therapy ,	,	 HIV therapy ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2000,	ProVax  ,	 Research    ,	HIV  co-receptor  technology: CD4  receptor ,	23,	,	,	,	2002,	4,	HIV ,	,	 HIV vaccine  ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2001,	GMK.,	Phase III,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2009,	-1,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2001,	MGV,	Phase II,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2004,	-0.52,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2001,	PRO 542     ,	Phase 1/2,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	2007,	-0.9167,	HIV therapy,	,	HIV Infected Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2001,	PRO  367,	Phase 1/2,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2001,	PRO 140 ,	 Preclinical,	 monoclonal antibody,,	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2001,	PRO 140 ,	 Preclinical,	 monoclonal antibody,,	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2001,	 HIV Co-receptor/HIV therapy           ,	    Research   ,	"HIV  co-receptor  technology CCR5 and
CXCR4.,"	23,	,	,	,	2006,	-1,	HIV therapy,	,	 HIV therapy ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2001,	HIV Attachment Drug,	 Research    ,	HIV  co-receptor  technology: CD4  receptor ,	23,	,	,	,	2006,	-1,	HIV therapy,	,	 HIV therapy ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2001,	  DHA   ,	 Preclinical,	dehydroascorbic acid,	40,	,	,	,	2003,	-1,	central nervous system diseases,	,	Stroke,	 Alzheimer's disease,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2002,	GMK.,	Phase III,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2009,	-1,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2002,	MGV,	Phase 3,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2004,	0.7143,	Cancer,	,	Melonoma,	,	yes,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2002,	PRO 542     ,	Phase 2,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	2007,	-0.9167,	HIV therapy,	,	HIV Infected Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2002,	PRO 542     ,	Phase 2,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV Infected Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2002,	PRO 140 ,	 Preclinical,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2002,	PRO 140 ,	 Preclinical,	 monoclonal antibody,,	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2002,	HIV Attachment Drug,	 Research    ,	HIV  co-receptor  technology: CD4  receptor ,	23,	,	,	,	2006,	-1,	HIV therapy,	,	 HIV therapy ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2002,	 HIV Co-receptor/HIV therapy           ,	    Research   ,	"HIV  co-receptor  technology CCR5 and
CXCR4.,"	23,	,	,	,	2006,	-1,	HIV therapy,	,	 HIV therapy ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2002,	 HIV Co-receptor/HIV therapy           ,	    Research   ,	"HIV  co-receptor  technology CCR5 and
CXCR4.,"	23,	,	,	,	,	,	HIV therapy,	,	 HIV therapy ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2002,	HIV Attachment Drug,	 Research    ,	HIV  co-receptor  technology: CD4  receptor ,	23,	,	,	,	,	,	HIV therapy,	,	 HIV therapy ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2002,	Methylnaltrexone,	Phase II,	Joint Program,	61,	62,	,	,	2009,	-0.8294,	"Symptom Management
and Supportive Care,"	,	chronic pain,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2002,	Methylnaltrexone,	Phase II,	Joint Program,	61,	26,	,	,	,	,	"Symptom Management
and Supportive Care,"	,	bowel dysfunction,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2002,	ProVax,	Research,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV vaccine,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2002,	DHA,	Preclinical,	licensed from Memorial Sloan-Kettering Cancer Center,	21,	40,	,	,	2004,	0.4,	Stroke,	,	Stroke,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2003,	GMK.,	Phase III,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2009,	-1,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2003,	PRO 542     ,	Phase 2,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	2007,	-0.9167,	HIV therapy,	,	HIV Infected Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2003,	PRO 140 ,	 Preclinical,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2003,	PRO 140 ,	 Preclinical,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2003,	CCR5 and gp41 fusion inhibition,	Research,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	HIV Attachment Drug,	2006,	-1,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2003,	CCR5 and gp41 fusion inhibition,	Research,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	 HIV Co-receptor/HIV therapy           ,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2003,	Methylnaltrexone,	Phase III,	Joint Program,	61,	,	,	,	2009,	-0.8294,	"Symptom Management
and Supportive Care,"	,	opioid-induced constipation,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2003,	Methylnaltrexone,	Phase I,	Joint Program,	61,	,	,	,	,	,	"Symptom Management
and Supportive Care,"	,	opioid-induced constipation,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2003,	Methylnaltrexone,	Phase I,	Joint Program,	61,	26,	,	,	,	,	"Symptom Management
and Supportive Care,"	,	bowel dysfunction,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2003,	ProVax,	Research,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV vaccine,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2004,	GMK.,	Phase III,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2009,	-1,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2004,	PRO 542     ,	Phase 2,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	2007,	-0.9167,	HIV therapy,	,	HIV Infected Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2004,	PRO 140 ,	 Preclinical,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2004,	Monoclonal antibody,	Preclinical,	PSMA,	22,	,	,	,	2010,	-0.2727,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2004,	Viral-vector vaccine,	Preclinical,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2004,	Recombinant protein vaccine,	Phase I,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2004,	CCR5 and gp41 fusion inhibition,	Research,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	2006,	-1,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2004,	Methylnaltrexone,	Phase III,	Joint Program,	61,	,	,	,	2009,	-0.8294,	"Symptom Management
and Supportive Care,"	,	opioid-induced constipation,	 advanced medical illness,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2004,	Methylnaltrexone,	Phase II,	Joint Program,	61,	26,	,	,	,	,	"Symptom Management
and Supportive Care,"	,	Bowel Dysfunction,	,	Phase I,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2004,	Methylnaltrexone,	Phase 1,	Joint Program,	61,	,	,	,	,	,	"Symptom Management
and Supportive Care,"	,	opioid-induced constipation,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2004,	ProVax,	Research,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV vaccine,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2005,	Methylnaltrexone,	Phase III,	Joint Program,	61,	,	,	,	2009,	-0.8294,	"Symptom Management
and Supportive Care,"	,	opioid-induced constipation,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2005,	Methylnaltrexone,	Phase II,	Joint Program,	61,	26,	,	,	,	,	"Symptom Management
and Supportive Care,"	,	Bowel Dysfunction,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2005,	Methylnaltrexone,	Phase 1,	Joint Program,	61,	,	,	,	,	,	"Symptom Management
and Supportive Care,"	,	opioid-induced constipation,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2005,	PRO 542     ,	Phase 2,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	2007,	-0.996,	HIV therapy,	,	HIV Infected Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2005,	PRO 140 ,	 Preclinical,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2005,	ProVax,	Research,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV vaccine,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2005,	Monoclonal antibody,	 Preclinical,	PSMA,	22,	,	,	,	2010,	-0.2727,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2005,	Viral-vector vaccine,	 Preclinical,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2005,	Recombinant protein vaccine,	Phase I,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2005,	GMK.,	Phase III,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2009,	-1,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2005,	Hepatitis C therapeutic,	Research,	2.antiviral binding agent ("UnAB"),	23,	,	,	,	,	,	Virus Infection,	,	 hepatitis C ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2006,	Methylnaltrexone,	Phase III,	Joint Program,	61,	,	,	,	2009,	-0.8294,	"Symptom Management
and Supportive Care,"	,	opioid-induced constipation,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2006,	Methylnaltrexone,	Phase III,	Joint Program,	61,	26,	,	,	,	,	"Symptom Management
and Supportive Care,"	,	Bowel Dysfunction,	,	Phase II,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2006,	PRO 140 ,	Phase I,	 monoclonal antibody,,	23,	,	,	,	,	,	HIV therapy,	,	HIV Treatment,	,	Preclinical,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2006,	ProVax,	Research,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	HIV therapy,	,	HIV vaccine,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2006,	Monoclonal antibody,	 Preclinical,	PSMA,	22,	,	,	,	2010,	-0.2727,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2006,	Viral-vector vaccine,	 Preclinical,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2006,	Recombinant protein vaccine,	Phase I,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2006,	GMK.,	Phase III,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2009,	-1,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2006,	Hepatitis C therapeutic,	Research,	2.antiviral binding agent ("UnAB"),	23,	,	,	,	,	,	Virus Infection,	,	 hepatitis C ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2007,	Methylnaltrexone,	Phase III,	Joint Program,	26,	,	,	,	2009,	5.1429,	Gastroenterology,	"Symptom Management
and Supportive Care,"	opioid-induced constipation,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2007,	Methylnaltrexone,	Phase III,	Joint Program,	26,	,	,	,	,	,	Gastroenterology,	"Symptom Management
and Supportive Care,"	Bowel Dysfunction,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2007,	PRO 140 ,	Phase I,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	Virology,	HIV therapy,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2007,	ProVax,	Research,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	Virology,	HIV therapy,	HIV vaccine,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2007,	Hepatitis C therapeutic,	Research,	2.antiviral binding agent ("UnAB"),	23,	,	,	,	,	,	Virology,	Virus Infection,	 hepatitis C ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2007,	Monoclonal antibody,	 Preclinical,	PSMA,	22,	,	,	,	2010,	-0.2727,	Oncology,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2007,	Viral-vector vaccine,	 Preclinical,	PSMA,	22,	,	,	,	,	,	Oncology,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2007,	Recombinant protein vaccine,	Phase I,	PSMA,	22,	,	,	,	,	,	Oncology,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2007,	GMK.,	Phase III,	"1.ganglioside conjugate vaccine technology, which the Company uses
in its cancer program;,"	22,	,	,	,	2009,	-1,	Cancer,	,	Melonoma,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2008,	RELISTOR-Subcutaneous,	Marketed,	mu-opioid-receptor antagonist ,	26,	,	,	,	,	,	Gastroenterology,	,	opioid-induced constipation in patients receiving palliative care,	opioid-induced constipation,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2008,	RELISTOR-Subcutaneous,	Phase 3,	mu-opioid-receptor antagonist ,	62,	26,	,	,	,	,	Gastroenterology,	,	opioid-induced constipation in patients w/ Pain,	opioid-induced constipation,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2008,	RELISTOR-Subcutaneous,	Phase 2,	mu-opioid-receptor antagonist ,	26,	,	,	,	,	,	Gastroenterology,	,	opioid-induced constipation in patients from Surgical Procedure,	opioid-induced constipation,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2008,	RELISTOR-Subcutaneous,	Phase III,	mu-opioid-receptor antagonist ,	26,	,	,	,	,	,	Gastroenterology,	,	Bowel Dysfunction,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2008,	PRO 140 ,	Phase II,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	Virology,	,	HIV Treatment,	,	Phase I,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2008,	ProVax,	Research,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	Virology,	,	HIV vaccine,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2008,	Hepatitis C therapeutic,	Research,	2.antiviral binding agent ("UnAB"),	23,	,	,	,	,	,	Virology,	,	 hepatitis C ,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2008,	Monoclonal antibody,	 Preclinical,	PSMA,	22,	,	,	,	2010,	0.1429,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2008,	Viral-vector vaccine,	 Preclinical,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2008,	Recombinant protein vaccine,	Phase I,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2009,	RELISTOR-Subcutaneous,	Marketed,	mu-opioid-receptor antagonist ,	26,	,	,	,	,	,	Gastroenterology,	,	opioid-induced constipation in patients receiving palliative care,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2009,	RELISTOR-Subcutaneous,	Phase 3,	mu-opioid-receptor antagonist ,	62,	26,	,	,	,	,	Gastroenterology,	,	opioid-induced constipation in patients w/ Pain,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2009,	RELISTOR-Subcutaneous,	Phase 2,	mu-opioid-receptor antagonist ,	26,	,	,	,	,	,	Gastroenterology,	,	opioid-induced constipation in patients from Surgical Procedure,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2009,	RELISTOR-Oral,	Phase II,	mu-opioid-receptor antagonist ,	26,	,	,	,	,	,	Gastroenterology,	,	" 
Treatment of OIC.,"	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2009,	PRO 140 ,	Phase II,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	Virology,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2009,	ProVax,	Research,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	Virology,	,	HIV vaccine,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2009,	PRO 206,	Preclinical,	2.antiviral binding agent ("UnAB"),	23,	,	,	Hepatitis C therapeutic,	,	,	Virology,	,	 hepatitis C ,	,	Research,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2009,	Viral-vector vaccine,	Phase I,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	Preclinical,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2009,	Viral-vector vaccine,	Phase I,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	Preclinical,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2009,	Viral-vector vaccine,	Phase I,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	Preclinical,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2009,	Recombinant protein vaccine,	Phase I,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2009,	Recombinant protein vaccine,	Phase I,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2009,	PSMA ADC,	 Preclinical,	PSMA,	22,	,	,	Monoclonol Antibody,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2010,	RELISTOR-Subcutaneous,	Marketed,	mu-opioid-receptor antagonist ,	26,	,	,	,	,	,	Gastroenterology,	,	opioid-induced constipation in patients receiving palliative care,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2010,	RELISTOR-Subcutaneous,	Phase 3,	mu-opioid-receptor antagonist ,	62,	26,	,	,	,	,	Gastroenterology,	,	opioid-induced constipation in patients w/ Pain,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2010,	RELISTOR-Oral,	Phase II,	mu-opioid-receptor antagonist ,	26,	,	,	,	,	,	Gastroenterology,	,	" 
Treatment of OIC.,"	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2010,	Viral-vector vaccine,	Phase I,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2010,	Viral-vector vaccine,	Phase I,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2010,	Viral-vector vaccine,	Phase I,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2010,	Recombinant protein vaccine,	Phase I,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2010,	Recombinant protein vaccine,	Phase I,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2010,	PSMA ADC,	Phase 1,	PSMA,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	Preclinical,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2010,	PRO 140 ,	Phase II,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	Virology,	,	HIV Treatment,	,	,
wvcs19970000835887,	PROGENICS PHARMACEUTICALS INC,	10-K,	1996,	2010,	ProVax,	Research,	"2.antiviral binding agent (""UnAB"")
technology, which the Company uses in its HIV program.,"	23,	,	,	,	,	,	Virology,	,	HIV vaccine,	,	,
wvcs20040001172480,	SANTARUS INC,	S-1,	2003,	2003,	Rapinex powder-for- suspension,	NDA ,	immediate-release PPI,	21,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	S-1,	2003,	2003,	Rapinex powder-for- suspension,	Phase III ,	immediate-release PPI,	26,	,	,	,	,	,	gastrointestinal diseases and disorders,	,	Prevention of Upper GI Bleeding in Critically Ill Patients,	,	,
wvcs20040001172480,	SANTARUS INC,	S-1,	2003,	2003,	Rapinex capsule,	Preclinical,	immediate-release PPI,	21,	26,	,	,	2011,	-0.0967,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	S-1,	2003,	2003,	Rapinex chewable tablet,	Preclinical,	immediate-release PPI,	21,	26,	,	,	2009,	0.458,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	424,	2003,	2004,	Rapinex powder-for- suspension,	NDA ,	immediate-release PPI,	21,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	424,	2003,	2004,	Rapinex powder-for- suspension,	Phase III ,	immediate-release PPI,	26,	,	,	,	,	,	gastrointestinal diseases and disorders,	,	Prevention of Upper GI Bleeding in Critically Ill Patients,	,	,
wvcs20040001172480,	SANTARUS INC,	424,	2003,	2004,	Rapinex capsule,	Preclinical,	immediate-release PPI,	21,	26,	,	,	2011,	-0.0967,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	424,	2003,	2004,	Rapinex chewable tablet,	Preclinical,	immediate-release PPI,	21,	26,	,	,	2009,	0.458,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2005,	Zegerid powder-for- suspension,	Marketed,	immediate-release PPI,	21,	26,	,	Rapinex powder-for- suspension,	,	,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	yes,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2005,	Zegerid  powder-for- suspension,	Marketed,	immediate-release PPI,	26,	,	,	Rapinex powder-for- suspension,	2010,	-0.2393,	gastrointestinal diseases and disorders,	,	Prevention of Upper GI Bleeding in Critically Ill Patients,	,	yes,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2005,	Zegerid capsule,	Clinical Trials,	immediate-release PPI,	21,	26,	,	Rapinex capsule,	2011,	-0.0967,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	yes,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2005,	Zegerid  chewable tablet,	Clinical Trials,	immediate-release PPI,	21,	26,	,	Rapinex chewable tablet,	2009,	0.458,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	yes,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2006,	Zegerid powder-for- suspension,	Marketed,	immediate-release PPI,	21,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2006,	Zegerid  powder-for- suspension,	Marketed,	immediate-release PPI,	26,	,	,	,	2010,	-0.2393,	gastrointestinal diseases and disorders,	,	Prevention of Upper GI Bleeding in Critically Ill Patients,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2006,	Zegerid capsule,	Marketed,	immediate-release PPI,	21,	26,	,	,	2011,	-0.0967,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	yes,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2006,	Zegerid  chewable tablet,	NDA,	immediate-release PPI,	21,	26,	,	Rapinex chewable tablet,	2009,	0.458,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	yes,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2007,	Zegerid powder-for- suspension,	Marketed,	immediate-release PPI,	21,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2007,	Zegerid  powder-for- suspension,	Marketed,	immediate-release PPI,	26,	,	,	,	2010,	-0.2393,	gastrointestinal diseases and disorders,	,	Prevention of Upper GI Bleeding in Critically Ill Patients,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2007,	Zegerid capsule,	Marketed,	immediate-release PPI,	21,	26,	,	,	2011,	-0.0967,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2007,	Zegerid  chewable tablet,	NDA,	immediate-release PPI,	21,	26,	,	,	2009,	0.29,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2008,	Zegerid powder-for- suspension,	Marketed,	immediate-release PPI,	21,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2008,	Zegerid  powder-for- suspension,	Marketed,	immediate-release PPI,	26,	,	,	,	2010,	0.1897,	gastrointestinal diseases and disorders,	,	Prevention of Upper GI Bleeding in Critically Ill Patients,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2008,	Zegerid capsule,	Marketed,	immediate-release PPI,	21,	26,	,	,	2011,	-0.0967,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2009,	Zegerid® Capsules and Powder for Oral Suspension ,	Marketed,	immediate-release PPI,	21,	26,	,	Zegerid powder-for- suspension,	,	,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2009,	Glumetza® Extended Release Tablets ,	Marketed,	patented drug delivery technology,	24,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Type 2 Diabetes,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2009,	Zegerid® Tablet Formulation,	NDA,	immediate-release PPI,	21,	26,	,	Zegerid capsule,	2011,	0.5283,	gastrointestinal diseases and disorders,	,	Heartburn/GERD, Erosive Esophagitis, Duodenal and Gastric Ulcers,	,	yes,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2009,	OTC Zegerid,	NDA,	immediate-release PPI,	21,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Heartburn,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2009,	Budesonide MMX®,	 phase III,	 MMX technology,	26,	,	,	,	,	,	gastrointestinal diseases and disorders,	,	Ulcerative Colitis,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2009,	Rifamycin SV MMX®,	phase III ,	 MMX technology,	26,	,	,	,	,	,	gastrointestinal diseases and disorders,	,	Traveler’s Diarrhea,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2010,	Zegerid® Capsules and Powder for Oral Suspension ,	Marketed,	immediate-release PPI,	21,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2010,	Glumetza® Extended Release Tablets ,	Marketed,	patented drug delivery technology,	24,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Type 2 Diabetes,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2010,	Immediate-release Omeprazole Tablets,	NDA,	immediate-release PPI,	21,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Heartburn/GERD, Erosive Esophagitis, Duodenal and Gastric Ulcers,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2010,	OTC Zegerid,	NDA,	immediate-release PPI,	21,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Heartburn,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2010,	Budesonide MMX®,	 phase III,	 MMX technology,	26,	,	,	,	,	,	gastrointestinal diseases and disorders,	,	Ulcerative Colitis,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2010,	Rifamycin SV MMX®,	phase III ,	 MMX technology,	26,	,	,	,	,	,	gastrointestinal diseases and disorders,	,	Traveler’s Diarrhea,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2011,	Zegerid® Capsules and Powder for Oral Suspension ,	Marketed,	immediate-release PPI,	21,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2011,	Glumetza® Extended Release Tablets ,	Marketed,	patented drug delivery technology,	24,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Type 2 Diabetes,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2011,	Cycloset® (bromocriptine mesylate) tablets,	Marketed ,	dopamine receptor,	24,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Type 2 Diabetes,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2011,	Rhucin® ,	phase III,	transgenic technology,	30,	,	,	,	,	,	Hereditary Diseases,	,	angioedema,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2011,	Budesonide MMX®,	 phase III,	 MMX technology,	26,	,	,	,	,	,	gastrointestinal diseases and disorders,	,	Ulcerative Colitis,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2011,	Rifamycin SV MMX®,	phase III ,	 MMX technology,	26,	,	,	,	,	,	gastrointestinal diseases and disorders,	,	Traveler’s Diarrhea,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2011,	Merck Zegerid OTC®,	Marketed ,	immediate-release PPI,	21,	26,	,	OTC Zegerid,	,	,	gastrointestinal diseases and disorders,	,	Heartburn,	,	yes,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2011,	GlaxoSmithKline Immediate-release Omeprazole products,	NDA,	immediate-release PPI,	21,	26,	,	Immediate-release Omeprazole Tablets,	,	,	gastrointestinal diseases and disorders,	,	Heartburn/GERD, Erosive Esophagitis, Duodenal and Gastric Ulcers,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2012,	Fenoglide® (fenofibrate) tablets,	Marketed ,	dopamine receptor,	24,	26,	,	Cycloset® (bromocriptine mesylate) tablets,	,	,	gastrointestinal diseases and disorders,	,	Type 2 Diabetes,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2012,	Zegerid® Capsules and Powder for Oral Suspension ,	Marketed,	immediate-release PPI,	21,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Heartburn/ GERD, EE, DU,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2012,	Glumetza® Extended Release Tablets ,	Marketed,	patented drug delivery technology,	24,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Type 2 Diabetes,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2012,	Cycloset® (bromocriptine mesylate) tablets,	Marketed ,	dopamine receptor,	24,	26,	,	,	,	,	gastrointestinal diseases and disorders,	,	Type 2 Diabetes,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2012,	Uceris™ (budesonide) tablets,	NDA,	 MMX technology,	26,	,	,	Budesonide MMX®,	,	,	gastrointestinal diseases and disorders,	,	Ulcerative Colitis,	,	yes,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2012,	Rifamycin SV MMX®,	phase III ,	 MMX technology,	26,	,	,	,	,	,	gastrointestinal diseases and disorders,	,	Traveler’s Diarrhea,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2012,	Rhucin® ,	phase III,	transgenic technology,	30,	,	,	,	,	,	Hereditary Diseases,	,	angioedema,	,	,
wvcs20040001172480,	SANTARUS INC,	10-K,	2003,	2012,	SAN-300 (anti-VLA-1 mAb,	Phase I,	monoclonal antibody,	5,	20,	,	,	,	,	autoimmune diseases,	,	rheumatoid arthritis,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	S-1,	2000,	2000,	SGN-15 ,	Phase II,	"mAb-drug
conjugate,"	22,	,	,	,	2007,	-0.6585,	therapeutic,	,	Breast Cancer,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	S-1,	2000,	2000,	SGN-10,	Phase I,	Single-chain immunotoxin,	22,	,	,	,	2004,	-0.9375,	therapeutic,	,	Lung Cancer,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	S-1,	2000,	2000,	SGN-14,	Preclinical,	Genetically-engineered mAb,	27,	,	,	,	2004,	-0.7143,	therapeutic,	,	Melonoma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	424,	2000,	2001,	SGN-15 ,	Phase II,	"mAb-drug
conjugate,"	22,	,	,	,	2007,	-0.6585,	therapeutic,	,	Breast Cancer,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	424,	2000,	2001,	SGN-10,	Phase I,	Single-chain immunotoxin,	22,	,	,	,	2004,	-0.9375,	therapeutic,	,	Lung Cancer,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	424,	2000,	2001,	SGN-14,	Preclinical,	Genetically engineered monoclonal antibody,	27,	,	,	,	2004,	-0.7143,	therapeutic,	,	Melonoma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2002,	SGN-15 ,	Phase II,	"mAb-drug
conjugate,"	22,	,	,	,	2007,	-0.6585,	therapeutic,	,	Breast Cancer,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2002,	SGN-10,	Phase I,	Single-chain immunotoxin,	22,	,	,	,	2004,	-0.9512,	therapeutic,	,	Lung Cancer,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2002,	SGN-30,	Phase I,	Genetically engineered monoclonal antibody,	27,	,	,	,	2009,	-0.6316,	therapeutic,	,	Hematologic malignancies,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2002,	SGN-14,	Phase I,	Genetically-engineered mAb,	27,	,	,	,	2004,	-0.8947,	therapeutic,	,	Melonoma,	,	yes,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2003,	SGN-15 ,	Phase II,	"mAb-drug
conjugate,"	22,	,	,	,	2007,	-0.6585,	therapeutic,	,	Breast Cancer,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2003,	SGN-30,	Phase I,	Genetically engineered monoclonal antibody,	,	,	,	,	2009,	-0.6316,	therapeutic,	,	Hematologic malignancies,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2003,	SGN-40,	Phase I,	Genetically engineered monoclonal antibody,	27,	,	,	formerly SGN-14,	,	,	therapeutic,	,	Hematologic malignancies,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2003,	SGN-15 ,	Phase II,	"mAb-drug
conjugate,"	22,	,	,	,	,	,	therapeutic,	,	Prostate Cancer,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2004,	SGN-15 ,	Phase II,	"mAb-drug
conjugate,"	22,	,	,	,	2007,	-0.6585,	therapeutic,	,	Non-small cell lung cancer i,	Breast Cancer,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2004,	SGN-30,	Phase II,	Genetically engineered monoclonal antibody,	,	,	,	,	2009,	-0.6316,	therapeutic,	,	Hodgkin’s disease,	Hematologic malignancies,	yes,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2004,	SGN-40,	Phase I,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	Multiple myeloma,	Non-Hodgkin’s lymphoma,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2004,	SGN-40,	Phase I,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	Non-Hodgkin’s lymphoma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2004,	SGN-30,	Phase II,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	Systemic anaplastic large cell lymphoma,	Hematologic malignancies,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2004,	SGN-35,	Pre Clinical,	"mAb-drug
conjugate,"	,	,	,	,	,	,	therapeutic,	,	Hematologic malignancies,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2005,	SGN-15 ,	Phase II,	"mAb-drug
conjugate,"	22,	,	,	,	2007,	-0.906,	therapeutic,	,	Non-small cell lung cancer i,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2005,	SGN-30,	Phase II,	Genetically engineered monoclonal antibody,	,	,	,	,	2009,	-0.6316,	therapeutic,	,	Hodgkin’s disease,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2005,	SGN-40,	Phase I,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	Multiple myeloma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2005,	SGN-40,	Phase I,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	Non-Hodgkin’s lymphoma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2005,	SGN-30,	Phase II,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	Systemic anaplastic large cell lymphoma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2005,	SGN-35,	Pre Clinical,	ADC,	,	,	,	,	,	,	therapeutic,	,	Hematologic malignancies,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2006,	SGN-33,	Phase I,	Genetically engineered monoclonal antibody,	9,	27,	,	,	,	,	therapeutic,	,	Acute myeloid leukemia (AML),	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2006,	SGN-30,	Phase II,	Genetically engineered monoclonal antibody,	,	,	,	,	2009,	-0.6316,	therapeutic,	,	Hodgkin’s disease,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2006,	SGN-30,	Phase II,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	Systemic anaplastic large cell lymphoma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2006,	SGN-30,	Phase II,	Genetically engineered monoclonal antibody,	,	,	,	,	,	,	therapeutic,	,	Cutaneous ALCL,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2006,	SGN-40,	Phase I,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	Multiple myeloma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2006,	SGN-40,	Phase I,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	Non-Hodgkin’s lymphoma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2006,	SGN-33,	Phase I,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	Myelodysplastic syndromes (MDS),	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2006,	SGN-35,	Phase I,	ADC,	27,	,	,	,	,	,	therapeutic,	,	Hematologic malignancies,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2007,	SGN-33,	Phase I,	Genetically engineered monoclonal antibody,	9,	27,	,	,	,	,	therapeutic,	,	Acute myeloid leukemia (AML),	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2007,	SGN-30,	Phase II,	Genetically engineered monoclonal antibody,	,	,	,	,	2009,	2.5,	therapeutic,	,	Hodgkin’s disease,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2007,	SGN-30,	Phase II,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	Systemic anaplastic large cell lymphoma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2007,	SGN-30,	Phase II,	Genetically engineered monoclonal antibody,	,	,	,	,	,	,	therapeutic,	,	Cutaneous ALCL,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2007,	SGN-40,	Phase I,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	Multiple myeloma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2007,	SGN-40,	Phase I,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	Non-Hodgkin’s lymphoma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2007,	SGN-33,	Phase I,	Genetically engineered monoclonal antibody,	,	,	,	,	,	,	therapeutic,	,	Myelodysplastic syndromes (MDS),	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2007,	SGN-35,	Phase I,	ADC,	,	,	,	,	,	,	therapeutic,	,	Hematologic malignancies,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2008,	SGN-40,	Phase II,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	Multiple myeloma,	,	yes,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2008,	SGN-40,	Phase I,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	Non-Hodgkin’s lymphoma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2008,	SGN-33,	Phase II,	Genetically engineered monoclonal antibody,	,	,	,	,	,	,	therapeutic,	,	Myelodysplastic syndromes (MDS),	,	yes,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2008,	SGN-35,	Phase I,	ADC,	27,	,	,	,	,	,	therapeutic,	,	Hodgkin lymphoma,	Hematologic malignancies,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2008,	SGN-75,	Preclinical,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	hematologic malignancies,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2009,	SGN-35,	Phase II,	ADC,	27,	,	,	,	,	,	therapeutic,	,	Hodgkin lymphoma,	,	yes,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2009,	Dacetuzumab (SGN-40),	Phase III,	Genetically engineered monoclonal antibody,	27,	,	,	yes,	,	,	therapeutic,	,	large B-cell lymphoma,	Non-Hodgkin’s lymphoma,	yes,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2009,	Lintuzumab (SGN-33),	Phase II,	Genetically engineered monoclonal antibody,	27,	,	,	yes,	,	,	therapeutic,	,	Myelodysplastic syndromes (MDS),	,	yes,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2009,	Lintuzumab,	Phase II,	Genetically engineered monoclonal antibody,	27,	,	,	SGN-33,	2011,	9,	therapeutic,	,	AML,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2009,	SGN-75,	Preclinical,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	hematologic malignancies,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2010,	Brentuximab vedotin,	Phase II,	Genetically engineered monoclonal antibody,	,	,	,	SGN-35,	,	,	therapeutic,	,	sALCL,	Hodgkin lymphoma,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2010,	Brentuximab vedotin (SGN-35),	Phase II,	ADC,	27,	,	,	,	,	,	therapeutic,	,	Hodgkin lymphoma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2010,	Lintuzumab (SGN-33),	Phase II,	Genetically engineered monoclonal antibody,	,	,	,	,	,	,	therapeutic,	,	AML,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2010,	Dacetuzumab (SGN-40),	Phase III,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	non-Hodgkin lymphoma,	large B-cell lymphoma,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2010,	SGN-75,	Phase I,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	hematologic malignancies,	,	yes,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2011,	Brentuximab vedotin (SGN-35),	Marketed,	Genetically engineered monoclonal antibody,	,	,	,	,	,	,	therapeutic,	,	sALCL,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2011,	Brentuximab vedotin (SGN-35),	Marketed,	ADC,	27,	,	,	,	,	,	therapeutic,	,	Hodgkin lymphoma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2011,	SGN-75,	Phase I,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	hematologic malignancies,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2011,	Dacetuzumab (SGN-40),	Phase III,	Genetically engineered monoclonal antibody,	27,	,	,	,	,	,	therapeutic,	,	non-Hodgkin lymphoma,	,	,
wvcs20010001060736,	SEATTLE GENETICS INC,	10-K,	2000,	2011,	ASG-5ME,	Phase I,	ADC,	22,	,	,	,	,	,	therapeutic,	,	Pancreatic Cancer,	,	,
wvcs20040001262175,	TERCICA INC,	S-1,	2004,	2004,	rhIGF-1,	Phase III ,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Severe Pediatric IGFD,	,	,
wvcs20040001262175,	TERCICA INC,	S-1,	2004,	2004,	rhIGF-1,	Phase III ,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Pediatric IGFD,	,	,
wvcs20040001262175,	TERCICA INC,	S-1,	2004,	2004,	rhIGF-1,	Phase II ,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Adult IGFD,	,	,
wvcs20040001262175,	TERCICA INC,	S-1,	2004,	2004,	rhIGF-1,	Phase II ,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Type A diabetes,	,	,
wvcs20040001262175,	TERCICA INC,	S-1,	2004,	2004,	rhIGF-1,	Phase II ,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Type 2 diabetes with Severe Insulin Resistance,	,	,
wvcs20040001262175,	TERCICA INC,	424,	2004,	2004,	rhIGF-1,	Phase III ,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Severe Pediatric IGFD,	,	,
wvcs20040001262175,	TERCICA INC,	424,	2004,	2004,	rhIGF-1,	Phase III ,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Pediatric IGFD,	,	,
wvcs20040001262175,	TERCICA INC,	424,	2004,	2004,	rhIGF-1,	Phase II ,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Adult IGFD,	,	,
wvcs20040001262175,	TERCICA INC,	424,	2004,	2004,	rhIGF-1,	Phase II ,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Type A diabetes,	,	,
wvcs20040001262175,	TERCICA INC,	424,	2004,	2004,	rhIGF-1,	Phase II ,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Type 2 diabetes with Severe Insulin Resistance,	Pediatric IGFD,	,
wvcs20040001262175,	TERCICA INC,	10-K,	2004,	2005,	rhIGF-1,	Phase III ,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Severe Pediatric IGFD,	,	,
wvcs20040001262175,	TERCICA INC,	10-K,	2004,	2005,	rhIGF-1,	Phase III ,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Primary IGFD,	Type 2 diabetes with Severe Insulin Resistance,	,
wvcs20040001262175,	TERCICA INC,	10-K,	2004,	2005,	rhIGF-1,	Assessing potential development strategy,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Adult IGFD,	,	yes,
wvcs20040001262175,	TERCICA INC,	10-K,	2004,	2005,	rhIGF-1,	Assessing potential development strategy,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Diabetes,	,	yes,
wvcs20040001262175,	TERCICA INC,	10-K,	2004,	2006,	Increlex,	Marketed,	IGF-1,	24,	,	,	rhIGF-1,	,	,	therapeutics,	,	Severe Pediatric IGFD,	,	Phase III ,
wvcs20040001262175,	TERCICA INC,	10-K,	2004,	2006,	Increlex,	Phase III ,	IGF-1,	24,	,	,	rhIGF-1,	,	,	therapeutics,	,	Primary IGFD,	,	,
wvcs20040001262175,	TERCICA INC,	10-K,	2004,	2006,	Increlex,	Assessing potential development strategy,	IGF-1,	24,	,	,	rhIGF-1,	,	,	therapeutics,	,	Adult IGFD,	,	,
wvcs20040001262175,	TERCICA INC,	10-K,	2004,	2006,	Increlex,	Assessing potential development strategy,	IGF-1,	24,	,	,	rhIGF-1,	,	,	therapeutics,	,	Diabetes,	,	,
wvcs20040001262175,	TERCICA INC,	10-K,	2004,	2007,	Increlex,	Marketed,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Severe Pediatric IGFD,	,	,
wvcs20040001262175,	TERCICA INC,	10-K,	2004,	2007,	Increlex,	Phase III ,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Primary IGFD,	,	,
wvcs20040001262175,	TERCICA INC,	10-K,	2004,	2007,	 Somatuline® Autogel®,	Marketed,	Somatostatin analogues,	24,	,	,	,	,	,	therapeutics,	,	 acromegaly ,	,	,
wvcs20040001262175,	TERCICA INC,	10-K,	2004,	2008,	Increlex,	Marketed,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Severe Pediatric IGFD,	,	,
wvcs20040001262175,	TERCICA INC,	10-K,	2004,	2008,	Increlex,	Phase III ,	IGF-1,	24,	,	,	,	,	,	therapeutics,	,	Primary IGFD,	,	,
wvcs20040001262175,	TERCICA INC,	10-K,	2004,	2008,	 Somatuline® Autogel®,	Marketed,	Somatostatin analogues,	,	,	,	,	,	,	therapeutics,	,	 acromegaly ,	,	,
wvcs20040001080014,	THERAVANCE INC,	S-1,	2004,	2004,	GSK 159797,	Phase II,	Multivalency,	5,	29,	,	,	2007,	0,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	S-1,	2004,	2004,	 GSK 159901,	Phase II,	Multivalency,	5,	29,	,	,	2007,	0,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	S-1,	2004,	2004,	TD-5742,	Pre clinical,	Multivalency,	5,	29,	,	,	2008,	-0.5,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	S-1,	2004,	2004,	 telavancin,	Phase 2 ,	Multivalency,	23,	,	,	,	2007,	0.8409,	Bacterial Infections,	,	Bacterial Infections,	,	,
wvcs20040001080014,	THERAVANCE INC,	S-1,	2004,	2004,	TD-6301,	Phase I,	Multivalency,	3,	,	,	,	2007,	-0.7273,	overactive bladder,	,	Overactive Bladder,	,	,
wvcs20040001080014,	THERAVANCE INC,	S-1,	2004,	2004,	 TD-2749,	Phase I,	Multivalency,	26,	,	,	,	2009,	-1,	Gastrointestinal Motility Dysfunction,	,	Gastrointestinal Motility Dysfunction,	,	,
wvcs20040001080014,	THERAVANCE INC,	S-1,	2004,	2004,	   TD-4756,	Pre clinical,	Multivalency,	61,	9,	25,	,	2007,	-1,	Anesthesia,	,	Anesthesia,	,	,
wvcs20040001080014,	THERAVANCE INC,	424,	2004,	2004,	GSK 159797,	Phase II,	Multivalency,	5,	29,	,	,	2007,	0,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	424,	2004,	2004,	 GSK 159901,	Phase II,	Multivalency,	5,	29,	,	,	2007,	0,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	424,	2004,	2004,	TD-5742,	Pre clinical,	Multivalency,	5,	29,	,	,	2008,	-0.5,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	424,	2004,	2004,	 telavancin,	Phase 2 ,	Multivalency,	23,	,	,	,	2007,	0.8409,	Bacterial Infections,	,	Bacterial Infections,	,	,
wvcs20040001080014,	THERAVANCE INC,	424,	2004,	2004,	TD-6301,	Phase I,	Multivalency,	3,	,	,	,	2007,	-0.7273,	overactive bladder,	,	Overactive Bladder,	,	,
wvcs20040001080014,	THERAVANCE INC,	424,	2004,	2004,	 TD-2749,	Phase I,	Multivalency,	26,	,	,	,	2009,	-1,	Gastrointestinal Motility Dysfunction,	,	Gastrointestinal Motility Dysfunction,	,	,
wvcs20040001080014,	THERAVANCE INC,	424,	2004,	2004,	   TD-4756,	Pre clinical,	Multivalency,	61,	9,	25,	,	2007,	-1,	Anesthesia,	,	Anesthesia,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2005,	GSK 159797,	Phase II,	Multivalency,	5,	29,	,	,	2007,	-0.6,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2005,	 GSK 159901,	Phase II,	Multivalency,	5,	29,	,	,	2007,	-0.6,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2005,	TD-5742,	Phase I,	Multivalency,	5,	29,	,	,	2008,	-0.5,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	yes,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2005,	 telavancin,	Phase III,	Multivalency,	23,	,	,	,	2007,	39.5,	Bacterial Infections,	,	Bacterial Infections,	,	yes,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2005,	TD-6301,	Phase I,	Multivalency,	3,	,	,	,	2007,	0.5,	overactive bladder,	,	Overactive Bladder,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2005,	 TD-2749,	Phase I,	Multivalency,	26,	,	,	,	2009,	-1,	Gastrointestinal Motility Dysfunction,	,	Gastrointestinal Motility Dysfunction,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2005,	   TD-4756,	Pre clinical,	Multivalency,	61,	9,	25,	,	2007,	-1,	Anesthesia,	,	Anesthesia,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2005,	GSK 1578007,	Phase II,	Multivalency,	5,	29,	,	,	2007,	-1,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2006,	 telavancin cSSSI ,	Phase III,	Multivalency,	8,	23,	,	,	,	,	Bacterial Infections,	,	 skin and skin structure infections,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2006,	 telavancin HAP,	Phase III,	Multivalency,	23,	29,	,	,	2011,	-0.5638,	Bacterial Infections,	,	 hospital-acquired pneumonia ,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2006,	 Beyond Advair,	 Phase 2,	Multivalency,	5,	29,	,	,	2010,	-0.25,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2006,	TD-5742,	Phase I,	Multivalency,	5,	29,	,	,	2008,	-0.75,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2006,	 TD-5108,	Pre clinical,	Multivalency,	26,	,	,	,	2011,	0.2,	Gastrointestinal Motility Dysfunction,	,	chronic idiopathic constipation (CIC), constipation-predominant irritable bowel syndrome (C-IBS),	Gastrointestinal Motility Dysfunction,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2006,	 TD-2749,	Phase I,	Multivalency,	26,	,	,	,	2009,	-1,	Gastrointestinal Motility Dysfunction,	,	chronic idiopathic constipation (CIC), constipation-predominant irritable bowel syndrome (C-IBS),	Gastrointestinal Motility Dysfunction,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2007,	 telavancin cSSSI ,	NDA,	Multivalency,	8,	23,	,	,	,	,	Bacterial Infections,	,	 skin and skin structure infections,	,	yes,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2007,	 telavancin HAP,	Phase III,	Multivalency,	23,	29,	,	,	2011,	-0.5638,	Bacterial Infections,	,	 hospital-acquired pneumonia ,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2007,	TD-1792,	 Phase 2,	Multivalency,	23,	,	,	,	2010,	-0.8182,	Bacterial Infections,	,	MRSA,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2007,	 Beyond Advair,	 Phase 2,	Multivalency,	5,	29,	,	,	2010,	-0.25,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2007,	TD-5742 t (LAMA),	Phase I,	Multivalency,	5,	29,	,	,	2010,	0,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2007,	GSK961081  (MABA),	Phase I,	Multivalency,	5,	29,	,	,	,	,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2007,	 TD-5108,	Phase I,	Multivalency,	26,	,	,	,	2011,	0.2,	Gastrointestinal Motility Dysfunction,	,	chronic idiopathic constipation (CIC), constipation-predominant irritable bowel syndrome (C-IBS),	,	yes,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2007,	 TD-2749,	Phase I,	Multivalency,	26,	,	,	,	2009,	-1,	Gastrointestinal Motility Dysfunction,	,	chronic idiopathic constipation (CIC), constipation-predominant irritable bowel syndrome (C-IBS),	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2008,	 telavancin cSSSI ,	NDA,	Multivalency,	8,	23,	,	,	,	,	Bacterial Infections,	,	 skin and skin structure infections,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2008,	 telavancin HAP,	Phase III,	Multivalency,	23,	29,	,	,	2011,	-0.5638,	Bacterial Infections,	,	 hospital-acquired pneumonia ,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2008,	TD-1792,	 Phase 2,	Multivalency,	23,	,	,	,	2010,	-0.9732,	Bacterial Infections,	,	MRSA,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2008,	 Beyond Advair,	 Phase 2,	Multivalency,	5,	29,	,	,	2010,	-0.9799,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2008,	TD-5742 t (LAMA),	Phase I,	Multivalency,	5,	29,	,	,	2010,	-0.9933,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2008,	Horizon ,	 Phase 2,	Multivalency,	5,	29,	,	,	2011,	-0.9574,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2008,	GSK961081  (MABA),	Phase II,	Multivalency,	5,	29,	,	,	,	,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	yes,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2008,	 TD-5108,	Phase II,	Multivalency,	26,	,	,	,	2011,	0.2,	Gastrointestinal Motility Dysfunction,	,	chronic idiopathic constipation (CIC), constipation-predominant irritable bowel syndrome (C-IBS),	,	yes,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2009,	 telavancin cSSSI ,	NDA,	Multivalency,	8,	23,	,	,	,	,	Bacterial Infections,	,	 skin and skin structure infections,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2009,	 telavancin HAP,	NDA,	Multivalency,	23,	29,	,	,	2011,	15.25,	Bacterial Infections,	,	 hospital-acquired pneumonia ,	,	yes,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2009,	Horizon ,	 Phase 2,	Multivalency,	5,	29,	,	,	2011,	-0.5,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2009,	GSK961081  (MABA),	Phase II,	Multivalency,	5,	29,	,	,	,	,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2009,	 TD-5108,	Phase II,	Multivalency,	26,	,	,	,	2011,	0.5,	Gastrointestinal Motility Dysfunction,	,	chronic idiopathic constipation (CIC), constipation-predominant irritable bowel syndrome (C-IBS),	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2010,	telavancin NP ,	NDA,	Multivalency,	8,	23,	,	 telavancin cSSSI ,	,	,	Bacterial Infections,	,	 skin and skin structure infections,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2010,	TD-1792,	 Phase 2,	Multivalency,	23,	,	,	,	,	,	Bacterial Infections,	,	MRSA,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2010,	RELOVAIRTM ,	Phase III,	Multivalency,	29,	,	,	,	,	,	Respiratory Disease,	,	 COPD,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2010,	RELOVAIRTM ,	Phase II,	Multivalency,	5,	29,	,	,	,	,	Respiratory Disease,	,	asthma,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2010,	GSK961081  (MABA),	Phase II,	Multivalency,	5,	29,	,	,	,	,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2011,	telavancin NP ,	NDA,	Multivalency,	8,	23,	,	 telavancin cSSSI ,	,	,	Bacterial Infections,	,	 skin and skin structure infections,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2011,	TD-1792,	 Phase 2,	Multivalency,	23,	,	,	,	,	,	Bacterial Infections,	,	MRSA,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2011,	RELOVAIRTM ,	Phase III,	Multivalency,	29,	,	,	,	,	,	Respiratory Disease,	,	 COPD,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2011,	RELOVAIRTM ,	Phase III,	Multivalency,	5,	29,	,	,	,	,	Respiratory Disease,	,	asthma,	,	yes,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2011,	LAMA GSK573719,	Phase III,	Multivalency,	29,	,	,	,	,	,	Respiratory Disease,	,	 COPD,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2011,	GSK961081  (MABA),	Phase II,	Multivalency,	5,	29,	,	,	,	,	Respiratory Disease,	,	Asthma and Chronic Obstructive Pulmonary Disease,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2011,	TD-1211,	Phase II,	Multivalency,	40,	,	,	,	,	,	Central Nervous System (CNS)/Pain,	,	 opioid-induced constipation,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2011,	TD-9855,	Phase I,	Multivalency,	62,	42,	,	,	,	,	Central Nervous System (CNS)/Pain,	,	neuropathic pain,,	,	,
wvcs20040001080014,	THERAVANCE INC,	10-K,	2004,	2011,	TD-5108,	Phase I,	Multivalency,	40,	,	,	,	,	,	cognitive disorders,	,	Alzheimer's disease,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	S-1,	2000,	2000,	Genotyping Product Catalog and Panels,	Preclinical,	Invader operating system,	30,	,	,	,	2006,	-1,	Research Market,	,	mutation or gene expression profiles,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	S-1,	2000,	2000,	Gene Expression Product Catalog and Panels.,	Preclinical,	Invader operating system,	30,	,	,	,	,	,	Research Market,	,	mutation or gene expression profiles,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	S-1,	2000,	2000,	Genotyping Product Catalog and Panels,	Preclinical,	Invader operating system,	23,	30,	,	,	,	,	Clinical Market,	,	infectious and inherited diseases.,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	S-1,	2000,	2000,	Quantification Product Catalog and Panels.,	Preclinical,	Invader operating system,	23,	30,	,	,	2003,	0.8333,	Clinical Market,	,	infectious and inherited diseases.,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	424,	2000,	2001,	Genotyping Product Catalog and Panels,	Preclinical,	Invader operating system,	30,	,	,	,	2006,	-1,	Research Market,	,	mutation or gene expression profiles,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	424,	2000,	2001,	Gene Expression Product Catalog and Panels.,	Preclinical,	Invader operating system,	30,	,	,	,	,	,	Research Market,	,	mutation or gene expression profiles,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	424,	2000,	2001,	Genotyping Product Catalog and Panels,	Preclinical,	Invader operating system,	23,	30,	,	,	,	,	Clinical Market,	,	infectious and inherited diseases.,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	424,	2000,	2001,	Quantification Product Catalog and Panels.,	Preclinical,	Invader operating system,	23,	30,	,	,	2003,	10,	Clinical Market,	,	infectious and inherited diseases.,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2002,	Genotyping Product Catalog and Panels,	Marketed,	Invader operating system,	30,	,	,	,	2006,	-1,	Research Market,	,	mutation or gene expression profiles,	,	yes,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2002,	Gene Expression Product Catalog and Panels.,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Research Market,	,	mutation or gene expression profiles,	,	yes,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2002,	Genotyping Product Catalog and Panels,	Marketed,	Invader operating system,	23,	30,	,	,	,	,	Clinical Market,	,	infectious and inherited diseases.,	,	yes,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2002,	Plant and Animal Agriculture Products,	Marketed,	Invader operating system,	30,	,	,	,	2005,	-1,	Research Market,	,	mutation or gene expression profiles,	,	yes,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2003,	Genotyping Product Catalog and Panels,	Marketed,	Invader operating system,	30,	,	,	,	2006,	-1,	Research Market,	,	mutation or gene expression profiles,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2003,	Gene Expression Product Catalog and Panels.,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Research Market,	,	mutation or gene expression profiles,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2003,	Genotyping Product Catalog and Panels,	Marketed,	Invader operating system,	23,	30,	,	,	,	,	Clinical Market,	,	infectious and inherited diseases.,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2003,	Plant and Animal Agriculture Products,	Marketed,	Invader operating system,	30,	,	,	,	2005,	-1,	Research Market,	,	mutation or gene expression profiles,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	Cystic Fibrosis Screen,	Marketed,	Invader operating system,	30,	,	,	Gene Expression Product Catalog and Panels.,	,	,	Genetics/Pharmacogenetics,	Research Market,	cystic fibrosis,	mutation or gene expression profiles,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	Connexin 26,	Marketed,	Invader operating system,	30,	,	,	Gene Expression Product Catalog and Panels.,	,	,	Genetics/Pharmacogenetics,	Research Market,	congenital hearing loss,	mutation or gene expression profiles,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	Factor V Leiden,	Marketed,	Invader operating system,	30,	,	,	Gene Expression Product Catalog and Panels.,	,	,	Genetics/Pharmacogenetics,	Research Market,	coagulation,	mutation or gene expression profiles,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	Factor II,	Marketed,	Invader operating system,	30,	,	,	Gene Expression Product Catalog and Panels.,	,	,	Genetics/Pharmacogenetics,	Research Market,	coagulation,	mutation or gene expression profiles,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	Factor VII,	Marketed,	Invader operating system,	30,	,	,	Gene Expression Product Catalog and Panels.,	2006,	-0.8519,	Genetics/Pharmacogenetics,	Research Market,	coagulation,	mutation or gene expression profiles,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	MTHFR,	Marketed,	Invader operating system,	21,	30,	,	Gene Expression Product Catalog and Panels.,	,	,	Genetics/Pharmacogenetics,	Research Market,	cardiovascular disease,	mutation or gene expression profiles,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	ApoE,	Marketed,	Invader operating system,	21,	30,	,	Gene Expression Product Catalog and Panels.,	,	,	Genetics/Pharmacogenetics,	Research Market,	cardiovascular disease,	mutation or gene expression profiles,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	PAI-1,	Marketed,	Invader operating system,	30,	,	,	Gene Expression Product Catalog and Panels.,	2006,	-1,	Genetics/Pharmacogenetics,	Research Market,	coagulation,	mutation or gene expression profiles,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	Tay-Sachs Disease (,	Marketed,	Invader operating system,	30,	,	,	Gene Expression Product Catalog and Panels.,	2006,	-1,	Genetics/Pharmacogenetics,	Research Market,	(Tay-Sachs,	mutation or gene expression profiles,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	HCV Genotyping,	Development,	Invader operating system,	23,	,	,	Genotyping Product Catalog and Panels,	2006,	-1,	Infectious Disease/Women's Health,	Clinical Market,	Hepatitis C,	infectious and inherited diseases.,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	HCV Viral Load,	Development,	Invader operating system,	23,	,	,	Genotyping Product Catalog and Panels,	2006,	-0.75,	Infectious Disease/Women's Health,	Clinical Market,	Hepatitis C,	infectious and inherited diseases.,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	HBV Genotyping,	Development,	Invader operating system,	23,	,	,	Genotyping Product Catalog and Panels,	2006,	-1,	Infectious Disease/Women's Health,	Clinical Market,	Hepatitis B,	infectious and inherited diseases.,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	SNP Genotyping,	Marketed,	Invader operating system,	30,	,	,	Gene Expression Product Catalog and Panels.,	2006,	-1,	Research Market,	,	mutation or gene expression profiles,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	Gene Expression,	Marketed,	Invader operating system,	30,	,	,	Gene Expression Product Catalog and Panels.,	2006,	0.25,	Research Market,	,	mutation or gene expression profiles,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	miRNA,	Marketed,	Invader operating system,	30,	,	,	Gene Expression Product Catalog and Panels.,	2006,	-1,	Research Market,	,	mutation or gene expression profiles,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2004,	2D6 gene variation,	Marketed,	Invader operating system,	30,	,	,	Gene Expression Product Catalog and Panels.,	2006,	-1,	Research Market,	,	mutation or gene expression profiles,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2005,	HCV,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	Hepatitis C,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2005,	CFTR,	Marketed,	Invader operating system,	30,	,	,	Cystic Fibrosis Screen,	,	,	Genetics/Pharmacogenetics,	,	cystic fibrosis,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2005,	CYP450 2D6,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	Drug Reactions,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2005,	HPV,	Marketed,	Invader operating system,	23,	30,	,	,	,	,	Genetics/Pharmacogenetics,	,	human papilloma virus,	,	yes,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2005,	Connexin 26,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	congenital hearing loss,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2005,	Factor V Leiden,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	coagulation,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2005,	Factor II,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	coagulation,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2005,	MTHFR,	Marketed,	Invader operating system,	21,	30,	,	,	,	,	Genetics/Pharmacogenetics,	,	cardiovascular disease,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2005,	ApoE,	Marketed,	Invader operating system,	21,	30,	,	,	,	,	Genetics/Pharmacogenetics,	,	cardiovascular disease,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2005,	Herpes Simplex Viruses 1 and 2,	Development,	Invader operating system,	23,	,	,	,	,	,	Infectious Disease/Women's Health,	,	Herpes,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2005,	CFTR with microfluidic format,	Development,	Invader operating system,	23,	,	,	Cystic Fibrosis Screen,	2007,	-1,	Infectious Disease/Women's Health,	,	cystic fibrosis,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2005,	Varicella-Zoster Virus,	Development,	Invader operating system,	23,	,	,	,	2007,	-1,	Infectious Disease/Women's Health,	,	Varicella-Zoster Virus,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2006,	HCV,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	Hepatitis C,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2006,	CFTR,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	cystic fibrosis,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2006,	CYP450 2D6,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	Drug Reactions,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2006,	HPV,	Marketed,	Invader operating system,	23,	30,	,	,	,	,	Genetics/Pharmacogenetics,	,	human papilloma virus,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2006,	Connexin 26,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	congenital hearing loss,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2006,	Factor V Leiden,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	coagulation,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2006,	Factor II,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	coagulation,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2006,	MTHFR,	Marketed,	Invader operating system,	21,	30,	,	,	,	,	Genetics/Pharmacogenetics,	,	cardiovascular disease,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2006,	ApoE,	Marketed,	Invader operating system,	21,	30,	,	,	,	,	Genetics/Pharmacogenetics,	,	cardiovascular disease,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2006,	Herpes Simplex Viruses 1 and 2,	Development,	Invader operating system,	23,	,	,	,	,	,	Infectious Disease/Women's Health,	,	Herpes,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2007,	HCV,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	Hepatitis C,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2007,	CFTR,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	cystic fibrosis,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2007,	CYP450 2D6,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	Drug Reactions,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2007,	HPV,	Marketed,	Invader operating system,	23,	30,	,	,	,	,	Genetics/Pharmacogenetics,	,	human papilloma virus,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2007,	Connexin 26,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	congenital hearing loss,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2007,	Factor V Leiden,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	coagulation,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2007,	Factor II,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	coagulation,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2007,	MTHFR,	Marketed,	Invader operating system,	21,	30,	,	,	,	,	Genetics/Pharmacogenetics,	,	cardiovascular disease,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2007,	ApoE,	Marketed,	Invader operating system,	21,	30,	,	,	,	,	Genetics/Pharmacogenetics,	,	cardiovascular disease,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2007,	Herpes Simplex Viruses 1 and 2,	Development,	Invader operating system,	23,	,	,	,	,	,	Infectious Disease/Women's Health,	,	Herpes,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2007,	Plasminogen Activator Inhibitor-1 (PAI-1) (4G/5G),	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	n/a,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2007,	Warfarin,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	n/a,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2007,	Platelet Glycoprotein IIIa,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	coagulation,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2007,	Herpes Simplex Viruses 1 and 2,	Development,	Invader operating system,	23,	,	,	,	,	,	Infectious Disease/Women's Health,	,	Herpes,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2008,	HCV,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	Hepatitis C,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2008,	CFTR,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	cystic fibrosis,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2008,	CYP450 2D6,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	Drug Reactions,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2008,	HPV,	Marketed,	Invader operating system,	23,	30,	,	,	,	,	Genetics/Pharmacogenetics,	,	human papilloma virus,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2008,	Connexin 26,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	congenital hearing loss,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2008,	Factor V Leiden,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	coagulation,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2008,	Factor II,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	coagulation,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2008,	MTHFR,	Marketed,	Invader operating system,	21,	30,	,	,	,	,	Genetics/Pharmacogenetics,	,	cardiovascular disease,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2008,	ApoE,	Marketed,	Invader operating system,	21,	30,	,	,	,	,	Genetics/Pharmacogenetics,	,	cardiovascular disease,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2008,	Herpes Simplex Viruses 1 and 2,	Development,	Invader operating system,	23,	,	,	,	,	,	Infectious Disease/Women's Health,	,	Herpes,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2008,	Plasminogen Activator Inhibitor-1 (PAI-1) (4G/5G),	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	n/a,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2008,	Warfarin,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	n/a,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2008,	Platelet Glycoprotein IIIa,	Marketed,	Invader operating system,	30,	,	,	,	,	,	Genetics/Pharmacogenetics,	,	coagulation,	,	,
wvcs20010001120438,	THIRD WAVE TECHNOLOGIE,	10-K,	2000,	2008,	Herpes Simplex Viruses 1 and 2,	Development,	Invader operating system,	23,	,	,	,	,	,	Infectious Disease/Women's Health,	,	Herpes,	,	,
wvcs19970001020910,	TRANSCEND THERAPEUTICS INC,	S-1,	1997,	1997,	Procysteine i.v,	Phase II,	intracellular glutathione-repleting agent,	9,	29,	,	,	,	,	pharmaceuticals,	,	Acute Respiratory Distress Syndrome,	,	,
wvcs19970001020910,	TRANSCEND THERAPEUTICS INC,	S-1,	1997,	1997,	Procysteine i.v,	Phase II,	intracellular glutathione-repleting agent,	25,	,	,	,	,	,	pharmaceuticals,	,	Multiple Organ Dysfunction,	,	,
wvcs19970001020910,	TRANSCEND THERAPEUTICS INC,	S-1,	1997,	1997,	Procysteine (oral),	Phase I/II,	intracellular glutathione-repleting agent,	,	,	,	,	,	,	pharmaceuticals,	,	1. Amyotrophic Lateral Sclerosis,	,	,
wvcs19970001020910,	TRANSCEND THERAPEUTICS INC,	S-1,	1997,	1997,	TR-500 compounds,	Pre Clinical,	intracellular glutathione-repleting agent,	27,	,	,	,	,	,	pharmaceuticals,	,	Hemolytic Anemias,	,	,
wvcs19970001020910,	TRANSCEND THERAPEUTICS INC,	S-1,	1997,	1997,	Procysteine i.v,	Phase II,	intracellular glutathione-repleting agent,	9,	29,	,	,	,	,	pharmaceuticals,	,	Acute Respiratory Distress Syndrome,	,	,
wvcs19970001020910,	TRANSCEND THERAPEUTICS INC,	S-1,	1997,	1997,	Procysteine i.v,	Phase II,	intracellular glutathione-repleting agent,	25,	,	,	,	,	,	pharmaceuticals,	,	Multiple Organ Dysfunction,	,	,
wvcs19970001020910,	TRANSCEND THERAPEUTICS INC,	424,	1997,	1997,	Procysteine (oral),	Phase I/II,	intracellular glutathione-repleting agent,	,	,	,	,	,	,	pharmaceuticals,	,	1. Amyotrophic Lateral Sclerosis,	,	,
wvcs19970001020910,	TRANSCEND THERAPEUTICS INC,	424,	1997,	1997,	TR-500 compounds,	Pre Clinical,	intracellular glutathione-repleting agent,	27,	,	,	,	,	,	pharmaceuticals,	,	Hemolytic Anemias,	,	,
wvcs19970001020910,	TRANSCEND THERAPEUTICS INC,	10-K,	1997,	1998,	Merged Non Existent,	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs19970000932352,	MEGABIOS CORP,	S-1,	1997,	1997,	MB100 Series,	Phase II,	in vivo gene delivery systems,	29,	,	,	,	2002,	-0.7778,	Lung Disease,	,	Cystic fibrosis,	,	,
wvcs19970000932352,	MEGABIOS CORP,	S-1,	1997,	1997,	MB100 Series,	Pre Clinical,	in vivo gene delivery systems,	5,	29,	,	,	,	,	Inflammation Diseases,	,	Asthma,	,	,
wvcs19970000932352,	MEGABIOS CORP,	S-1,	1997,	1997,	MB200 Series,	Pre Clinical,	in vivo gene delivery systems,	22,	,	,	,	2001,	-1,	Oncology,	,	Angiogenesis inhibition (cancer),	,	,
wvcs19970000932352,	MEGABIOS CORP,	S-1,	1997,	1997,	MB300 Series,	Pre Clinical,	in vivo gene delivery systems,	22,	,	,	,	2000,	-1,	Oncology,	,	Cancer,	,	,
wvcs19970000932352,	MEGABIOS CORP,	S-1,	1997,	1997,	MB400 Series,	Research,	in vivo gene delivery systems,	5,	,	,	,	2000,	-1,	Autoimmune,	,	Therapeutic vaccines,	,	,
wvcs19970000932352,	MEGABIOS CORP,	S-1,	1997,	1997,	MB400 Series,	Research,	in vivo gene delivery systems,	5,	,	,	,	,	,	Autoimmune,	,	Preventive vaccines,	,	,
wvcs19970000932352,	MEGABIOS CORP,	S-1,	1997,	1997,	MB500 Series,	Research,	in vivo gene delivery systems,	23,	,	,	,	2000,	-1,	Infectious diseases,	,	Infectious diseases,	,	,
wvcs19970000932352,	MEGABIOS CORP,	S-1,	1997,	1997,	MB600 Series,	Research,	in vivo gene delivery systems,	40,	,	,	,	2000,	-1,	Central Nervous System,	,	Neurodegenerative diseases,	,	,
wvcs19970000932352,	MEGABIOS CORP,	S-1,	1997,	1997,	MB700 Series,	Research,	in vivo gene delivery systems,	22,	,	,	,	2000,	-1,	Oncology,	,	Cancer,	,	,
wvcs19970000932352,	MEGABIOS CORP,	424,	1997,	1997,	MB100 Series,	Phase II,	in vivo gene delivery systems,	29,	,	,	,	2002,	-0.7778,	Lung Disease,	,	Cystic fibrosis,	,	,
wvcs19970000932352,	MEGABIOS CORP,	424,	1997,	1997,	MB100 Series,	Pre Clinical,	in vivo gene delivery systems,	5,	29,	,	,	,	,	Inflammation Diseases,	,	Asthma,	,	,
wvcs19970000932352,	MEGABIOS CORP,	424,	1997,	1997,	MB200 Series,	Pre Clinical,	in vivo gene delivery systems,	22,	,	,	,	2001,	-1,	Oncology,	,	Angiogenesis inhibition (cancer),	,	,
wvcs19970000932352,	MEGABIOS CORP,	424,	1997,	1997,	MB300 Series,	Pre Clinical,	in vivo gene delivery systems,	22,	,	,	,	2000,	-1,	Oncology,	,	Cancer,	,	,
wvcs19970000932352,	MEGABIOS CORP,	424,	1997,	1997,	MB400 Series,	Research,	in vivo gene delivery systems,	5,	,	,	,	2000,	-1,	Autoimmune,	,	Therapeutic vaccines,	,	,
wvcs19970000932352,	MEGABIOS CORP,	424,	1997,	1997,	MB400 Series,	Research,	in vivo gene delivery systems,	5,	,	,	,	,	,	Autoimmune,	,	Preventive vaccines,	,	,
wvcs19970000932352,	MEGABIOS CORP,	424,	1997,	1997,	MB500 Series,	Research,	in vivo gene delivery systems,	23,	,	,	,	2000,	-1,	Infectious diseases,	,	Infectious diseases,	,	,
wvcs19970000932352,	MEGABIOS CORP,	424,	1997,	1997,	MB600 Series,	Research,	in vivo gene delivery systems,	40,	,	,	,	2000,	-1,	Central Nervous System,	,	Neurodegenerative diseases,	,	,
wvcs19970000932352,	MEGABIOS CORP,	424,	1997,	1997,	MB700 Series,	Research,	in vivo gene delivery systems,	22,	,	,	,	2000,	-1,	Oncology,	,	Cancer,	,	,
wvcs19970000932352,	MEGABIOS CORP,	10-K,	1997,	1998,	MB100 Series,	Phase II,	in vivo gene delivery systems,	29,	,	,	,	2002,	-0.7778,	Lung Disease,	,	Cystic fibrosis,	,	,
wvcs19970000932352,	MEGABIOS CORP,	10-K,	1997,	1998,	MB100 Series,	Pre Clinical,	in vivo gene delivery systems,	5,	29,	,	,	,	,	Inflammation Diseases,	,	Asthma,	,	,
wvcs19970000932352,	MEGABIOS CORP,	10-K,	1997,	1998,	MB200 Series,	Pre Clinical,	in vivo gene delivery systems,	22,	,	,	,	2001,	-1,	Oncology,	,	Angiogenesis inhibition (cancer),	,	,
wvcs19970000932352,	MEGABIOS CORP,	10-K,	1997,	1998,	MB300 Series,	Phase II,	in vivo gene delivery systems,	22,	,	,	,	2000,	-1,	Oncology,	,	Cancer,	,	yes,
wvcs19970000932352,	MEGABIOS CORP,	10-K,	1997,	1998,	MB400 Series,	Research,	in vivo gene delivery systems,	5,	,	,	,	2000,	-1,	Autoimmune,	,	Therapeutic vaccines,	,	,
wvcs19970000932352,	MEGABIOS CORP,	10-K,	1997,	1998,	MB400 Series,	Research,	in vivo gene delivery systems,	5,	,	,	,	,	,	Autoimmune,	,	Preventive vaccines,	,	,
wvcs19970000932352,	MEGABIOS CORP,	10-K,	1997,	1998,	MB500 Series,	Research,	in vivo gene delivery systems,	23,	,	,	,	2000,	-1,	Infectious diseases,	,	Infectious diseases,	,	,
wvcs19970000932352,	MEGABIOS CORP,	10-K,	1997,	1998,	MB600 Series,	Research,	in vivo gene delivery systems,	40,	,	,	,	2000,	-1,	Central Nervous System,	,	Neurodegenerative diseases,	,	,
wvcs19970000932352,	MEGABIOS CORP,	10-K,	1997,	1998,	MB700 Series,	Pre Clinical,	in vivo gene delivery systems,	22,	,	,	,	2000,	-1,	Oncology,	,	Cancer,	,	yes,
wvcs19970000932352,	MEGABIOS CORP,	10-K,	1997,	1998,	MB800 Series,	Pre Clinical,	in vivo gene delivery systems,	5,	20,	,	,	2001,	0.1429,	Autoimmune,	,	Rheumatoid arthritis,	,	,
wvcs19970000932352,	MEGABIOS CORP,	10-K,	1997,	1998,	MB900 Series,	Pre Clinical,	in vivo gene delivery systems,	21,	20,	,	,	2000,	-1,	CARDIOVASCULAR DISEASE,	,	Ischemia,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	1999,	Interleukin-2 ("IL-2"),	Phase II,	plasmid-based gene delivery systems,	22,	,	,	,	2003,	-1,	Oncology,	,	Solid tumors and metastases,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	1999,	Interferon-alpha,	Phase II,	plasmid-based gene delivery systems,	22,	,	,	,	2002,	0,	Oncology,	,	Solid tumors and metastases,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	1999,	Interleukin-12,	Phase II,	plasmid-based gene delivery systems,	22,	,	,	,	2002,	1,	Oncology,	,	Solid tumors and metastases,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	1999,	IL-2/superantigen B,	Phase II,	plasmid-based gene delivery systems,	22,	,	,	,	2001,	-0.5,	Oncology,	,	Solid tumors and metastases,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	1999,	BRCA-1,	Pre Clinical,	plasmid-based gene delivery systems,	22,	,	,	,	2002,	-0.75,	Oncology,	,	Breast and ovarian cancer,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	1999,	dnDel-1 (anti-angiogenesis),	Pre Clinical,	plasmid-based gene delivery systems,	22,	,	,	MB200 Series,	2001,	-1,	Oncology,	,	Solid tumors and metastases,	Angiogenesis inhibition (cancer),	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	1999,	VEGF,	Phase II,	plasmid-based gene delivery systems,	21,	,	,	,	2003,	-0.56,	CARDIOVASCULAR DISEASE,	,	Restenosis (CAD/PVD),	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	1999,	CFTR,	Phase II,	plasmid-based gene delivery systems,	29,	,	,	MB100 Series,	2002,	-0.7778,	Lung Disease,	,	Cystic fibrosis,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	1999,	RHEUMATOLOGY,	Pre Clinical,	plasmid-based gene delivery systems,	5,	20,	,	MB800 Series,	2001,	0.7778,	Autoimmune,	,	RA, OA, cartilage repair,	Rheumatoid arthritis,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2000,	VEGF,	Phase II,	plasmid-based gene delivery systems,	21,	,	,	,	2003,	-0.56,	CARDIOVASCULAR DISEASE,	,	Coronary artery disease,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2000,	VEGF,	Phase II,	plasmid-based gene delivery systems,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Peripheral vascular disease,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2000,	VEGF,	Phase II,	plasmid-based gene delivery systems,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Restenosis,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2000,	Del-1,	Pre Clinical,	plasmid-based gene delivery systems,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Coronary artery disease,	Solid tumors and metastases,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2000,	Del-1,	Pre Clinical,	plasmid-based gene delivery systems,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Peripheral vascular disease,	Solid tumors and metastases,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2000,	Interleukin-2 ("IL-2"),	Phase II,	plasmid-based gene delivery systems,	22,	2,	,	,	2003,	-1,	ONCOLOGY,	,	Head and neck cancer,	Solid tumors and metastases,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2000,	Interferon-alpha,	Phase II,	plasmid-based gene delivery systems,	22,	2,	,	,	2002,	0,	ONCOLOGY,	,	Head and neck cancer,	Solid tumors and metastases,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2000,	Interleukin-12,	Phase II,	plasmid-based gene delivery systems,	22,	2,	,	,	2002,	0,	ONCOLOGY,	,	Head and neck cancer,	Solid tumors and metastases,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2000,	Interleukin-2 ("IL-2"),	Phase II,	plasmid-based gene delivery systems,	22,	,	,	,	,	,	ONCOLOGY,	,	Melanoma,	Solid tumors and metastases,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2000,	Interleukin-12,	Phase II,	plasmid-based gene delivery systems,	22,	,	,	,	,	,	ONCOLOGY,	,	Solid tumors,	Solid tumors and metastases,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2000,	CFTR,	Research,	plasmid-based gene delivery systems,	30,	,	,	,	2002,	-0.5,	Genetic Disorders,	,	Cystic fibrosis,	,	Phase II,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2000,	PEGylated ONYX-015,	Pre Clinical,	PEGYLATION TECHNOLOGY,	22,	,	,	,	2002,	6.75,	Oncology,	,	Solid tumors,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2000,	BRCA-1,	Pre Clinical,	plasmid-based gene delivery systems,	22,	,	,	,	2002,	-0.25,	ONCOLOGY,	,	Breast and ovarian cancer,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2000,	PEGylated Factor VIII,	Feasibility   ,	PEGYLATION TECHNOLOGY,	27,	30,	,	,	2002,	6.75,	Genetic Disorders,	,	Hemophilia A   ,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2001,	VEGF,	Phase II,	plasmid-based gene delivery systems,	21,	,	,	,	2003,	1.75,	CARDIOVASCULAR DISEASE,	,	Coronary artery disease,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2001,	VEGF,	Phase II,	plasmid-based gene delivery systems,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Peripheral vascular disease,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2001,	VEGF,	Phase II,	plasmid-based gene delivery systems,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Restenosis,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2001,	Del-1,	Pre Clinical,	plasmid-based gene delivery systems,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Coronary artery disease,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2001,	Del-1,	Phase I,	plasmid-based gene delivery systems,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Peripheral vascular disease,	,	Preclinical,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2001,	Interleukin-2 ("IL-2"),	Phase II,	plasmid-based gene delivery systems,	22,	2,	,	,	2003,	-1,	ONCOLOGY,	,	Head and neck cancer,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2001,	Interleukin-2 ("IL-2"),	Phase II,	plasmid-based gene delivery systems,	22,	,	,	,	,	,	ONCOLOGY,	,	Melanoma,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2001,	Intravenous IL-2,	Phase I,	plasmid-based gene delivery systems,	22,	,	,	,	2003,	-0.8261,	ONCOLOGY,	,	Lung tumors and metastases,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2001,	IL-2 + superantigen B,	Phase I,	plasmid-based gene delivery systems,	22,	,	,	,	2003,	-0.9783,	ONCOLOGY,	,	Melanoma,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2001,	PEGylated Omniferon™ (IFN-a),	Pre Clinical,	PEGYLATION TECHNOLOGY,	23,	,	,	,	2003,	-0.6304,	Infectious diseases,	,	Hepatitis C,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2001,	PEGylated CI-1042,	Pre Clinical,	PEGYLATION TECHNOLOGY,	22,	,	,	,	2003,	-0.6304,	Oncology,	,	Cancer,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2001,	EpoSwitch™,	Pre Clinical,	plasmid-based gene delivery systems,	27,	20,	,	,	2004,	-0.4,	HEMATOLOGY ,	,	 Anemia,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2002,	Del-1,	Pre Clinical,	PINC™ (Polymeric, non-condensing) polymers ,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Coronary artery disease,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2002,	Del-1,	Phase I,	PINC™ (Polymeric, non-condensing) polymers ,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Peripheral vascular disease,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2002,	EpoSwitch™,	Pre Clinical,	GeneSwitch®,	27,	20,	,	,	2004,	-0.8696,	HEMATOLOGY ,	,	 Anemia,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2002,	PEDF,	Research,	PINC™ (Polymeric, non-condensing) polymers ,	22,	,	,	,	2004,	-1,	ONCOLOGY,	,	Cancer,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2003,	Del-1,	Pre Clinical,	PINC™ (Polymeric, non-condensing) polymers ,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Ischemic heart disease,	Coronary artery disease,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2003,	Del-1,	Phase II,	PINC™ (Polymeric, non-condensing) polymers ,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Peripheral vascular disease,	,	Phase I,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2003,	Del-1,	Research,	PINC™ (Polymeric, non-condensing) polymers ,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Cerebrovascular disease,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2003,	DNA Vaccine,	Phase I ,	PINC™ gene delivery technology,	23,	,	,	,	2006,	0.6667,	Viral Infections,	,	HIV and HCV,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2004,	Deltavasc,	Pre Clinical,	PINC™ (Polymeric, non-condensing) polymers ,	21,	,	,	Del-1,	,	,	CARDIOVASCULAR DISEASE,	,	Ischemic heart disease,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2004,	Deltavasc,	Phase II,	PINC™ (Polymeric, non-condensing) polymers ,	21,	,	,	Del-1,	,	,	CARDIOVASCULAR DISEASE,	,	Peripheral vascular disease,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2004,	DNA Vaccine,	Phase I ,	PINC™ gene delivery technology,	23,	,	,	,	2006,	-0.8913,	Viral Infections,	,	HIV ,	HIV and HCV,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2005,	VLTS 934,	Phase II,	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology,	21,	,	,	,	2009,	0,	CARDIOVASCULAR DISEASE,	,	Intermittent Claudication,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2005,	Deltavasc,	Pre Clinical,	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Intermittent Claudication,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2005,	DEL-1 Antibody Product,	Phase I,	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology,	22,	,	,	,	,	,	Oncology,	,	: Oncology,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2005,	DEL-1 Protein Product,	Phase I,	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Critical Limb Ischemia,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2006,	VLTS 934,	Phase II,	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology,	21,	,	,	,	2009,	0,	CARDIOVASCULAR DISEASE,	,	Intermittent Claudication,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2006,	Deltavasc,	Phase II,	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Intermittent Claudication,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2006,	DEL-1 Antibody Product,	Phase I,	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology,	22,	,	,	,	,	,	Oncology,	,	: Oncology,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2006,	DEL-1 Protein Product,	Phase I,	PINC™ Polymers - Delivery Hermes™ Gene Expression Technology,	21,	,	,	,	,	,	CARDIOVASCULAR DISEASE,	,	Critical Limb Ischemia,	,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2007,	URG301/URG 302,	 IND ,	,	3,	,	,	VLTS 934,	2009,	-0.413,	urological ailments,	CARDIOVASCULAR DISEASE,	 Overactive Bladder (OAB),	Intermittent Claudication,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2007,	URG101,	Phase III,	,	62,	3,	,	Deltavasc,	,	,	urological ailments,	CARDIOVASCULAR DISEASE,	Painful Bladder Syndrome,	Intermittent Claudication,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2007,	URG101,	Phase II,	,	22,	70,	3,	DEL-1 Antibody Product,	,	,	urological ailments,	 Oncology,	Radiation Cystitis,	: Oncology,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2007,	URG101,	Pre Clinical,	,	3,	,	,	DEL-1 Protein Product,	,	,	urological ailments,	CARDIOVASCULAR DISEASE,	Dyspareunia,	Critical Limb Ischemia,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2007,	URG301,	Phase II,	,	9,	70,	3,	DEL-1 Protein Product,	,	,	urological ailments,	CARDIOVASCULAR DISEASE,	Acute Urethral Discomfort (AUD),	Critical Limb Ischemia,	,
wvcs19970000932352,	VALENTIS INC,	10-K,	1997,	2007,	URG301,	Phase II,	,	3,	,	,	DEL-1 Protein Product,	,	,	urological ailments,	CARDIOVASCULAR DISEASE,	Urethritis,	Critical Limb Ischemia,	,
wvcs19970000932352,	Urigen Pharmaceuticals, Inc,	10-K,	1997,	2008,	URG101,	Phase II,	,	62,	3,	,	,	,	,	urological ailments,	CARDIOVASCULAR DISEASE,	Painful Bladder Syndrome/Interstitial Cystitis,	Radiation Cystitis,	,
wvcs19970000932352,	Urigen Pharmaceuticals, Inc,	10-K,	1997,	2008,	URG301,	 IND,	urethral suppository,	70,	3,	,	,	,	,	urological ailments,	,	urethritis and nocturia,	Urethritis,	Phase II,
wvcs19970000932352,	Urigen Pharmaceuticals, Inc,	10-K,	1997,	2008,	URG301,	 IND,	intraurethral suppository,	9,	3,	,	,	,	,	urological ailments,	,	 Overactive Bladder (OAB),	,	,
wvcs19970000932352,	Urigen Pharmaceuticals, Inc,	10-K,	1997,	2009,	URG101,	Phase II,	bladder instillation,	62,	3,	,	,	,	,	urological ailments,	,	Painful Bladder Syndrome/Interstitial Cystitis,	Radiation Cystitis,	,
wvcs19970000932352,	Urigen Pharmaceuticals, Inc,	10-K,	1997,	2009,	URG301,	 IND,	urethral suppository,	70,	3,	,	,	,	,	urological ailments,	,	urethritis and nocturia,	Urethritis,	,
wvcs19970000932352,	Urigen Pharmaceuticals, Inc,	10-K,	1997,	2009,	URG301,	 IND,	intraurethral suppository,	9,	3,	,	,	,	,	urological ailments,	,	 Overactive Bladder (OAB),	,	,
wvcs19970000921439,	ZYMETX INC,	S-1,	1997,	1997,	ZstatFlu,	Phase III,	ViraZyme technology,	,	,	,	,	,	,	"physicians'
office laboratories,"	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	S-1,	1997,	1997,	VIRAZYME CULTURE SCREEN.,	marketed,	ViraZyme technology,	,	,	,	,	,	,	clinical lab,	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	S-1,	1997,	1997,	VIRASTAT PARAINFLUENZA 1, 2 AND 3,	marketed,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	S-1,	1997,	1997,	VIRAZYME INFLUENZA ID A/B.,	clinical studies,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	INFLUENZA,	,	,
wvcs19970000921439,	ZYMETX INC,	S-1,	1997,	1997,	VIRASTAT FITC LABELED MONOCLONAL ANTIBODIES,	clinical studies,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	INFLUENZA,	,	,
wvcs19970000921439,	ZYMETX INC,	424,	1997,	1997,	ZstatFlu,	Phase III,	ViraZyme technology,	,	,	,	,	,	,	"physicians'
office laboratories,"	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	424,	1997,	1997,	VIRAZYME CULTURE SCREEN.,	marketed,	ViraZyme technology,	,	,	,	,	,	,	clinical lab,	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	424,	1997,	1997,	VIRASTAT PARAINFLUENZA 1, 2 AND 3,	marketed,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	424,	1997,	1997,	VIRAZYME INFLUENZA ID A/B.,	clinical studies,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	INFLUENZA,	,	,
wvcs19970000921439,	ZYMETX INC,	424,	1997,	1997,	VIRASTAT FITC LABELED MONOCLONAL ANTIBODIES,	clinical studies,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	INFLUENZA,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	1998,	ZstatFlu,	Marketed,	ViraZyme technology,	,	,	,	,	,	,	"physicians'
office laboratories,"	,	influenza,	,	yes,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	1998,	VIRAZYME CULTURE SCREEN.,	marketed,	ViraZyme technology,	,	,	,	,	,	,	clinical lab,	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	1998,	VIRASTAT PARAINFLUENZA 1, 2 AND 3,	marketed,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	1998,	VIRAZYME INFLUENZA ID A/B.,	clinical studies,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	INFLUENZA,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	1998,	VIRASTAT FITC LABELED MONOCLONAL ANTIBODIES,	clinical studies,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	INFLUENZA,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	1999,	ZstatFlu,	Marketed,	ViraZyme technology,	,	,	,	,	,	,	"physicians'
office laboratories,"	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	1999,	VIRAZYME CULTURE SCREEN.,	marketed,	ViraZyme technology,	,	,	,	,	,	,	clinical lab,	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	1999,	VIRASTAT PARAINFLUENZA 1, 2 AND 3,	marketed,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	1999,	VIRAZYME INFLUENZA ID A/B.,	clinical studies,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	INFLUENZA,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	1999,	VIRASTAT FITC LABELED MONOCLONAL ANTIBODIES,	clinical studies,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	INFLUENZA,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	2000,	ZstatFlu,	Marketed,	ViraZyme technology,	,	,	,	,	,	,	"physicians'
office laboratories,"	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	2000,	VIRAZYME CULTURE SCREEN.,	marketed,	ViraZyme technology,	,	,	,	,	,	,	clinical lab,	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	2000,	VIRASTAT PARAINFLUENZA 1, 2 AND 3,	marketed,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	2000,	VIRAZYME INFLUENZA ID A/B.,	marketed,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	INFLUENZA,	,	yes,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	2000,	VIRASTAT FITC LABELED MONOCLONAL ANTIBODIES,	clinical studies,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	INFLUENZA,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	2001,	ZstatFlu,	Marketed,	ViraZyme technology,	,	,	,	,	,	,	"physicians'
office laboratories,"	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	2001,	VIRAZYME CULTURE SCREEN.,	marketed,	ViraZyme technology,	,	,	,	,	,	,	clinical lab,	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	2001,	VIRASTAT PARAINFLUENZA 1, 2 AND 3,	marketed,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	influenza,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	2001,	VIRAZYME INFLUENZA ID A/B.,	marketed,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	INFLUENZA,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	2001,	VIRASTAT FITC LABELED MONOCLONAL ANTIBODIES,	clinical studies,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	INFLUENZA,	,	,
wvcs19970000921439,	ZYMETX INC,	10-K,	1997,	2001,	ADVANCED VIRAL TESTING PLATFORM TECHNOLOGY.,	Development,	MAb technology,	,	,	,	,	,	,	clinical lab,	,	viral diseases,	,	,
wvcs20030001203866,	PHARMION CORP,	S-1,	2003,	2003,	 Thalomid® ,	Phase III,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	multiple myeloma,	,	,
wvcs20030001203866,	PHARMION CORP,	S-1,	2003,	2003,	 Thalomid® ,	Phase III,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	multiple myeloma,	,	,
wvcs20030001203866,	PHARMION CORP,	S-1,	2003,	2003,	 Thalomid® ,	Phase II,	 S.T.E.P.S.® program ,	22,	28,	20,	,	,	,	Oncology,	,	Renal cell carcinoma,	,	,
wvcs20030001203866,	PHARMION CORP,	S-1,	2003,	2003,	 Thalomid® ,	Phase II,	 S.T.E.P.S.® program ,	22,	28,	20,	,	,	,	Oncology,	,	Renal cell carcinoma,	,	,
wvcs20030001203866,	PHARMION CORP,	S-1,	2003,	2003,	 Thalomid® ,	Phase II,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	Additional solid tumors,	,	,
wvcs20030001203866,	PHARMION CORP,	S-1,	2003,	2003,	 Thalomid® ,	Phase II,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	Additional solid tumors,	,	,
wvcs20030001203866,	PHARMION CORP,	S-1,	2003,	2003,	Innohep®,	Marketed,	,	21,	22,	,	,	,	,	Oncology,	,	DVT,	,	,
wvcs20030001203866,	PHARMION CORP,	S-1,	2003,	2003,	Innohep®,	Marketed,	,	21,	22,	,	,	,	,	Oncology,	,	DVT,	,	,
wvcs20030001203866,	PHARMION CORP,	S-1,	2003,	2003,	Vidaza,	Phase III,	,	27,	20,	,	,	,	,	hematology ,	,	 myelodysplastic syndromes,,	,	,
wvcs20030001203866,	PHARMION CORP,	S-1,	2003,	2003,	Refludan®,	Marketed,	,	21,	27,	,	,	,	,	hematology ,	,	heparin-induced thrombocytopenia, ,	,	,
wvcs20030001203866,	PHARMION CORP,	424,	2003,	2003,	 Thalomid® ,	Phase III,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	multiple myeloma,	,	,
wvcs20030001203866,	PHARMION CORP,	424,	2003,	2003,	 Thalomid® ,	Phase III,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	multiple myeloma,	,	,
wvcs20030001203866,	PHARMION CORP,	424,	2003,	2003,	 Thalomid® ,	Phase II,	 S.T.E.P.S.® program ,	22,	28,	20,	,	,	,	Oncology,	,	Renal cell carcinoma,	,	,
wvcs20030001203866,	PHARMION CORP,	424,	2003,	2003,	 Thalomid® ,	Phase II,	 S.T.E.P.S.® program ,	22,	28,	20,	,	,	,	Oncology,	,	Renal cell carcinoma,	,	,
wvcs20030001203866,	PHARMION CORP,	424,	2003,	2003,	 Thalomid® ,	Phase II,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	Additional solid tumors,	,	,
wvcs20030001203866,	PHARMION CORP,	424,	2003,	2003,	 Thalomid® ,	Phase II,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	Additional solid tumors,	,	,
wvcs20030001203866,	PHARMION CORP,	424,	2003,	2003,	Innohep®,	Marketed,	,	21,	22,	,	,	,	,	Oncology,	,	DVT,	,	,
wvcs20030001203866,	PHARMION CORP,	424,	2003,	2003,	Innohep®,	Marketed,	,	21,	22,	,	,	,	,	Oncology,	,	DVT,	,	,
wvcs20030001203866,	PHARMION CORP,	424,	2003,	2003,	Vidaza,	Phase III,	,	27,	20,	,	,	,	,	hematology ,	,	 myelodysplastic syndromes,,	,	,
wvcs20030001203866,	PHARMION CORP,	424,	2003,	2003,	Refludan®,	Marketed,	,	21,	27,	,	,	,	,	hematology ,	,	heparin-induced thrombocytopenia, ,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2004,	 Thalomid® ,	Phase III,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	multiple myeloma,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2004,	 Thalomid® ,	Phase III,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	multiple myeloma,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2004,	 Thalomid® ,	Phase III,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	Newly-diagnosed multiple myeloma,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2004,	 Thalomid® ,	Phase III,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	Newly-diagnosed multiple myeloma,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2004,	Vidaza,	NDA,	,	27,	20,	,	,	,	,	hematology ,	,	 myelodysplastic syndromes,,	,	yes,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2004,	Innohep®,	Marketed,	,	21,	22,	,	,	,	,	Oncology,	,	DVT,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2004,	Innohep®,	Marketed,	,	21,	22,	,	,	,	,	Oncology,	,	DVT,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2004,	Refludan®,	Marketed,	,	21,	27,	,	,	,	,	hematology ,	,	heparin-induced thrombocytopenia, ,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2005,	 Thalomid® ,	Phase III,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	multiple myeloma,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2005,	 Thalomid® ,	Phase III,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	multiple myeloma,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2005,	 Thalomid® ,	Phase III,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	Newly-diagnosed multiple myeloma,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2005,	 Thalomid® ,	Phase III,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	Newly-diagnosed multiple myeloma,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2005,	Vidaza,	MArketed,	,	27,	20,	,	,	,	,	hematology ,	,	 myelodysplastic syndromes,,	,	yes,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2005,	Vidaza,	Phase II,	,	27,	20,	,	,	,	,	hematology ,	,	Hematological malignancies,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2005,	Vidaza,	Phase II,	,	22,	27,	20,	,	,	,	hematology ,	,	Solid tumors,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2005,	Satraplatin,	Phase III,	,	22,	,	,	,	,	,	Oncology,	,	2nd Line Hormone Refractory Prostate Cancer (HRPC),	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2005,	Satraplatin,	Phase III,	,	22,	,	,	,	,	,	Oncology,	,	2nd Line Hormone Refractory Prostate Cancer (HRPC),	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2005,	MGCD0103,	Phase II,	 HDAC inhibitor program,	22,	27,	,	,	,	,	hematology ,	,	Hematological Malignancies Solid Tumors,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2005,	Innohep®,	Marketed,	,	21,	22,	,	,	,	,	Oncology,	,	DVT,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2005,	Innohep®,	Marketed,	,	21,	22,	,	,	,	,	Oncology,	,	DVT,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2005,	Refludan®,	Marketed,	,	21,	27,	,	,	,	,	hematology ,	,	heparin-induced thrombocytopenia, ,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2006,	 Thalomid® ,	Marketed,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	multiple myeloma,	,	yes,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2006,	 Thalomid® ,	marketed,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	multiple myeloma,	,	yes,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2006,	Vidaza,	MArketed,	,	27,	20,	,	,	,	,	hematology ,	,	 myelodysplastic syndromes,,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2006,	Vidaza,	Phase II,	,	27,	20,	,	,	,	,	hematology ,	,	Hematological malignancies,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2006,	Vidaza,	Phase II,	,	22,	27,	20,	,	,	,	hematology ,	,	Solid tumors,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2006,	Satraplatin,	Phase III,	,	22,	,	,	,	,	,	Oncology,	,	2nd Line Hormone Refractory Prostate Cancer (HRPC),	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2006,	Satraplatin,	Phase III,	,	22,	,	,	,	,	,	Oncology,	,	2nd Line Hormone Refractory Prostate Cancer (HRPC),	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2006,	MGCD0103,	Phase II,	 HDAC inhibitor program,	22,	27,	,	,	,	,	hematology ,	,	Hematological Malignancies Solid Tumors,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2006,	Amrubicin,	Phase II,	,	22,	,	,	,	,	,	Oncology,	,	Small cell lung cancer;,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2006,	Amrubicin,	Phase II,	,	22,	,	,	,	,	,	Oncology,	,	breast cancer,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2006,	Innohep®,	Marketed,	,	21,	22,	,	,	,	,	Oncology,	,	DVT,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2006,	Innohep®,	Marketed,	,	21,	22,	,	,	,	,	Oncology,	,	DVT,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2006,	Refludan®,	Marketed,	,	21,	27,	,	,	,	,	hematology ,	,	heparin-induced thrombocytopenia, ,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2007,	 Thalomid® ,	Marketed,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	multiple myeloma,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2007,	 Thalomid® ,	marketed,	 S.T.E.P.S.® program ,	22,	20,	,	,	,	,	Oncology,	,	multiple myeloma,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2007,	Vidaza,	MArketed,	,	27,	20,	,	,	,	,	hematology ,	,	 myelodysplastic syndromes,,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2007,	Vidaza,	Phase II,	,	27,	20,	,	,	,	,	hematology ,	,	Hematological malignancies,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2007,	Vidaza,	Phase II,	,	22,	27,	20,	,	,	,	hematology ,	,	Solid tumors,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2007,	Satraplatin,	Phase III,	,	22,	,	,	,	,	,	Oncology,	,	2nd Line Hormone Refractory Prostate Cancer (HRPC),	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2007,	Satraplatin,	Phase III,	,	22,	,	,	,	,	,	Oncology,	,	2nd Line Hormone Refractory Prostate Cancer (HRPC),	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2007,	MGCD0103,	Phase II,	 HDAC inhibitor program,	22,	27,	,	,	,	,	hematology ,	,	Hematological Malignancies Solid Tumors,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2007,	Amrubicin,	Phase II,	,	22,	,	,	,	,	,	Oncology,	,	Small cell lung cancer;,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2007,	Amrubicin,	Phase II,	,	22,,	,	,	,	,	,	Oncology,	,	breast cancer,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2007,	Innohep®,	Marketed,	,	21,	22,	,	,	,	,	Oncology,	,	DVT,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2007,	Innohep®,	Marketed,	,	21,	22,	,	,	,	,	Oncology,	,	DVT,	,	,
wvcs20030001203866,	PHARMION CORP,	10-K,	2003,	2007,	Refludan®,	Marketed,	,	21,	27,	,	,	,	,	hematology ,	,	heparin-induced thrombocytopenia, ,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	S-1,	2004,	2004,	CS-917,	Phase II,	NuMimetic technology,	24,	,	,	,	2008,	-0.0909,	Metabolic Diseases,	,	Type II Diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	S-1,	2004,	2004,	CS-917,	Phase II,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	Type II Diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	S-1,	2004,	2004,	Hepavir B™,	Phase II,	 HepDirect technology,	26,	28,	,	,	,	,	liver diseases,	,	 hepatitis B,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	S-1,	2004,	2004,	Hepavir B™,	Phase II,	 HepDirect technology,	26,	28,	,	,	,	,	liver diseases,	,	 hepatitis B,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	S-1,	2004,	2004,	MB07133,	Phase II,	 HepDirect technology,	22,	26,	27,	,	,	,	liver diseases,	,	liver cancer ,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	S-1,	2004,	2004,	MB07811,	Research,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	hyperlipidemia and obesity,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	S-1,	2004,	2004,	Unnamed,	Research,	 HepDirect technology,	26,	28,	,	,	,	,	liver diseases,	,	 hepatitis ,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	424,	2004,	2004,	CS-917,	Phase II,	NuMimetic technology,	24,	,	,	,	2008,	-0.0909,	Metabolic Diseases,	,	Type II Diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	424,	2004,	2004,	CS-917,	Phase II,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	Type II Diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	424,	2004,	2004,	Hepavir B™,	Phase II,	 HepDirect technology,	26,	28,	,	,	,	,	liver diseases,	,	 hepatitis B,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	424,	2004,	2004,	Hepavir B™,	Phase II,	 HepDirect technology,	26,	28,	,	,	,	,	liver diseases,	,	 hepatitis B,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	424,	2004,	2004,	MB07133,	Phase II,	 HepDirect technology,	22,	26,	27,	,	,	,	liver diseases,	,	liver cancer ,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	424,	2004,	2004,	MB07811,	Research,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	hyperlipidemia and obesity,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	424,	2004,	2004,	,	,	,	,	,	,	,	2008,	-0.0909,	,	,	,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2004,	CS-917,	Phase II,	NuMimetic technology,	24,	,	,	,	2008,	-0.0909,	Metabolic Diseases,	,	Type II Diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2004,	CS-917,	Phase II,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	Type II Diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2004,	Pradefovir mesylate,	Phase II,	 HepDirect technology,	26,	28,	,	Hepavir B™,	,	,	liver diseases,	,	 hepatitis B,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2004,	Pradefovir mesylate,	Phase II,	 HepDirect technology,	26,	28,	,	Hepavir B™,	,	,	liver diseases,	,	 hepatitis B,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2004,	MB07133,	Phase II,	 HepDirect technology,	22,	26,	27,	,	,	,	liver diseases,	,	liver cancer ,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2004,	MB07811,	Pre Clinical,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	hyperlipidemia and obesity,	,	yes,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2004,	Unnamed,	Research,	 HepDirect technology,	26,	28,	,	,	,	,	liver diseases,	,	 hepatitis ,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2004,	 MB07100,	Research,	 HepDirect technology,	26,	28,	,	,	2007,	-1,	liver diseases,	,	Liver Fibrosis,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2005,	CS-917,	Phase II,	NuMimetic technology,	24,	,	,	,	2008,	-0.0909,	Metabolic Diseases,	,	Type II Diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2005,	CS-917,	Phase II,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	Type II Diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2005,	Pradefovir mesylate,	Phase III,	 HepDirect technology,	26,	28,	,	Hepavir B™,	,	,	liver diseases,	,	 hepatitis B,	,	yes,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2005,	Pradefovir mesylate,	Phase III,	 HepDirect technology,	26,	28,	,	Hepavir B™,	,	,	liver diseases,	,	 hepatitis B,	,	yes,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2005,	MB07133,	Phase II,	 HepDirect technology,	22,	26,	27,	,	,	,	liver diseases,	,	liver cancer ,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2005,	MB07803,	Phase I,	NuMimetic technology,	24,	26,	28,	,	,	,	liver diseases,	,	type 2 diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2005,	MB07811,	Pre Clinical,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	hyperlipidemia and obesity,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2005,	Unnamed,	Research,	 HepDirect technology,	26,	28,	,	,	,	,	liver diseases,	,	 hepatitis ,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2005,	 MB07100,	Research,	 HepDirect technology,	26,	28,	,	,	2007,	-1,	liver diseases,	,	Liver Fibrosis,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2005,	AMPK,	Discovery,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	Diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2006,	CS-917,	Phase II,	NuMimetic technology,	24,	,	,	,	2008,	9,	Metabolic Diseases,	,	Type II Diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2006,	CS-917,	Phase II,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	Type II Diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2006,	Pradefovir mesylate,	Phase III,	 HepDirect technology,	26,	28,	,	Hepavir B™,	,	,	liver diseases,	,	 hepatitis B,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2006,	Pradefovir mesylate,	Phase III,	 HepDirect technology,	26,	28,	,	Hepavir B™,	,	,	liver diseases,	,	 hepatitis B,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2006,	MB07133,	Phase II,	 HepDirect technology,	22,	26,	27,	,	,	,	liver diseases,	,	liver cancer ,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2006,	MB07803,	Phase I,	NuMimetic technology,	24,	26,	28,	,	,	,	liver diseases,	,	type 2 diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2006,	MB07811,	Phase I,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	hyperlipidemia and obesity,	,	yes,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2006,	Unnamed,	Research,	 HepDirect technology,	26,	28,	,	,	,	,	liver diseases,	,	 hepatitis ,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2006,	Unnamed,	Research,	 HepDirect technology,	26,	28,	,	,	,	,	liver diseases,	,	 hepatitis ,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2006,	AMPK,	Discovery,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	Diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2007,	Pradefovir mesylate,	Phase III,	 HepDirect technology,	26,	28,	,	Hepavir B™,	,	,	liver diseases,	,	 hepatitis B,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2007,	Pradefovir mesylate,	Phase III,	 HepDirect technology,	26,	28,	,	Hepavir B™,	,	,	liver diseases,	,	 hepatitis B,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2007,	MB07133,	Phase II,	 HepDirect technology,	22,	26,	27,	,	,	,	liver diseases,	,	liver cancer ,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2007,	MB07803,	Phase IIA,	NuMimetic technology,	24,	26,	28,	,	,	,	liver diseases,	,	type 2 diabetes,	,	yes,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2007,	MB07811,	Phase IB,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	hyperlipidemia and obesity,	,	yes,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2007,	Unnamed,	Lead Optimization,	 HepDirect technology,	26,	28,	,	,	,	,	liver diseases,	,	 hepatitis ,	,	yes,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2007,	Unnamed,	Lead Optimization,	 HepDirect technology,	26,	28,	,	,	,	,	liver diseases,	,	 hepatitis ,	,	yes,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2007,	AMPK,	Lead Optimization,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	Diabetes,	,	yes,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2008,	Pradefovir mesylate,	Phase III,	 HepDirect technology,	26,	28,	,	Hepavir B™,	,	,	liver diseases,	,	 hepatitis B,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2008,	Pradefovir mesylate,	Phase III,	 HepDirect technology,	26,	28,	,	Hepavir B™,	,	,	liver diseases,	,	 hepatitis B,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2008,	MB07133,	Phase II,	 HepDirect technology,	22,	26,	27,	,	,	,	liver diseases,	,	liver cancer ,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2008,	MB07803,	Phase IIA,	NuMimetic technology,	24,	26,	28,	,	,	,	liver diseases,	,	type 2 diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2008,	MB07811,	Phase II,	NuMimetic technology,	26,	28,	,	,	,	,	liver diseases,	,	hyperlipidemia and obesity,	,	yes,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2008,	Unnamed,	Lead Optimization,	 HepDirect technology,	26,	28,	,	,	,	,	liver diseases,	,	 hepatitis ,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2008,	AMPK,	Lead Optimization,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	Diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2008,	Glucagon Antagonist,	Lead Optimization,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	Diabetes,	,	,
wvcs20040001053221,	METABASIS THERAPEUTICS INC,	10-K,	2004,	2008,	TRß Agonist,	Lead Optimization,	NuMimetic technology,	24,	,	,	,	,	,	Metabolic Diseases,	,	hyperlipidemia,	,	,
newx20021066833,	Euthymics Bioscience Inc,	S-1,	2002,	2002,	 NBI-34060,	Phase III,	non-BDZ/GABA (A) Receptors,	46,	,	,	,	2004,	-1,	Central Nervous System Disorders,	,	Insomnia,	,	,
newx20021066833,	Euthymics Bioscience Inc,	S-1,	2002,	2002,	OCINAPLON,	Phase II,	non-BDZ/GABA (A) Receptors,	30,	40,	,	,	2006,	-0.0909,	Central Nervous System Disorders,	,	general anxiety disorder,	,	,
newx20021066833,	Euthymics Bioscience Inc,	S-1,	2002,	2002,	BICIFADINE,	Phase II,	controlled-release formulation of bicifadine,	62,	9,	,	,	,	,	Pain,	,	Pain,	,	,
newx20021066833,	Euthymics Bioscience Inc,	S-1,	2002,	2002,	DOV 216,303,	Phase IB,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Depression,	,	,
newx20021066833,	Euthymics Bioscience Inc,	S-1,	2002,	2002,	DOV DILTIAZEM,	Phase II,	formulation of diltiazem,	21,	,	,	,	2007,	-0.1765,	CARDIOVASCULAR DISEASE,	,	ANGINA AND HYPERTENSION.,	,	,
newx20021066833,	Euthymics Bioscience Inc,	S-1,	2002,	2002,	DOV 21,947,	Pre Clinical,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Depression,	,	,
newx20021066833,	Euthymics Bioscience Inc,	S-1,	2002,	2002,	DOV 22,047,	Pre Clinical,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Panic Disorders,	,	,
newx20021066833,	Euthymics Bioscience Inc,	S-1,	2002,	2002,	DOV 102,677 ,	Pre Clinical,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	ADD and Parkinsons,	,	,
newx20021066833,	Euthymics Bioscience Inc,	S-1,	2002,	2002,	DOV 102,177,	Pre Clinical,	neurochemical profile of bicifadine,,	3,	,	,	,	,	,	UROLOGICAL DISORDERS,	,	Stress Incontinence,	,	,
newx20021066833,	Euthymics Bioscience Inc,	424,	2002,	2002,	 NBI-34060,	Phase III,	non-BDZ/GABA (A) Receptors,	46,	,	,	,	2004,	-1,	Central Nervous System Disorders,	,	Insomnia,	,	,
newx20021066833,	Euthymics Bioscience Inc,	424,	2002,	2002,	OCINAPLON,	Phase II,	non-BDZ/GABA (A) Receptors,	30,	40,	,	,	2006,	-0.0909,	Central Nervous System Disorders,	,	general anxiety disorder,	,	,
newx20021066833,	Euthymics Bioscience Inc,	424,	2002,	2002,	BICIFADINE,	Phase II,	controlled-release formulation of bicifadine,	62,	9,	,	,	,	,	Pain,	,	Pain,	,	,
newx20021066833,	Euthymics Bioscience Inc,	424,	2002,	2002,	DOV 216,303,	Phase IB,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Depression,	,	,
newx20021066833,	Euthymics Bioscience Inc,	424,	2002,	2002,	DOV DILTIAZEM,	Phase II,	formulation of diltiazem,	21,	,	,	,	2007,	-0.1765,	CARDIOVASCULAR DISEASE,	,	ANGINA AND HYPERTENSION.,	,	,
newx20021066833,	Euthymics Bioscience Inc,	424,	2002,	2002,	DOV 21,947,	Pre Clinical,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Depression,	,	,
newx20021066833,	Euthymics Bioscience Inc,	424,	2002,	2002,	DOV 22,047,	Pre Clinical,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Panic Disorders,	,	,
newx20021066833,	Euthymics Bioscience Inc,	424,	2002,	2002,	DOV 102,677 ,	Pre Clinical,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	ADD and Parkinsons,	,	,
newx20021066833,	Euthymics Bioscience Inc,	424,	2002,	2002,	DOV 102,177,	Pre Clinical,	neurochemical profile of bicifadine,,	3,	,	,	,	,	,	UROLOGICAL DISORDERS,	,	Stress Incontinence,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2002,	Indiplon,	Phase III,	non-BDZ/GABA (A) Receptors,	46,	,	,	 NBI-34060,	,	,	Central Nervous System Disorders,	,	Insomnia,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2002,	Indiplon,	Phase III,	non-BDZ/GABA (A) Receptors,	46,	,	,	 NBI-34060,	,	,	Central Nervous System Disorders,	,	Insomnia,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2002,	OCINAPLON,	Phase III,	non-BDZ/GABA (A) Receptors,	30,	40,	,	,	2006,	-0.0909,	Central Nervous System Disorders,	,	general anxiety disorder,	,	yes,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2002,	BICIFADINE,	Phase III,	controlled-release formulation of bicifadine,	62,	9,	,	,	,	,	Pain,	,	Pain,	,	yes,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2002,	DOV 216,303,	Phase II,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Depression,	,	yes,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2002,	DOV 21,947,	Phase I,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Depression,	,	yes,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2002,	DOV DILTIAZEM,	Phase II,	formulation of diltiazem,	21,	,	,	,	2007,	-0.1765,	CARDIOVASCULAR DISEASE,	,	ANGINA AND HYPERTENSION.,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2002,	DOV 22,047,	Pre Clinical,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Panic Disorders,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2002,	DOV 102,677 ,	Pre Clinical,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	ADD and Parkinsons,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2002,	DOV 102,177,	Pre Clinical,	neurochemical profile of bicifadine,,	3,	,	,	,	,	,	UROLOGICAL DISORDERS,	,	Stress Incontinence,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2003,	Indiplon,	Phase III,	non-BDZ/GABA (A) Receptors,	46,	,	,	,	,	,	Central Nervous System Disorders,	,	Insomnia,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2003,	OCINAPLON,	Phase III,	non-BDZ/GABA (A) Receptors,	30,	40,	,	,	2006,	-0.0909,	Central Nervous System Disorders,	,	general anxiety disorder,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2003,	BICIFADINE,	Phase III,	controlled-release formulation of bicifadine,	62,	9,	,	,	,	,	Pain,	,	Pain,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2003,	DOV 216,303,	Phase II,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Depression,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2003,	DOV 21,947,	Phase I,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Depression,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2003,	DOV DILTIAZEM,	Phase II,	formulation of diltiazem,	21,	,	,	,	2007,	-0.1765,	CARDIOVASCULAR DISEASE,	,	ANGINA AND HYPERTENSION.,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2003,	DOV 102,677 ,	Pre Clinical,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	ADD and Parkinsons,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2003,	DOV 51,892,	Pre Clinical,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Anxiety Disorders,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2004,	Indiplon,	NDA,	non-BDZ/GABA (A) Receptors,	46,	,	,	,	,	,	Central Nervous System Disorders,	,	Insomnia,	,	yes,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2004,	OCINAPLON,	Phase III,	non-BDZ/GABA (A) Receptors,	30,	40,	,	,	2006,	0.1111,	Central Nervous System Disorders,	,	general anxiety disorder,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2004,	DOV 216,303,	Phase II,	Dual uptake inhibitors, referred to as SNRI,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Depression,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2004,	DOV 21,947,	Phase I,	Dual uptake inhibitors, referred to as SNRI,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Depression,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2004,	DOV 102,677 ,	Phase I,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	ADD and Parkinsons,	,	yes,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2004,	DOV DILTIAZEM,	Phase II,	formulation of diltiazem,	21,	,	,	,	2007,	-0.1765,	CARDIOVASCULAR DISEASE,	,	ANGINA AND HYPERTENSION.,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2004,	DOV 51,892,	Pre Clinical,	non-BDZ/GABA (A) Receptors,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Anxiety Disorders,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2004,	BICIFADINE,	Phase III,	controlled-release formulation of bicifadine,	62,	9,	,	,	,	,	Pain,	,	Pain,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2005,	Indiplon,	NDA,	non-BDZ/GABA (A) Receptors,	46,	,	,	,	,	,	Central Nervous System Disorders,	,	Insomnia,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2005,	BICIFADINE,	Phase III,	controlled-release formulation of bicifadine,	62,	9,	,	,	,	,	Pain,	,	Acute Pain,	yes,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2005,	BICIFADINE,	Phase III,	controlled-release formulation of bicifadine,	62,	9,	,	,	,	,	Pain,	,	severe CLBP,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2005,	BICIFADINE,	Phase III,	controlled-release formulation of bicifadine,	62,	9,	,	,	,	,	Pain,	,	post-surgical dental pain,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2005,	BICIFADINE,	Phase II,	controlled-release formulation of bicifadine,	62,	9,	20,	,	,	,	Pain,	,	osteoarthritis,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2005,	DOV 21,947,	Phase I,	triple reuptake inhibitor, or TRI,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Depression,	,	yes,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2005,	DOV 102,677 ,	Phase I,	triple reuptake inhibitor, or TRI,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	ADD and Parkinsons,	,	yes,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2005,	DOV 216,303,	Phase II,	triple reuptake inhibitor, or TRI,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Depression, Anxiety and Addiction,	yes,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2005,	DOV 216,303,	Pre Clinical,	triple reuptake inhibitor, or TRI,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	"Indications other than Depression,
Anxiety and Addiction,"	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2005,	DOV DILTIAZEM,	Phase II,	formulation of diltiazem,	21,	,	,	,	2007,	-0.0667,	CARDIOVASCULAR DISEASE,	,	ANGINA AND HYPERTENSION.,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2006,	Indiplon,	NDA,	non-BDZ/GABA (A) Receptors,	46,	,	,	,	,	,	Central Nervous System Disorders,	,	Insomnia,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2006,	BICIFADINE,	Phase III,	controlled-release formulation of bicifadine,	62,	9,	,	,	,	,	Pain,	,	Acute Pain,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2006,	BICIFADINE,	Phase III,	controlled-release formulation of bicifadine,	62,	9,	,	,	,	,	Pain,	,	severe CLBP,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2006,	BICIFADINE,	Phase III,	controlled-release formulation of bicifadine,	62,	9,	,	,	,	,	Pain,	,	post-surgical dental pain,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2006,	BICIFADINE,	Phase II,	controlled-release formulation of bicifadine,	62,	9,	20,	,	,	,	Pain,	,	osteoarthritis,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2006,	DOV 21,947,	Phase I,	triple reuptake inhibitor, or TRI,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Depression,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2006,	DOV 21,947,	Pre Clinical,	triple reuptake inhibitor, or TRI,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Obesity,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2006,	DOV 102,677 ,	Phase I,	triple reuptake inhibitor, or TRI,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Alcohol Abuse,	yes,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2006,	Triple reuptake inhibitor,	PRE-IND,	triple reuptake inhibitor, or TRI,	42,	,	,	,	,	,	Central Nervouse System Disorders,	,	Depression,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2007,	DOV 21,947,	Phase II,	triple reuptake inhibitor, or TRI,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Depression,	,	yes,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2007,	DOV 21,947,	Phase I,	triple reuptake inhibitor, or TRI,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Obesity,	,	yes,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2007,	BICIFADINE,	Phase III,	controlled-release formulation of bicifadine,	62,	9,	,	,	,	,	Pain,	,	Acute Pain,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2007,	BICIFADINE,	Phase III,	controlled-release formulation of bicifadine,	62,	9,	,	,	,	,	Pain,	,	post-surgical pain,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2007,	BICIFADINE,	Phase III,	controlled-release formulation of bicifadine,	62,	,	,	,	,	,	Pain,	,	chronic lower back pain,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2007,	BICIFADINE,	Phase II,	controlled-release formulation of bicifadine,	62,	9,	20,	,	,	,	Pain,	,	osteoarthritis,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2007,	Indiplon,	NDA,	non-BDZ/GABA (A) Receptors,	46,	,	,	,	,	,	Central Nervous System Disorders,	,	Insomnia,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2007,	DOV 102,677 ,	Phase I,	triple reuptake inhibitor, or TRI,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Alcohol Abuse,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2007,	DOV 216,419,	Discovery,	triple reuptake inhibitor, or TRI,	62,	42,	,	,	,	,	Central Nervouse System Disorders,	,	Depression and Pain,	,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2007,	Uptake Inhibitors,	Discovery,	triple reuptake inhibitor, or TRI,	42,	,	,	yes,	,	,	Central Nervouse System Disorders,	,	Various CNS Disorders,	yes,	,
newx20021066833,	Euthymics Bioscience Inc,	10-K,	2002,	2007,	GABA modulators,	Discovery,	triple reuptake inhibitor, or TRI,	40,	,	,	,	,	,	Central Nervouse System Disorders,	,	Various CNS Disorders,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	S-1,	2002,	2002,	TACI-Ig,	Pre-IND,	 bioinformatics-based,	5,	,	,	,	,	,	autoimmune diseases,	,	Systemic lupus ,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	S-1,	2002,	2002,	TACI-Ig,	PRE-IND,	 bioinformatics-based,	5,	,	,	,	,	,	autoimmune diseases,	,	Systemic lupus ,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	S-1,	2002,	2002,	IL-21,	Pre-development,	 bioinformatics-based,	22,	27,	,	,	,	,	Cancer,	,	Non-Hodgkin's lymphoma ,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	S-1,	2002,	2002,	Zsig37,	Pre-development,	 bioinformatics-based,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Cardiovascular Disease,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	S-1,	2002,	2002,	rh Factor XIII,	PRE-IND,	 bioinformatics-based,	25,	9,	30,	,	,	,	Critical Care,	,	Major cardiac surgery,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	S-1,	2002,	2002,	rh Thrombin,	PRE-IND,	 bioinformatics-based,	25,	9,	,	,	,	,	Critical Care,	,	Critical care hemostat,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	424,	2002,	2002,	TACI-Ig,	Pre-IND,	 bioinformatics-based,	5,	,	,	,	,	,	autoimmune diseases,	,	Systemic lupus ,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	424,	2002,	2002,	TACI-Ig,	PRE-IND,	 bioinformatics-based,	5,	,	,	,	,	,	autoimmune diseases,	,	erythematosus,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	424,	2002,	2002,	IL-21,	Pre-development,	 bioinformatics-based,	22,	27,	,	,	,	,	Cancer,	,	Non-Hodgkin's lymphoma ,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	424,	2002,	2002,	Zsig37,	Pre-development,	 bioinformatics-based,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Cardiovascular Disease,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	424,	2002,	2002,	rh Factor XIII,	PRE-IND,	 bioinformatics-based,	25,	9,	30,	,	,	,	Critical Care,	,	Major cardiac surgery,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	424,	2002,	2002,	rh Thrombin,	PRE-IND,	 bioinformatics-based,	25,	9,	,	,	,	,	Critical Care,	,	Critical care hemostat,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2002,	TACI-Ig,	Pre-IND,	 bioinformatics-based,	5,	,	,	,	,	,	autoimmune diseases,	,	Systemic lupus ,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2002,	TACI-Ig,	PRE-IND,	 bioinformatics-based,	5,	,	,	,	,	,	autoimmune diseases,	,	erythematosus,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2002,	IL-21,	Pre-development,	 bioinformatics-based,	22,	27,	,	,	,	,	Cancer,	,	Non-Hodgkin's lymphoma ,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2002,	Zsig37,	Pre-development,	 bioinformatics-based,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Cardiovascular Disease,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2002,	rh Factor XIII,	PRE-IND,	 bioinformatics-based,	25,	9,	30,	,	,	,	Critical Care,	,	Major cardiac surgery,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2002,	rh Thrombin,	PRE-IND,	 bioinformatics-based,	25,	9,	,	,	,	,	Critical Care,	,	Critical care hemostat,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2003,	TACI-Ig,	Phase I,	 patent portfolio for TACI-Ig,	5,	,	,	,	,	,	autoimmune diseases,	,	Systemic lupus ,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2003,	TACI-Ig,	Phase I,	 patent portfolio for TACI-Ig,	5,	,	,	,	,	,	autoimmune diseases,	,	erythematosus,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2003,	IL-21,	Pre -IND,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	,	,	,	,	,	Cancer,	,	Cancer,	yes,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2003,	rh Factor XIII,	Phase I,	 bioinformatics-based,	25,	9,	30,	,	,	,	Critical Care,	,	Major cardiac surgery,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2003,	rh Thrombin,	Phase II,	 recombinant human thrombin, methods of producing recombinant human thrombin,	25,	9,	,	,	,	,	Critical Care,	,	Critical care hemostat,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2004,	TACI-Ig,	Phase I,	 patent portfolio for TACI-Ig,	5,	,	,	,	,	,	autoimmune diseases,	,	Systemic lupus /erythematosus,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2004,	TACI-Ig,	Phase I,	 patent portfolio for TACI-Ig,	5,	20,	,	,	,	,	autoimmune diseases,	,	Rheumatoid arthritis,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2004,	TACI-Ig,	Phase I,	 patent portfolio for TACI-Ig,	5,	22,	27,	,	,	,	Cancer,	,	Non-Hodgkin's lymphoma ,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2004,	TACI-Ig,	Phase I,	 patent portfolio for TACI-Ig,	5,	22,	,	,	,	,	Cancer,	,	Multiple myeloma,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2004,	IL-21,	Phase I,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	,	,	,	,	,	Cancer,	,	Metastatic melanoma,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2004,	IL-21,	Pre-clinical,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	,	,	,	,	,	Cancer,	,	Combination with anti-cancer monoclonal antibodies,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2004,	rh Thrombin,	Phase II,	 recombinant human thrombin, methods of producing recombinant human thrombin,	25,	9,	,	,	,	,	Critical Care,	,	Critical care hemostat,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2004,	rh Thrombin,	Preclinical,	 recombinant human thrombin, methods of producing recombinant human thrombin,	25,	9,	,	,	,	,	Critical Care,	,	Line extensions,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2004,	IL-29,	Preclinical,	 bioinformatics-based,	23,	,	,	,	,	,	Viral Diseases,	,	Hepatitis C virus infection,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2004,	IL-31,	Preclinical,	 bioinformatics-based,	5,	29,	,	,	,	,	Inflammatory Diseases,	,	Inflammatory Diseases,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2005,	TACI-Ig,	Phase I,	 patent portfolio for TACI-Ig,	5,	,	,	,	,	,	autoimmune diseases,	,	Systemic lupus /erythematosus,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2005,	TACI-Ig,	Phase I,	 patent portfolio for TACI-Ig,	5,	20,	,	,	,	,	autoimmune diseases,	,	Rheumatoid arthritis,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2005,	TACI-Ig,	Phase I,	 patent portfolio for TACI-Ig,	5,	22,	27,	,	,	,	Cancer,	,	Non-Hodgkin's lymphoma ,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2005,	TACI-Ig,	Phase I,	 patent portfolio for TACI-Ig,	5,	22,	,	,	,	,	Cancer,	,	Multiple myeloma,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2005,	TACI-Ig,	Research,	 patent portfolio for TACI-Ig,	5,	22,	,	,	,	,	Cancer,	,	Multiple sclerosis,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2005,	TACI-Ig,	Phase I,	 patent portfolio for TACI-Ig,	5,	22,	27,	,	,	,	Cancer,	,	Chronic lymphocytic leukemia,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2005,	IL-21,	Phase I,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	,	,	,	,	,	Cancer,	,	Metastatic melanoma,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2005,	IL-21,	IND,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	,	,	,	,	,	Cancer,	,	Combination with anti-cancer monoclonal antibodies,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2005,	IL-29,	Preclinical,	 bioinformatics-based,	23,	,	,	,	,	,	Viral Diseases,	,	Hepatitis C virus infection,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2005,	IL-31,	Preclinical,	 bioinformatics-based,	5,	8,	29,	,	,	,	Inflammatory Diseases,	,	Atopic dermatitis,	yes,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2005,	rh Thrombin,	Phase III,	 recombinant human thrombin, methods of producing recombinant human thrombin,	25,	9,	,	,	,	,	Critical Care,	,	Critical care hemostat,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2005,	rh Thrombin,	Preclinical,	 recombinant human thrombin, methods of producing recombinant human thrombin,	25,	9,	,	,	,	,	Critical Care,	,	Line extensions,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	Atacicept,	Phase I,	 patent portfolio for TACI-Ig,	5,	,	,	yes,	,	,	autoimmune diseases,	,	Systemic lupus /erythematosus,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	Atacicept,	Phase II,	 patent portfolio for TACI-Ig,	5,	20,	,	yes,	,	,	autoimmune diseases,	,	Rheumatoid arthritis,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	Atacicept,	Phase I,	 patent portfolio for TACI-Ig,	5,	22,	27,	yes,	,	,	Cancer,	,	Non-Hodgkin's lymphoma ,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	Atacicept,	Phase I,	 patent portfolio for TACI-Ig,	5,	22,	,	yes,	,	,	Cancer,	,	Multiple myeloma,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	Atacicept,	Pre Clinical,	 patent portfolio for TACI-Ig,	5,	22,	,	yes,	,	,	Cancer,	,	Multiple sclerosis,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	Atacicept,	Phase I,	 patent portfolio for TACI-Ig,	5,	22,	27,	yes,	,	,	Cancer,	,	Chronic lymphocytic leukemia,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	IL-21,	Phase I,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	,	,	,	,	,	Cancer,	,	Metastatic melanoma,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	IL-21,	Phase II,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	,	,	,	,	,	Cancer,	,	Metastatic renal cell carcinoma,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	IL-21,	Phase I,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	27,	,	,	,	,	Cancer,	,	Non-Hodgkin’s lymphoma,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	PEG-IFN-l,	Phase I,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	23,	,	,	yes,	,	,	Viral Diseases,	,	Hepatitis C virus infection,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	PEG-IFN-l,	Preclinical,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	22,	23,	,	yes,	,	,	Viral Diseases,	,	Cancer,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	PEG-IFN-l,	Preclinical,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	23,	,	,	yes,	,	,	Viral Diseases,	,	Multiple sclerosis,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	IL-31,	Preclinical,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	5,	8,	29,	,	,	,	Inflammatory Diseases,	,	Atopic dermatitis,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	rh Thrombin,	BLA ,	 recombinant human thrombin, methods of producing recombinant human thrombin,	25,	9,	,	,	,	,	Critical Care,	,	Critical care hemostat,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	rh Thrombin,	Phase II,	 recombinant human thrombin, methods of producing recombinant human thrombin,	25,	9,	,	,	,	,	Critical Care,	,	Spray application,	yes,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2006,	IL-17RC,	Preclinical,	 bioinformatics-based,	5,	20,	,	,	,	,	Inflammatory diseases,	,	Inflammatory diseases,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	Atacicept,	Phase III,	 patent portfolio for TACI-Ig,	5,	,	,	,	,	,	autoimmune diseases,	,	Systemic lupus /erythematosus,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	Atacicept,	Phase II,	 patent portfolio for TACI-Ig,	5,	20,	,	,	,	,	autoimmune diseases,	,	Rheumatoid arthritis,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	Atacicept,	Phase I,	 patent portfolio for TACI-Ig,	5,	22,	27,	,	,	,	Cancer,	,	Non-Hodgkin's lymphoma ,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	Atacicept,	Phase I,	 patent portfolio for TACI-Ig,	5,	22,	,	,	,	,	Cancer,	,	Multiple myeloma,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	Atacicept,	Phase II,	 patent portfolio for TACI-Ig,	5,	22,	,	,	,	,	Cancer,	,	Multiple sclerosis,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	Atacicept,	Phase I,	 patent portfolio for TACI-Ig,	5,	22,	27,	,	,	,	Cancer,	,	Chronic lymphocytic leukemia,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	IL-21,	Phase II,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	,	,	,	,	,	Cancer,	,	Metastatic melanoma,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	IL-21,	Phase II,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	,	,	,	,	,	Cancer,	,	Metastatic renal cell carcinoma,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	IL-21,	Phase I,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	27,	,	,	,	,	Cancer,	,	Non-Hodgkin’s lymphoma,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	IL-21,	Phase I,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	,	,	,	,	,	Cancer,	,	Colorectal cancer,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	IL-21,	Phase II,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	,	,	,	,	,	Cancer,	,	Ovarian cancer,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	RECOTHROM,	Marketed,	 recombinant human thrombin, methods of producing recombinant human thrombin,	25,	9,	,	rh Thrombin,	,	,	Critical Care,	,	Critical care hemostat,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	RECOTHROM,	Marketed,	 recombinant human thrombin, methods of producing recombinant human thrombin,	25,	9,	,	rh Thrombin,	,	,	Critical Care,	,	Critical care hemostat,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	PEG-IFN-l,	Phase I,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	23,	,	,	,	,	,	Viral Diseases,	,	Hepatitis C virus infection,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	PEG-IFN-l,	Preclinical,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	23,	,	,	,	,	,	Viral Diseases,	,	Multiple sclerosis,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	IL-17RC,	Preclinical,	 bioinformatics-based,	5,	20,	,	,	,	,	Inflammatory diseases,	,	Inflammatory diseases,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2007,	IL-31 MAB,	Preclinical,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	5,	8,	29,	,	,	,	Inflammatory Diseases,	,	Atopic dermatitis,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2008,	IL-21,	Phase II,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	,	,	,	,	,	Cancer,	,	Metastatic melanoma,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2008,	IL-21,	Phase II,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	,	,	,	,	,	Cancer,	,	Metastatic renal cell carcinoma,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2008,	RECOTHROM,	Marketed,	 recombinant human thrombin, methods of producing recombinant human thrombin,	25,	9,	,	,	,	,	Critical Care,	,	Critical care hemostat,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2008,	PEG-IFN-l,	Phase I,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	23,	,	,	,	,	,	Viral Diseases,	,	Hepatitis C virus infection,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2008,	PEG-IFN-l,	Preclinical,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	23,	,	,	,	,	,	Viral Diseases,	,	Multiple sclerosis,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2008,	PEG-IFN-l,	Phase I,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	23,	,	,	,	,	,	Viral Diseases,	,	Hepatitis B virus infection,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2008,	PEG-IFN-l,	Preclinical,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	23,	,	,	,	,	,	Viral Diseases,	,	Multiple sclerosis,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2008,	IL-21 mAb,	PRE-IND,	anti-IL-21 monoclonal antibodies and their use in disease, including autoimmune and inflammatory diseases.,	5,	20,	,	,	,	,	Inflammatory Diseases,	,	Inflammatory Diseases,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2008,	IL-31 MAB,	Preclinical,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	5,	8,	29,	,	,	,	Inflammatory Diseases,	,	Atopic dermatitis,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2009,	IL-21,	Phase II,	 IL-21 polypeptides, polynucleotides and methods of using IL-21,	22,	,	,	,	,	,	Cancer,	,	Metastatic melanoma,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2009,	RECOTHROM,	Marketed,	 recombinant human thrombin, methods of producing recombinant human thrombin,	25,	9,	,	,	,	,	Critical Care,	,	Critical care hemostat,	,	,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2009,	PEG-IFN-l,	Phase II,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	23,	,	,	,	,	,	Viral Diseases,	,	Hepatitis C virus infection,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2009,	PEG-IFN-l,	Phase I,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	23,	,	,	,	,	,	Viral Diseases,	,	Hepatitis B virus infection,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2009,	PEG-IFN-l,	Phase II,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	23,	,	,	,	,	,	Viral Diseases,	,	Hepatitis C virus infection,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2009,	PEG-IFN-l,	Phase I,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	23,	,	,	,	,	,	Viral Diseases,	,	Hepatitis B virus infection,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2009,	IL-31 MAB,	Pre -IND,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	5,	8,	29,	,	,	,	Inflammatory Diseases,	,	Atopic dermatitis,	,	yes,
wvcs20020001129425,	ZYMOGENETICS INC,	10-K,	2002,	2009,	IL-31 MAB,	Research,	patent for IFN-l1 polynucleotides, expression vectors, cells and method of producing IFN-l1,	5,	62,	29,	,	,	,	Inflammatory Diseases,	,	Neuropathic Pain,	,	,
wvcs20030001115143,	ACUSPHERE INC,	S-1,	2003,	2003,	AI-700,	Phase III,	Porous Microparticle Technology,	21,	20,	60,	,	,	,	Cardiovascular Disease,	,	myocardial perfusion,	,	,
wvcs20030001115143,	ACUSPHERE INC,	S-1,	2003,	2003,	AI-850,	Phase I,	Porous Microparticle Technology,	22,	,	,	,	,	,	oncology,	,	Cancer,	,	,
wvcs20030001115143,	ACUSPHERE INC,	S-1,	2003,	2003,	AI-128,	Phase I,	Porous Microparticle Technology,	5,	29,	,	,	,	,	respiratory disease. ,	,	Asthma,	,	,
wvcs20030001115143,	ACUSPHERE INC,	424,	2003,	2003,	AI-700,	Phase III,	Porous Microparticle Technology,	21,	20,	60,	,	,	,	Cardiovascular Disease,	,	myocardial perfusion,	,	,
wvcs20030001115143,	ACUSPHERE INC,	424,	2003,	2003,	AI-850,	Phase I,	Porous Microparticle Technology,	22,	,	,	,	,	,	oncology,	,	Cancer,	,	,
wvcs20030001115143,	ACUSPHERE INC,	424,	2003,	2003,	AI-128,	Phase I,	Porous Microparticle Technology,	5,	29,	,	,	,	,	respiratory disease. ,	,	Asthma,	,	Phase IA,
wvcs20030001115143,	ACUSPHERE INC,	10-K,	2003,	2003,	AI-700,	Phase III,	Porous Microparticle Technology,	21,	20,	60,	,	,	,	Cardiovascular Disease,	,	myocardial perfusion,	,	,
wvcs20030001115143,	ACUSPHERE INC,	10-K,	2003,	2003,	AI-850,	Phase I,	Porous Microparticle Technology,	22,	,	,	,	,	,	oncology,	,	Cancer,	,	,
wvcs20030001115143,	ACUSPHERE INC,	10-K,	2003,	2003,	AI-128,	Phase I,	Porous Microparticle Technology,	5,	29,	,	,	,	,	respiratory disease. ,	,	Asthma,	,	,
wvcs20030001115143,	ACUSPHERE INC,	10-K,	2003,	2004,	AI-700,	Phase III,	Porous Microparticle Technology,	21,	20,	60,	,	,	,	Cardiovascular Disease,	,	myocardial perfusion,	,	,
wvcs20030001115143,	ACUSPHERE INC,	10-K,	2003,	2004,	AI-850,	Phase I,	Porous Microparticle Technology,	22,	,	,	,	,	,	 oncology,	,	Cancer,	,	,
wvcs20030001115143,	ACUSPHERE INC,	10-K,	2003,	2004,	AI-128,	Phase I,	Porous Microparticle Technology,	5,	29,	,	,	,	,	respiratory disease. ,	,	Asthma,	,	,
wvcs20030001115143,	ACUSPHERE INC,	10-K,	2003,	2005,	AI-700,	Phase III,	Porous Microparticle Technology,	21,	20,	60,	,	,	,	Cardiovascular Disease,	,	myocardial perfusion,	,	,
wvcs20030001115143,	ACUSPHERE INC,	10-K,	2003,	2005,	AI-850,	Phase I,	Porous Microparticle Technology,	22,	,	,	,	,	,	oncology,	,	Cancer,	,	,
wvcs20030001115143,	ACUSPHERE INC,	10-K,	2003,	2005,	AI-128,	Phase I,	Porous Microparticle Technology,	5,	29,	,	,	,	,	respiratory disease. ,	,	Asthma,	,	,
wvcs20030001115143,	ACUSPHERE INC,	10-K,	2003,	2006,	Imagify,	Phase III,	Porous Microparticle Technology,	21,	20,	60,	AI-700,	,	,	Cardiovascular Disease,	,	myocardial perfusion,	,	,
wvcs20030001115143,	ACUSPHERE INC,	10-K,	2003,	2006,	Hydrophobic Drug Delivery System™, HDDS.  ,	Phase I,	Porous Microparticle Technology,	22,	,	,	AI-850,	,	,	oncology,	,	Cancer,	,	,
wvcs20030001115143,	ACUSPHERE INC,	10-K,	2003,	2006,	       Pulmonary Drug Delivery System™, PDDS. ,	Phase I,	Porous Microparticle Technology,	5,	29,	,	AI-128,	,	,	respiratory disease. ,	,	Asthma,	,	,
wvcs20030001115143,	ACUSPHERE INC,	10-K,	2003,	2007,	Imagify,	Phase III,	Porous Microparticle Technology,	21,	20,	60,	,	,	,	Cardiovascular Disease,	,	myocardial perfusion,	,	,
wvcs20030001115143,	ACUSPHERE INC,	10-K,	2003,	2007,	Hydrophobic Drug Delivery System™, HDDS.  ,	Phase I,	Porous Microparticle Technology,	22,	,	,	,	,	,	oncology,	,	Cancer,	,	,
wvcs20030001115143,	ACUSPHERE INC,	10-K,	2003,	2007,	       Pulmonary Drug Delivery System™, PDDS. ,	Phase I,	Porous Microparticle Technology,	5,	29,	,	,	,	,	respiratory disease. ,	,	Asthma,	,	,
wvcu19970001016518,	APOLLON INC,	S-1,	1997,	1997,	GENEVAX vaccine product,	Phase I,	proprietary facilitated DNA,	23,	,	,	,	,	,	infectious Diseases,	,	 human immunodeficiency Virus,	,	,
wvcu19970001016518,	APOLLON INC,	S-1,	1997,	1997,	GENEVAX vaccine product,	Phase I,	proprietary facilitated DNA,	23,	,	,	,	,	,	infectious Diseases,	,	 hepatitis B virus ("HBV"),	,	,
wvcu19970001016518,	APOLLON INC,	S-1,	1997,	1997,	GENEVAX vaccine product,	Phase II,	proprietary facilitated DNA,	23,	,	,	,	,	,	infectious Diseases,	,	 herpes simplex virus ("HSV") ,	,	,
wvcu19970001016518,	APOLLON INC,	S-1,	1997,	1997,	GENEVAX vaccine product,	Phase II,	proprietary facilitated DNA,	5,	27,	,	,	,	,	autoimmune diseases.,	,	"T-cell lymphoma
(""CTCL""),"	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	S-1,	1997,	1997,	FGN-1(TM),	Phase III,	Proprietary,	22,	,	,	,	,	,	Cancer,	,	Adenomatous Polyposis Coli,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	S-1,	1997,	1997,	FGN-1(TM),	Phase III,	Proprietary,	22,	,	,	,	,	,	Cancer,	,	Sporadic Adenomatous Colonic Polyps,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	S-1,	1997,	1997,	FGN-1(TM),	Phase III,	Proprietary,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	S-1,	1997,	1997,	FGN-1(TM),	Phase III,	Proprietary,	22,	,	,	,	,	,	Cancer,	,	Breast Cancer,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	S-1,	1997,	1997,	FGN-1(TM),	Phase III,	Proprietary,	22,	,	,	,	,	,	Cancer,	,	Lung Cancer,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	S-1,	1997,	1997,	FGN-1(TM),	Phase II,	Proprietary,	22,	,	,	,	,	,	Cancer,	,	Barrett's Esophagus ,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	1999,	PREVATAC(TM),	IND,	Proprietary,	22,	,	,	FGN-1(TM),	,	,	Cancer,	Cancer,	Adenomatous Polyposis Coli,	,	Phase III,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	1999,	PREVATAC(TM),	Phase III,	Proprietary,	22,	,	,	FGN-1(TM),	,	,	Cancer,	Cancer,	Sporadic Adenomatous Colonic Polyps,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	1999,	PREVATAC(TM),	Phase II,	Proprietary,	22,	,	,	FGN-1(TM),	,	,	Cancer,	Cancer,	Barrett's Esophagus,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	1999,	PREVATAC(TM),	Phase II,	Proprietary,	22,	,	,	FGN-1(TM),	,	,	Cancer,	,	Bronchial Dysplasia..,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	1999,	PREVATAC(TM),	Phase I,	Proprietary,	22,	,	,	FGN-1(TM),	,	,	Cancer,	,	Cervical Dysplasia,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	1999,	PREVATAC(TM),	Phase III,	Proprietary,	22,	,	,	FGN-1(TM),	,	,	Cancer,	,	Prostate Cancer Recurrence,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	1999,	PREVATAC(TM),	Phase II,	Proprietary,	22,	,	,	FGN-1(TM),	,	,	Cancer,	,	Lung Cancer,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	1999,	PREVATAC(TM),	Phase III,	Proprietary,	22,	,	,	FGN-1(TM),	,	,	Cancer,	,	Breast Cancer Recurrence,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	1999,	CP 461,	IND,	Proprietary,	22,	,	,	,	,	,	Cancer,	,	Cancer Indications,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2000,	Aptosyn(TM),	Terminated,	selective apoptotic anti-neoplastic drugs,	22,	,	,	PREVATAC(TM),	,	,	Cancer,	,	Adenomatous Polyposis Coli,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2000,	Aptosyn(TM),	Have NO Plans,	selective apoptotic anti-neoplastic drugs,	22,	,	,	PREVATAC(TM),	,	,	Cancer,	,	Sporadic Adenomatous Colonic Polyps,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2000,	Aptosyn(TM),	Phase II,	selective apoptotic anti-neoplastic drugs,	22,	,	,	PREVATAC(TM),	,	,	Cancer,	,	Barrett's Esophagus,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2000,	Aptosyn(TM),	Have NO Plans,	selective apoptotic anti-neoplastic drugs,	22,	,	,	PREVATAC(TM),	,	,	Cancer,	,	Bronchial Dysplasia..,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2000,	Aptosyn(TM),	Have NO Plans,	selective apoptotic anti-neoplastic drugs,	22,	,	,	PREVATAC(TM),	,	,	Cancer,	,	Cervical Dysplasia,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2000,	Aptosyn(TM),	Phase II,	selective apoptotic anti-neoplastic drugs,	22,	,	,	PREVATAC(TM),	,	,	Cancer,	,	Prostate Cancer Recurrence,	,	Phase III,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2000,	Aptosyn(TM),	Phase II,	selective apoptotic anti-neoplastic drugs,	22,	,	,	PREVATAC(TM),	,	,	Cancer,	,	Lung Cancer,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2000,	Aptosyn(TM),	Phase II,	selective apoptotic anti-neoplastic drugs,	22,	,	,	PREVATAC(TM),	,	,	Cancer,	,	Lung Cancer,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2000,	Aptosyn(TM),	Phase II,	selective apoptotic anti-neoplastic drugs,	22,	,	,	PREVATAC(TM),	,	,	Cancer,	,	Breast Cancer Recurrence,	,	Phase III,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2000,	CP 461,	IND,	selective apoptotic anti-neoplastic drugs,	22,	,	,	,	,	,	Cancer,	,	Cancer Indications,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2001,	Aptosyn(TM),	Have NO Plans,	selective apoptotic anti-neoplastic drugs,	22,	,	,	,	,	,	Cancer,	,	Sporadic Adenomatous Colonic Polyps,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2001,	Aptosyn(TM),	Phase II,	selective apoptotic anti-neoplastic drugs,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer Recurrence,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2001,	Aptosyn(TM),	Phase III,	selective apoptotic anti-neoplastic drugs,	22,	,	,	,	,	,	Cancer,	,	Lung Cancer,	,	Phase II,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2001,	Aptosyn(TM),	Phase III,	selective apoptotic anti-neoplastic drugs,	22,	,	,	,	,	,	Cancer,	,	Lung Cancer,	,	Phase II,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2001,	Aptosyn(TM),	Phase II,	selective apoptotic anti-neoplastic drugs,	22,	,	,	,	,	,	Cancer,	,	Breast Cancer Recurrence,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2001,	CP 461,	Phase II,	selective apoptotic anti-neoplastic drugs,	22,	27,	,	,	,	,	Cancer,	,	CHRONIC LYMPHOCYTIC LEUKEMIA (CLL),	Cancer Indications,	IND,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2001,	CP 461,	Phase II,	selective apoptotic anti-neoplastic drugs,	22,	,	,	,	,	,	Cancer,	,	 HORMONE-REFRACTORY PROSTATE CANCER,	Cancer Indications,	IND,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2001,	CP 461,	Phase II,	selective apoptotic anti-neoplastic drugs,	22,	28,	,	,	,	,	Cancer,	,	RENAL CELL (KIDNEY) CARCINOMA,	Cancer Indications,	IND,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2002,	CP 461,	Phase II,	selective apoptotic anti-neoplastic drugs,	26,	,	,	,	,	,	Gastrointestinal Disease,	,	Crohn's Disease,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2002,	Aptosyn(TM),	No Plans,	selective apoptotic anti-neoplastic drugs,	22,	,	,	,	,	,	Cancer,	,	Prostate Cancer Recurrence,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2002,	Aptosyn(TM),	No Plans,	selective apoptotic anti-neoplastic drugs,	22,	,	,	,	,	,	Cancer,	,	Lung Cancer,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2002,	Aptosyn(TM),	No Plans,	selective apoptotic anti-neoplastic drugs,	22,	,	,	,	,	,	Cancer,	,	Lung Cancer,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2002,	Aptosyn(TM),	No Plans,	selective apoptotic anti-neoplastic drugs,	22,	,	,	,	,	,	Cancer,	,	Breast Cancer Recurrence,	,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2002,	CP 461,	No Plans,	selective apoptotic anti-neoplastic drugs,	22,	27,	,	,	,	,	Cancer,	,	CHRONIC LYMPHOCYTIC LEUKEMIA (CLL),	Cancer Indications,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2002,	CP 461,	No Plans,	selective apoptotic anti-neoplastic drugs,	22,	,	,	,	,	,	Cancer,	,	 HORMONE-REFRACTORY PROSTATE CANCER,	Cancer Indications,	,
wvcu19970000925732,	CELL PATHWAYS INC,	10-K,	1997,	2002,	CP 461,	No Plans,	selective apoptotic anti-neoplastic drugs,	22,	28,	,	,	,	,	Cancer,	,	RENAL CELL (KIDNEY) CARCINOMA,	Cancer Indications,	,
wvcu19970000944753,	SCRIPTGEN PHARMACEUTICALS INC,	S-1,	1997,	1997,	ST61769,	Pre Clinical,	"GATE  ATLAS (Any Target Ligand Affinity Screen) and SCAN (Screen for
Compounds with Affinity for Nucleic Acids),,"	23,	,	,	,	,	,	ANTIFUNGALS,	,	ANTIFUNGALS,	,	,
wvcu19970000944753,	SCRIPTGEN PHARMACEUTICALS INC,	S-1,	1997,	1997,	ST61219,	Pre Clinical,	"GATE  ATLAS (Any Target Ligand Affinity Screen) and SCAN (Screen for
Compounds with Affinity for Nucleic Acids),,"	23,	,	,	,	,	,	ANTIFUNGALS,	,	ANTIFUNGALS,	,	,
wvcu19970000944753,	SCRIPTGEN PHARMACEUTICALS INC,	S-1,	1997,	1997,	ST61219,	Pre Clinical,	"GATE  ATLAS (Any Target Ligand Affinity Screen) and SCAN (Screen for
Compounds with Affinity for Nucleic Acids),,"	23,	,	,	,	,	,	ANTIFUNGALS,	,	ANTIFUNGALS,	,	,
wvcu19970000944753,	SCRIPTGEN PHARMACEUTICALS INC,	S-1,	1997,	1997,	 ST41590,	Pre Clinical,	"GATE  ATLAS (Any Target Ligand Affinity Screen) and SCAN (Screen for
Compounds with Affinity for Nucleic Acids),,"	23,	,	,	,	,	,	ANTIBACTERIALS,	,	"bacterial Infections
infections,"	,	,
wvcu19970000944753,	SCRIPTGEN PHARMACEUTICALS INC,	S-1,	1997,	1997,	ST135647,	Pre Clinical,	"GATE  ATLAS (Any Target Ligand Affinity Screen) and SCAN (Screen for
Compounds with Affinity for Nucleic Acids),,"	23,	,	,	,	,	,	AntiViral,	,	 Hepatitis B virus,	,	,
wvcs20000000934473,	GENVEC INC,	S-1,	1998,	1998,	BIOBYPASS angiogen,	Phase II,	VEGF/121/ gene,	21,	,	,	,	,	,	CARDIOVASCULAR,	,	CAD,	,	,
wvcs20000000934473,	GENVEC INC,	S-1,	1998,	1998,	BIOBYPASS angiogen,	Phase II,	VEGF/121/ gene,	21,	,	,	,	,	,	CARDIOVASCULAR,	,	PAD,	,	,
wvcs20000000934473,	GENVEC INC,	S-1,	1998,	1998,	Ad.TNF(alpha),	Preclinical,	TNF(alpha),	22,	,	,	,	,	,	Oncology,	,	Cancer,	,	,
wvcs20000000934473,	GENVEC INC,	S-1,	1998,	1998,	 Ad.iNOS,	Preclinical,	iNOS,	21,	,	,	,	,	,	CARDIOVASCULAR,	,	CAD,	,	,
wvcs20000000934473,	GENVEC INC,	S-1,	1998,	1998,	 Ad.CD.,	Phase II,	 CD  ,	22,	,	,	,	,	,	Oncology,	,	Cancer,	,	,
wvcs20000000934473,	GENVEC INC,	S-1,	1998,	1998,	Immunotherapy Program,	Research,	None,	22,	,	,	,	,	,	Oncology,	,	Cancer,	,	,
wvcs20000000934473,	GENVEC INC,	S-1,	1998,	1998,	Neurology Program,	Research,	None,	45,	,	,	,	,	,	Neurology,	,	Neurology,	,	,
wvcu19980001001557,	INTRACEL CORP,	S-1,	1999,	1999,	 OncoVAX(CL),	Phase III,	Active Specific Immunotherapy,	22,	,	,	,	,	,	Cancer,	,	Colon Cancer,	,	,
wvcu19980001001557,	INTRACEL CORP,	S-1,	1999,	1999,	HumaSPECT,	Phase III,	 Antibody-Based Diagnosis,	22,	,	,	,	,	,	Cancer,	,	Colon Cancer,	,	,
wvcu19980001001557,	INTRACEL CORP,	S-1,	1999,	1999,	KLH ,	Phase III,	Active Non-Specfic Immunotherapy,	22,	3,	,	,	,	,	Cancer,	,	Refractory bladder cancer,	,	,
wvcu19980001001557,	INTRACEL CORP,	S-1,	1999,	1999,	ASI(BCL,	Phase III,	Active Specfic Immunotherapy,	22,	27,	,	,	,	,	Cancer,	,	B-cell lymphoma,	,	,
wvcu19980001001557,	INTRACEL CORP,	S-1,	1999,	1999,	HumaRAD(16.88),	Phase I,	Antibody-Based Diagnosis  ,	22,	2,	,	,	,	,	Cancer,	,	Head and neck cancer   ,	,	,
wvcu19980001001557,	INTRACEL CORP,	S-1,	1999,	1999,	HumaRAD(88BV59)      ,	Phase I,	Antibody-Based Diagnosis  ,	22,	,	,	,	,	,	Cancer,	,	Ovarian cancer,	,	,
wvcu19980001001557,	INTRACEL CORP,	S-1,	1999,	1999,	HumaSPECT,	Phase II,	Antibody-Based Diagnosis  ,	22,	,	,	,	,	,	Cancer,	,	Ovarian cancer ,	,	,
wvcu19980001001557,	INTRACEL CORP,	S-1,	1999,	1999,	MONOGENE(INT) ,	Phase I,	Antibody-Based gene therapy,	22,	,	,	,	,	,	Cancer,	,	HIV  ,	,	,
wvcu19980001001557,	INTRACEL CORP,	S-1,	1999,	1999,	Confirmatory diagnostic Products,	Marketed,	,	23,	,	,	,	,	,	Viral Diseases,	,	Viruses and bacteria,	,	,
wvcu19980001001557,	INTRACEL CORP,	S-1,	1999,	1999,	 ZYMMUNE CD4/CD8,	Marketed,	,	23,	,	,	,	,	,	Viral Diseases,	,	HIV  ,	,	,
wvcu19980001001557,	INTRACEL CORP,	S-1,	1999,	1999,	Accu-D(x),	Marketed,	,	22,	3,	,	,	,	,	Cancer,	,	Bladder Cancer,	,	,
wvcu19980001001557,	INTRACEL CORP,	S-1,	1999,	1999,	 Apo-Tek Lp(a),	Marketed,	,	21,	,	,	,	,	,	cardiovascular disease,	,	cardiovascular disease,	,	,
wvcu19980001001557,	INTRACEL CORP,	424B,	1999,	1999,	 OncoVAX(CL),	Phase III,	Active Specific Immunotherapy,	22,	,	,	,	,	,	Cancer,	,	Colon Cancer,	,	,
wvcu19980001001557,	INTRACEL CORP,	424B,	1999,	1999,	KLH ,	Phase III,	Active Non-Specfic Immunotherapy,	22,	3,	,	,	,	,	Cancer,	,	Refractory bladder cancer,	,	,
wvcu19980001001557,	INTRACEL CORP,	424B,	1999,	1999,	ASI(BCL,	Phase III,	Active Specfic Immunotherapy,	22,	27,	,	,	,	,	Cancer,	,	B-cell lymphoma,	,	,
wvcu19980001001557,	INTRACEL CORP,	424B,	1999,	1999,	HumaRAD(16.88),	Phase I,	Antibody-Based Diagnosis  ,	22,	2,	,	,	,	,	Cancer,	,	Head and neck cancer   ,	,	,
wvcu19980001001557,	INTRACEL CORP,	424B,	1999,	1999,	HumaRAD(88BV59)      ,	Phase I,	Antibody-Based Diagnosis  ,	22,	,	,	,	,	,	Cancer,	,	Ovarian cancer,	,	,
wvcu19980001001557,	INTRACEL CORP,	424B,	1999,	1999,	MONOGENE(INT) ,	Phase I,	Antibody-Based gene therapy,	22,	,	,	,	,	,	Cancer,	,	HIV  ,	,	,
wvcu19980001001557,	INTRACEL CORP,	424B,	1999,	1999,	Confirmatory diagnostic Products,	Marketed,	,	23,	,	,	,	,	,	Viral Diseases,	,	Viruses and bacteria,	,	,
wvcu19980001001557,	INTRACEL CORP,	424B,	1999,	1999,	 ZYMMUNE CD4/CD8,	Marketed,	,	23,	,	,	,	,	,	Viral Diseases,	,	HIV  ,	,	,
wvcu19980001001557,	INTRACEL CORP,	424B,	1999,	1999,	Accu-D(x),	Marketed,	,	22,	3,	,	,	,	,	Cancer,	,	Bladder Cancer,	,	,
wvcu19980001001557,	INTRACEL CORP,	424B,	1999,	1999,	 Apo-Tek Lp(a),	Marketed,	,	21,	,	,	,	,	,	cardiovascular disease,	,	cardiovascular disease,	,	,
wvcu19980001001557,	INTRACEL CORP,	424B,	1999,	1999,	HumaSPECT ,	BLA,	,	22,	,	,	,	,	,	Cancer,	,	Colon Cancer,	,	,
wvcu19980001001557,	INTRACEL CORP,	424B,	1999,	1999,	HumaSPECT ,	Phase II,	,	22,	,	,	,	,	,	Cancer,	,	Ovarian Cancer,	,	,
wvcu19980000949175,	SENSUS DRUG DEVELOPMENT CORP,	S-1,	1998,	1998,	Trovert (B2036PEG),	Phase III,	growth hormone antagonists ("GHAs"),	24,	,	,	,	,	,	endocrine and metabolic diseases and disorders,	,	acromegaly,	,	,
wvcu19980000949175,	SENSUS DRUG DEVELOPMENT CORP,	S-1,	1998,	1998,	Trovert (B2036PEG),	Phase III,	growth hormone antagonists ("GHAs"),	24,	,	,	,	,	,	endocrine and metabolic diseases and disorders,	,	acromegaly,	,	,
wvcu19980000949175,	SENSUS DRUG DEVELOPMENT CORP,	S-1,	1998,	1998,	Trovert (B2036PEG),	Phase II,	growth hormone antagonists ("GHAs"),	24,	,	,	,	,	,	endocrine and metabolic diseases and disorders,	,	DIABETIC RETINOPATHY,	,	,
wvcu19980000949175,	SENSUS DRUG DEVELOPMENT CORP,	S-1,	1998,	1998,	Trovert (B2036PEG),	Phase II,	growth hormone antagonists ("GHAs"),	24,	,	,	,	,	,	endocrine and metabolic diseases and disorders,	,	DIABETIC RETINOPATHY,	,	,
wvcu19980000949175,	SENSUS DRUG DEVELOPMENT CORP,	S-1,	1998,	1998,	Trovert (B2036PEG),	Research,	growth hormone antagonists ("GHAs"),	24,	,	,	,	,	,	endocrine and metabolic diseases and disorders,	,	DIABETIC NEPHROPATHY,	,	,
wvcu19980000949175,	SENSUS DRUG DEVELOPMENT CORP,	S-1,	1998,	1998,	Trovert (B2036PEG),	Research,	growth hormone antagonists ("GHAs"),	24,	,	,	,	,	,	endocrine and metabolic diseases and disorders,	,	DIABETIC NEPHROPATHY,	,	,
wvcu20000001123959,	CONTROL DELIVERY SYSTEM,	S-1,	2000,	2000,	Vitrasert,	Marketed,	Aeon Platform Technology,	1,	,	,	,	,	,	Eye Disease,	,	CMV Retinitis,	,	,
wvcu20000001123959,	CONTROL DELIVERY SYSTEM,	S-1,	2000,	2000,	Aeon Platform Technology,	Pre Clinical,	Aeon Platform Technology,	1,	,	,	,	,	,	Eye Disease,	,	  Diabetic Macular Edema,	,	,
wvcu20000001123959,	CONTROL DELIVERY SYSTEM,	S-1,	2000,	2000,	Aeon Platform Technology,	Phase II,	Aeon Platform Technology,	1,	,	,	,	,	,	Eye Disease,	,	 Uveitis,	,	,
wvcu20000001123959,	CONTROL DELIVERY SYSTEM,	S-1,	2000,	2000,	Aeon Platform Technology,	Phase II,	Aeon Platform Technology,	1,	,	,	,	,	,	Eye Disease,	,	 Age-related Macular Degeneration,	,	,
wvcu20000001123959,	CONTROL DELIVERY SYSTEM,	S-1,	2000,	2000,	Aeon Platform Technology,	Research,	Aeon Platform Technology,	20,	,	,	,	,	,	Osteoarthritis,	,	Osteoarthritis.,	,	,
wvcu20000001123959,	CONTROL DELIVERY SYSTEM,	S-1,	2000,	2000,	Ceredur,	Phase II,	Aeon Platform Technology,	22,	40,	,	,	,	,	Oncology,	,	Brain Tumors,	,	,
wvcu20000001123959,	CONTROL DELIVERY SYSTEM,	S-1,	2000,	2000,	Codrug Platform Technology,	Research,	Codrug Platform Technology,	62,	,	,	,	,	,	Surgery ,	,	 post-surgical pain,	,	,
wvcu20000001123959,	CONTROL DELIVERY SYSTEM,	S-1,	2000,	2000,	Codrug Platform Technology,	Research,	Codrug Platform Technology,	22,	,	,	,	,	,	Oncology,	,	Prostate Cancer,	,	,
wvcu20000001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2000,	2000,	Xcellerate Therapy,	Phase I,	Xcellerate Technology,	22,	,	,	,	,	,	Oncology,	,	Kidney Cancer,	,	,
wvcu20000001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2000,	2000,	Xcellerate Therapy,	Research,	Xcellerate Technology,	22,	27,	,	,	,	,	Oncology,	,	Non-Hodgkin's Lymphoma,	,	,
wvcu20000001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2000,	2000,	Xcellerate Therapy,	Research,	Xcellerate Technology,	22,	,	,	,	,	,	Oncology,	,	Ovarian.,	,	,
wvcu20000001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2000,	2000,	Xcellerate Therapy,	Research,	Xcellerate Technology,	22,	,	,	,	,	,	Oncology,	,	Melanoma,	,	,
wvcu20000001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2000,	2000,	Xcellerate Therapy,	Research,	Xcellerate Technology,	22,	,	,	,	,	,	Oncology,	,	Multiple Myeloma,	,	,
wvcu20000001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2000,	2000,	Xcellerate Therapy,	Research,	Xcellerate Technology,	22,	,	,	,	,	,	Oncology,	,	Colorectal,	,	,
wvcu20000001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2000,	2000,	Xcellerate Therapy,	Research,	Xcellerate Technology,	22,	,	,	,	,	,	Oncology,	,	Lung,	,	,
wvcu20000001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2000,	2000,	Xcellerate Therapy,	Research,	Xcellerate Technology,	27,	20,	,	,	,	,	Hematological Malignancies,	,	leukemia,	,	,
wvcu20000001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2000,	2000,	Xcellerate Therapy,	Research,	Xcellerate Technology,	27,	20,	,	,	,	,	Hematological Malignancies,	,	non-Hodgkin's lymphoma,	,	,
wvcu20000001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2000,	2000,	Xcellerate Therapy,	Research,	Xcellerate Technology,	27,	20,	,	,	,	,	Hematological Malignancies,	,	Multiple Myeloma,	,	,
wvcu20000001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2000,	2000,	Xcellerate Therapy,	Research,	Xcellerate Technology,	27,	20,	,	,	,	,	Hematological Malignancies,	,	Hodgkin's disease.,	,	,
wvcu20000001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2000,	2000,	Xcellerate Therapy,	Research,	Xcellerate Technology,	23,	,	,	,	,	,	Infectious Diseases,	,	HIV  ,	,	,
wvcu20000001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2000,	2000,	Xcellerate Therapy,	Research,	Xcellerate Technology,	23,	,	,	,	,	,	Infectious Diseases,	,	Hepatitis C,	,	,
wvcu20000001130166,	Cyclacel Pharmaceuticals, Inc.,	S-1,	2000,	2000,	Xcellerate Therapy,	Research,	Xcellerate Technology,	23,	,	,	,	,	,	Infectious Diseases,	,	tuberculosis,	,	,
wvcu20000001029142,	DYNAVAX TECHNOLOGIES CORP,	S-1,	2000,	2000,	AIC,	Phase II,	 immunostimulatory sequences, or ISS,	5,	,	,	,	,	,	Immunotherapy,	,	Seasonal Allergy,	,	,
wvcu20000001029142,	DYNAVAX TECHNOLOGIES CORP,	S-1,	2000,	2000,	 Lol p 1,	Pre Clinical,	 immunostimulatory sequences, or ISS,	5,	,	,	,	,	,	Immunotherapy,	,	Grass Allergy,	,	,
wvcu20000001029142,	DYNAVAX TECHNOLOGIES CORP,	S-1,	2000,	2000,	ISS linked to peanut Allergy,	Pre Clinical,	 immunostimulatory sequences, or ISS,	5,	,	,	,	,	,	Immunotherapy,	,	Peanut Allergy,	,	,
wvcu20000001029142,	DYNAVAX TECHNOLOGIES CORP,	S-1,	2000,	2000,	ISS linked or combined with,	Phase I ,	 immunostimulatory sequences, or ISS,	23,	,	,	,	,	,	INFECTIOUS DISEASES,	,	 Hepatitis B,	,	,
wvcu20000001029142,	DYNAVAX TECHNOLOGIES CORP,	S-1,	2000,	2000,	ISS linked or combined with HIV antigens,	Pre Clinical,	 immunostimulatory sequences, or ISS,	23,	,	,	,	,	,	INFECTIOUS DISEASES,	,	AIDS Prevention and Therapy,	,	,
wvcu20000001029142,	DYNAVAX TECHNOLOGIES CORP,	S-1,	2000,	2000,	ISS alone in various  formulations ,	Pre Clinical,	 immunostimulatory sequences, or ISS,	5,	,	,	,	,	,	CHRONIC INFLAMMATION,	,	 Idiopathic Pulmonary,	,	,
wvcu20000001029142,	DYNAVAX TECHNOLOGIES CORP,	S-1,	2000,	2000,	TZP I-153 ,	Pre Clinical,	thiazolopyrimidine, or TZP, class,	5,	20,	,	,	,	,	CHRONIC INFLAMMATION,	,	Rheumatoid Arthritis ,	,	,
wvcu20010001115143,	ACUSPHERE INC,	S-1,	2001,	2001,	 AI-700,	Phase II,	POROUS MICROPARTICLE TECHNOLOGY,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	myocardial perfusion,	,	,
wvcu20010001115143,	ACUSPHERE INC,	S-1,	2001,	2001,	AI-850 ,	Pre Clinical,	POROUS MICROPARTICLE TECHNOLOGY,	22,	,	,	,	,	,	Cancer,	,	Cancer,	,	,
wvcu20010001115143,	ACUSPHERE INC,	S-1,	2001,	2001,	 Pulmonary Drug Delivery System,	Pre Clinical,	POROUS MICROPARTICLE TECHNOLOGY,	5,	29,	,	,	,	,	respiratory disease,	,	Asthma,	,	,
wvcu20010001014455,	AGRAQUEST INC,	S-1,	2001,	2001,	Serenade,	Registration EPA,	microorganism database,	,	,	,	,	,	,	Pesticides,	,	high value specialty crops,	,	,
wvcu20010001014455,	AGRAQUEST INC,	S-1,	2001,	2001,	Sonata,	Registration EPA,	microorganism database,	70,	,	,	,	,	,	pesticides,	,	high value specialty crops,	,	,
wvcu20010001014455,	AGRAQUEST INC,	S-1,	2001,	2001,	Virtuoso,	Registration EPA,	microorganism database,	,	,	,	,	,	,	insecticides,	,	high value specialty crops,	,	,
wvcu20010001014455,	AGRAQUEST INC,	S-1,	2001,	2001,	Vivace,	Registration EPA,	microorganism database,	,	,	,	,	,	,	pesticides,	,	high value specialty crops,	,	,
wvcu20010001088856,	CORCEPT THERAPEUTICS INC,	S-1,	2001,	2001,	C-1073,	Phase III,	GR-II Antagonist Platform,	40,	,	,	,	,	,	psychiatric and neurological diseases,	,	psychotic major depression,	,	,
wvcu20010001115616,	PROTARGA INC,	S-1,	2001,	2001,	 Taxoprexin®,	Phase II,	 Targaceutical® platform technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Breast cancer,	,	,
wvcu20010001115616,	PROTARGA INC,	S-1,	2001,	2001,	 Taxoprexin®,	Phase II,	 Targaceutical® platform technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Colorectal cancer,	,	,
wvcu20010001115616,	PROTARGA INC,	S-1,	2001,	2001,	 Taxoprexin®,	Phase II,	 Targaceutical® platform technology,	22,	26,	,	,	,	,	ONCOLOGY,	,	Stomach cancer,	,	,
wvcu20010001115616,	PROTARGA INC,	S-1,	2001,	2001,	 Taxoprexin®,	Phase II,	 Targaceutical® platform technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Hormone-refractory prostate cancer,	,	,
wvcu20010001115616,	PROTARGA INC,	S-1,	2001,	2001,	 Taxoprexin®,	Phase II,	 Targaceutical® platform technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Melanoma,	,	,
wvcu20010001115616,	PROTARGA INC,	S-1,	2001,	2001,	 Taxoprexin®,	Phase II,	 Targaceutical® platform technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Non-small cell lung cancer,	,	,
wvcu20010001115616,	PROTARGA INC,	S-1,	2001,	2001,	 Taxoprexin®,	Phase II,	 Targaceutical® platform technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Pancreatic cancer,	,	,
wvcu20010001115616,	PROTARGA INC,	S-1,	2001,	2001,	 Taxoprexin®,	Phase II,	 Targaceutical® platform technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Kidney cancer,	,	,
wvcu20010001115616,	PROTARGA INC,	S-1,	2001,	2001,	P-232,	Pre Clinical,	 Targaceutical® platform technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Various cancers,	,	,
wvcu20010001115616,	PROTARGA INC,	S-1,	2001,	2001,	P-274,	Pre Clinical,	 Targaceutical® platform technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Various cancers,	,	,
wvcu20010001115616,	PROTARGA INC,	S-1,	2001,	2001,	P-309,	Pre Clinical,	 Targaceutical® platform technology,	22,	,	,	,	,	,	ONCOLOGY,	,	Various cancers,	,	,
wvcu20010001115616,	PROTARGA INC,	S-1,	2001,	2001,	Clozaprexin™,	Pre Clinical,	 Targaceutical® platform technology,	40,	,	,	,	,	,	Central Nervous Diseases,	,	Schizophrenia,	,	,
wvcu20020001164722,	ADERIS PHARMACEUTICALS INC,	S-1,	2002,	2002,	Rotigotine-CDS,	Phase III,	Agonist,	40,	,	,	,	,	,	Central Nervous Diseases,	,	Parkinson's disease,	,	,
wvcu20020001164722,	ADERIS PHARMACEUTICALS INC,	S-1,	2002,	2002,	Rotigotine-CDS,	Phase II,	Agonist,	40,	,	,	,	,	,	Central Nervous Diseases,	,	Restless Legs Syndrome,,	,	,
wvcu20020001164722,	ADERIS PHARMACEUTICALS INC,	S-1,	2002,	2002,	 MRE-470,	Phase II,	Agonist,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	 diagnosis of coronary artery disease,	,	,
wvcu20020001164722,	ADERIS PHARMACEUTICALS INC,	S-1,	2002,	2002,	DTI-0009,	Phase II,	(antagonists) ,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Atrial fibrillation,	,	,
wvcu20020001164722,	ADERIS PHARMACEUTICALS INC,	S-1,	2002,	2002,	DTI-0017 ,	Phase I,	(antagonists) ,	21,	,	,	,	,	,	Cardiovascular Disease,	,	 congestive heart failure,	,	,
wvcu20030001008848,	ACORDA THERAPEUTICS INC,	S-1,	2003,	2003,	Fampridine-SR,	Phase III,	core technologies,	25,	40,	70,	,	,	,	Central Nervous Diseases,	,	SCI,	,	,
wvcu20030001008848,	ACORDA THERAPEUTICS INC,	S-1,	2003,	2003,	Fampridine-SR,	Phase II,	core technologies,	25,	40,	70,	,	,	,	Central Nervous Diseases,	,	MS,	,	,
wvcu20030001008848,	ACORDA THERAPEUTICS INC,	S-1,	2003,	2003,	Valrocemide,	Phase II,	core technologies,	43,	,	,	,	,	,	neurological disorders,	,	Epilepsy,	,	,
wvcu20030001008848,	ACORDA THERAPEUTICS INC,	S-1,	2003,	2003,	Valrocemide,	Phase II,	core technologies,	43,	,	,	,	,	,	neurological disorders,	,	Bipolar disorder,	,	,
wvcu20030001008848,	ACORDA THERAPEUTICS INC,	S-1,	2003,	2003,	GGF-2,	Pre Clinical,	 remyelinating antibodies,	40,	,	,	,	,	,	neurological disorders,	,	MS,	,	,
wvcu20030001008848,	ACORDA THERAPEUTICS INC,	S-1,	2003,	2003,	Remyelinating Antibodies,	Pre Clinical,	 remyelinating antibodies,	40,	,	,	,	,	,	neurological disorders,	,	MS,	,	,
wvcu20030001008848,	ACORDA THERAPEUTICS INC,	S-1,	2003,	2003,	Chondroitinase,	research,	 Scar Matrix Modification,	45,	,	,	,	,	,	neurological disorders,	,	SCI,	,	,
wvcu20030001008848,	ACORDA THERAPEUTICS INC,	S-1,	2003,	2003,	Regenerative Antibodies,	research,	 Scar Matrix Modification,	40,	,	,	,	,	,	neurological disorders,	,	SCI,	,	,
wvcu20030001164722,	ADERIS PHARMACEUTICALS INC,	S-1,	2003,	2003,	Rotigotine-CDS,	Phase III,	Agonist,	40,	,	,	,	,	,	Central Nervous Diseases,	,	Parkinson's disease,	,	,
wvcu20030001164722,	ADERIS PHARMACEUTICALS INC,	S-1,	2003,	2003,	Rotigotine-CDS,	Phase II,	Agonist,	40,	,	,	,	,	,	Central Nervous Diseases,	,	Restless Legs Syndrome,,	,	,
wvcu20030001164722,	ADERIS PHARMACEUTICALS INC,	S-1,	2003,	2003,	Binodenoson     ,	Phase II,	Agonist,	21,	60,	,	,	,	,	Cardiovascular Disease,	,	 diagnosis of coronary artery disease,	,	,
wvcu20030001164722,	ADERIS PHARMACEUTICALS INC,	S-1,	2003,	2003,	Selodenoson  ,	Phase II,	Agonist,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Atrial fibrillation,	,	,
wvcu20030001164722,	ADERIS PHARMACEUTICALS INC,	S-1,	2003,	2003,	MRE-0094  ,	IND,	Agonist,	5,	,	,	,	,	,	"inflammatory
conditions,"	,	 Diabetic foot ulcers,	,	,
nvcs20040001131517,	ANESIVA, INC.,	S-1,	2004,	2004,	E2F Decoy,	Phase III,	TF decoy technology.,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Bypass Surgery and Bypass Graft Failure,	,	,
nvcs20040001131517,	ANESIVA, INC.,	S-1,	2004,	2004,	E2F Decoy,	Phase I,	TF decoy technology.,	28,	,	,	,	,	,	renal disease,	,	AV Graft Failure,	,	,
nvcs20040001131517,	ANESIVA, INC.,	S-1,	2004,	2004,	NF-kB Decoy,	Pre Clinical,	TF decoy technology.,	5,	20,	,	,	,	,	inflammatory Diseases,	,	Inflammation,	,	,
nvcs20040001131517,	ANESIVA, INC.,	S-1,	2004,	2004,	Cancer Decoys,	Pre Clinical,	TF decoy technology.,	22,	,	,	,	,	,	Oncology,	,	Cancer,	,	,
nvcs20040001131517,	ANESIVA, INC.,	424B,	2004,	2004,	E2F Decoy,	Phase III,	TF decoy technology.,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Bypass Surgery and Bypass Graft Failure,	,	,
nvcs20040001131517,	ANESIVA, INC.,	424B,	2004,	2004,	E2F Decoy,	Phase I,	TF decoy technology.,	28,	,	,	,	,	,	renal disease,	,	AV Graft Failure,	,	,
nvcs20040001131517,	ANESIVA, INC.,	424B,	2004,	2004,	NF-kB Decoy,	Pre Clinical,	TF decoy technology.,	5,	20,	,	,	,	,	inflammatory Diseases,	,	Inflammation,	,	,
nvcs20040001131517,	ANESIVA, INC.,	424B,	2004,	2004,	Cancer Decoys,	Pre Clinical,	TF decoy technology.,	22,	,	,	,	2007,	-1,	Oncology,	,	Cancer,	,	,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2004,	E2F Decoy,	Phase III,	TF decoy technology.,	21,	,	,	,	2007,	-1,	Cardiovascular Disease,	,	Bypass Surgery and Bypass Graft Failure,	,	,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2004,	E2F Decoy,	Phase I,	TF decoy technology.,	28,	,	,	,	,	,	renal disease,	,	AV Graft Failure,	,	,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2004,	NF-kB Decoy,	Pre Clinical,	TF decoy technology.,	5,	20,	,	,	,	,	inflammatory Diseases,	,	Inflammation,	,	,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2004,	Cancer Decoys,	Pre Clinical,	TF decoy technology.,	22,	,	,	,	2007,	-1,	Oncology,	,	Cancer,	,	,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2005,	E2F Decoy,	Phase III,	TF decoy technology.,	21,	,	,	,	2007,	-1,	Cardiovascular Disease,	,	Bypass Surgery and Bypass Graft Failure,	,	,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2005,	E2F Decoy,	Phase I,	TF decoy technology.,	28,	,	,	,	,	,	renal disease,	,	AV Graft Failure,	,	,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2005,	NF-kB Decoy,	Phase II,	TF decoy technology.,	5,	8,	20,	,	,	,	inflammatory Diseases,	,	Atopic dermatitis,	Inflammation,	Preclinical,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2005,	 HIF Decoy,	Pre Clinical,	TF decoy technology.,	22,	,	,	Cancer Decoy,	2007,	0,	Oncology,	,	Lung Cancer,	Cancer,	,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2005,	 HIF Decoy,	Pre Clinical,	TF decoy technology.,	22,	,	,	Cancer Decoy,	,	,	Oncology,	,	Pancreatic cancer,	Cancer,	,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2005,	 HIF Decoy,	Pre Clinical,	TF decoy technology.,	22,	,	,	Cancer Decoy,	,	,	Oncology,	,	Colon,	Cancer,	,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2006,	3268,	Phase III,	TARGETED SPECIFITY,	62,	9,	25,	,	,	,	Pain Management,	,	Pain associated with venipuncture and cannulation,	,	,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2006,	4975,	Phase II,	TARGETED SPECIFITY,	62,	9,	25,	,	,	,	Pain Management,	,	Post-surgical, neuropathic and musculoskeletal pain,	,	,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2006,	Avrina (NF-KB Decoy),	Phase II,	TF decoy technology.,	5,	8,	20,	NF-kB Decoy,	,	,	inflammatory Diseases,	,	Atopic dermatitis,	Inflammation,	Preclinical,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2006,	1207,	Phase I,	TARGETED SPECIFITY,	62,	9,	42,	,	,	,	Pain Management,	,	Neuropathic pain,	,	,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2007,	Zingo,	NDA,	TARGETED SPECIFITY,	62,	9,	25,	,	,	,	Pain Management,	,	Pain associated with venipuncture and cannulation,	,	Phase III,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2007,	4975,	Phase II,	TARGETED SPECIFITY,	62,	9,	25,	,	,	,	Pain Management,	,	Post-surgical, neuropathic and musculoskeletal pain,	,	,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2008,	Zingo,	NDA,	TARGETED SPECIFITY,	62,	9,	25,	,	,	,	Pain Management,	,	Pain associated with venipuncture and cannulation,	,	Phase III,
nvcs20040001131517,	ANESIVA, INC.,	10-K,	2004,	2008,	Adlea™,	Phase II,	TARGETED SPECIFITY,	62,	9,	25,	4975,	,	,	Pain Management,	,	Post-surgical, neuropathic and musculoskeletal pain,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	S-1,	2004,	2004,	AIC,	Phase II,	ISS,	5,	,	,	,	2010,	-0.8605,	Allergy Immunotherapy,	,	Ragweed Allergy,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	S-1,	2004,	2004,	 HBV vaccine,	Phase II,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	HBV prophylaxis,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	S-1,	2004,	2004,	Asthma Vaccine,	Phase II,	ISS,	5,	29,	,	,	,	,	CHRONIC INFLAMMATION,	,	Asthma,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	S-1,	2004,	2004,	1018 ISS,	Pre Clinical,	ISS,	22,	27,	,	,	2009,	0.7778,	ONCOLOGY,	,	Non-Hodkins Lymphoma,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	S-1,	2004,	2004,	 rheumatoid arthritis,	Pre Clinical,	 TZPs,	5,	20,	,	,	2007,	-0.6667,	CHRONIC INFLAMMATION,	,	 rheumatoid arthritis,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	S-1,	2004,	2004,	Crohn's Disease,	Pre Clinical,	 TZPs,	5,	20,	,	,	2007,	0,	CHRONIC INFLAMMATION,	,	Crohn's Disease,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	S-1,	2004,	2004,	Human viral influenza,	Pre Clinical,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	Influenza,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	424B,	2004,	2004,	AIC,	Phase II,	ISS,	5,	,	,	,	2010,	-0.8605,	Allergy Immunotherapy,	,	Ragweed Allergy,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	424B,	2004,	2004,	 HBV vaccine,	Phase II,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	HBV prophylaxis,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	424B,	2004,	2004,	Asthma Vaccine,	Phase II,	ISS,	5,	29,	,	,	,	,	CHRONIC INFLAMMATION,	,	Asthma,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	424B,	2004,	2004,	1018 ISS,	Pre Clinical,	ISS,	22,	27,	,	,	2009,	0.7778,	ONCOLOGY,	,	Non-Hodkins Lymphoma,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	424B,	2004,	2004,	 rheumatoid arthritis,	Pre Clinical,	 TZPs,	5,	20,	,	,	2007,	-0.6667,	CHRONIC INFLAMMATION,	,	 rheumatoid arthritis,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	424B,	2004,	2004,	Crohn's Disease,	Pre Clinical,	 TZPs,	5,	20,	,	,	2007,	0,	CHRONIC INFLAMMATION,	,	Crohn's Disease,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	424B,	2004,	2004,	Human viral influenza,	Pre Clinical,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	Influenza,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2005,	AIC,	Phase II,	ISS,	5,	,	,	,	2010,	-0.8605,	Allergy Immunotherapy,	,	Ragweed Allergy,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2005,	 HBV vaccine,	Phase II,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	HBV prophylaxis,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2005,	Asthma Vaccine,	Phase IIA,	ISS,	5,	29,	,	,	,	,	CHRONIC INFLAMMATION,	,	Asthma,	,	Phase II,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2005,	1018 ISS,	Pre Clinical,	ISS,	22,	27,	,	,	2009,	0.7778,	ONCOLOGY,	,	Non-Hodkins Lymphoma,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2005,	 rheumatoid arthritis,	Pre Clinical,	 TZPs,	5,	20,	,	,	2007,	-0.8889,	CHRONIC INFLAMMATION,	,	 rheumatoid arthritis,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2005,	Crohn's Disease,	Pre Clinical,	 TZPs,	5,	20,	,	,	2007,	-1,	CHRONIC INFLAMMATION,	,	Crohn's Disease,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2005,	Human viral influenza,	Pre Clinical,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	Influenza,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2006,	TOLAMBAtm,	Phase II,	ISS,	5,	,	,	AIC,	2010,	-0.8605,	Allergy Immunotherapy,	,	Ragweed Allergy,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2006,	Hepatitis B Therapy,	Pre Clinical,	ISS,	23,	,	,	,	2010,	1.2,	Infectious Diseases,	,	HBV,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2006,	 HEPLISAVtm,	Phase III,	ISS,	23,	,	,	 HBV vaccine,	,	,	Infectious Diseases,	,	HBV prophylaxis,	,	Phase II,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2006,	Asthma Vaccine,	Phase IIA,	ISS/TLR9 agonists,	5,	29,	,	,	,	,	CHRONIC INFLAMMATION,	,	Asthma,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2006,	1018 ISS,	Phase I,	ISS,	22,	27,	,	,	2009,	0.7778,	ONCOLOGY,	,	Non-Hodkins Lymphoma,	,	Pre clinical,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2006,	Human viral influenza,	Pre Clinical,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	Influenza,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2007,	TOLAMBAtm,	Phase II,	ISS,	5,	,	,	,	2010,	-0.8605,	Allergy Immunotherapy,	,	Ragweed Allergy,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2007,	Hepatitis B Therapy,	Phase I,	ISS,	23,	,	,	,	2010,	1.2,	Infectious Diseases,	,	HBV,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2007,	 HEPLISAVtm,	Phase III,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	HBV prophylaxis,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2007,	(COPD) program,	Pre Clinical,	ISS/TLR9 agonists,	5,	29,	,	Asthma Vaccine,	,	,	CHRONIC INFLAMMATION,	,	asthma and chronic obstructive pulmonary disease ,	,	Phase IIA,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2007,	1018 ISS,	Phase I,	ISS,	22,	27,	,	,	2009,	1.6667,	ONCOLOGY,	,	Non-Hodkins Lymphoma,	,	Pre clinical,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2007,	Human viral influenza,	Pre Clinical,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	Influenza,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2007,	metastatic colorectal ,	Phase I,	ISS,	22,	,	,	,	2011,	0,	ONCOLOGY,	,	 metastatic colorectal cancer,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2007,	hepatitis B virus (HBV) ,	Phase I,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	chronic hepatitis B virus (HBV) infection,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2008,	TOLAMBAtm,	Phase II,	ISS,	5,	,	,	,	2010,	-0.3333,	Allergy Immunotherapy,	,	Ragweed Allergy,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2008,	Hepatitis B Therapy,	Phase I,	ISS,	23,	,	,	,	2010,	0.2222,	Infectious Diseases,	,	HBV,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2008,	 HEPLISAVtm,	Phase III,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	HBV prophylaxis,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2008,	(COPD) program,	Pre Clinical,	ISS/TLR9 agonists,	5,	29,	,	,	,	,	CHRONIC INFLAMMATION,	,	asthma and chronic obstructive pulmonary disease ,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2008,	metastatic colorectal ,	Phase I,	ISS,	22,	,	,	,	2011,	0,	ONCOLOGY,	,	 metastatic colorectal cancer,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2008,	hepatitis B virus (HBV) ,	Phase I,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	chronic hepatitis B virus (HBV) infection,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2008,	Human viral influenza,	Pre Clinical,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	Influenza,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2009,	 HEPLISAVtm,	Phase III,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	HBV prophylaxis,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2009,	DV-601,	PhaseIB,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	HBV,	,	Phase I,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2009,	SD-101,	PhaseIB,	ISS,	23,	,	,	hepatitis B virus (HBV) ,	,	,	Infectious Diseases,	,	hepatitis C therapy,	HBV,	Phase I,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2009,	AZD1419,	Pre Clinical,	ISS/TLR9 agonists,	5,	29,	,	(COPD) program,	,	,	CHRONIC INFLAMMATION,	,	asthma and chronic obstructive pulmonary disease ,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2009,	metastatic colorectal ,	Phase I,	ISS,	22,	,	,	,	2011,	-1,	ONCOLOGY,	,	 metastatic colorectal cancer,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2009,	DV1079,	Pre Clinical,	ISS,	5,	,	,	,	,	,	Autoimmune,	,	Inflammatory,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2009,	Human viral influenza,	Pre Clinical,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	Influenza,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2010,	 HEPLISAVtm,	Phase III,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	HBV prophylaxis,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2010,	DV-601,	PhaseIB,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	HBV,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2010,	SD-101,	PhaseIB,	ISS,	23,	,	,	hepatitis B virus (HBV) ,	,	,	Infectious Diseases,	,	hepatitis C therapy,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2010,	AZD1419,	Pre Clinical,	ISS/TLR9 agonists,	5,	29,	,	(COPD) program,	,	,	CHRONIC INFLAMMATION,	,	asthma and chronic obstructive pulmonary disease ,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2010,	Human viral influenza,	Pre Clinical,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	Influenza,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2010,	DV1079,	Pre Clinical,	ISS,	5,	,	,	,	,	,	Autoimmune,	,	Inflammatory,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2011,	 HEPLISAVtm,	Phase III,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	HBV prophylaxis,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2011,	DV-601,	PhaseIB,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	HBV,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2011,	SD-101,	PhaseIB,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	hepatitis C therapy,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2011,	AZD1419,	Pre Clinical,	ISS/TLR9 agonists,	5,	29,	,	,	,	,	CHRONIC INFLAMMATION,	,	asthma and chronic obstructive pulmonary disease ,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2011,	Human viral influenza,	Pre Clinical,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	Influenza,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2011,	DV1079,	Pre Clinical,	ISS,	5,	,	,	,	,	,	Autoimmune,	,	Inflammatory,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2012,	 HEPLISAVtm,	Phase III,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	HBV prophylaxis,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2012,	DV-601,	PhaseIB,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	HBV,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2012,	AZD1419,	Pre Clinical,	ISS/TLR9 agonists,	5,	29,	,	,	,	,	CHRONIC INFLAMMATION,	,	asthma and chronic obstructive pulmonary disease ,	,	,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2012,	Human viral influenza,	Phase IB,	ISS,	23,	,	,	,	,	,	Infectious Diseases,	,	Influenza,	,	Preclinical,
wvcs20040001029142,	DYNAVAX TECHNOLOGIES CORP,	10-K,	2004,	2012,	DV1079,	Phase I,	ISS,	5,	,	,	,	,	,	Autoimmune,	,	Inflammatory,	,	Preclinical,
nvcs20040001118361,	RENOVIS INC,	S-1,	2003,	2003,	Cerovive ,	Phase III,	neuroprotectant( nitrones),	9,	45,	,	,	2008,	-0.8045,	Neurodegenerative Disease,	,	acute ischemic stroke,	,	,
nvcs20040001118361,	RENOVIS INC,	S-1,	2003,	2003,	REN-1654,	Phase II,	 TNFa inhibition,	62,	9,	42,	,	2007,	-0.7667,	Pain ,	,	neuropathic pain,	,	,
nvcs20040001118361,	RENOVIS INC,	S-1,	2003,	2003,	REN-213,	Phase I,	 nalbuphine, a kappa-opiate, with naloxone, an opiate antagonist ,	62,	9,	29,	,	2006,	-0.7949,	Pain ,	,	acute post-operative pain,	,	,
nvcs20040001118361,	RENOVIS INC,	S-1,	2003,	2003,	VR1 Antagonist,	research,	(VR1) Blocker,	5,	62,	29,	,	,	,	Pain ,	,	chronic pain ,	,	,
nvcs20040001118361,	RENOVIS INC,	S-1,	2003,	2003,	Nitrone Analgesic,	research,	neuroprotectant( nitrones),	62,	,	,	,	2007,	0,	Pain ,	,	chronic pain ,	,	,
nvcs20040001118361,	RENOVIS INC,	S-1,	2003,	2003,	Leukocyte Trafficking Inhibitor,	research,	 inhibitor of leukocyte trafficking,	40,	,	,	,	2007,	-0.825,	Neurodegenerative Disease,	,	Neurodegenerative Disease,	,	,
nvcs20040001118361,	RENOVIS INC,	424B,	2003,	2004,	Cerovive ,	Phase III,	neuroprotectant( nitrones),	9,	45,	,	,	2008,	-0.8045,	Neurodegenerative Disease,	,	acute ischemic stroke,	,	,
nvcs20040001118361,	RENOVIS INC,	424B,	2003,	2004,	REN-1654,	Phase II,	 TNFa inhibition,	62,	9,	42,	,	2007,	-0.7667,	Pain ,	,	neuropathic pain,	,	,
nvcs20040001118361,	RENOVIS INC,	424B,	2003,	2004,	REN-213,	Phase II,	 nalbuphine, a kappa-opiate, with naloxone, an opiate antagonist ,	62,	9,	29,	,	2006,	-0.7333,	Pain ,	,	acute post-operative pain,	,	Phase I,
nvcs20040001118361,	RENOVIS INC,	424B,	2003,	2004,	VR1 Antagonist,	research,	(VR1) Blocker,	5,	62,	29,	,	,	,	Pain ,	,	chronic pain ,	,	,
nvcs20040001118361,	RENOVIS INC,	424B,	2003,	2004,	Nitrone Analgesic,	research,	neuroprotectant( nitrones),	62,	,	,	,	2007,	0,	Pain ,	,	chronic pain ,	,	,
nvcs20040001118361,	RENOVIS INC,	424B,	2003,	2004,	Leukocyte Trafficking Inhibitor,	research,	 inhibitor of leukocyte trafficking,	40,	,	,	,	2007,	-0.825,	Neurodegenerative Disease,	,	Neurodegenerative Disease,	,	,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2005,	Cerovive ,	Phase III,	neuroprotectant( nitrones),	9,	45,	,	,	2008,	-0.8045,	Neurodegenerative Disease,	,	acute ischemic stroke,	,	,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2005,	REN-1654,	Phase II,	 TNFa inhibition,	62,	9,	42,	,	2007,	-0.8947,	Pain ,	,	neuropathic pain,	,	,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2005,	REN-850,	Phase I,	 inhibitor of leukocyte trafficking,	5,	,	,	Leukocyte Trafficking Inhibitor,	2007,	-0.9474,	Autoimmune disease,	,	 MS,	,	,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2005,	VR1 Antagonist,	research,	(VR1) Blocker,	5,	62,	29,	,	,	,	Pain ,	,	chronic pain ,	,	,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2005,	Nerve Growth/Angiogenesis,	research,	neuroprotectant( nitrones),	25,	45,	,	,	2008,	-0.1111,	Neurodegenerative Disease,	,	spinal cord injury,	,	,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2005,	Oral Cytoprotectant,	research,	neuroprotectant( nitrones),	9,	42,	,	Nitrone Analgesic,	2007,	-1,	Neurodegenerative Disease,	,	ischemia,	chronic pain ,	,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2006,	NXY-059 ,	Phase III,	neuroprotectant( nitrones),	9,	25,	45,	Cerovive ,	2008,	1.8889,	Neurodegenerative Disease,	,	acute ischemic stroke,	,	,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2006,	VR1 Antagonist,	research,	(VR1) Blocker,	5,	62,	9,	,	,	,	Pain ,	,	inflammatory pain and neuropathic pain,	chronic pain ,	,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2006,	Nerve Growth/Angiogenesis,	research,	neuroprotectant( nitrones),	25,	45,	,	,	2008,	-0.2,	Neurodegenerative Disease,	,	spinal cord injury,	,	,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2007,	VR1 Antagonist,	Pre Clinical,	(VR1) Blocker,	5,	62,	29,	,	,	,	Pain ,	,	chronic pain ,	,	research,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2007,	P2X7 Antagonist Program,	Pre Clinical,	receptor antagonists ,	5,	26,	20,	,	,	,	Inflammatory Diseases,	,	rheumatoid arthritis (RA) and inflammatory bowel disease (IBD),	,	,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2007,	P2X3, P2X2/3,	Pre Clinical,	receptor antagonists ,	62,	9,	42,	,	,	,	Pain ,	,	neuropathic pain,	,	,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2007,	TRPV4,	research,	receptor antagonists ,	62,	,	,	,	,	,	Pain ,	,	chronic pain ,	,	,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2008,	VR1 Antagonist,	Phase I,	(VR1) Blocker,	5,	62,	29,	,	,	,	Pain ,	,	chronic pain ,	,	Preclinical,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2008,	P2X7 Antagonist Program,	Pre Clinical,	receptor antagonists ,	5,	26,	20,	,	,	,	Inflammatory Diseases,	,	rheumatoid arthritis (RA) and inflammatory bowel disease (IBD),	,	,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2008,	P2X3, P2X2/3,	Pre Clinical,	receptor antagonists ,	62,	9,	42,	,	,	,	Pain ,	,	neuropathic pain,	,	,
nvcs20040001118361,	RENOVIS INC,	10-K,	2003,	2008,	TRPV4,	research,	receptor antagonists ,	62,	,	,	,	,	,	Pain ,	,	chronic pain ,	,	,
wvcs19980001041652,	IOMED LLC,	S-1,	1997,	1997,	   Dexamethasone,	Marketed,	iontophoretic    technology,	9,	,	,	,	1999,	-0.5,	Physical Therapy,	,	"acute inflammatory
 conditions,"	,	,
wvcs19980001041652,	IOMED LLC,	S-1,	1997,	1997,	Iontocaine,	NDA,	iontophoretic    technology ,	61,	8,	9,	,	2001,	-0.4091,	pediatric Anestesiology,	,	Local Dermal Anesthesia,	,	,
wvcs19980001041652,	IOMED LLC,	S-1,	1997,	1997,	iontophoretic  drug  delivery  systems,	Phase I,	iontophoretic    technology ,	70,	,	,	,	,	,	Labor/Preganancy/ ,	,	Remission of Pre-Term Labor,	,	,
wvcs19980001041652,	IOMED LLC,	S-1,	1997,	1997,	iontophoretic  drug  delivery  systems,	Pre Clinical,	iontophoretic    technology ,	62,	,	,	,	,	,	" diagnostic tests
,"	,	Conscious Sedation,	,	,
wvcs19980001041652,	IOMED LLC,	S-1,	1997,	1997,	iontophoretic  drug  delivery  systems,	Phase II,	iontophoretic    technology ,	62,	,	,	,	,	,	Pain Management,	,	post  operative and chronic pain control,	,	,
wvcs19980001041652,	IOMED LLC,	S-1,	1997,	1997,	iontophoretic  drug  delivery  systems,	Pre Clinical,	iontophoretic    technology ,	20,	,	,	,	,	,	Osteoporosis,	,	Osteoporosis,	,	,
wvcs19980001041652,	IOMED LLC,	424,	1997,	1997,	iontophoretic  drug  delivery  systems,	Marketed,	iontophoretic    technology,	9,	,	,	   Dexamethasone,	,	,	Physical Therapy,	,	"acute inflammatory
 conditions,"	,	,
wvcs19980001041652,	IOMED LLC,	424,	1997,	1997,	Numby Stuff,	MArketed,	iontophoretic    technology ,	61,	8,	9,	,	,	,	pediatric Anestesiology,	,	Local Dermal Anesthesia,	,	NDA,
wvcs19980001041652,	IOMED LLC,	424,	1997,	1997,	iontophoretic  drug  delivery  systems,	Phase I,	iontophoretic    technology ,	70,	,	,	,	,	,	Labor/Preganancy/ ,	,	Remission of Pre-Term Labor,	,	,
wvcs19980001041652,	IOMED LLC,	424,	1997,	1997,	iontophoretic  drug  delivery  systems,	Phase I,	iontophoretic    technology ,	62,	,	,	,	,	,	" diagnostic tests
,"	,	Conscious Sedation,	,	Preclinical,
wvcs19980001041652,	IOMED LLC,	424,	1997,	1997,	iontophoretic  drug  delivery  systems,	Phase II,	iontophoretic    technology ,	62,	,	,	,	,	,	Pain Management,	,	post  operative and chronic pain control,	,	,
wvcs19980001041652,	IOMED LLC,	424,	1997,	1997,	iontophoretic  drug  delivery  systems,	Pre Clinical,	iontophoretic    technology ,	20,	,	,	,	,	,	Osteoporosis,	,	Osteoporosis,	,	,
wvcs19980001041652,	IOMED LLC,	424,	1997,	1997,	Iontocaine,	Pre Clinical,	iontophoretic    technology ,	61,	9,	,	,	2001,	-0.4091,	pediatric Anestesiology,	,	Local mucosal anesthetic,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	1998,	iontophoretic  drug  delivery  systems,	Marketed,	iontophoretic    technology,	9,	,	,	,	,	,	Physical Therapy,	,	"acute inflammatory
 conditions,"	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	1998,	Numby Stuff,	MArketed,	iontophoretic    technology ,	61,	8,	9,	,	,	,	pediatric Anestesiology,	,	Local Dermal Anesthesia,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	1998,	iontophoretic  drug  delivery  systems,	Phase I,	iontophoretic    technology ,	70,	,	,	,	,	,	Labor/Preganancy/ ,	,	Remission of Pre-Term Labor,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	1998,	iontophoretic  drug  delivery  systems,	Phase I,	iontophoretic    technology ,	62,	,	,	,	,	,	" diagnostic tests
,"	,	Conscious Sedation,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	1998,	iontophoretic  drug  delivery  systems,	Phase II,	iontophoretic    technology ,	62,	,	,	,	,	,	Pain Management,	,	post  operative and chronic pain control,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	1998,	Iontocaine,	Pre Clinical,	iontophoretic    technology ,	61,	9,	,	,	2001,	-0.4091,	pediatric Anestesiology,	,	Local mucosal anesthetic,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	1999,	iontophoretic  drug  delivery  systems,	Marketed,	iontophoretic    technology,	9,	,	,	,	,	,	Physical Therapy,	,	"acute inflammatory
 conditions,"	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	1999,	Numby Stuff,	MArketed,	iontophoretic    technology ,	61,	8,	9,	,	,	,	pediatric Anestesiology,	,	Local Dermal Anesthesia,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	1999,	 OcuPhor(TM) System,	Pre Clinical,	iontophoretic    technology ,	1,	,	,	iontophoretic  drug  delivery  systems,	2005,	-0.1111,	Ophthalmic disease ,	,	 AMD and diabetic retinopathy,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	1999,	iontophoretic  drug  delivery  systems,	Phase I,	iontophoretic    technology ,	62,	,	,	,	,	,	" diagnostic tests
,"	,	Conscious Sedation,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	1999,	iontophoretic  drug  delivery  systems,	Phase II,	iontophoretic    technology ,	62,	,	,	,	,	,	Pain Management,	,	post  operative and chronic pain control,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	1999,	Iontocaine,	Pre Clinical,	iontophoretic    technology ,	61,	9,	,	,	2001,	12,	pediatric Anestesiology,	,	Local mucosal anesthetic,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2000,	iontophoretic  drug  delivery  systems,	Marketed,	iontophoretic    technology,	9,	,	,	,	,	,	Physical Therapy,	,	"acute inflammatory
 conditions,"	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2000,	Numby Stuff,	MArketed,	iontophoretic    technology ,	61,	8,	9,	,	,	,	pediatric Anestesiology,	,	Local Dermal Anesthesia,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2000,	 OcuPhor(TM) System,	Pre Clinical,	iontophoretic    technology ,	1,	,	,	,	2005,	-0.1111,	Ophthalmic disease ,	,	 AMD and diabetic retinopathy,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2000,	 OcuPhor(TM) System,	Pre Clinical,	iontophoretic    technology ,	1,	,	,	,	,	,	Ophthalmic disease ,	,	 AMD and diabetic retinopathy,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2001,	IontoDex™ ,	Marketed,	iontophoretic    technology,	9,	,	,	iontophoretic  drug  delivery  systems,	,	,	Physical Therapy,	,	"acute inflammatory
 conditions,"	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2001,	Numby Stuff,	MArketed,	iontophoretic    technology ,	61,	8,	9,	Iontocaine,	,	,	pediatric Anestesiology,	,	Local Dermal Anesthesia,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2001,	 OcuPhor(TM) System,	Pre Clinical,	iontophoretic    technology ,	1,	,	,	,	2005,	-0.1111,	Ophthalmic disease ,	,	 AMD and diabetic retinopathy,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2001,	 OcuPhor(TM) System,	Pre Clinical,	iontophoretic    technology ,	1,	,	,	,	,	,	Ophthalmic disease ,	,	 AMD and diabetic retinopathy,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2002,	IontoDex™ ,	Marketed,	iontophoretic    technology,	9,	,	,	,	,	,	Physical Therapy,	,	"acute inflammatory
 conditions,"	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2002,	Numby Stuff,	MArketed,	iontophoretic    technology ,	61,	8,	9,	,	,	,	pediatric Anestesiology,	,	Local Dermal Anesthesia,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2002,	 OcuPhor(TM) System,	Pre Clinical,	iontophoretic    technology ,	1,	,	,	,	2005,	-0.1111,	Ophthalmic disease ,	,	 AMD and diabetic retinopathy,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2002,	 OcuPhor(TM) System,	Pre Clinical,	iontophoretic    technology ,	1,	,	,	,	,	,	Ophthalmic disease ,	,	 AMD and diabetic retinopathy,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2003,	IontoDex™ ,	Marketed,	iontophoretic    technology,	9,	,	,	,	,	,	Physical Therapy,	,	"acute inflammatory
 conditions,"	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2003,	Numby Stuff,	MArketed,	iontophoretic    technology ,	61,	8,	9,	,	,	,	pediatric Anestesiology,	,	Local Dermal Anesthesia,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2003,	 OcuPhor(TM) System,	Pre Clinical,	iontophoretic    technology ,	1,	,	,	,	2005,	0,	Ophthalmic disease ,	,	 AMD and diabetic retinopathy,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2003,	 OcuPhor(TM) System,	Pre Clinical,	iontophoretic    technology ,	1,	,	,	,	,	,	Ophthalmic disease ,	,	 AMD and diabetic retinopathy,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2004,	IontoDex™ ,	Marketed,	iontophoretic    technology,	9,	,	,	,	,	,	Physical Therapy,	,	"acute inflammatory
 conditions,"	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2004,	Numby Stuff,	MArketed,	iontophoretic    technology ,	61,	8,	9,	,	,	,	pediatric Anestesiology,	,	Local Dermal Anesthesia,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2005,	IontoDex™ ,	Marketed,	iontophoretic    technology,	9,	,	,	,	,	,	Physical Therapy,	,	"acute inflammatory
 conditions,"	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2005,	Numby Stuff,	MArketed,	iontophoretic    technology ,	61,	8,	9,	,	,	,	pediatric Anestesiology,	,	Local Dermal Anesthesia,	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2006,	IontoDex™ ,	Marketed,	iontophoretic    technology,	9,	,	,	,	,	,	Physical Therapy,	,	"acute inflammatory
 conditions,"	,	,
wvcs19980001041652,	IOMED LLC,	10-K,	1997,	2006,	Numby Stuff,	MArketed,	iontophoretic    technology ,	61,	8,	9,	,	,	,	pediatric Anestesiology,	,	Local Dermal Anesthesia,	,	,
wvcs19980001025573,	NATROL INC,	S-1,	1998,	1998,	ESTER-C,	Marketed,	proprietary formulations,	,	,	,	,	,	,	Health Food Stores,	,	Vitamin C market,	,	,
wvcs19980001025573,	NATROL INC,	S-1,	1998,	1998,	HERBALS.  ,	Marketed,	proprietary formulations,	,	,	,	,	2000,	-0.2,	Health Food Stores,	,	Health Extracts,	,	,
wvcs19980001025573,	NATROL INC,	S-1,	1998,	1998,	LIFESTYLE PRODUCTS.,	Marketed,	proprietary formulations,	,	,	,	,	2000,	-1,	Health Food Stores,	,	Lifestyle Needs,	,	,
wvcs19980001025573,	NATROL INC,	S-1,	1998,	1998,	 NATROL PREMIUM.,	Marketed,	proprietary formulations,	,	,	,	,	2002,	0.119,	Health Food Stores,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	S-1,	1998,	1998,	GARLIC.,	Marketed,	proprietary formulations,	,	,	,	,	2002,	0.1875,	Health Food Stores,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	S-1,	1998,	1998,	 SPECIALTY DIETARY SUPPLEMENTS,	Marketed,	proprietary formulations,	,	,	,	,	,	,	Health Food Stores,	,	Dietary Supplements,	,	,
wvcs19980001025573,	NATROL INC,	S-1,	1998,	1998,	 NATURAL DIET CONTROL.,	Marketed,	proprietary formulations,	,	,	,	,	2000,	15,	Health Food Stores,	,	Dietary Supplements,	,	,
wvcs19980001025573,	NATROL INC,	424,	1998,	1998,	ESTER-C,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Vitamin C market,	,	,
wvcs19980001025573,	NATROL INC,	424,	1998,	1998,	HERBALS.  ,	Marketed,	proprietary formulations,	,	,	,	,	2000,	-0.2,	dietary supplements,	,	Health Extracts,	,	,
wvcs19980001025573,	NATROL INC,	424,	1998,	1998,	LIFESTYLE PRODUCTS.,	Marketed,	proprietary formulations,	,	,	,	,	2000,	-1,	dietary supplements,	,	Lifestyle Needs,	,	,
wvcs19980001025573,	NATROL INC,	424,	1998,	1998,	 NATROL PREMIUM.,	Marketed,	proprietary formulations,	,	,	,	,	2002,	0.119,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	424,	1998,	1998,	GARLIC.,	Marketed,	proprietary formulations,	,	,	,	,	2002,	0.1875,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	424,	1998,	1998,	 SPECIALTY DIETARY SUPPLEMENTS,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Dietary Supplements,	,	,
wvcs19980001025573,	NATROL INC,	424,	1998,	1998,	 NATURAL DIET CONTROL.,	Marketed,	proprietary formulations,	,	,	,	,	2000,	15,	dietary supplements,	,	Dietary Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	1999,	ESTER-C,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Vitamin C market,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	1999,	herbal teas,	Marketed,	proprietary formulations,	,	,	,	Herbals,	,	,	dietary supplements,	,	Health Extracts,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	1999,	 NATROL PREMIUM.,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	1999,	GARLIC.,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	1999,	Melatonin,	Marketed,	proprietary formulations,	,	,	,	 SPECIALTY DIETARY SUPPLEMENTS,	,	,	dietary supplements,	,	Dietary Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2000,	ESTER-C,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Vitamin C market,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2000,	herbal teas,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Extracts,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2000,	 NATROL PREMIUM.,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2000,	GARLIC.,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2000,	Melatonin,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Dietary Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2001,	 Dietary supplements,	Marketed,	proprietary formulations,	,	,	,	ESTER-C,	,	,	dietary supplements,	,	Health Supplements,	Vitamin C Market,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2001,	nutraceutical grade ingredients,	Marketed,	proprietary formulations,	,	,	,	Melatonin,Garlic,	,	,	 ingredient supply business.,	,	 ingredient supply business.,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2001,	herbal teas,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Extracts,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2001,	sports nutrition line of products,	Marketed,	proprietary formulations,	20,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2002,	 Dietary supplements,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2002,	nutraceutical grade ingredients,	Marketed,	proprietary formulations,	,	,	,	,	,	,	 ingredient supply business.,	,	 ingredient supply business.,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2002,	herbal teas,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Extracts,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2002,	sports nutrition line of products,	Marketed,	proprietary formulations,	20,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2003,	 Dietary supplements,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2003,	nutraceutical grade ingredients,	Marketed,	proprietary formulations,	,	,	,	,	,	,	 ingredient supply business.,	,	 ingredient supply business.,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2003,	herbal teas,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Extracts,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2003,	sports nutrition line of products,	Marketed,	proprietary formulations,	20,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2004,	 Dietary supplements,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2004,	nutraceutical grade ingredients,	Marketed,	proprietary formulations,	,	,	,	,	,	,	 ingredient supply business.,	,	 ingredient supply business.,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2004,	herbal teas,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Extracts,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2004,	sports nutrition line of products,	Marketed,	proprietary formulations,	20,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2005,	 Dietary supplements,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2005,	Essentially Pure Ingredients® (EPI),	Marketed,	proprietary formulations,	,	,	,	nutraceutical grade ingredients,	,	,	 ingredient supply business.,	,	 ingredient supply business.,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2005,	herbal teas,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Extracts,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2005,	sports nutrition line of products,	Marketed,	proprietary formulations,	20,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2006,	 Dietary supplements,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2006,	Essentially Pure Ingredients® (EPI),	Marketed,	proprietary formulations,	,	,	,	nutraceutical grade ingredients,	,	,	 ingredient supply business.,	,	 ingredient supply business.,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2006,	herbal teas,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Extracts,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2006,	sports nutrition line of products,	Marketed,	proprietary formulations,	20,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2007,	 Dietary supplements,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2007,	Essentially Pure Ingredients® (EPI),	Marketed,	proprietary formulations,	,	,	,	nutraceutical grade ingredients,	,	,	 ingredient supply business.,	,	 ingredient supply business.,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2007,	herbal teas,	Marketed,	proprietary formulations,	,	,	,	,	,	,	dietary supplements,	,	Health Extracts,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2007,	sports nutrition line of products,	Marketed,	proprietary formulations,	20,	,	,	,	,	,	dietary supplements,	,	Health Supplements,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2007,	  Nu Hair® and Shen Min®,	Marketed,	Acquired,	,	,	,	,	,	,	Health Supplements,	,	Natural Products,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2007,	 Promensil® ,	Marketed,	Acquired,	21,	20,	,	,	,	,	Health Supplements,	,	 bone and heart health,	,	,
wvcs19980001025573,	NATROL INC,	10K,	1998,	2007,	     Trinovin®,	Marketed,	Acquired,	21,	20,	3,	,	,	,	UROLOGy,	,	 bone and heart health,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	s-1,	1999,	1999,	BM101,	BLA,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	MPS-I,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	s-1,	1999,	1999,	BM102,	Preclinical,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	 MPS-VI,,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	s-1,	1999,	1999,	BM201,	Preclinical,	Carbohydrate-active Enzymes,	8,	,	,	,	2008,	-1,	"debridement
products,"	,	Burn,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	s-1,	1999,	1999,	BM202.,	Preclinical,	Carbohydrate-active Enzymes,	8,	,	,	,	2002,	-1,	"debridement
products,"	,	Burn,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	s-1,	1999,	1999,	BM301 and BM302,	Preclinical,	Carbohydrate-active Enzymes,	23,	,	,	,	2002,	-1,	Infectious Diseases,	,	Aspergillus spp,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	s-1,	1999,	1999,	carbohydrate-active enzyme,	Development,	Carbohydrate-active Enzymes,	5,	,	,	,	2001,	1,	inflammatory ,	,	psoriasis,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	s-1,	1999,	1999,	 FACE Imaging System,	Marketed,	FACE(R),	60,	2,	,	,	2001,	-0.75,	carbohydrate analysis.,	,	carbohydrate analysis.,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	424B,	1999,	1999,	BM101,	BLA,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	MPS-I,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	424B,	1999,	1999,	BM102,	Preclinical,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	 MPS-VI,,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	424B,	1999,	1999,	BM201,	Preclinical,	Carbohydrate-active Enzymes,	8,	,	,	,	2008,	-1,	"debridement
products,"	,	Burn,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	424B,	1999,	1999,	BM202.,	Preclinical,	Carbohydrate-active Enzymes,	8,	,	,	,	2002,	-1,	"debridement
products,"	,	Burn,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	424B,	1999,	1999,	BM301 and BM302,	Preclinical,	Carbohydrate-active Enzymes,	23,	,	,	,	2002,	-1,	Infectious Diseases,	,	Aspergillus spp,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	424B,	1999,	1999,	carbohydrate-active enzyme,	Development,	Carbohydrate-active Enzymes,	5,	,	,	,	2001,	1,	inflammatory ,	,	psoriasis,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	424B,	1999,	1999,	 FACE Imaging System,	Marketed,	FACE(R),	60,	2,	,	,	2001,	-0.75,	carbohydrate analysis.,	,	carbohydrate analysis.,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2000,	2000,	AldurazymeTM,	Phase II,	Carbohydrate-active Enzymes,	30,	,	,	BM101,	,	,	Genetic Disorders,	,	MPS-I,	,	BLA,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2000,	2000,	BM102,	orphan  drug  designation,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	 MPS-VI,,	,	Preclinical,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2000,	2000,	BM201,	Preclinical,	Carbohydrate-active Enzymes,	8,	,	,	,	,	,	"debridement
products,"	,	Burn,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2000,	2000,	BM202.,	Preclinical,	Carbohydrate-active Enzymes,	8,	,	,	,	,	,	"debridement
products,"	,	Burn,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2000,	2000,	BM301 and BM302,	Preclinical,	Carbohydrate-active Enzymes,	23,	,	,	,	,	,	Infectious Diseases,	,	Aspergillus spp,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2001,	2001,	AldurazymeTM,	Phase II,	Carbohydrate-active Enzymes,	30,	,	,	BM101,	,	,	Genetic Disorders,	,	MPS-I,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2001,	2001,	RhASB ,	Phase I,	Carbohydrate-active Enzymes,	30,	,	,	BM102,	,	,	Genetic Disorders,	,	 MPS-VI,,	,	orphan  drug  designation,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2001,	2001,	Vibriolysin ,	Preclinical,	Carbohydrate-active Enzymes,	8,	,	,	BM201,	,	,	Burn Debridement,	,	Burn Debridement,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2002,	2002,	AldurazymeTM,	Phase III,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	MPS-I,	,	Phase II,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2002,	2002,	 AryplaseTM,	Phase I,	Carbohydrate-active Enzymes,	30,	,	,	RhASB ,	,	,	Genetic Disorders,	,	 MPS-VI,,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2002,	2002,	Vibriolysin ,	Phase I,	Carbohydrate-active Enzymes,	8,	,	,	,	,	,	Burn Debridement,	,	Burn Debridement,	,	Preclinical,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2002,	2002,	 Neutralase(TM),	Phase II,	Carbohydrate-active Enzymes,	,	,	,	,	,	,	Surgery,	,	CABG surgery,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2002,	2002,	Phenylase,	PreClincal,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2003,	2003,	AldurazymeTM,	Pre-Market,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	MPS-I,	,	Phase III,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2003,	2003,	 AryplaseTM,	Phase II,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	 MPS-VI,,	,	Phase I,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2003,	2003,	Vibrilase,	Phase I,	Carbohydrate-active Enzymes,	8,	,	,	Vibriolysin ,	,	,	Burn Debridement,	,	Burn Debridement,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2003,	2003,	 Neutralase(TM),	Phase III,	Carbohydrate-active Enzymes,	,	,	,	,	,	,	Surgery,	,	CABG surgery,	,	Phase II,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2003,	2003,	Phenylase,	PreClincal,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2004,	2004,	AldurazymeTM,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	MPS-I,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2004,	2004,	 AryplaseTM,	Phase III,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	 MPS-VI,,	,	Phase II,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2004,	2004,	Vibrilase,	Phase IB,	Carbohydrate-active Enzymes,	8,	,	,	,	,	,	Burn Debridement,	,	Burn Debridement,	,	Phase I,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2004,	2004,	 Neutralase(TM),	Phase III,	Carbohydrate-active Enzymes,	,	,	,	,	,	,	Surgery,	,	CABG surgery,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2004,	2004,	Phenoptin and Phenylase™,	PreClincal,	Carbohydrate-active Enzymes,	30,	,	,	Phenylase,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2004,	2004,	NeuroTrans,	Development,	NeuroTrans,	27,	,	,	,	,	,	lysosomal storage disorders,	,	lysosomal storage disorders,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2004,	2004,	Immune Tolerance Technology,	Development,	Immune Tolerance Technology,	27,	,	,	,	,	,	 lysosomal storage disorders,	,	 lysosomal storage disorders,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2005,	2005,	AldurazymeTM,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	MPS-I,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2005,	2005,	rhASB,	Phase III,	Carbohydrate-active Enzymes,	30,	,	,	 AryplaseTM,	,	,	Genetic Disorders,	,	 MPS-VI,,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2005,	2005,	Vibrilase,	Phase IB,	Carbohydrate-active Enzymes,	8,	,	,	,	,	,	Burn Debridement,	,	Burn Debridement,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2005,	2005,	Phenylase,	PreClincal,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2005,	2005,	Phenoptin,	Phase II,	Carbohydrate-active Enzymes,	30,	,	,	Phenoptin and Phenylase™,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	Preclinical,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2005,	2005,	NeuroTrans,	Development,	NeuroTrans,	27,	,	,	,	,	,	lysosomal storage disorders,	,	lysosomal storage disorders,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2005,	2005,	Immune Tolerance Technology,	Preclinical,	Immune Tolerance Technology,	27,	,	,	,	,	,	 lysosomal storage disorders,	,	 lysosomal storage disorders,	,	Development,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2005,	2005,	Orapred,	Marketed,	Orapred intellectual property,	5,	29,	,	,	,	,	Lung Disease,	,	 asthma,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2006,	2006,	AldurazymeTM,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	MPS-I,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2006,	2006,	Naglazyme,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	rhASB,	,	,	Genetic Disorders,	,	 MPS-VI,,	,	Phase III,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2006,	2006,	Vibrilase,	Phase IB,	Carbohydrate-active Enzymes,	8,	,	,	,	,	,	Burn Debridement,	,	Burn Debridement,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2006,	2006,	Phenylase,	PreClincal,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2006,	2006,	Phenoptin,	Phase III,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	Phase II,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2006,	2006,	Immune Tolerance Technology,	Preclinical,	Immune Tolerance Technology,	27,	,	,	,	,	,	 lysosomal storage disorders,	,	 lysosomal storage disorders,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2006,	2006,	Orapred,	Marketed,	Orapred intellectual property,	5,	29,	,	,	,	,	Lung Disease,	,	 asthma,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2007,	2007,	AldurazymeTM,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	MPS-I,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2007,	2007,	Naglazyme,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	 MPS-VI,,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2007,	2007,	6R-BH4,	Phase II,	Carbohydrate-active Enzymes,	21,	,	,	,	,	,	Cardiovascular Disease,	,	 Cardiovascular Indications,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2007,	2007,	Phenylase,	PreClincal,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2007,	2007,	Kuvan,	Phase III,	Carbohydrate-active Enzymes,	30,	,	,	Phenoptin,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2007,	2007,	Immune Tolerance Technology,	Preclinical,	Immune Tolerance Technology,	27,	,	,	,	,	,	 lysosomal storage disorders,	,	 lysosomal storage disorders,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2008,	2008,	AldurazymeTM,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	MPS-I,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2008,	2008,	Naglazyme,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	 MPS-VI,,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2008,	2008,	6R-BH4,	Phase II,	Carbohydrate-active Enzymes,	21,	,	,	,	,	,	Cardiovascular Disease,	,	 Cardiovascular Indications,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2008,	2008,	PEG-PAL,	PreClincal,	Carbohydrate-active Enzymes,	30,	,	,	Phenylase,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2008,	2008,	Kuvan,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	Phase III,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2008,	2008,	Immune Tolerance Technology,	Preclinical,	Immune Tolerance Technology,	27,	,	,	,	,	,	 lysosomal storage disorders,	,	 lysosomal storage disorders,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2009,	2009,	AldurazymeTM,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	MPS-I,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2009,	2009,	Naglazyme,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	 MPS-VI,,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2009,	2009,	6R-BH4,	Phase II,	Carbohydrate-active Enzymes,	21,	,	,	,	,	,	Cardiovascular Disease,	,	 Cardiovascular Indications,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2009,	2009,	PEG-PAL,	PreClincal,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2009,	2009,	Kuvan,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2009,	2009,	GALNS for Morquio Syndrome Type A,	PreClincal,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	MPS IVA,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2010,	2010,	AldurazymeTM,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	MPS-I,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2010,	2010,	Naglazyme,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	 MPS-VI,,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2010,	2010,	PEG-PAL,	Phase I,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	Preclinical,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2010,	2010,	Kuvan,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2010,	2010,	GALNS for Morquio Syndrome Type A,	Phase II,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	MPS IVA,	,	Preclinical,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2010,	2010,	Firdapse ,	Marketed,	,	5,	,	,	,	,	,	autoimmune disease,	,	Lambert Eaton Myasthenic Syndrome, or LEMS.,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2010,	2010,	BMN-195 ,	Phase I,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	Duchenne muscular dystrophy,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2011,	2011,	AldurazymeTM,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	MPS-I,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2011,	2011,	Naglazyme,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	Genetic Disorders,	,	 MPS-VI,,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2011,	2011,	PEG-PAL,	Phase II,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	Phase I,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2011,	2011,	Kuvan,	Marketed,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	phenylketonuria  (PKU) ,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2011,	2011,	GALNS for Morquio Syndrome Type A,	Phase II,	Carbohydrate-active Enzymes,	30,	,	,	,	,	,	genetic  disease,	,	MPS IVA,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2011,	2011,	Firdapse ,	Marketed,	,	5,	,	,	,	,	,	autoimmune disease,	,	Lambert Eaton Myasthenic Syndrome, or LEMS.,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2011,	2011,	BMN-701,	Phase I,	,	,	,	,	,	,	,	,	,	 Pompe disease,	,	,
wvcs19990001048477,	BIOMARIN PHARMACEUTICAL INC,	10K,	2011,	2011,	BMN-673,	Phase I,	 (PARP) inhibitor,	22,	,	,	,	,	,	ONCOLOGY,	,	Cancer,	,	,
wvcs19990000815508,	BIOPURE CORP,	S-1,	1999,	1999,	 Hemopure,	Phase III,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	"red blood cell transfusions for elective
surgery,"	,	elective orthopedic surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	S-1,	1999,	1999,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Post cardiopulmonary bypass surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	S-1,	1999,	1999,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Aortic aneurysm  reconstruction surgery  ,	,	,
wvcs19990000815508,	BIOPURE CORP,	S-1,	1999,	1999,	 Hemopure,	Preclinical,	OXYGENATION TECHNOLOGY,	22,	25,	,	,	,	,	ONCOLOGY,	,	Cancer Therapy Adjunct,	,	,
wvcs19990000815508,	BIOPURE CORP,	S-1,	1999,	1999,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Trauma,	,	,
wvcs19990000815508,	BIOPURE CORP,	S-1,	1999,	1999,	 Hemopure,	Preclinical,	OXYGENATION TECHNOLOGY,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	Ischemia,	,	,
wvcs19990000815508,	BIOPURE CORP,	S-1,	1999,	1999,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Erythropoietic Agent,	,	,
wvcs19990000815508,	BIOPURE CORP,	S-1,	1999,	1999,	Oxyglobin,	Marketed,	OXYGENATION TECHNOLOGY,	27,	,	,	,	,	,	Veterinarian,	,	anemia in dogs,	,	,
wvcs19990000815508,	BIOPURE CORP,	424B,	1999,	1999,	 Hemopure,	Phase III,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	"red blood cell transfusions for elective
surgery,"	,	elective orthopedic surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	424B,	1999,	1999,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Post cardiopulmonary bypass surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	424B,	1999,	1999,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Aortic aneurysm  reconstruction surgery  ,	,	,
wvcs19990000815508,	BIOPURE CORP,	424B,	1999,	1999,	 Hemopure,	Preclinical,	OXYGENATION TECHNOLOGY,	22,	25,	,	,	,	,	ONCOLOGY,	,	Cancer Therapy Adjunct,	,	,
wvcs19990000815508,	BIOPURE CORP,	424B,	1999,	1999,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Trauma,	,	,
wvcs19990000815508,	BIOPURE CORP,	424B,	1999,	1999,	 Hemopure,	Preclinical,	OXYGENATION TECHNOLOGY,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	Ischemia,	,	,
wvcs19990000815508,	BIOPURE CORP,	424B,	1999,	1999,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Erythropoietic Agent,	,	,
wvcs19990000815508,	BIOPURE CORP,	424B,	1999,	1999,	Oxyglobin,	Marketed,	OXYGENATION TECHNOLOGY,	27,	,	,	,	,	,	Veterinarian,	,	anemia in dogs,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2000,	 Hemopure,	Phase III,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	elective orthopedic surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2000,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Non-cardiac elective surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2000,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Post cardiopulmonary bypass surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2000,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Aortic aneurysm  reconstruction surgery  ,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2000,	 Hemopure,	Preclinical,	OXYGENATION TECHNOLOGY,	22,	25,	,	,	,	,	ONCOLOGY,	,	Cancer Therapy Adjunct,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2000,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Trauma,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2000,	 Hemopure,	Preclinical,	OXYGENATION TECHNOLOGY,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	Ischemia,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2000,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Erythropoietic Agent,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2000,	Oxyglobin,	Marketed,	OXYGENATION TECHNOLOGY,	27,	,	,	,	,	,	Veterinarian,	,	anemia in dogs,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2001,	 Hemopure,	Phase III,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	elective orthopedic surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2001,	 Hemopure,	Phase III,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Non-cardiac elective surgery,	,	Phase II,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2001,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Post cardiopulmonary bypass surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2001,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Aortic aneurysm  reconstruction surgery  ,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2001,	 Hemopure,	Preclinical,	OXYGENATION TECHNOLOGY,	22,	25,	,	,	,	,	ONCOLOGY,	,	glioblastoma,	Cancer Therapy Adjunct,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2001,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Trauma,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2001,	 Hemopure,	Preclinical,	OXYGENATION TECHNOLOGY,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	Ischemia,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2001,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	cardiac surgery,	Erythropoietic Agent,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2001,	Oxyglobin,	Marketed,	OXYGENATION TECHNOLOGY,	27,	,	,	,	,	,	Veterinarian,	,	anemia in dogs,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2002,	 Hemopure,	Phase III,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	elective orthopedic surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2002,	 Hemopure,	Phase III,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Non-cardiac elective surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2002,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Post cardiopulmonary bypass surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2002,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Aortic aneurysm  reconstruction surgery  ,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2002,	 Hemopure,	Preclinical,	OXYGENATION TECHNOLOGY,	22,	25,	,	,	,	,	ONCOLOGY,	,	glioblastoma,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2002,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Trauma,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2002,	 Hemopure,	Preclinical,	OXYGENATION TECHNOLOGY,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	Ischemia,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2002,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	cardiac surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2002,	Oxyglobin,	Marketed,	OXYGENATION TECHNOLOGY,	27,	,	,	,	,	,	Veterinarian,	,	anemia in dogs,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2003,	 Hemopure,	Post Clinical,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	elective orthopedic surgery,	,	Phase III,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2003,	 Hemopure,	Phase III,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Non-cardiac elective surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2003,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Post cardiopulmonary bypass surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2003,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Aortic aneurysm  reconstruction surgery  ,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2003,	 Hemopure,	Phase I,	OXYGENATION TECHNOLOGY,	22,	25,	,	,	,	,	ONCOLOGY,	,	glioblastoma,	,	Preclinical,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2003,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Trauma,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2003,	 Hemopure,	Preclinical,	OXYGENATION TECHNOLOGY,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	Ischemia,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2003,	Oxyglobin,	Marketed,	OXYGENATION TECHNOLOGY,	27,	,	,	,	,	,	Veterinarian,	,	anemia in dogs,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2004,	 Hemopure,	Post Clinical,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	elective orthopedic surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2004,	 Hemopure,	Phase III,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Non-cardiac elective surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2004,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Post cardiopulmonary bypass surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2004,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Aortic aneurysm  reconstruction surgery  ,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2004,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Trauma,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2004,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	Ischemia,	,	Preclinical,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2004,	Oxyglobin,	Marketed,	OXYGENATION TECHNOLOGY,	27,	,	,	,	,	,	Veterinarian,	,	anemia in dogs,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2005,	 Hemopure,	Post Clinical,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	elective orthopedic surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2005,	 Hemopure,	Phase III,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Non-cardiac elective surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2005,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Post cardiopulmonary bypass surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2005,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Aortic aneurysm  reconstruction surgery  ,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2005,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Trauma,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2005,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	Ischemia,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2005,	Oxyglobin,	Marketed,	OXYGENATION TECHNOLOGY,	27,	,	,	,	,	,	Veterinarian,	,	anemia in dogs,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2006,	 Hemopure,	Post Clinical,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	elective orthopedic surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2006,	 Hemopure,	Phase III,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Non-cardiac elective surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2006,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Post cardiopulmonary bypass surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2006,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Aortic aneurysm  reconstruction surgery  ,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2006,	 Hemopure,	Phase III,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Trauma,	,	Phase II,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2006,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	Cardiac Surgery.,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2006,	 Hemopure,	Preclinical,	OXYGENATION TECHNOLOGY,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	Wound Healing,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2006,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	Ischemia,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2006,	Oxyglobin,	Marketed,	OXYGENATION TECHNOLOGY,	27,	,	,	,	,	,	Veterinarian,	,	anemia in dogs,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2007,	 Hemopure,	Post Clinical,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	elective orthopedic surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2007,	 Hemopure,	Phase III,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Non-cardiac elective surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2007,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Post cardiopulmonary bypass surgery,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2007,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Aortic aneurysm  reconstruction surgery  ,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2007,	 Hemopure,	Phase III,	OXYGENATION TECHNOLOGY,	25,	27,	,	,	,	,	red blood cell transfusions surgery,	,	Trauma,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2007,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	Cardiac Surgery.,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2007,	 Hemopure,	Preclinical,	OXYGENATION TECHNOLOGY,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	Wound Healing,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2007,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	Heart Attack ,	Ischemia,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2007,	Oxyglobin,	Marketed,	OXYGENATION TECHNOLOGY,	27,	,	,	,	,	,	Veterinarian,	,	anemia in dogs,	,	,
wvcs19990000815508,	BIOPURE CORP,	10K,	1999,	2007,	 Hemopure,	Phase II,	OXYGENATION TECHNOLOGY,	21,	25,	,	,	,	,	Cardiovascular Disease,	,	PCI,	,	,
wvcs19990001036968,	diaDexus, Inc.,	S-1,	1999,	1999,	AIDSVAX,	Phase III,	,	23,	,	,	,	2004,	-0.3301,	Infectious Diseases,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	424B,	1999,	1999,	AIDSVAX,	Phase III,	,	23,	,	,	,	2004,	-0.3301,	Infectious Diseases,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	424B,	1999,	1999,	AIDSVAX B ,	Phase II,	,	23,	,	,	,	2004,	2.1667,	Infectious Diseases -North America /Europe,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	424B,	1999,	1999,	AIDSVAX B/B',	Phase II,	,	23,	,	,	,	,	,	Infectious Diseases -North America /Europe,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	424B,	1999,	1999,	AIDSVAX B/E,	Phase II,	,	23,	,	,	,	,	,	Infectious Diseases -Asia,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2000,	AIDSVAX,	Phase III,	,	23,	,	,	,	2004,	-0.3301,	Infectious Diseases,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2000,	AIDSVAX B ,	Phase II,	,	23,	,	,	,	2004,	2.1667,	Infectious Diseases -North America /Europe,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2000,	AIDSVAX B/B',	Phase II,	,	23,	,	,	,	,	,	Infectious Diseases -North America /Europe,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2000,	AIDSVAX B/E,	Phase II,	,	23,	,	,	,	,	,	Infectious Diseases -Asia,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2001,	AIDSVAX,	Phase III,	,	23,	,	,	,	2004,	-0.3301,	Infectious Diseases,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2001,	AIDSVAX B ,	Phase II,	,	23,	,	,	,	2004,	2.1667,	Infectious Diseases -North America /Europe,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2001,	AIDSVAX B/B',	Phase II,	,	23,	,	,	,	,	,	Infectious Diseases -North America /Europe,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2001,	AIDSVAX B/E,	Phase II,	,	23,	,	,	,	,	,	Infectious Diseases -Asia,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2002,	AIDSVAX,	Phase III,	,	23,	,	,	,	2004,	27,	Infectious Diseases,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2002,	AIDSVAX B ,	Phase II,	,	23,	,	,	,	2004,	2.8,	Infectious Diseases -North America /Europe,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2002,	AIDSVAX B/B',	Phase II,	,	23,	,	,	,	,	,	Infectious Diseases -North America /Europe,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2002,	AIDSVAX B/E,	Phase II,	,	23,	,	,	,	,	,	Infectious Diseases -Asia,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2003,	rPA102 vaccine,	Phase I,	,	23,	,	,	,	,	,	Infetious Disease,	,	Anthrax,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2003,	rPA102 vaccine,	Phase I,	,	23,	,	,	,	,	,	Infetious Disease,	,	Anthrax,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2003,	LC16-Kaketsuken,	Preclinical,	,	23,	,	,	,	2005,	-0.8667,	Infetious Disease,	,	Smallpox,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2003,	AIDSVAX B/B',	Phase III,	Genentech version of the gp120 protein,	23,	,	,	,	,	,	Infectious Diseases -North America /Europe,	,	HIV ,	,	Phase II,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2003,	AIDSVAX B/E,	Phase III,	Genentech version of the gp120 protein,	23,	,	,	,	,	,	Infectious Diseases -Asia,	,	HIV ,	,	Phase II,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2004,	rPA102 vaccine,	Phase I,	,	23,	,	,	,	,	,	Infetious Disease,	,	Anthrax,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2004,	rPA102 vaccine,	Phase I,	,	23,	,	,	,	,	,	Infetious Disease,	,	Anthrax,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2004,	LC16m8 ,	Preclinical,	,	23,	,	,	,	,	,	Infetious Disease,	,	Smallpox,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2004,	Anthrax Monoclonal Antibody,	Preclinical,	,	23,	,	,	,	,	,	Infetious Disease,	,	Anthrax,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2004,	AIDSVAX B/B',	Phase III,	Genentech version of the gp120 protein,	23,	,	,	,	,	,	Infectious Diseases -North America /Europe,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2004,	AIDSVAX B/E,	Phase III,	Genentech version of the gp120 protein,	23,	,	,	,	,	,	Infectious Diseases -Asia,	,	HIV ,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2005,	rPA102 vaccine,	Phase II,	,	23,	,	,	,	,	,	Infetious Disease,	,	Anthrax,	,	Phase I,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2005,	LC16m8 ,	Phase I,	,	23,	,	,	,	,	,	Infetious Disease,	,	Smallpox,	,	Preclinical,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2006,	rPA102 vaccine,	Phase II,	,	23,	,	,	,	,	,	Infetious Disease,	,	Anthrax,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2006,	LC16m8 ,	Phase II,	,	23,	,	,	,	,	,	Infetious Disease,	,	Smallpox,	,	Phase I,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2006,	MERGER,	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2006,	MERGER,	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2006,	MERGER,	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs19990001036968,	diaDexus, Inc.,	10-K,	1999,	2006,	MERGER,	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs19990001073431,	INVITROGEN CORP,	S-1,	1998,	1998,	FastTrack Kit,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-1,	molecular biology products and supplies,	,	 GENE IDENTIFICATION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	S-1,	1998,	1998,	Micro-FastTrack Kit,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-1,	molecular biology products and supplies,	,	 GENE IDENTIFICATION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	S-1,	1998,	1998,	TA Cloning Kit ,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-0.1429,	molecular biology products and supplies,	,	 GENE CLONING PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	S-1,	1998,	1998,	Zero Blunt PCR Cloning ,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-1,	molecular biology products and supplies,	,	 GENE CLONING PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	S-1,	1998,	1998,	 TOPO TA Cloning Kit ,	Marketed,	TOPO TA Cloning technology,	30,	,	,	,	2005,	0,	molecular biology products and supplies,	,	 GENE CLONING PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	S-1,	1998,	1998,	Expression Vectors ,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-0.6154,	molecular biology products and supplies,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	S-1,	1998,	1998,	MaxBac Baculovirus,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2005,	0,	molecular biology products and supplies,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	S-1,	1998,	1998,	Ecdysone-Inducible Mammalian Expression ,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2005,	0,	molecular biology products and supplies,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	S-1,	1998,	1998,	 GeneStorm Expression- Ready Clones   ,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	,	,	molecular biology products and supplies,	,	 GENE ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	S-1,	1998,	1998,	Hybrid Hunter Systems,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-0.75,	molecular biology products and supplies,	,	 GENE ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	S-1,	1998,	1998,	"One Shot INVALPHAF',       
 Competent E. COLI,"	Marketed,	gene cloning and gene expression technologies.,	,	,	,	,	,	,	molecular biology products and supplies,	,	SUPPORT PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	S-1,	1998,	1998,	Zeocin Antibiotic ,	Marketed,	gene cloning and gene expression technologies.,	,	,	,	,	2002,	-1,	molecular biology products and supplies,	,	SUPPORT PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	S-1,	1998,	1998,	Invitrogenomics,	Marketed,	TOPO TA Cloning technology,	,	,	,	,	2002,	8.7778,	Research Services,	,	RESEARCH SERVICES,	,	,
wvcs19990001073431,	INVITROGEN CORP,	424,	1998,	1999,	FastTrack Kit,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-1,	molecular biology products and supplies,	,	 GENE IDENTIFICATION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	424,	1998,	1999,	Micro-FastTrack Kit,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-1,	molecular biology products and supplies,	,	 GENE IDENTIFICATION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	424,	1998,	1999,	TA Cloning Kit ,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-0.1429,	molecular biology products and supplies,	,	 GENE CLONING PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	424,	1998,	1999,	Zero Blunt PCR Cloning ,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-1,	molecular biology products and supplies,	,	 GENE CLONING PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	424,	1998,	1999,	 TOPO TA Cloning Kit ,	Marketed,	TOPO TA Cloning technology,	30,	,	,	,	2005,	0,	molecular biology products and supplies,	,	 GENE CLONING PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	424,	1998,	1999,	Expression Vectors ,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-0.6154,	molecular biology products and supplies,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	424,	1998,	1999,	MaxBac Baculovirus,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2005,	0,	molecular biology products and supplies,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	424,	1998,	1999,	Ecdysone-Inducible Mammalian Expression ,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2005,	0,	molecular biology products and supplies,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	424,	1998,	1999,	 GeneStorm Expression- Ready Clones   ,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	8.8,	molecular biology products and supplies,	,	 GENE ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	424,	1998,	1999,	Hybrid Hunter Systems,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-0.75,	molecular biology products and supplies,	,	 GENE ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	424,	1998,	1999,	"One Shot INVALPHAF',       
 Competent E. COLI,"	Marketed,	gene cloning and gene expression technologies.,	,	,	,	,	,	,	molecular biology products and supplies,	,	SUPPORT PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	424,	1998,	1999,	Zeocin Antibiotic ,	Marketed,	gene cloning and gene expression technologies.,	,	,	,	,	2002,	-1,	molecular biology products and supplies,	,	SUPPORT PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	424,	1998,	1999,	Invitrogenomics,	Marketed,	TOPO TA Cloning technology,	,	,	,	,	2002,	8.7778,	Research Services,	,	RESEARCH SERVICES,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	FastTrack Kit,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-1,	molecular biology products and supplies,	,	 GENE IDENTIFICATION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	Micro-FastTrack Kit,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-1,	molecular biology products and supplies,	,	 GENE IDENTIFICATION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	TA Cloning Kit ,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-0.7778,	molecular biology products and supplies,	,	 GENE CLONING PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	Zero Blunt PCR Cloning ,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-1,	molecular biology products and supplies,	,	 GENE CLONING PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	 TOPO TA Cloning Kit ,	Marketed,	TOPO TA Cloning technology,	30,	,	,	,	,	,	molecular biology products and supplies,	,	 GENE CLONING PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	Expression Vectors ,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	-0.8148,	molecular biology products and supplies,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	MaxBac Baculovirus,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2005,	0,	molecular biology products and supplies,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	Ecdysone-Inducible Mammalian Expression ,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2005,	0,	molecular biology products and supplies,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	 GeneStorm Expression- Ready Clones   ,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	0,	molecular biology products and supplies,	,	 GENE ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	Hybrid Hunter Systems,	Marketed,	gene cloning and gene expression technologies.,	30,	,	,	,	2002,	0,	molecular biology products and supplies,	,	 GENE ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	Pre-Cast NuPAGE Gels,	Marketed,	re-cast gel electrophoresis system,	30,	,	,	,	2005,	0,	molecular biology products and supplies,	,	 GENE ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	Pre-Cast Tris Glycine Gels ,	Marketed,	re-cast gel electrophoresis system,	30,	,	,	,	2002,	0,	molecular biology products and supplies,	,	 GENE ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	Pre-Cast Isoelectric Focusing Gels,	Marketed,	re-cast gel electrophoresis system,	30,	,	,	,	2002,	0,	molecular biology products and supplies,	,	 GENE ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	Pre-Cast TBE Polyacrylamide Gels,	Marketed,	re-cast gel electrophoresis system,	30,	,	,	,	2002,	0,	molecular biology products and supplies,	,	 GENE ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	WesternBreeze,	Marketed,	re-cast gel electrophoresis system,	30,	,	,	,	2002,	0,	molecular biology products and supplies,	,	 GENE ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	XCell II Mini-Cell and Blotting Apparatus,	Marketed,	re-cast gel electrophoresis system,	30,	,	,	,	2002,	0,	molecular biology products and supplies,	,	 GENE ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	"One Shot INVALPHAF',       
 Competent E. COLI,"	Marketed,	gene cloning and gene expression technologies.,	,	,	,	,	,	,	molecular biology products and supplies,	,	SUPPORT PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	Zeocin Antibiotic ,	Marketed,	gene cloning and gene expression technologies.,	,	,	,	,	2002,	0,	molecular biology products and supplies,	,	SUPPORT PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2000,	Invitrogenomics,	Marketed,	TOPO TA Cloning technology,	,	,	,	,	2002,	0,	Research Services,	,	RESEARCH SERVICES,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2001,	TOPO(R) Cloning Systems,	Marketed,	TOPO TA Cloning technology,	,	,	,	 TOPO TA Cloning Kit ,	2005,	0,	Life Sciences Research,	molecular biology products and supplies,	PRODUCTS FOR DNA CLONING,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2001,	GATEWAY(3) Cloning Technology,	Marketed,	GATEWAY(3) Cloning Technology,	,	,	,	,	2005,	0,	Life Sciences Research,	molecular biology products and supplies,	PRODUCTS FOR DNA CLONING,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2001,	Mammalian Expression System,	Marketed,	Mammalian Expression System,	30,	,	,	MaxBac Baculovirus,	2005,	0,	Life Sciences Research,	molecular biology products and supplies,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2001,	Baculovirus Expression Systems,	Marketed,	Bac-To-Bac System,	30,	,	,	Ecdysone-Inducible Mammalian Expression ,	2005,	0,	Life Sciences Research,	molecular biology products and supplies,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2001,	PICHIA PASTORIS Expression Systems,	Marketed,	PICHIA System,	30,	,	,	,	2005,	0,	Life Sciences Research,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2001,	NuPAGE(R) Precast PAGE Gels,	Marketed,	NuPAGE gel formulations,	,	,	,	Pre-Cast NuPAGE Gels,	2005,	0,	Life Sciences Research,	,	SEPARATIONS & ANALYSIS PRODUCTS,	 GENE ANALYSIS PRODUCTS,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2001,	E-Gel(R) Precast Agarose Gels,	Marketed,	re-cast gel electrophoresis system,	,	,	,	,	2005,	0,	Life Sciences Research,	,	SEPARATIONS & ANALYSIS PRODUCTS,	 GENE ANALYSIS PRODUCTS,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2001,	CUSTOM OLIGONUCLEOTIDE SYNTHESIS,	Marketed,	 Parallel Array Synthesis technology,	30,	,	,	,	2005,	0,	Life Sciences Research,	,	 PCR, DNA sequencing and gene detection,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2001,	COMPETENT BACTERIAL STRAINS,	Marketed,	N/A,	,	,	,	,	2005,	0.1,	Life Sciences Research,	,	molecular biology products and supplies,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2001,	ResGen(TM),	Marketed,	ResGen(TM),	30,	,	,	,	2005,	0,	Life Sciences Research,	,	GENE DISCOVERY PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2001,	PLATINUM(R) Taq DNA Polymerase,	Marketed,	PLATINUM(R) Taq DNA Polymerase,	,	,	,	,	2005,	0,	Life Sciences Research,	,	 DNA AND RNA AMPLIFICATION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2001,	PLATINUM(R) Pfx DNA Polymerase,	Marketed,	PLATINUM(R) Pfx DNA Polymerase,	,	,	,	,	2005,	0,	Life Sciences Research,	,	 DNA AND RNA AMPLIFICATION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2001,	Fetal Bovine Serum,	Marketed,	N/A,	,	,	,	,	2005,	-0.2,	Commercial Production,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2001,	 Liquid and Powdered Culture Media:,	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	,	,	,	,	2005,	1.4286,	Commercial Production,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2002,	TOPO(R) Cloning Systems,	Marketed,	TOPO TA Cloning technology,	,	,	,	,	2005,	0,	Life Sciences Research,	,	PRODUCTS FOR DNA CLONING,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2002,	GATEWAY(3) Cloning Technology,	Marketed,	GATEWAY(3) Cloning Technology,	,	,	,	,	2005,	0,	Life Sciences Research,	,	PRODUCTS FOR DNA CLONING,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2002,	Mammalian Expression System,	Marketed,	Mammalian Expression System,	30,	,	,	,	2005,	0,	Life Sciences Research,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2002,	Baculovirus Expression Systems,	Marketed,	Bac-To-Bac System,	30,	,	,	,	2005,	0,	Life Sciences Research,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2002,	PICHIA PASTORIS Expression Systems,	Marketed,	PICHIA System,	30,	,	,	,	2005,	0,	Life Sciences Research,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2002,	NuPAGE(R) Precast PAGE Gels,	Marketed,	NuPAGE gel formulations,	,	,	,	,	2005,	0,	Life Sciences Research,	,	SEPARATIONS & ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2002,	E-Gel(R) Precast Agarose Gels,	Marketed,	re-cast gel electrophoresis system,	,	,	,	,	2005,	0,	Life Sciences Research,	,	SEPARATIONS & ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2002,	CUSTOM OLIGONUCLEOTIDE SYNTHESIS,	Marketed,	 Parallel Array Synthesis technology,	30,	,	,	,	2005,	0,	Life Sciences Research,	,	 PCR, DNA sequencing and gene detection,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2002,	COMPETENT BACTERIAL STRAINS,	Marketed,	N/A,	,	,	,	,	2005,	0.1,	Life Sciences Research,	,	molecular biology products and supplies,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2002,	ResGen(TM),	Marketed,	ResGen(TM),	30,	,	,	,	2005,	0,	Life Sciences Research,	,	GENE DISCOVERY PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2002,	PLATINUM(R) Taq DNA Polymerase,	Marketed,	PLATINUM(R) Taq DNA Polymerase,	,	,	,	,	2005,	0,	Life Sciences Research,	,	 DNA AND RNA AMPLIFICATION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2002,	PLATINUM(R) Pfx DNA Polymerase,	Marketed,	PLATINUM(R) Pfx DNA Polymerase,	,	,	,	,	2005,	0,	Life Sciences Research,	,	 DNA AND RNA AMPLIFICATION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2002,	Fetal Bovine Serum,	Marketed,	N/A,	,	,	,	,	2005,	-0.2,	Commercial Production,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2002,	 Liquid and Powdered Culture Media:,	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	,	,	,	,	2005,	1.4286,	Commercial Production,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2003,	TOPO(R) Cloning Systems,	Marketed,	TOPO TA Cloning technology,	,	,	,	,	2005,	-1,	Life Sciences Research,	,	PRODUCTS FOR DNA CLONING,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2003,	GATEWAY(3) Cloning Technology,	Marketed,	GATEWAY(3) Cloning Technology,	,	,	,	,	2005,	-1,	Life Sciences Research,	,	PRODUCTS FOR DNA CLONING,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2003,	Mammalian Expression System,	Marketed,	Mammalian Expression System,	30,	,	,	,	2005,	-0.8571,	Life Sciences Research,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2003,	Baculovirus Expression Systems,	Marketed,	Bac-To-Bac System,	30,	,	,	,	2005,	-1,	Life Sciences Research,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2003,	PICHIA PASTORIS Expression Systems,	Marketed,	PICHIA System,	30,	,	,	,	2005,	-1,	Life Sciences Research,	,	GENE EXPRESSION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2003,	NuPAGE(R) Precast PAGE Gels,	Marketed,	NuPAGE gel formulations,	,	,	,	,	2005,	-1,	Life Sciences Research,	,	SEPARATIONS & ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2003,	E-Gel(R) Precast Agarose Gels,	Marketed,	re-cast gel electrophoresis system,	,	,	,	,	2005,	-1,	Life Sciences Research,	,	SEPARATIONS & ANALYSIS PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2003,	CUSTOM OLIGONUCLEOTIDE SYNTHESIS,	Marketed,	 Parallel Array Synthesis technology,	30,	,	,	,	2005,	-0.2857,	Life Sciences Research,	,	 PCR, DNA sequencing and gene detection,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2003,	COMPETENT BACTERIAL STRAINS,	Marketed,	N/A,	,	,	,	,	2005,	0.5714,	Life Sciences Research,	,	molecular biology products and supplies,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2003,	ResGen(TM),	Marketed,	ResGen(TM),	30,	,	,	,	2005,	-1,	Life Sciences Research,	,	GENE DISCOVERY PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2003,	PLATINUM(R) Taq DNA Polymerase,	Marketed,	PLATINUM(R) Taq DNA Polymerase,	,	,	,	,	2005,	-1,	Life Sciences Research,	,	 DNA AND RNA AMPLIFICATION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2003,	PLATINUM(R) Pfx DNA Polymerase,	Marketed,	PLATINUM(R) Pfx DNA Polymerase,	,	,	,	,	2005,	-1,	Life Sciences Research,	,	 DNA AND RNA AMPLIFICATION PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2003,	Fetal Bovine Serum,	Marketed,	N/A,	,	,	,	,	2005,	-0.4286,	Commercial Production,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2003,	 Liquid and Powdered Culture Media:,	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	,	,	,	,	2005,	1.4286,	Commercial Production,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2004,	, BioDiscovery products,	Marketed,	Prop. Cloning Technology,	30,	,	,	,	,	,	Life Sciences Research,	,	gene cloning,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2004,	, BioDiscovery products,	Marketed,	Expression System,	30,	,	,	,	,	,	Life Sciences Research,	,	gene expression,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2004,	, BioDiscovery products,	Marketed,	Gel Formulations,	30,	,	,	,	,	,	Life Sciences Research,	,	gene analysis techniques,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2004,	 BioProduction products,	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	Commercial Production,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2004,	 BioProduction products,	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	Life Sciences Research,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2005,	, BioDiscovery products,	Marketed,	Prop. Cloning Technology,	30,	,	,	,	,	,	Life Sciences Research,	,	gene cloning,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2005,	, BioDiscovery products,	Marketed,	Expression System,	30,	,	,	,	,	,	Life Sciences Research,	,	gene expression,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2005,	, BioDiscovery products,	Marketed,	Gel Formulations,	30,	,	,	,	,	,	Life Sciences Research,	,	gene analysis techniques,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2005,	 BioProduction products,	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	Commercial Production,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2005,	 BioProduction products,	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	Life Sciences Research,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2006,	, BioDiscovery products,	Marketed,	Prop. Cloning Technology,	30,	,	,	,	,	,	Life Sciences Research,	,	gene cloning,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2006,	, BioDiscovery products,	Marketed,	Expression System,	30,	,	,	,	,	,	Life Sciences Research,	,	gene expression,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2006,	, BioDiscovery products,	Marketed,	Gel Formulations,	30,	,	,	,	,	,	Life Sciences Research,	,	gene analysis techniques,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2006,	 BioProduction products,	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	Commercial Production,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2006,	 BioProduction products,	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	Life Sciences Research,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2007,	, BioDiscovery products,	Marketed,	 Molecular Biology Systems,	30,	,	,	,	,	,	Life Sciences Research,	,	gene cloning,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2007,	, BioDiscovery products,	Marketed,	 Molecular Biology Systems,	30,	,	,	,	,	,	Life Sciences Research,	,	gene expression,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2007,	, BioDiscovery products,	Marketed,	 Molecular Biology Systems,	30,	,	,	,	,	,	Life Sciences Research,	,	gene analysis techniques,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2007,	 BioProduction products,	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	Commercial Production,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2007,	 BioProduction products,	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	Life Sciences Research,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2008,	, BioDiscovery products,	Marketed,	 Molecular Biology Systems,	30,	,	,	,	,	,	Life Sciences Research,	,	gene cloning,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2008,	, BioDiscovery products,	Marketed,	 Molecular Biology Systems,	30,	,	,	,	,	,	Life Sciences Research,	,	gene expression,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2008,	, BioDiscovery products,	Marketed,	 Molecular Biology Systems,	30,	,	,	,	,	,	Life Sciences Research,	,	gene analysis techniques,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2008,	Cell Systems (CS),	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	 BioProduction products,	,	,	Commercial Production,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	INVITROGEN CORP,	10-K,	1998,	2008,	Cell Systems (CS),	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	 BioProduction products,	,	,	Life Sciences Research,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2009,	, BioDiscovery products,	Marketed,	 Molecular Biology Systems,	30,	,	,	,	,	,	Life Sciences Research,	,	gene cloning,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2009,	, BioDiscovery products,	Marketed,	 Molecular Biology Systems,	30,	,	,	,	,	,	Life Sciences Research,	,	gene expression,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2009,	, BioDiscovery products,	Marketed,	 Molecular Biology Systems,	30,	,	,	,	,	,	Life Sciences Research,	,	gene analysis techniques,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2009,	Cell Systems (CS),	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	Commercial Production,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2009,	Cell Systems (CS),	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	Life Sciences Research,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2009,	Applied Biosystems (AB,	Marketed,	Applied Biosystems,	,	,	,	,	,	,	Life Sciences Research,	,	DNA, RNA, protein, and small molecule analysis,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2009,	Applied Biosystems (AB,	Marketed,	Applied Biosystems,	,	,	,	,	,	,	Commercial Production,	,	DNA, RNA, protein, and small molecule analysis,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2010,	 Molecular Biology Systems,	Marketed,	 Molecular Biology Systems,	30,	,	,	, BioDiscovery products,	,	,	Life Sciences Research,	,	gene cloning,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2010,	 Molecular Biology Systems,	Marketed,	 Molecular Biology Systems,	30,	,	,	, BioDiscovery products,	,	,	Life Sciences Research,	,	gene expression,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2010,	 Molecular Biology Systems,	Marketed,	 Molecular Biology Systems,	30,	,	,	, BioDiscovery products,	,	,	Life Sciences Research,	,	gene analysis techniques,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2010,	Cell Systems (CS),	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	Commercial Production,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2010,	Cell Systems (CS),	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	Life Sciences Research,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2010,	 Genetic Systems,	Marketed,	 Genetic Systems,	,	,	,	,	,	,	Commercial Production,	,	forensics, food and water safety and pharmaceutical quality ,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2010,	 Genetic Systems,	Marketed,	 Genetic Systems,	,	,	,	,	,	,	Life Sciences Research,	,	forensics, food and water safety and pharmaceutical quality ,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2010,	Applied Biosystems (AB,	Marketed,	Applied Biosystems,	,	,	,	,	,	,	 applied markets,	,	DNA, RNA, protein, and small molecule analysis,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2010,	Cell Systems (CS),	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	 applied markets,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2011,	 Molecular Biology Systems,	Marketed,	 Molecular Biology Systems,	30,	,	,	, BioDiscovery products,	,	,	Life Sciences Research,	,	gene cloning,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2011,	 Molecular Biology Systems,	Marketed,	 Molecular Biology Systems,	30,	,	,	, BioDiscovery products,	,	,	Life Sciences Research,	,	gene expression,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2011,	 Molecular Biology Systems,	Marketed,	 Molecular Biology Systems,	30,	,	,	, BioDiscovery products,	,	,	Life Sciences Research,	,	gene analysis techniques,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2011,	Cell Systems (CS),	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	Commercial Production,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2011,	Cell Systems (CS),	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	Life Sciences Research,	,	CELL CULTURE PRODUCTS,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2011,	 Genetic Systems,	Marketed,	 Genetic Systems,	,	,	,	,	,	,	Commercial Production,	,	forensics, food and water safety and pharmaceutical quality ,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2011,	 Genetic Systems,	Marketed,	 Genetic Systems,	,	,	,	,	,	,	Life Sciences Research,	,	forensics, food and water safety and pharmaceutical quality ,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2011,	Applied Biosystems (AB,	Marketed,	Applied Biosystems,	,	,	,	,	,	,	 applied markets,	,	DNA, RNA, protein, and small molecule analysis,	,	,
wvcs19990001073431,	Life Technologies Corp,	10-K,	1998,	2011,	Cell Systems (CS),	Marketed,	Proprietary Serum Free, Protein Free and  Chemically Defined formulations ,	70,	,	,	,	,	,	 applied markets,	,	CELL CULTURE PRODUCTS,	,	,
wvcs20000000914201,	3 DIMENSIONAL PHARMACEUTICALS INC,	S-1,	2000,	2000,	DiscoverWorks Technology Platform,	Marketed,	DiscoverWorks Technology Platform,	,	,	,	,	,	,	Drug Discovery,	,	,	,	,
wvcs20000000914201,	3 DIMENSIONAL PHARMACEUTICALS INC,	S-1,	2000,	2000,	 GPCR Technology Program,	Marketed,	 GPCR Technology Program,	5,	29,	,	,	,	,	Drug Discovery,	,	,	,	,
wvcs20000000914201,	3 DIMENSIONAL PHARMACEUTICALS INC,	S-1,	2000,	2000,	3DP-4815,	Phase I,	 DiscoverWorks,	21,	,	,	,	,	,	Cardiovascular,	,	 Thrombosis ,	,	,
wvcs20000000914201,	3 DIMENSIONAL PHARMACEUTICALS INC,	S-1,	2000,	2000,	AvB3/AvB5,	Preclinical,	 DiscoverWorks,	22,	20,	,	,	,	,	Oncology,	,	Solid Tumours,	,	,
wvcs20000000914201,	3 DIMENSIONAL PHARMACEUTICALS INC,	S-1,	2000,	2000,	AvB3/AvB5,	Preclinical,	 DiscoverWorks,	20,	,	,	,	,	,	Bone Disorders  ,	,	Osteoporosis,	,	,
wvcs20000000914201,	3 DIMENSIONAL PHARMACEUTICALS INC,	S-1,	2000,	2000,	AvB3/AvB5,	Preclinical,	 DiscoverWorks,	21,	20,	,	,	,	,	Cardiovascular,	,	Restenosis,	,	,
wvcs20000000914201,	3 DIMENSIONAL PHARMACEUTICALS INC,	S-1,	2000,	2000,	  C1s-1,	Preclinical,	 GPCR Technology Program,	5,	,	,	,	,	,	Autoimmune Disease,	,	Lupus,	,	,
wvcs20000000914201,	3 DIMENSIONAL PHARMACEUTICALS INC,	S-1,	2000,	2000,	  C1s-1,	Preclinical,	 DiscoverWorks,	29,	,	,	,	,	,	Pulmonary ,	,	Adult Respiratory Distress,	,	,
wvcs20000000914201,	3 DIMENSIONAL PHARMACEUTICALS INC,	S-1,	2000,	2000,	 FXa,	Discovery,	 DiscoverWorks,	21,	,	,	,	,	,	Cardiovascular,	,	 Thrombosis ,	,	,
wvcs20000000914201,	3 DIMENSIONAL PHARMACEUTICALS INC,	S-1,	2000,	2000,	PAI-1,	Discovery,	 DiscoverWorks,	21,	,	,	,	,	,	Cardiovascular,	,	 Adjunct to tPA Therapy,	,	,
wvcs20000000914201,	3 DIMENSIONAL PHARMACEUTICALS INC,	S-1,	2000,	2000,	PAI-1,	Discovery,	 DiscoverWorks,	22,	,	,	,	,	,	Oncology,	,	Solid Tumors,	,	,
wvcs20000000914201,	3 DIMENSIONAL PHARMACEUTICALS INC,	S-1,	2000,	2000,	hdm2 (mdm),	Discovery,	 DiscoverWorks,	22,	,	,	,	,	,	Oncology,	,	Adjunct to Chemotherapy,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	S-1,	2000,	2000,	RSR13,	Phase II,	allosteric modification,	22,	40,	,	,	2009,	-0.76,	Oncology,	,	brain metastases,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	S-1,	2000,	2000,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	non-small cell lung cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	S-1,	2000,	2000,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Glioblastoma multiforme     ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	S-1,	2000,	2000,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Recurrent glioblastoma multiforme ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	S-1,	2000,	2000,	RSR13,	Phase II,	allosteric modification,	,	,	,	,	,	,	Surgical,	,	Cardiopulmonary bypass surgery ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	S-1,	2000,	2000,	RSR13,	Phase II,	allosteric modification,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Angina  ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	S-1,	2000,	2000,	RSR13,	Preclinical,	allosteric modification,	21,	,	,	,	,	,	Cardiovascular Disease,	,	 Myocardial infarction,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	S-1,	2000,	2000,	RSR46   ,	Preclinical,	allosteric modification,	9,	21,	,	,	2004,	-1,	Acute hypoxia      ,	,	 Acute hypoxia,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	S-1,	2000,	2000,	JP7 ,	Preclinical,	allosteric modification,	9,	21,	,	,	2004,	-1,	Acute hypoxia      ,	,	 Acute hypoxia      ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	424B,	2000,	2000,	RSR13,	Phase III,	allosteric modification,	22,	40,	,	,	2009,	-0.76,	Oncology,	,	brain metastases,	,	Phase II,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	424B,	2000,	2000,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	non-small cell lung cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	424B,	2000,	2000,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Glioblastoma multiforme     ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	424B,	2000,	2000,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Recurrent glioblastoma multiforme ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	424B,	2000,	2000,	RSR13,	Phase II,	allosteric modification,	,	,	,	,	,	,	Surgical,	,	Cardiopulmonary bypass surgery ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	424B,	2000,	2000,	RSR13,	Phase II,	allosteric modification,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Angina  ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	424B,	2000,	2000,	RSR13,	Preclinical,	allosteric modification,	21,	,	,	,	,	,	Cardiovascular Disease,	,	 Myocardial infarction,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	424B,	2000,	2000,	RSR46   ,	Preclinical,	allosteric modification,	9,	21,	,	,	2004,	-1,	Acute hypoxia      ,	,	 Acute hypoxia,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	424B,	2000,	2000,	JP7 ,	Preclinical,	allosteric modification,	9,	21,	,	,	2004,	-1,	Acute hypoxia      ,	,	 Acute hypoxia      ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2001,	RSR13,	Phase III,	allosteric modification,	22,	40,	,	,	2009,	-0.76,	Oncology,	,	brain metastases,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2001,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	non-small cell lung cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2001,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Glioblastoma multiforme     ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2001,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Recurrent glioblastoma multiforme ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2001,	RSR13,	Phase II,	allosteric modification,	,	,	,	,	,	,	Surgical,	,	Cardiopulmonary bypass surgery ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2001,	RSR13,	Phase II,	allosteric modification,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Angina  ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2001,	RSR13,	Preclinical,	allosteric modification,	21,	,	,	,	,	,	Cardiovascular Disease,	,	 Myocardial infarction,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2001,	RSR46   ,	Preclinical,	allosteric modification,	9,	21,	,	,	2004,	-1,	Acute hypoxia      ,	,	 Acute hypoxia,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2001,	JP7 ,	Preclinical,	allosteric modification,	9,	21,	,	,	2004,	-1,	Acute hypoxia      ,	,	 Acute hypoxia      ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2002,	RSR13,	Phase III,	allosteric modification,	22,	40,	,	,	2009,	-0.76,	Oncology,	,	brain metastases,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2002,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	non-small cell lung cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2002,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Glioblastoma multiforme     ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2002,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Cervical Cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2002,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Recurrent glioblastoma multiforme ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2002,	RSR13,	Phase II,	allosteric modification,	,	,	,	,	,	,	Surgical,	,	Cardiopulmonary bypass surgery ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2002,	RSR13,	Phase II,	allosteric modification,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Angina  ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2002,	RSR13,	Preclinical,	allosteric modification,	21,	,	,	,	,	,	Cardiovascular Disease,	,	 Myocardial infarction,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2002,	RSR46   ,	Preclinical,	allosteric modification,	9,	21,	,	,	2004,	-1,	Acute hypoxia      ,	,	 Acute hypoxia,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2002,	JP7 ,	Preclinical,	allosteric modification,	9,	21,	,	,	2004,	-1,	Acute hypoxia      ,	,	 Acute hypoxia      ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2003,	RSR13,	Phase III,	allosteric modification,	22,	40,	,	,	2009,	-0.76,	Oncology,	,	brain metastases,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2003,	RSR13,	Phase III,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	non-small cell lung cancer,	,	Phase II,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2003,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Glioblastoma multiforme     ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2003,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Cervical Cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2003,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Recurrent glioblastoma multiforme ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2003,	RSR13,	Phase II,	allosteric modification,	,	,	,	,	,	,	Surgical,	,	Cardiopulmonary bypass surgery ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2003,	RSR13,	Phase II,	allosteric modification,	21,	,	,	,	,	,	Cardiovascular Disease,	,	Angina  ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2003,	RSR13,	Preclinical,	allosteric modification,	21,	,	,	,	,	,	Cardiovascular Disease,	,	 Myocardial infarction,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2003,	PDX,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Non-small cell lung cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2003,	PDX,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Mesothelioma,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2003,	PDX,	Phase I,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Non-Hodgkin's lymphoma,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2003,	BGP-15,	Preclinical,	 license from N-Gene Research Laboratories to intellectual property covering BGP-15, ,	22,	70,	,	,	2005,	-0.9878,	Oncology,	,	Chemoprotectant,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2004,	RSR13,	Phase III,	allosteric modification,	22,	40,	,	,	2009,	-0.76,	Oncology,	,	brain metastases,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2004,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	non-small cell lung cancer,	,	Phase III,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2004,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Glioblastoma multiforme     ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2004,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Cervical Cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2004,	RSR13,	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Recurrent glioblastoma multiforme ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2004,	PDX,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Non-small cell lung cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2004,	PDX,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Mesothelioma,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2004,	PDX,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Non-Hodgkin's lymphoma,	,	Phase I,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2005,	EFAPROXYN (efaproxiral),	Phase III,	allosteric modification,	22,	40,	,	RSR13,	2009,	-0.76,	Oncology,	,	brain metastases,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2005,	EFAPROXYN (efaproxiral),	Phase I,	allosteric modification,	22,	,	,	RSR13,	,	,	Oncology,	,	non-small cell lung cancer,	,	Phase II,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2005,	EFAPROXYN (efaproxiral),	Phase II,	allosteric modification,	22,	,	,	RSR13,	,	,	Oncology,	,	Glioblastoma multiforme     ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2005,	EFAPROXYN (efaproxiral),	Phase II,	allosteric modification,	22,	,	,	RSR13,	,	,	Oncology,	,	Cervical Cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2005,	EFAPROXYN (efaproxiral),	Phase II,	allosteric modification,	22,	,	,	RSR13,	,	,	Oncology,	,	Recurrent glioblastoma multiforme ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2005,	PDX,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Non-small cell lung cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2005,	PDX,	Phase I,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Advanced Cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2005,	PDX,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Non-Hodgkin's lymphoma,	,	Phase I,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2005,	RH1,	Phase I,	 license from the University of Colorado Health Sciences Center, the University of Salford and Cancer Research Technology to certain intellectual property surrounding a proprietary molecule known as RH1,	22,	,	,	,	2010,	-0.0714,	Oncology,	,	Solid Tumors,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2006,	EFAPROXYN (efaproxiral),	Phase III,	allosteric modification,	22,	40,	,	,	2009,	-0.76,	Oncology,	,	brain metastases,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2006,	EFAPROXYN (efaproxiral),	Phase I,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	non-small cell lung cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2006,	EFAPROXYN (efaproxiral),	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Glioblastoma multiforme     ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2006,	PDX,	Phase I,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Non-small cell lung cancer,	,	Phase II,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2006,	PDX,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Peripheral T-cell lymphomas, or PTCLs,	Advanced Cancer,	Phase I,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2006,	PDX,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Non-Hodgkin's lymphoma,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2006,	RH1,	Phase I,	 license from the University of Colorado Health Sciences Center, the University of Salford and Cancer Research Technology to certain intellectual property surrounding a proprietary molecule known as RH1,	22,	,	,	,	2010,	-0.0714,	Oncology,	,	Solid Tumors,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2007,	EFAPROXYN (efaproxiral),	Phase III,	allosteric modification,	22,	40,	,	,	2009,	-0.4286,	Oncology,	,	brain metastases,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2007,	EFAPROXYN (efaproxiral),	Phase I,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	non-small cell lung cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2007,	EFAPROXYN (efaproxiral),	Phase II,	allosteric modification,	22,	,	,	,	,	,	Oncology,	,	Glioblastoma multiforme     ,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2007,	PDX,	Phase I,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Non-small cell lung cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2007,	PDX,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Peripheral T-cell lymphomas, or PTCLs,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2007,	PDX,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Non-Hodgkin's lymphoma,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2007,	RH1,	Phase I,	 license from the University of Colorado Health Sciences Center, the University of Salford and Cancer Research Technology to certain intellectual property surrounding a proprietary molecule known as RH1,	22,	,	,	,	2010,	-0.0714,	Oncology,	,	Solid Tumors,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2008,	PDX,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Peripheral T-cell lymphomas, or PTCLs,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2008,	PDX,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Non-Hodgkin's lymphoma,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2008,	PDX,	Phase I,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	cutaneous T-cell lymphoma,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2008,	PDX,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	,	,	,	Oncology,	,	Non-small cell lung cancer,	,	Phase I,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2008,	RH1,	Phase I,	 license from the University of Colorado Health Sciences Center, the University of Salford and Cancer Research Technology to certain intellectual property surrounding a proprietary molecule known as RH1,	22,	,	,	,	2010,	-0.9206,	Oncology,	,	 NHL.,	Solid Tumors,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2009,	Pralatrexate (PDX),	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	PDX,	,	,	Oncology,	,	Peripheral T-cell lymphomas, or PTCLs,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2009,	Pralatrexate (PDX),	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	PDX,	,	,	Oncology,	,	Non-Hodgkin's lymphoma,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2009,	Pralatrexate (PDX),	Phase I,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	PDX,	,	,	Oncology,	,	cutaneous T-cell lymphoma,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2009,	Pralatrexate (PDX),	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	PDX,	,	,	Oncology,	,	Non-small cell lung cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2009,	Pralatrexate (PDX),	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	3,	,	,	,	Oncology,	,	Bladder Cancer,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2010,	FOLOTYNTM ,	Marketed,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	Pralatrexate (PDX),	,	,	Oncology,	,	Peripheral T-cell lymphomas, or PTCLs,	,	Phase II,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2010,	FOLOTYNTM ,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	Pralatrexate (PDX),	,	,	Oncology,	,	Non-Hodgkin's lymphoma,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2010,	FOLOTYNTM ,	Phase I,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	27,	,	Pralatrexate (PDX),	,	,	Oncology,	,	cutaneous T-cell lymphoma,	,	,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2010,	FOLOTYNTM ,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	,	,	Pralatrexate (PDX),	,	,	Oncology,	,	Non-small cell lung cancer,	,	Phase II,
wvcs20000001097264,	ALLOS THERAPEUTICS INC,	10-K,	2000,	2010,	FOLOTYNTM ,	Phase II,	e license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering a novel, small molecule cytotoxic injectable anti-folate identified as PDX,	22,	3,	,	Pralatrexate (PDX),	,	,	Oncology,	,	Bladder Cancer,	,	,
wvcs20000001103390,	Ardea Bioscience,	S-1,	2000,	2000,	Ramoplanin Oral,	Phase II,	in-licensed five antibiotic technologies,	23,	,	,	,	2003,	-0.8621,	Infectious Diseases,	,	VRE infections,	,	,
wvcs20000001103390,	Ardea Bioscience,	S-1,	2000,	2000,	Protegrin IB-367 Rinse,	Phase II,	in-licensed five antibiotic technologies,	22,	,	,	,	,	,	Oncology,	,	 oral mucositis,	,	,
wvcs20000001103390,	Ardea Bioscience,	S-1,	2000,	2000,	Protegrin IB-367 Gel ,	Phase I,	in-licensed five antibiotic technologies,	23,	29,	,	,	,	,	Infectious Diseases,	,	Pneumonia,	,	,
wvcs20000001103390,	Ardea Bioscience,	S-1,	2000,	2000,	IB-880 SERIES,	Preclinical,	in-licensed five antibiotic technologies,	23,	,	,	,	2003,	-0.4,	Infectious Diseases,	,	 infections,	,	,
wvcs20000001103390,	Ardea Bioscience,	S-1,	2000,	2000,	IB-863 SERIES,	Preclinical,	in-licensed five antibiotic technologies,	23,	,	,	,	2003,	-0.25,	Infectious Diseases,	,	Fungi Infections,	,	,
wvcs20000001103390,	Ardea Bioscience,	S-1,	2000,	2000,	IB-974 SERIES,	Preclinical,	in-licensed five antibiotic technologies,	23,	70,	,	,	2002,	-1,	Infectious Diseases,	,	Yeast/Fungi Infections,	,	,
wvcs20000001103390,	Ardea Bioscience,	424B,	2000,	2000,	Ramoplanin Oral,	Phase II,	in-licensed five antibiotic technologies,	23,	,	,	,	2003,	-0.8621,	Infectious Diseases,	,	VRE infections,	,	,
wvcs20000001103390,	Ardea Bioscience,	424B,	2000,	2000,	Protegrin IB-367 Rinse,	Phase II,	in-licensed five antibiotic technologies,	22,	,	,	,	,	,	Oncology,	,	 oral mucositis,	,	,
wvcs20000001103390,	Ardea Bioscience,	424B,	2000,	2000,	Protegrin IB-367 Gel ,	Phase I,	in-licensed five antibiotic technologies,	23,	29,	,	,	,	,	Infectious Diseases,	,	Pneumonia,	,	,
wvcs20000001103390,	Ardea Bioscience,	424B,	2000,	2000,	IB-880 SERIES,	Preclinical,	in-licensed five antibiotic technologies,	23,	,	,	,	2003,	-0.4,	Infectious Diseases,	,	 infections,	,	,
wvcs20000001103390,	Ardea Bioscience,	424B,	2000,	2000,	IB-863 SERIES,	Preclinical,	in-licensed five antibiotic technologies,	23,	,	,	,	2003,	-0.25,	Infectious Diseases,	,	Fungi Infections,	,	,
wvcs20000001103390,	Ardea Bioscience,	424B,	2000,	2000,	IB-974 SERIES,	Preclinical,	in-licensed five antibiotic technologies,	23,	70,	,	,	2002,	-1,	Infectious Diseases,	,	Yeast/Fungi Infections,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2001,	Ramoplanin Oral,	Phase III,	in-licensed five antibiotic technologies,	23,	,	,	,	2003,	-0.3333,	Infectious Diseases,	,	VRE infections,	,	Phase II,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2001,	Iseganan HCl oral solution,	Phase III,	in-licensed five antibiotic technologies,	22,	,	,	Protegrin IB-367 Rinse,	,	,	Oncology,	,	 oral mucositis,	,	Phase II,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2001,	Iseganan HCl oral solution,	Phase II,	in-licensed five antibiotic technologies,	23,	29,	,	Protegrin IB-367 Gel ,	,	,	Infectious Diseases,	,	Pneumonia,	,	Phase I,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2001,	Ramoplanin ointment,	Phase I,	in-licensed five antibiotic technologies,	23,	70,	,	,	2004,	-0.3333,	Infectious Diseases,	,	 nasal Staphylococus Aureus,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2001,	Ramoplanin Oral,	IND,	in-licensed five antibiotic technologies,	23,	,	,	,	,	,	Infectious Diseases,	,	gram-positive bacteria,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2001,	IB-880 SERIES,	Preclinical,	in-licensed five antibiotic technologies,	23,	,	,	,	2003,	-0.5,	Infectious Diseases,	,	bacterial infections,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2001,	IB-863 SERIES,	Preclinical,	in-licensed five antibiotic technologies,	23,	,	,	,	2003,	-0.5,	Infectious Diseases,	,	Fungi Infections,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2002,	Iseganan HCl oral solution,	Phase III,	in-licensed five antibiotic technologies,	22,	,	,	,	,	,	Oncology,	,	 oral mucositis,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2002,	Iseganan HCl oral solution,	Phase II,	in-licensed five antibiotic technologies,	23,	29,	,	,	,	,	Infectious Diseases,	,	Pneumonia,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2002,	Iseganan HCl Solution,	Phase I,	in-licensed five antibiotic technologies,	23,	29,	,	,	,	,	Infectious Diseases,	,	Respiratory Infections,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2002,	Ramoplanin ointment,	Phase I,	in-licensed five antibiotic technologies,	23,	70,	,	,	2004,	-0.954,	Infectious Diseases,	,	 nasal Staphylococus Aureus,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2003,	Iseganan HCl oral solution,	Phase III,	in-licensed five antibiotic technologies,	23,	29,	,	,	,	,	Infectious Diseases,	,	Pneumonia,	,	Phase II,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2003,	Iseganan HCl Solution,	Phase I,	in-licensed five antibiotic technologies,	23,	29,	,	,	,	,	Infectious Diseases,	,	Respiratory Infections,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2004,	Iseganan HCl oral solution,	Phase III,	in-licensed five antibiotic technologies,	23,	29,	,	,	,	,	Infectious Diseases,	,	Pneumonia,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2004,	Iseganan HCl Solution,	Phase I,	in-licensed five antibiotic technologies,	23,	29,	,	,	,	,	Infectious Diseases,	,	Respiratory Infections,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2005,	"  Prior to the termination of our iseganan development program our clinical pipeline had included development of an iseganan oral solution for the prevention of ventilator-associated pneumonia and for the treatment of respiratory infections in cystic fibrosis patients. We currently have no clinical pipeline. Our research and development expenditures will depend upon the strategic alternative we elect to pursue.
      Research and development expense for the three years ended December 31, 2004, 2003 and 2002 was $11.5 million, $7.7 million and $23.1 million, respectively.,"	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2005,	"  Prior to the termination of our iseganan development program our clinical pipeline had included development of an iseganan oral solution for the prevention of ventilator-associated pneumonia and for the treatment of respiratory infections in cystic fibrosis patients. We currently have no clinical pipeline. Our research and development expenditures will depend upon the strategic alternative we elect to pursue.
      Research and development expense for the three years ended December 31, 2004, 2003 and 2002 was $11.5 million, $7.7 million and $23.1 million, respectively.,"	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2006,	"  Prior to the termination of our iseganan development program our clinical pipeline had included development of an iseganan oral solution for the prevention of ventilator-associated pneumonia and for the treatment of respiratory infections in cystic fibrosis patients. We currently have no clinical pipeline. Our research and development expenditures will depend upon the strategic alternative we elect to pursue.
      Research and development expense for the three years ended December 31, 2004, 2003 and 2002 was $11.5 million, $7.7 million and $23.1 million, respectively.,"	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2006,	"  Prior to the termination of our iseganan development program our clinical pipeline had included development of an iseganan oral solution for the prevention of ventilator-associated pneumonia and for the treatment of respiratory infections in cystic fibrosis patients. We currently have no clinical pipeline. Our research and development expenditures will depend upon the strategic alternative we elect to pursue.
      Research and development expense for the three years ended December 31, 2004, 2003 and 2002 was $11.5 million, $7.7 million and $23.1 million, respectively.,"	,	,	,	,	,	,	,	,	,	,	,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2007,	800 Series Program,	Phase I,	 intellectual property and other assets related to three distinct pharmaceutical research and development programs from Valeant Research & Development, Inc.,	23,	,	,	,	,	,	Infectious Diseases,	,	HIV,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2007,	900 Series Program,,	Preclinical,	 intellectual property and other assets related to three distinct pharmaceutical research and development programs from Valeant Research & Development, Inc.,	23,	,	,	,	,	,	Infectious Diseases,	,	HIV,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2007,	100 Series Program,	Preclinical,	 intellectual property and other assets related to three distinct pharmaceutical research and development programs from Valeant Research & Development, Inc.,	5,	,	,	,	,	,	Inflammation,	,	Inflammation,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2007,	100 Series Program,	Preclinical,	 intellectual property and other assets related to three distinct pharmaceutical research and development programs from Valeant Research & Development, Inc.,	22,	,	,	,	,	,	Oncology,	,	cancer ,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2008,	RDEA806 ,	Phase II,	(NNRTI,	23,	,	,	800 Series Program,	,	,	Infectious Diseases,	,	HIV,	,	Phase I,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2008,	2nd generation NNRTI,	Preclinical,	(NNRTI,	23,	,	,	900 Series Program,,	,	,	Infectious Diseases,	,	HIV,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2008,	RDEA806,	Phase II,	(NNRTI,	5,	,	,	800 Series Program,	,	,	Inflammation,	,	Gout,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2008,	RDEA119 ,	Phase I,	 intellectual property and other assets related to three distinct pharmaceutical research and development programs from Valeant Research & Development, Inc.,	22,	,	,	100 Series Program,	,	,	Oncology,	,	cancer ,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2008,	RDEA119,	Phase I,	MEK Inhibitor Program,	5,	,	,	100 Series Program,	,	,	Inflammation,	,	Inflammation,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2008,	2nd Generation MEK Inhibitor Program,	Preclinical,	MEK Inhibitor Program,	22,	,	,	,	,	,	Oncology,	,	cancer ,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2009,	RDEA806 ,	Phase II,	(NNRTI,	23,	,	,	,	,	,	Infectious Diseases,	,	HIV,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2009,	RDEA119 ,	Phase II,	 intellectual property and other assets related to three distinct pharmaceutical research and development programs from Valeant Research & Development, Inc.,	22,	,	,	,	,	,	Oncology,	,	cancer ,	,	Phase I,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2009,	RDEA119,	Phase I,	 intellectual property and other assets related to three distinct pharmaceutical research and development programs from Valeant Research & Development, Inc.,	5,	,	,	,	,	,	Inflammation,	,	Inflammation,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2009,	RDEA436,	Preclinical,	MEK inhibitor program,	5,	,	,	,	,	,	Inflammation,	,	Inflammation,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2009,	RDEA594,	Phase I,	(NNRTI,	5,	,	,	RDEA806,	,	,	Inflammation,	,	Gout,	,	,
wvcs20000001103390,	Ardea Bioscience,	10-K,	2000,	2009,	RDEA427,	Preclinical,	(NNRTI,	23,	,	,	,	,	,	Infectious Diseases,	,	HIV,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	S-1,	2000,	2000,	AGI-1067,	Phase II,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	 Atherosclerosis,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	S-1,	2000,	2000,	AGI-series,	Preclinical,	 v-protectant,	5,	29,	,	,	2006,	-0.6207,	Inflammation,	,	Exacerbations of asthma and cystic fibrosis,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	S-1,	2000,	2000,	AGI-series, oral ,	Preclinical,	 v-protectant,	5,	20,	,	,	,	,	Inflammation,	,	Rheumatoid arthritis ,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	S-1,	2000,	2000,	AGI-series, oral ,	Preclinical,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Solid organ transplant,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	S-1,	2000,	2000,	Oral product,	Research,	 v-protectant,	5,	29,	,	,	2006,	-1,	Inflammation,	,	Chronic asthma ,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	S-1,	2000,	2000,	Oxykine diagnostic ,	Preclinical,	 v-protectant,	5,	,	,	,	2004,	-0.6667,	Inflammation,	,	Atherosclerosis ,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	424B,	2000,	2000,	AGI-1067,	Phase II,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	 Atherosclerosis,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	424B,	2000,	2000,	AGI-series,	Preclinical,	 v-protectant,	5,	29,	,	,	2006,	-0.6207,	Inflammation,	,	Exacerbations of asthma and cystic fibrosis,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	424B,	2000,	2000,	AGI-series, oral ,	Preclinical,	 v-protectant,	5,	20,	,	,	,	,	Inflammation,	,	Rheumatoid arthritis ,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	424B,	2000,	2000,	AGI-series, oral ,	Preclinical,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Solid organ transplant,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	424B,	2000,	2000,	Oral product,	Research,	 v-protectant,	5,	29,	,	,	2006,	-1,	Inflammation,	,	Chronic asthma ,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	424B,	2000,	2000,	Oxykine diagnostic ,	Preclinical,	 v-protectant,	5,	,	,	,	2004,	-0.6667,	Inflammation,	,	Atherosclerosis ,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2001,	AGI-1067,	Phase II,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	 Atherosclerosis,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2001,	AGIX-4207 ,	 IND filed     ,	 v-protectant,	5,	20,	,	AGI-series, oral ,	2006,	-0.6207,	Inflammation,	,	Rheumatoid arthritis,	,	Preclinical,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2001,	AGI-series,	Preclinical,	 v-protectant,	5,	29,	20,	,	2004,	0,	Inflammation,	,	Exacerbations of rheumatological diseases,	Exacerbations of asthma and cystic fibrosis,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2001,	AGI-series, oral ,	Preclinical,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Solid organ transplant,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2001,	Oral product,	Research,	 v-protectant,	5,	29,	,	,	2006,	-1,	Inflammation,	,	Chronic asthma ,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2001,	 OXYKINE® assay,	Preclinical,	 v-protectant,	5,	,	,	Oxykine diagnostic ,	2004,	-0.6667,	Inflammation,	,	Atherosclerosis ,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2002,	AGI-1067,	Phase IIB,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Restenosis, atherosclerosis,	 Atherosclerosis,	Phase II,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2002,	AGIX-4207 ,	Phase I,	 v-protectant,	5,	20,	,	,	2006,	-0.6207,	Inflammation,	,	Rheumatoid arthritis,	,	IND,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2002,	AGI-series,	Preclinical,	 v-protectant,	5,	29,	20,	,	2004,	-0.9655,	Inflammation,	,	Exacerbations of rheumatological diseases,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2002,	AGI-1096,	Phase I,	 v-protectant,	5,	,	,	AGI-series, oral ,	,	,	Inflammation,	,	Solid organ transplant,	,	Preclinical,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2002,	Oral product,	Research,	 v-protectant,	5,	29,	,	,	2006,	-1,	Inflammation,	,	Chronic asthma ,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2002,	 OXYKINE® assay,	Preclinical,	 v-protectant,	5,	,	,	,	2004,	0,	Inflammation,	,	Atherosclerosis ,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2002,	diagnostics and therapeutic,	Disovery,	MEKK Technology,	5,	29,	,	,	,	,	Inflammation,	,	inflammation and asthma,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2003,	AGI-1067,	Phase III,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Restenosis, atherosclerosis,	,	Phase IIB,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2003,	AGIX-4207 ,	Phase II,	 v-protectant,	5,	20,	,	,	2006,	-0.6207,	Inflammation,	,	Rheumatoid arthritis,	,	Phase I,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2003,	AGI-1096,	Phase I,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Solid organ transplant,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2003,	Oral product,	Pre IND,	 v-protectant,	5,	29,	,	,	2006,	-1,	Inflammation,	,	Chronic asthma ,	,	Preclinical,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2003,	diagnostics and therapeutic,	Disovery,	MEKK Technology,	5,	29,	,	,	,	,	Inflammation,	,	inflammation and asthma,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2004,	AGI-1067,	Phase III,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Restenosis, atherosclerosis,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2004,	AGIX-4207 ,	Phase II,	 v-protectant,	5,	20,	,	,	2006,	-0.89,	Inflammation,	,	Rheumatoid arthritis,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2004,	AGI-1096,	Phase I,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Solid organ transplant,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2004,	Oral product,	Pre IND,	 v-protectant,	5,	29,	,	,	2006,	-1,	Inflammation,	,	Chronic asthma ,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2004,	diagnostics and therapeutic,	Disovery,	MEKK Technology,	5,	29,	,	,	,	,	Inflammation,	,	inflammation and asthma,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2005,	AGI-1067,	Phase III,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Restenosis, atherosclerosis,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2005,	AGI-1096,	Phase I,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Solid organ transplant,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2005,	AGI Series,	Pre IND,	 v-protectant,	5,	29,	,	,	,	,	Inflammation,	,	Chronic asthma ,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2005,	diagnostics and therapeutic,	Disovery,	MEKK Technology,	5,	29,	,	,	,	,	Inflammation,	,	inflammation and asthma,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2005,	AGI Series,	Pre IND,	 v-protectant,	5,	20,	,	,	,	,	Inflammation,	,	Rheumatoid arthritis,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2006,	AGI-1067,	Phase III,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Restenosis, atherosclerosis,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2006,	AGI-1096,	Phase I,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Solid organ transplant,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2006,	AGI Series,	Pre IND,	 v-protectant,	5,	29,	,	,	,	,	Inflammation,	,	Chronic asthma ,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2006,	diagnostics and therapeutic,	Disovery,	MEKK Technology,	5,	29,	,	,	,	,	Inflammation,	,	inflammation and asthma,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2006,	AGI Series,	Pre IND,	 v-protectant,	5,	20,	,	,	,	,	Inflammation,	,	Rheumatoid arthritis,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2007,	AGI-1067,	Phase III,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Restenosis, atherosclerosis,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2007,	AGI-1096,	Phase I,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Solid organ transplant,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2007,	AGI Series,	Research,	 v-protectant,	5,	29,	,	,	,	,	Inflammation,	,	Chronic asthma ,	,	Pre IND,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2007,	diagnostics and therapeutic,	Disovery,	MEKK Technology,	5,	29,	,	,	,	,	Inflammation,	,	inflammation and asthma,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2007,	AGI Series,	Research,	 v-protectant,	5,	20,	,	,	,	,	Inflammation,	,	Rheumatoid arthritis,	,	Pre IND,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2008,	AGI-1067,	Phase III,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Restenosis, atherosclerosis,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2008,	AGI-1067,	Phase III,	 v-protectant,	5,	24,	,	,	,	,	Inflammation,	,	Type 2 diabetes,	,	,
wvcs20000001107601,	ATHEROGENICS INC,	10-K,	2000,	2008,	AGI-1096,	Phase I,	 v-protectant,	5,	,	,	,	,	,	Inflammation,	,	Solid organ transplant,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	 Provenge(TM)     ,	Phase III,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	APC8020    ,	Phase II,	Antigen Delivery Cassette technology,	22,	,	,	,	2002,	-0.9589,	Oncology,	,	Multiple myeloma,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	APC8020    ,	Phase II,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Amyloidosis,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer  ,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Colorectal cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Pancreatic cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	APC80NY   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	2003,	-0.6667,	Oncology,	,	Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	APC80NY   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	APC80NY   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	 APC80TR,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	2003,	1,	Oncology,	,	Breast cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	 APC80TR,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Prostate cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	 APC80TR,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Colorectal cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	 Danton(TM),	Preclinical,	Antigen Delivery Cassette technology,	22,	27,	,	,	2007,	-1,	Oncology,	,	Non-Hodgkin lymphoma,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	 Danton(TM),	Preclinical,	Antigen Delivery Cassette technology,	5,	22,	27,	,	,	,	Oncology,	,	 Hodgkin's lymphoma,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	Dantes(TM),	Preclinical,	Antigen Delivery Cassette technology,	5,	20,	,	,	2007,	-1,	Autoimmune diseases,	,	 Autoimmune diseases,	,	,
wvcs20000001107332,	DENDREON CORP,	S-1,	2000,	2000,	DACS(R)SC Kit ,	FDA Approved,	cell separation technology,	27,	,	,	,	2005,	0,	Blood Transfer,	,	Blood stem cell preparation,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	 Provenge(TM)     ,	Phase III,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	 Mylovenge(TM),	Phase II,	Antigen Delivery Cassette technology,	22,	,	,	APC8020    ,	2005,	-0.7692,	Oncology,	,	Multiple myeloma,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	 Mylovenge(TM),	Phase II,	Antigen Delivery Cassette technology,	22,	,	,	APC8020    ,	,	,	Oncology,	,	Amyloidosis,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer  ,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Colorectal cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Pancreatic cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	APC80NY   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	2003,	-0.6667,	Oncology,	,	Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	APC80NY   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	APC80NY   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	 APC80TR,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	2003,	1,	Oncology,	,	Breast cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	 APC80TR,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Prostate cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	 APC80TR,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Colorectal cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	 Danton(TM),	Preclinical,	Antigen Delivery Cassette technology,	22,	27,	,	,	2007,	-1,	Oncology,	,	Non-Hodgkin lymphoma,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	 Danton(TM),	Preclinical,	Antigen Delivery Cassette technology,	5,	22,	27,	,	,	,	Oncology,	,	 Hodgkin's lymphoma,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	Dantes(TM),	Preclinical,	Antigen Delivery Cassette technology,	5,	20,	,	,	2007,	-1,	Autoimmune diseases,	,	 Autoimmune diseases,	,	,
wvcs20000001107332,	DENDREON CORP,	424B,	2000,	2000,	DACS(R)SC Kit ,	FDA Approved,	cell separation technology,	27,	,	,	,	2005,	0,	Blood Transfer,	,	Blood stem cell preparation,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	 Provenge(TM)     ,	Phase III,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Hormone Refractory Prostate cancer,	Prostate cancer,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	 Mylovenge(TM),	Phase II,	Antigen Delivery Cassette technology,	22,	,	,	,	2005,	-0.7692,	Oncology,	,	Multiple myeloma,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	 Mylovenge(TM),	Phase II,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Amyloidosis,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer  ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Colorectal cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Pancreatic cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	APC80NY   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	2003,	-0.5,	Oncology,	,	Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	APC80NY   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	APC80NY   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	 APC80TR,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	2003,	3,	Oncology,	,	Breast cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	 APC80TR,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Prostate cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	 APC80TR,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Colorectal cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	 Danton(TM),	Preclinical,	Antigen Delivery Cassette technology,	22,	27,	,	,	2007,	-1,	Oncology,	,	Non-Hodgkin lymphoma,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	 Danton(TM),	Preclinical,	Antigen Delivery Cassette technology,	5,	22,	27,	,	,	,	Oncology,	,	 Hodgkin's lymphoma,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	Dantes(TM),	Preclinical,	Antigen Delivery Cassette technology,	5,	20,	,	,	2007,	-1,	Autoimmune diseases,	,	 Autoimmune diseases,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	DACS(R)SC Kit ,	FDA Approved,	cell separation technology,	27,	,	,	,	2005,	0,	Blood Transfer,	,	Blood stem cell preparation,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2001,	PRI-Immunotherapy (2) ,	Preclinical,	R.W. Johnson technology,	22,	,	,	,	2004,	-0.6,	Oncology,	,	Breast Cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	 Provenge(TM)     ,	Phase III,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Hormone Refractory Prostate cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	 Mylovenge(TM),	Phase II,	Antigen Delivery Cassette technology,	22,	,	,	,	2005,	-0.7692,	Oncology,	,	Multiple myeloma,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	 Mylovenge(TM),	Phase II,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Amyloidosis,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer  ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Colorectal cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Pancreatic cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	CTL8004,	Phase I,	R.W. Johnson technology,	22,	,	,	PRI-Immunotherapy (2) ,	2004,	0,	Oncology,	,	Breast Cancer,	,	Preclinical,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	NY-ESO ,	Preclinical,	Antigen Delivery Cassette technology,	22,	3,	,	,	2007,	-1,	Oncology,	,	Bladder cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	NY-ESO ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	NY-ESO ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Ovarian/Uterine cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	Trp-p8  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	2007,	0,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	Trp-p8  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	Trp-p8  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Prostate cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	CEA ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	  Breast cancer,,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	MN   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Kidney cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	MN   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Cervical cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	 DN1924  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	27,	,	 Danton(TM),	2007,	-1,	Oncology,	,	Non-Hodgkin lymphoma,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	 DN1924  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	27,	,	 Danton(TM),	,	,	Oncology,	,	 Hodgkin's lymphoma,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	 DN1921  ,	Preclinical,	Antigen Delivery Cassette technology,	5,	20,	,	Dantes(TM),	2007,	-1,	Autoimmune diseases,	,	 Autoimmune diseases,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	Trp-p8,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	Trp-p8,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2002,	DACS(R)SC Kit ,	FDA Approved,	cell separation technology,	27,	,	,	,	2005,	0,	Blood Transfer,	,	Blood stem cell preparation,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	 Provenge(TM)     ,	Phase III,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Hormone Refractory Prostate cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	 Mylovenge(TM),	Phase II,	Antigen Delivery Cassette technology,	22,	,	,	,	2005,	-0.9863,	Oncology,	,	Multiple myeloma,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	 Mylovenge(TM),	Phase II,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Amyloidosis,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer  ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Colorectal cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Pancreatic cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	Trp-p8  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	2007,	0,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	Trp-p8  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	Trp-p8  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Prostate cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	NY-ESO ,	Preclinical,	Antigen Delivery Cassette technology,	22,	3,	,	,	2007,	-1,	Oncology,	,	Bladder cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	NY-ESO ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	NY-ESO ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Ovarian/Uterine cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	CEA ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	  Breast cancer,,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	MN   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Kidney cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	MN   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Cervical cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	 DN1924  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	27,	,	,	2007,	-1,	Oncology,	,	Non-Hodgkin lymphoma,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	 DN1924  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	27,	,	,	,	,	Oncology,	,	 Hodgkin's lymphoma,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	 DN1921  ,	Preclinical,	Antigen Delivery Cassette technology,	5,	20,	,	,	2007,	-1,	Autoimmune diseases,	,	 Autoimmune diseases,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	Trp-p8,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	Trp-p8,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	DACS(R)SC Kit ,	FDA Approved,	cell separation technology,	27,	,	,	,	2005,	-1,	Blood Transfer,	,	Blood stem cell preparation,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2003,	Telomerase,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	2007,	-1,	Oncology,	,	Multiple Cancers,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	 Provenge(TM)     ,	Phase III,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Androgen Independent Prostate cancer (D9902B),	Hormone Refractory Prostate cancer,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer  ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	APC8024,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Colorectal cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	Trp-p8  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	2007,	0,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	Trp-p8  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	Trp-p8  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Prostate cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	NY-ESO ,	Preclinical,	Antigen Delivery Cassette technology,	22,	3,	,	,	2007,	-1,	Oncology,	,	Bladder cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	NY-ESO ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	NY-ESO ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Ovarian/Uterine cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	CEA ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	  Breast cancer,,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	MN   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Kidney cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	MN   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Cervical cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	Telomerase,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	2007,	-1,	Oncology,	,	Multiple Cancers,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	Trp-p8,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	Trp-p8,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	PACT,	Preclinical,	proteases that are present on the surface of tumor cells,	22,	,	,	,	2006,	13,	Oncology,	,	 Prostate cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	Anti-Endotheliase,	Preclinical,	 human antibody technologies ,	22,	,	,	,	2007,	-1,	Oncology,	,	Multiple Cancers,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	Anti-Matriptase,	Preclinical,	 human antibody technologies ,	22,	,	,	,	,	,	Oncology,	,	Multiple Cancers,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	 DN1924  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	27,	,	,	2007,	-1,	Oncology,	,	Non-Hodgkin lymphoma,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	 DN1924  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	27,	,	,	,	,	Oncology,	,	 Hodgkin's lymphoma,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2004,	 DN1921  ,	Preclinical,	Antigen Delivery Cassette technology,	5,	20,	,	,	2007,	-1,	Autoimmune diseases,	,	 Autoimmune diseases,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	 Provenge(TM)     ,	Phase III,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Androgen Independent Prostate cancer (D9902B),	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	APC8024 (Neuvenge),	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	APC8024,	,	,	Oncology,	,	Breast cancer  ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	APC8024 (Neuvenge),	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	APC8024,	,	,	Oncology,	,	Prostate cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	APC8024 (Neuvenge),	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	APC8024,	,	,	Oncology,	,	Colorectal cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	Trp-p8  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	2007,	8,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	Trp-p8  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	Trp-p8  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Prostate cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	NY-ESO ,	Preclinical,	Antigen Delivery Cassette technology,	22,	3,	,	,	2007,	-1,	Oncology,	,	Bladder cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	NY-ESO ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	NY-ESO ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Ovarian/Uterine cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	CEA ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	  Breast cancer,,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	MN   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Kidney cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	MN   ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Cervical cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	Telomerase,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	2007,	-1,	Oncology,	,	Multiple Cancers,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	Trp-p8,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	Trp-p8,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	Anti-Endotheliase,	Preclinical,	 human antibody technologies ,	22,	,	,	,	2007,	-1,	Oncology,	,	Multiple Cancers,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	Anti-Matriptase,	Preclinical,	 human antibody technologies ,	22,	,	,	,	,	,	Oncology,	,	Multiple Cancers,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	 DN1924  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	27,	,	,	2007,	-1,	Oncology,	,	Non-Hodgkin lymphoma,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	 DN1924  ,	Preclinical,	Antigen Delivery Cassette technology,	22,	27,	,	,	,	,	Oncology,	,	 Hodgkin's lymphoma,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2005,	 DN1921  ,	Preclinical,	Antigen Delivery Cassette technology,	5,	20,	,	,	2007,	-1,	Autoimmune diseases,	,	 Autoimmune diseases,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2006,	 Provenge(TM)     ,	Phase III,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Androgen Independent Prostate cancer (D9902B),	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2006,	Neuvenge (lapuleucel-T,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	APC8024 (Neuvenge),	,	,	Oncology,	,	Breast cancer  ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2006,	Neuvenge (lapuleucel-T,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	APC8024 (Neuvenge),	,	,	Oncology,	,	Prostate cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2006,	Neuvenge (lapuleucel-T,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	APC8024 (Neuvenge),	,	,	Oncology,	,	Colorectal cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2006,	Trp-p8,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2006,	Trp-p8,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2006,	CEA ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	  Breast cancer,,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2006,	CA-9,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	MN   ,	,	,	Oncology,	,	Kidney cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2006,	CA-9,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	MN   ,	,	,	Oncology,	,	 Cervical cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2006,	Anti-Serine Protease,	Preclinical,	 human antibody technologies ,	22,	,	,	Anti-Matriptase,	,	,	Oncology,	,	Multiple Cancers,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2007,	 Provenge(TM)     ,	BLA,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Androgen Independent Prostate cancer (D9902B),	,	Phase III,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2007,	Neuvenge (lapuleucel-T,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer  ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2007,	Neuvenge (lapuleucel-T,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2007,	Neuvenge (lapuleucel-T,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Colorectal cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2007,	Trp-p8,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2007,	Trp-p8,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2007,	CEA ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	  Breast cancer,,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2007,	CA-9,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Kidney cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2007,	CA-9,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Cervical cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2007,	Anti-Serine Protease,	Preclinical,	 human antibody technologies ,	22,	,	,	,	,	,	Oncology,	,	Multiple Cancers,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2008,	 Provenge(TM)     ,	BLA,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Androgen Independent Prostate cancer (D9902B),	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2008,	Neuvenge (lapuleucel-T,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer  ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2008,	Neuvenge (lapuleucel-T,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2008,	Neuvenge (lapuleucel-T,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Colorectal cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2008,	Trp-p8,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2008,	Trp-p8,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2008,	CEA ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	  Breast cancer,,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2008,	CA-9,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Kidney cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2008,	CA-9,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Cervical cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2008,	Anti-Serine Protease,	Preclinical,	 human antibody technologies ,	22,	,	,	,	,	,	Oncology,	,	Multiple Cancers,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2009,	 Provenge(TM)     ,	BLA,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Androgen Independent Prostate cancer (D9902B),	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2009,	Neuvenge (lapuleucel-T,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer  ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2009,	Neuvenge (lapuleucel-T,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2009,	Neuvenge (lapuleucel-T,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Colorectal cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2009,	D3263,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	Trp-p8,	,	,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2009,	CEA ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	  Breast cancer,,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2009,	CA-9,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Kidney cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2009,	CA-9,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Cervical cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2009,	Anti-Serine Protease,	Preclinical,	 human antibody technologies ,	22,	,	,	,	,	,	Oncology,	,	Multiple Cancers,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2009,	Anti-HLA-DR,	Preclinical,	Antigen Delivery Cassette technology,	22,	27,	,	,	,	,	Oncology,	,	Hematologic Malignancies,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2010,	 Provenge(TM)     ,	BLA,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Androgen Independent Prostate cancer (D9902B),	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2010,	Neuvenge (lapuleucel-T,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Breast cancer  ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2010,	Neuvenge (lapuleucel-T,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Prostate cancer ,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2010,	Neuvenge (lapuleucel-T,	Phase I,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Colorectal cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2010,	D3263,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Lung cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2010,	CEA ,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	  Breast cancer,,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2010,	CA-9,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	Kidney cancer,	,	,
wvcs20000001107332,	DENDREON CORP,	10-K,	2000,	2010,	CA-9,	Preclinical,	Antigen Delivery Cassette technology,	22,	,	,	,	,	,	Oncology,	,	 Cervical cancer,	,	,
wvcs20000001082038,	DURECT CORP,	S-1,	2000,	2000,	Sufentanil  ,	Phase I,	proprietary formulations of traditional small molecule drugs,	62,	,	,	,	2011,	-0.1,	Chronic Pain,	,	Opioid-Responsive Non-Malignant Pain,	,	,
wvcs20000001082038,	DURECT CORP,	S-1,	2000,	2000,	Hydromorphone,	Preclinical,	proprietary formulations of traditional small molecule drugs,	62,	22,	42,	,	2003,	-1,	Central Nervous Sytem,	,	Cancer Pain ,	,	,
wvcs20000001082038,	DURECT CORP,	S-1,	2000,	2000,	Gentamycin   ,	Preclinical,	proprietary formulations of traditional small molecule drugs,	2,	,	,	,	2003,	-1,	Ear Disorders,	,	Meniere's Disease,	,	,
wvcs20000001082038,	DURECT CORP,	S-1,	2000,	2000,	Cardiovascular Diseases,	Research,	proprietary formulations of traditional small molecule drugs,	21,	,	,	,	2003,	1.75,	Cardiovascular Diseases,	,	Cardiovascular Diseases,	,	,
wvcs20000001082038,	DURECT CORP,	S-1,	2000,	2000,	Vascular Graft,	Research,	proprietary formulations of traditional small molecule drugs,	21,	,	,	,	2003,	0.8889,	Vascular Graft,	,	Vascular Graft,	,	,
wvcs20000001082038,	DURECT CORP,	S-1,	2000,	2000,	 Cancer Immunotherapy,	Research,	proprietary formulations of traditional small molecule drugs,	22,	,	,	,	2003,	-0.3333,	Oncology,	,	Cancer,	,	,
wvcs20000001082038,	DURECT CORP,	424B4,	2000,	2000,	Sufentanil  ,	Phase I,	proprietary formulations of traditional small molecule drugs,	62,	,	,	,	2011,	-0.1,	Chronic Pain,	,	Opioid-Responsive Non-Malignant Pain,	,	,
wvcs20000001082038,	DURECT CORP,	424B4,	2000,	2000,	Hydromorphone,	Preclinical,	proprietary formulations of traditional small molecule drugs,	62,	22,	42,	,	2003,	-1,	Central Nervous Sytem,	,	Cancer Pain ,	,	,
wvcs20000001082038,	DURECT CORP,	424B4,	2000,	2000,	Gentamycin   ,	Preclinical,	proprietary formulations of traditional small molecule drugs,	2,	,	,	,	2003,	-1,	Ear Disorders,	,	Meniere's Disease,	,	,
wvcs20000001082038,	DURECT CORP,	424B4,	2000,	2000,	Cardiovascular Diseases,	Research,	proprietary formulations of traditional small molecule drugs,	21,	,	,	,	2003,	1.75,	Cardiovascular Diseases,	,	Cardiovascular Diseases,	,	,
wvcs20000001082038,	DURECT CORP,	424B4,	2000,	2000,	Vascular Graft,	Research,	proprietary formulations of traditional small molecule drugs,	21,	,	,	,	2003,	0.8889,	Vascular Graft,	,	Vascular Graft,	,	,
wvcs20000001082038,	DURECT CORP,	424B4,	2000,	2000,	 Cancer Immunotherapy,	Research,	proprietary formulations of traditional small molecule drugs,	22,	,	,	,	2003,	-0.3333,	Oncology,	,	Cancer,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2001,	Sufentanil  ,	Phase II,	proprietary formulations of traditional small molecule drugs,	62,	,	,	,	2011,	-0.1,	Chronic Pain,	,	Opioid-Responsive Non-Malignant Pain,	,	Phase I,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2001,	Hydromorphone,	Preclinical,	proprietary formulations of traditional small molecule drugs,	62,	22,	42,	,	2003,	-1,	Central Nervous Sytem,	,	Cancer Pain ,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2001,	Gentamycin   ,	Preclinical,	proprietary formulations of traditional small molecule drugs,	2,	,	,	,	2003,	-1,	Ear Disorders,	,	Meniere's Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2001,	Cardiovascular Diseases,	Research,	proprietary formulations of traditional small molecule drugs,	21,	,	,	,	2003,	-0.45,	Cardiovascular Diseases,	,	Cardiovascular Diseases,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2001,	Vascular Graft,	Research,	proprietary formulations of traditional small molecule drugs,	21,	,	,	,	2003,	-0.15,	Vascular Graft,	,	Vascular Graft,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2001,	 Cancer Immunotherapy,	Research,	proprietary formulations of traditional small molecule drugs,	22,	,	,	,	2003,	-0.5,	Oncology,	,	Cancer,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2002,	CHRONOGESIC,	Phase II,	proprietary formulations of traditional small molecule drugs,	62,	,	,	Sufentanil  ,	2011,	-0.1,	Chronic Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2002,	SABER Injection,	Research,	 SABER,	62,	9,	,	,	,	,	Pain,	,	Post Operative Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2002,	Spinal Delivery,	Preclinical,	proprietary formulations of traditional small molecule drugs,	62,	,	,	,	2004,	-0.9237,	Chronic Pain,	,	Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2002,	Antipsychotic,	Research,	 SABER,	40,	,	,	,	2004,	-0.9924,	CNS,	,	Psychotic Disorders,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2002,	Brain Tumor Local Delivery,	Preclinical,	proprietary formulations of traditional small molecule drugs,	22,	40,	,	,	,	,	CNS,	,	Brain Cancer,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2002,	Pericardial,	Preclinical,	proprietary formulations of traditional small molecule drugs,	21,	,	,	,	,	,	Cardiovascular,	,	Coronary Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2002,	ALZET®,	Marketed,	 DUROS technology (Alzet Technology),	70,	,	,	,	2008,	0.1429,	Research,	,	Drug Delivery,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2002,	IntraEAR®,	Marketed,	proprietary formulations of traditional small molecule drugs,	2,	,	,	,	2005,	-0.3,	Ear Disorders,	,	Meniere's Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2002,	SABER delivery system,	Marketed,	 SABER,	,	,	,	,	2004,	-0.5,	 pharmaceutical,	,	Manufacturing,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2002,	 DURIN bioerodable implant,	Marketed,	DURIN technology,	,	,	,	,	2004,	0.2,	 pharmaceutical,	,	Manufacturing,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2003,	CHRONOGESIC,	Phase II,	proprietary formulations of traditional small molecule drugs,	62,	,	,	,	2011,	-0.1,	Chronic Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2003,	SABER Injection,	Research,	 SABER,	62,	9,	,	,	,	,	Pain,	,	Post Operative Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2003,	Central Nervous System Disorders,	Preclinical,	proprietary formulations of traditional small molecule drugs,	22,	45,	,	Brain Tumor Local Delivery,	,	,	CNS,	,	Various Cancers,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2003,	Pericardial,	Preclinical,	proprietary formulations of traditional small molecule drugs,	21,	,	,	,	,	,	Cardiovascular,	,	Coronary Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2003,	Controlled Release Injection,	Preclinical,	Saber,	23,	,	,	,	2005,	0,	Infectious Diseases,	,	Hepatitis C,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2003,	Controlled Release Injection of Cromolyn Sodium,	Preclinical,	 SABER/DURIN,	5,	29,	,	,	2006,	-0.4286,	Inflammation,	,	Asthma/Allergic Rhinitis,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2003,	Various,	Research,	DURIN technology,	40,	,	,	,	2011,	-0.625,	CNS,	,	Alzheimer’s Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2003,	ALZET®,	Marketed,	 DUROS technology (Alzet Technology),	70,	,	,	,	2008,	0.1429,	Research,	,	Drug Delivery,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2003,	IntraEAR®,	Marketed,	proprietary formulations of traditional small molecule drugs,	2,	,	,	,	2005,	-0.6667,	Ear Disorders,	,	Meniere's Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2004,	CHRONOGESIC,	Phase III,	 DUROS technology,	62,	,	,	,	2011,	-0.1,	Chronic Pain,	,	Chronic Pain,	,	Phase II,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2004,	Post Operative Pain,	Phase I,	 SABER,	62,	9,	,	SABER Injection,	,	,	Pain,	,	Post Operative Pain,	,	Research,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2004,	Remoxy™,	Phase I,	  ORADUR,	62,	,	,	,	,	,	Chronic Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2004,	Central Nervous System Disorders,	Preclinical,	 DUROS technology,	22,	45,	,	Brain Tumor Local Delivery,	,	,	CNS,	,	Various Cancers,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2004,	Pericardial,	Preclinical,	 DUROS technology,	21,	,	,	,	,	,	Cardiovascular,	,	Coronary Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2004,	Controlled Release Injection of Cromolyn Sodium,	Preclinical,	 SABER/DURIN,	5,	29,	,	,	2006,	0,	Inflammation,	,	Asthma/Allergic Rhinitis,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2004,	Controlled Release Implant,	Research,	DURIN technology,	40,	,	,	Various,	2011,	-0.625,	CNS,	,	Alzheimer’s Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2004,	ALZET®,	Marketed,	 DUROS technology (Alzet Technology),	70,	,	,	,	2008,	0.1429,	Research,	,	Drug Delivery,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2005,	CHRONOGESIC,	Phase III,	 DUROS technology,	62,	,	,	,	2011,	-0.1,	Chronic Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2005,	Post Operative Pain,	Phase II,	 SABER,	62,	9,	,	,	,	,	Pain,	,	Post Operative Pain,	,	Phase I,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2005,	Remoxy™,	Phase III,	  ORADUR,	62,	,	,	,	,	,	Chronic Pain,	,	Chronic Pain,	,	Phase I,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2005,	Central Nervous System Disorders,	Preclinical,	 DUROS technology,	22,	45,	,	,	,	,	CNS,	,	Various Cancers,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2005,	Pericardial,	Preclinical,	 DUROS technology,	21,	,	,	,	,	,	Cardiovascular,	,	Coronary Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2005,	Transdermal sufentanil,	Phase II,	TRANSDUR,	62,	,	,	,	,	,	Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2005,	Controlled Release Implant,	Phase I,	DURIN technology,	40,	,	,	,	2011,	-0.625,	CNS,	,	Alzheimer’s Disease,	,	Research,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2005,	LACTEL® brand,	Marketed,	N/A,	,	,	,	,	2008,	1.8,	Manufacturing Polymers,	,	biodegradable polymers,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2005,	ALZET®,	Marketed,	 DUROS technology (Alzet Technology),	70,	,	,	,	2008,	0.1429,	Research,	,	Drug Delivery,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2006,	CHRONOGESIC,	Phase III,	 DUROS technology,	62,	,	,	,	2011,	-0.1,	Chronic Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2006,	SABER-Bupivacaine,	Phase II,	 SABER,	62,	9,	,	Post Operative Pain,	,	,	Pain,	,	Post Operative Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2006,	Remoxy™,	Phase III,	  ORADUR,	62,	,	,	,	,	,	Chronic Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2006,	Central Nervous System Disorders,	Preclinical,	 DUROS technology,	22,	45,	,	,	,	,	CNS,	,	Various Cancers,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2006,	Pericardial,	Preclinical,	 DUROS technology,	21,	,	,	,	,	,	Cardiovascular,	,	Coronary Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2006,	TRANSDUR-Sufentanil,	Phase II,	TRANSDUR,	62,	,	,	Transdermal sufentanil,	,	,	Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2006,	Memryte,	Phase III,	DURIN technology,	40,	,	,	Controlled Release Implant,	2011,	-0.625,	CNS,	,	Alzheimer’s Disease,	,	Phase I,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2006,	ALZET®,	Marketed,	 DUROS technology (Alzet Technology),	70,	,	,	,	2008,	-0.4,	Research,	,	Drug Delivery,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2006,	LACTEL® brand,	Marketed,	N/A,	,	,	,	,	2008,	-0.65,	Manufacturing Polymers,	,	biodegradable polymers,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2007,	POSIDUR,	Phase II,	 SABER,	62,	9,	,	SABER-Bupivacaine,	,	,	Pain,	,	Post Operative Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2007,	TRANSDUR-Sufentanil,	Phase II,	TRANSDUR,	62,	,	,	,	,	,	Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2007,	Remoxy™,	Phase III,	  ORADUR,	62,	,	,	,	,	,	Chronic Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2007,	Memryte,	Phase III,	DURIN technology,	40,	,	,	,	2011,	-0.625,	CNS,	,	Alzheimer’s Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2007,	Central Nervous System Disorders,	Preclinical,	 DUROS technology,	22,	45,	,	,	,	,	CNS,	,	Various Cancers,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2007,	Pericardial,	Preclinical,	 DUROS technology,	21,	,	,	,	,	,	Cardiovascular,	,	Coronary Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2007,	CHRONOGESIC,	Phase III,	 DUROS technology,	62,	,	,	,	2011,	-0.1,	Chronic Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2007,	TRANSDUR-Bupivacaine,	Phase II,	TRANSDUR,	62,	9,	42,	,	,	,	Pain,	,	Neuropathic Pain associated with Post-Hepetic Neuralgia (PHN),	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2008,	POSIDUR,	Phase II,	 SABER,	62,	9,	,	,	,	,	Pain,	,	Post Operative Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2008,	TRANSDUR-Sufentanil,	Phase II,	TRANSDUR,	62,	,	,	,	,	,	Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2008,	Remoxy™,	NDA,	  ORADUR,	62,	,	,	,	,	,	Chronic Pain,	,	Chronic Pain,	,	Phase III,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2008,	Memryte,	Phase III,	DURIN technology,	40,	,	,	,	2011,	-0.625,	CNS,	,	Alzheimer’s Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2008,	Central Nervous System Disorders,	Preclinical,	 DUROS technology,	22,	45,	,	,	,	,	CNS,	,	Various Cancers,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2008,	Pericardial,	Preclinical,	 DUROS technology,	21,	,	,	,	,	,	Cardiovascular,	,	Coronary Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2008,	ELADUR,	Phase II,	TRANSDUR,	62,	9,	42,	TRANSDUR-Bupivacaine,	,	,	Pain,	,	Neuropathic Pain associated with Post-Hepetic Neuralgia (PHN),	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2008,	CHRONOGESIC,	System Redesign,	 DUROS technology,	62,	,	,	,	2011,	-0.1,	Chronic Pain,	,	Chronic Pain,	,	Phase III,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2009,	POSIDUR,	Phase II,	 SABER,	62,	9,	,	,	,	,	Pain,	,	Post Operative Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2009,	TRANSDUR-Sufentanil,	Phase II,	TRANSDUR,	62,	,	,	,	,	,	Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2009,	Remoxy™,	NDA,	  ORADUR,	62,	,	,	,	,	,	Chronic Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2009,	Memryte,	Phase III,	DURIN technology,	40,	,	,	,	2011,	-0.8421,	CNS,	,	Alzheimer’s Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2009,	Central Nervous System Disorders,	Preclinical,	 DUROS technology,	22,	45,	,	,	,	,	CNS,	,	Various Cancers,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2009,	Pericardial,	Preclinical,	 DUROS technology,	21,	,	,	,	,	,	Cardiovascular,	,	Coronary Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2009,	ELADUR,	Phase II,	TRANSDUR,	62,	9,	42,	,	,	,	Pain,	,	Neuropathic Pain associated with Post-Hepetic Neuralgia (PHN),	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2009,	CHRONOGESIC,	System Redesign,	 DUROS technology,	62,	,	,	,	2011,	-0.6727,	Chronic Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2009,	Oral controlled release opioid,	Phase I,	ORADUR-,	62,	,	,	,	,	,	Pain,	,	Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2010,	POSIDUR,	Phase III,	 SABER,	62,	9,	,	,	,	,	Pain,	,	Post Operative Pain,	,	Phase II,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2010,	TRANSDUR-Sufentanil,	Phase II,	TRANSDUR,	62,	,	,	,	,	,	Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2010,	Remoxy™,	NDA,	  ORADUR,	62,	,	,	,	,	,	Chronic Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2010,	Central Nervous System Disorders,	Preclinical,	 DUROS technology,	22,	45,	,	,	,	,	CNS,	,	Various Cancers,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2010,	Pericardial,	Preclinical,	 DUROS technology,	21,	,	,	,	,	,	Cardiovascular,	,	Coronary Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2010,	ELADUR,	Phase II,	TRANSDUR,	62,	9,	42,	,	,	,	Pain,	,	Neuropathic Pain associated with Post-Hepetic Neuralgia (PHN),	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2010,	Oral controlled release opioid,	Phase I,	ORADUR-,	62,	,	,	,	,	,	Pain,	,	Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2010,	ORADUR-ADHD,	Preclinical,	ORADUR-,	40,	,	,	,	,	,	neurobehavioral ,	,	ADHD,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2011,	POSIDUR,	Phase III,	 SABER,	62,	9,	,	,	,	,	Pain,	,	Post Operative Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2011,	TRANSDUR-Sufentanil,	Phase II,	TRANSDUR,	62,	,	,	,	,	,	Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2011,	Remoxy™,	NDA,	  ORADUR,	62,	,	,	,	,	,	Chronic Pain,	,	Chronic Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2011,	Central Nervous System Disorders,	Preclinical,	 DUROS technology,	22,	45,	,	,	,	,	CNS,	,	Various Cancers,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2011,	Pericardial,	Preclinical,	 DUROS technology,	21,	,	,	,	,	,	Cardiovascular,	,	Coronary Disease,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2011,	ELADUR,	Phase II,	TRANSDUR,	62,	9,	42,	,	,	,	Pain,	,	Neuropathic Pain associated with Post-Hepetic Neuralgia (PHN),	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2011,	Oral controlled release opioid,	Phase I,	ORADUR-,	62,	,	,	,	,	,	Pain,	,	Pain,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2011,	ORADUR-ADHD,	Preclinical,	ORADUR-,	40,	,	,	,	,	,	neurobehavioral ,	,	ADHD,	,	,
wvcs20000001082038,	DURECT CORP,	10-K,	2000,	2011,	•ORADUR-based opioid (oxymorphone),	Phase I,	ORADUR-,	62,	,	,	,	,	,	Pain,	,	Pain,	,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	S-1,	2000,	2000,	ProApoA-I,	Preclinical,	recombinant DNA sequence for ProApoA-1,,	9,	21,	,	,	,	,	Cardiovascular Disease,	,	 ischemic patients,	,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	S-1,	2000,	2000,	A-I Milano, or AIM,,	Preclinical,	worldwide rights to AIM ,	21,	,	,	,	,	,	Cardiovascular Disease,	,	angina and restenosis,	,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	S-1,	2000,	2000,	RLT Peptide,	Preclinical,	RLT peptide technology,	9,	21,	,	,	,	,	Cardiovascular Disease,	,	ischemia and angina,	,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	S-1,	2000,	2000,	HDL Elevators,	Preclinical,	HDL Therapy,	21,	,	,	,	,	,	Cardiovascular Disease,	,	HDL stimulation,	,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	S-1,	2000,	2000,	LUVs,	Preclinical,	LUV technology,	9,	21,	,	,	,	,	Cardiovascular Disease,	,	ischemia,	,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	424B4,	2000,	2000,	ProApoA-I,	Phase I,	recombinant DNA sequence for ProApoA-1,,	9,	21,	,	,	,	,	Cardiovascular Disease,	,	 ischemic patients,	,	Preclinical,
wvcs20000001066745,	ESPERION THERAPEUTICS,	424B4,	2000,	2000,	A-I Milano, or AIM,,	Preclinical,	worldwide rights to AIM ,	21,	,	,	,	,	,	Cardiovascular Disease,	,	angina and restenosis,	,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	424B4,	2000,	2000,	RLT Peptide,	Preclinical,	RLT peptide technology,	9,	21,	,	,	,	,	Cardiovascular Disease,	,	ischemia and angina,	,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	424B4,	2000,	2000,	HDL Elevators,	Preclinical,	HDL Therapy,	21,	,	,	,	,	,	Cardiovascular Disease,	,	HDL stimulation,	,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	424B4,	2000,	2000,	LUVs,	Preclinical,	LUV technology,	9,	21,	,	,	,	,	Cardiovascular Disease,	,	ischemia,	,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	10-K,	2000,	2001,	ETC-276,	Phase I,	recombinant DNA sequence for ProApoA-1,,	9,	21,	,	ProApoA-I,	,	,	Cardiovascular Disease,	,	atherosclerosis,	 ischemic patients,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	10-K,	2000,	2001,	ETC-216,	Phase I,	worldwide rights to AIM ,	21,	,	,	A-I Milano, or AIM,,	,	,	Cardiovascular Disease,	,	atherosclerosis,	angina and restenosis,	Preclinical,
wvcs20000001066745,	ESPERION THERAPEUTICS,	10-K,	2000,	2001,	ETC-642,	Preclinical,	RLT peptide technology,	9,	21,	,	RLT Peptide,	,	,	Cardiovascular Disease,	,	atherosclerosis,	ischemia and angina,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	10-K,	2000,	2001,	HDL Elevators,	Preclinical,	HDL Therapy,	21,	,	,	,	,	,	Cardiovascular Disease,	,	HDL stimulation,	,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	10-K,	2000,	2001,	ETC-588,	Phase II,	LUV technology,	9,	21,	,	LUVs,	,	,	Cardiovascular Disease,	,	atherosclerosis,	ischemia,	Preclinical,
wvcs20000001066745,	ESPERION THERAPEUTICS,	10-K,	2000,	2002,	ETC-276,	Phase I,	recombinant DNA sequence for ProApoA-1,,	9,	21,	,	,	,	,	Cardiovascular Disease,	,	atherosclerosis,	,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	10-K,	2000,	2002,	ETC-216,	Phase II,	worldwide rights to AIM ,	21,	,	,	,	,	,	Cardiovascular Disease,	,	atherosclerosis,	,	Phase I,
wvcs20000001066745,	ESPERION THERAPEUTICS,	10-K,	2000,	2002,	ETC-642,	Phase I,	RLT peptide technology,	9,	21,	,	,	,	,	Cardiovascular Disease,	,	atherosclerosis,	,	Preclinical,
wvcs20000001066745,	ESPERION THERAPEUTICS,	10-K,	2000,	2002,	ESP 31015,	IND,	HDL Therapy,	21,	,	,	HDL Elevators,	,	,	Cardiovascular Disease,	,	HDL stimulation,	,	Preclinical,
wvcs20000001066745,	ESPERION THERAPEUTICS,	10-K,	2000,	2002,	ETC-588,	Phase IIA,	LUV technology,	9,	21,	,	,	,	,	Cardiovascular Disease,	,	atherosclerosis,	,	phase II,
wvcs20000001066745,	ESPERION THERAPEUTICS,	10-K,	2000,	2003,	ETC-588,	Phase IIA,	LUV technology,	9,	21,	,	,	,	,	Cardiovascular Disease,	,	atherosclerosis,	,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	10-K,	2000,	2003,	ETC-216,	Phase II,	worldwide rights to AIM ,	21,	,	,	,	,	,	Cardiovascular Disease,	,	atherosclerosis,	,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	10-K,	2000,	2003,	ETC-642,	Phase I,	RLT peptide technology,	9,	21,	,	,	,	,	Cardiovascular Disease,	,	atherosclerosis,	,	,
wvcs20000001066745,	ESPERION THERAPEUTICS,	10-K,	2000,	2003,	 ETC-1001,	IND,	HDL Therapy,	21,	,	,	ESP 31015,	,	,	Cardiovascular Disease,	,	HDL stimulation,	,	Preclinical,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	S-1,	2000,	2000,	INS365 Respiratory ,	Phase IIA,	P2Y receptor technology platform.,	29,	,	,	,	2004,	-0.5,	Respiratory Disease,	,	chronic bronchitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	S-1,	2000,	2000,	INS365 Respiratory ,	Phase IIA,	P2Y receptor technology platform.,	29,	,	,	,	,	,	Respiratory Disease,	,	chronic bronchitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	S-1,	2000,	2000,	 INS365 Ophthalmic,	Phase IIB,	P2Y receptor technology platform.,	1,	,	,	,	,	,	Retinal Disease,	,	dry eye disease;,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	S-1,	2000,	2000,	 INS316 Diagnostic,	Phase III,	P2Y receptor technology platform.,	9,	29,	,	,	2006,	-0.6111,	Respiratory Disease,	,	Diagnostic aid for  lung disease ,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	S-1,	2000,	2000,	INS37217 Respiratory,	Phase I,	P2Y receptor technology platform.,	29,	,	,	,	,	,	Respiratory Disease,	,	cystic fibrosis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	S-1,	2000,	2000,	 INS37217 Ophthalmic,	Phase I,	P2Y receptor technology platform.,	1,	,	,	,	,	,	Retinal Disease,	,	retinal detachment,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	S-1,	2000,	2000,	P2Y\\2\\ Agonist ,	Preclinical,	P2Y receptor technology platform.,	29,	2,	,	,	2003,	0.3871,	Respiratory Disease,	,	sinusitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	424B1,	2000,	2000,	INS365 Respiratory ,	Phase II,	P2Y receptor technology platform.,	29,	,	,	,	2004,	-0.5,	Respiratory Disease,	,	chronic bronchitis,	,	Phase IIA,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	424B1,	2000,	2000,	INS365 Respiratory ,	Phase II,	P2Y receptor technology platform.,	29,	,	,	,	,	,	Respiratory Disease,	,	chronic bronchitis,	,	Phase IIA,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	424B1,	2000,	2000,	 INS365 Ophthalmic,	Phase III,	P2Y receptor technology platform.,	1,	,	,	,	,	,	Retinal Disease,	,	dry eye disease;,	,	Phase IIB,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	424B1,	2000,	2000,	 INS316 Diagnostic,	Phase III,	P2Y receptor technology platform.,	9,	29,	,	,	2006,	-0.6111,	Respiratory Disease,	,	Diagnostic aid for  lung disease ,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	424B1,	2000,	2000,	INS37217 Respiratory,	Phase I,	P2Y receptor technology platform.,	29,	,	,	,	,	,	Respiratory Disease,	,	cystic fibrosis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	424B1,	2000,	2000,	 INS37217 Ophthalmic,	Phase I,	P2Y receptor technology platform.,	1,	,	,	,	,	,	Retinal Disease,	,	retinal detachment,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	424B1,	2000,	2000,	P2Y\\2\\ Agonist ,	Preclinical,	P2Y receptor technology platform.,	29,	2,	,	,	2003,	0.3871,	Respiratory Disease,	,	sinusitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2001,	INS365 Respiratory ,	Phase II,	P2Y receptor technology platform.,	29,	,	,	,	2004,	-0.5,	Respiratory Disease,	,	chronic bronchitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2001,	INS365 Respiratory ,	Phase II,	P2Y receptor technology platform.,	29,	,	,	,	,	,	Respiratory Disease,	,	chronic bronchitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2001,	INS37217 Respiratory,	Phase I,	P2Y receptor technology platform.,	29,	,	,	,	,	,	Respiratory Disease,	,	cystic fibrosis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2001,	 INS37217  Respiratory ,	Preclinical,	P2Y receptor technology platform.,	29,	2,	,	P2Y\\2\\ Agonist ,	2003,	2.9091,	Respiratory Disease,	,	sinusitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2001,	 INS365 Ophthalmic,	Phase III,	P2Y receptor technology platform.,	1,	,	,	,	,	,	Retinal Disease,	,	dry eye disease;,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2001,	 INS316 Diagnostic,	Phase III,	P2Y receptor technology platform.,	9,	29,	,	,	2006,	-0.6111,	Respiratory Disease,	,	Diagnostic aid for  lung disease ,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2001,	 INS37217 Ophthalmic,	Phase I,	P2Y receptor technology platform.,	1,	,	,	,	,	,	Retinal Disease,	,	retinal detachment,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2002,	 INS365 Ophthalmic,	Phase III,	P2Y receptor technology platform.,	29,	1,	,	,	,	,	Respiratory Disease,	,	dry eye disease;,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2002,	 INS365 Ophthalmic,	Phase III,	P2Y receptor technology platform.,	29,	1,	,	,	,	,	Respiratory Disease,	,	dry eye disease;,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2002,	 INS37217 Ophthalmic,	Phase II,	P2Y receptor technology platform.,	1,	,	,	,	,	,	Retinal Disease,	,	retinal detachment,	,	Phase I,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2002,	 INS316 Diagnostic,	Phase III,	P2Y receptor technology platform.,	9,	29,	,	,	2006,	-0.6111,	Respiratory Disease,	,	Diagnostic aid for  lung disease ,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2002,	INS37217 Respiratory,	Phase I,	P2Y receptor technology platform.,	29,	,	,	,	,	,	Respiratory Disease,	,	cystic fibrosis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2002,	INS365 Respiratory ,	Phase II,	P2Y receptor technology platform.,	29,	,	,	,	2004,	0.0909,	Respiratory Disease,	,	chronic bronchitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2002,	 INS37217   Intranasal,	Phase II,	P2Y receptor technology platform.,	29,	2,	,	,	2006,	0.4074,	Respiratory Disease,	,	Upper Respiratory Disorders,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2003,	Diquafosol tetrasodium,	Phase II,	P2Y receptor technology platform.,	29,	1,	,	 INS365 Ophthalmic,	,	,	Respiratory Disease,	,	Dry Eye Disease,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2003,	Diquafosol tetrasodium,	Phase II,	P2Y receptor technology platform.,	29,	1,	,	 INS365 Ophthalmic,	,	,	Respiratory Disease,	,	Dry Eye Disease,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2003,	 INS37217   Intranasal,	Phase III,	P2Y receptor technology platform.,	29,	2,	,	,	2006,	0.4074,	Respiratory Disease,	,	Upper Respiratory Disorders,	,	Phase II,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2003,	INS37217 Respiratory,	Phase II,	P2Y receptor technology platform.,	29,	,	,	,	,	,	Respiratory Disease,	,	cystic fibrosis,	,	Phase I,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2003,	 INS316 Diagnostic,	Phase III,	P2Y receptor technology platform.,	9,	29,	,	,	2006,	-0.6111,	Respiratory Disease,	,	Diagnostic aid for  lung disease ,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2003,	Denufosol tetrasodium ,	Phase II,	P2Y receptor technology platform.,	1,	,	,	 INS37217 Ophthalmic,	,	,	Retinal Disease,	,	retinal detachment,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2004,	Elestat™,	Marketed,	N/A,	5,	1,	,	,	,	,	Inflammation,	,	allergic conjunctivitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2004,	Restasis®,	Marketed,	N/A,	1,	,	,	,	,	,	Retinal Disease,	,	Dry Eye Disease,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2004,	Diquafosol tetrasodium,	Phase III,	P2Y receptor technology platform.,	29,	1,	,	,	,	,	Respiratory Disease,	,	Dry Eye Disease,	,	Phase II,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2004,	Diquafosol tetrasodium,	Phase III,	P2Y receptor technology platform.,	29,	1,	,	,	,	,	Respiratory Disease,	,	Dry Eye Disease,	,	Phase II,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2004,	 INS37217   Intranasal,	Phase II,	P2Y receptor technology platform.,	29,	2,	,	,	2006,	-0.3091,	Respiratory Disease,	,	Upper Respiratory Disorders,	,	Phase III,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2004,	Denufosol tetrasodium,	Phase II,	P2Y receptor technology platform.,	29,	,	,	INS37217 Respiratory,	,	,	Respiratory Disease,	,	cystic fibrosis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2004,	 INS316 Diagnostic,	Phase III,	P2Y receptor technology platform.,	9,	29,	,	,	2006,	-0.3636,	Respiratory Disease,	,	Diagnostic aid for  lung disease ,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2004,	Denufosol tetrasodium ,	Phase II,	P2Y receptor technology platform.,	1,	,	,	,	,	,	Retinal Disease,	,	retinal detachment,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2004,	INS50589 Cardiovascular,	Preclinical,	P2Y receptor technology platform.,	9,	21,	,	,	2007,	1.1111,	Cardiovascular Diseases,	,	 acute cardiovascular or cerebrovascular indications,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2005,	Elestat™,	Marketed,	N/A,	5,	1,	,	,	,	,	Inflammation,	,	allergic conjunctivitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2005,	Restasis®,	Marketed,	N/A,	1,	,	,	,	,	,	Retinal Disease,	,	Dry Eye Disease,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2005,	Diquafosol tetrasodium,	NDA,	P2Y receptor technology platform.,	29,	1,	,	,	,	,	Respiratory Disease,	,	Dry Eye Disease,	,	Phase III,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2005,	Diquafosol tetrasodium,	Phase II,	P2Y receptor technology platform.,	29,	,	,	,	,	,	Respiratory Disease,	,	Corneal wound healing,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2005,	Denufosol tetrasodium,	Phase II,	P2Y receptor technology platform.,	29,	,	,	,	,	,	Respiratory Disease,	,	cystic fibrosis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2005,	Denufosol tetrasodium ,	Phase II,	P2Y receptor technology platform.,	1,	,	,	,	,	,	Retinal Disease,	,	Macular Edema,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2005,	Denufosol tetrasodium ,	Phase II,	P2Y receptor technology platform.,	1,	,	,	,	,	,	Retinal Disease,	,	retinal detachment,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2005,	INS50589 Antiplatelet,	Phase I,	P2Y receptor technology platform.,	9,	21,	,	INS50589 Cardiovascular,	2007,	0.7273,	Cardiovascular Diseases,	,	 acute cardiovascular or cerebrovascular indications,	,	Preclinical,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2006,	Elestat™,	Marketed,	N/A,	5,	1,	,	,	,	,	Inflammation,	,	allergic conjunctivitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2006,	Restasis®,	Marketed,	N/A,	1,	,	,	,	,	,	Retinal Disease,	,	Dry Eye Disease,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2006,	Diquafosol tetrasodium,	NDA,	P2Y receptor technology platform.,	29,	1,	,	,	,	,	Respiratory Disease,	,	Dry Eye Disease,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2006,	Denufosol tetrasodium,	Phase II,	P2Y receptor technology platform.,	29,	,	,	,	,	,	Respiratory Disease,	,	cystic fibrosis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2006,	INS50589 Cardiovascular,	Phase I,	P2Y receptor technology platform.,	9,	21,	,	,	2008,	-0.4545,	Cardiovascular Diseases,	,	 acute cardiovascular or cerebrovascular indications,	,	Preclinical,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2006,	Intranasal epinastine,	Preclinical,	 Boehringer Ingelheim- Liscense,	29,	,	,	,	2010,	-0.8333,	Respiratory Disease,	,	Seasonal allergic rhinitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2006,	Outflow enhancer,	Preclinical,	 WARF,	1,	,	,	,	,	,	Retinal Disease,	,	Glaucoma,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2007,	Elestat™,	Marketed,	N/A,	5,	1,	,	,	,	,	Inflammation,	,	allergic conjunctivitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2007,	Restasis®,	Marketed,	N/A,	1,	,	,	,	,	,	Retinal Disease,	,	Dry Eye Disease,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2007,	ProlacriaTM,	NDA,	P2Y receptor technology platform.,	29,	1,	,	Diquafosol tetrasodium,	,	,	Respiratory Disease,	,	Dry Eye Disease,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2007,	Denufosol tetrasodium,	Phase III,	P2Y receptor technology platform.,	29,	,	,	,	,	,	Respiratory Disease,	,	cystic fibrosis,	,	Phase II,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2007,	INS115644,	Phase I,	 WARF,	1,	,	,	Outflow enhancer,	,	,	Retinal Disease,	,	Glaucoma,	,	Preclinical,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2007,	Intranasal epinastine,	Phase II,	 Boehringer Ingelheim- Liscense,	29,	,	,	,	2010,	-0.8333,	Respiratory Disease,	,	Seasonal allergic rhinitis,	,	Preclinical,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2007,	AzaSite™,	Phase III,	 InSite Vision -Technology,	1,	,	,	,	,	,	ophthalmic indications,	,	Bacterial conjunctivitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2007,	Bilastine,	Phase III,	 oral H1-antihistamine compound ,	29,	,	,	,	2009,	-0.9372,	Respiratory Disease,	,	Seasonal allergic rhinitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2008,	Elestat™,	Marketed,	N/A,	5,	1,	,	,	,	,	Inflammation,	,	allergic conjunctivitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2008,	Restasis®,	Marketed,	N/A,	1,	,	,	,	,	,	Retinal Disease,	,	Dry Eye Disease,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2008,	AzaSite™,	Marketed,	 InSite Vision -Technology,	1,	,	,	,	,	,	ophthalmic indications,	,	Bacterial conjunctivitis,	,	Phase III,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2008,	ProlacriaTM,	NDA,	P2Y receptor technology platform.,	29,	1,	,	,	,	,	Respiratory Disease,	,	Dry Eye Disease,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2008,	Denufosol tetrasodium,	Phase III,	P2Y receptor technology platform.,	29,	,	,	,	,	,	Respiratory Disease,	,	cystic fibrosis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2008,	Intranasal epinastine,	Phase III,	 Boehringer Ingelheim- Liscense,	29,	,	,	,	2010,	-0.9091,	Respiratory Disease,	,	Seasonal allergic rhinitis,	,	Phase II,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2008,	INS115644,	Phase I,	 WARF,	1,	,	,	,	,	,	Retinal Disease,	,	Glaucoma,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2009,	Elestat™,	Marketed,	N/A,	5,	1,	,	,	,	,	Inflammation,	,	allergic conjunctivitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2009,	Restasis®,	Marketed,	N/A,	1,	,	,	,	,	,	Retinal Disease,	,	Dry Eye Disease,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2009,	AzaSite™,	Marketed,	 InSite Vision -Technology,	1,	,	,	,	,	,	ophthalmic indications,	,	Bacterial conjunctivitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2009,	ProlacriaTM,	NDA,	P2Y receptor technology platform.,	29,	1,	,	,	,	,	Respiratory Disease,	,	Dry Eye Disease,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2009,	AzaSite™,	Phase II,	 InSite Vision -Technology,	1,	,	,	,	,	,	ophthalmic indications,	,	Blepharitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2009,	Denufosol tetrasodium,	Phase III,	P2Y receptor technology platform.,	29,	,	,	,	,	,	Respiratory Disease,	,	cystic fibrosis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2009,	INS115644,	Phase I,	 WARF,	1,	,	,	,	,	,	Retinal Disease,	,	Glaucoma,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2010,	Elestat™,	Marketed,	N/A,	5,	1,	,	,	,	,	Inflammation,	,	allergic conjunctivitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2010,	Restasis®,	Marketed,	N/A,	1,	,	,	,	,	,	Retinal Disease,	,	Dry Eye Disease,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2010,	AzaSite™,	Marketed,	 InSite Vision -Technology,	1,	,	,	,	,	,	ophthalmic indications,	,	Bacterial conjunctivitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2010,	ProlacriaTM,	NDA,	P2Y receptor technology platform.,	29,	1,	,	,	,	,	Respiratory Disease,	,	Dry Eye Disease,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2010,	AzaSite™,	Phase II,	 InSite Vision -Technology,	1,	,	,	,	,	,	ophthalmic indications,	,	Blepharitis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2010,	Denufosol tetrasodium,	Phase III,	P2Y receptor technology platform.,	29,	,	,	,	,	,	Respiratory Disease,	,	cystic fibrosis,	,	,
wvcs20000001040416,	INSPIRE PHARMACEUTICALS INC,	10-K,	2000,	2010,	INS115644,	Phase I,	 WARF,	1,	,	,	,	,	,	Retinal Disease,	,	Glaucoma,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	S-1,	2000,	2000,	INGN 201,	Phase III,	INTROGEN ENABLING TECHNOLOGIES,	22,	2,	,	,	,	,	Oncology,	,	 Head & Neck ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	S-1,	2000,	2000,	INGN 201,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Non-Small Cell Lung,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	S-1,	2000,	2000,	INGN 201,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Prostate  ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	S-1,	2000,	2000,	INGN 201,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	3,	,	,	,	,	Oncology,	,	Bladder ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	S-1,	2000,	2000,	INGN 201,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Ovarian ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	S-1,	2000,	2000,	INGN 241,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Breast,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	S-1,	2000,	2000,	INGN 251,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	0.3158,	Oncology,	,	 Colorectal ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	S-1,	2000,	2000,	INGN 251,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	22,	40,	,	,	,	,	Oncology,	,	  Brain (glioblastoma),	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	S-1,	2000,	2000,	INGN 231,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2002,	9.2105,	Oncology,	,	 Prostate  ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	S-1,	2000,	2000,	 BAK PROGRAM      ,	Research,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	0,	Oncology,	,	Various Cancers,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	S-1,	2000,	2000,	P16 PROGRAM     ,	Research,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	-1,	Oncology,	,	 Pancreatic ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	S-1,	2000,	2000,	 DBCCR1* PROGRAM  ,	Research,	INTROGEN ENABLING TECHNOLOGIES,	22,	3,	,	,	2002,	3,	Oncology,	,	  Bladder ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	S-1,	2000,	2000,	RSK3* PROGRAM   ,	Research,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2002,	-1,	Oncology,	,	Ovarian ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	424B4,	2000,	2000,	INGN 201,	Phase III,	INTROGEN ENABLING TECHNOLOGIES,	22,	2,	,	,	,	,	Oncology,	,	 Head & Neck ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	424B4,	2000,	2000,	INGN 201,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Non-Small Cell Lung,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	424B4,	2000,	2000,	INGN 201,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Prostate  ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	424B4,	2000,	2000,	INGN 201,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	3,	,	,	,	,	Oncology,	,	Bladder ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	424B4,	2000,	2000,	INGN 201,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Ovarian ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	424B4,	2000,	2000,	INGN 241,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Solid Tumors,	Breast,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	424B4,	2000,	2000,	INGN 251,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	0.3158,	Oncology,	,	 Colorectal ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	424B4,	2000,	2000,	INGN 251,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	22,	40,	,	,	,	,	Oncology,	,	  Brain (glioblastoma),	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	424B4,	2000,	2000,	INGN 231,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2002,	9.2105,	Oncology,	,	 Prostate  ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	424B4,	2000,	2000,	 BAK PROGRAM      ,	Research,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	0,	Oncology,	,	Various Cancers,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	424B4,	2000,	2000,	P16 PROGRAM     ,	Research,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	-1,	Oncology,	,	 Pancreatic ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	424B4,	2000,	2000,	 DBCCR1* PROGRAM  ,	Research,	INTROGEN ENABLING TECHNOLOGIES,	22,	3,	,	,	2002,	3,	Oncology,	,	  Bladder ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	424B4,	2000,	2000,	RSK3* PROGRAM   ,	Research,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2002,	-1,	Oncology,	,	Ovarian ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2001,	INGN 201,	Phase III,	INTROGEN ENABLING TECHNOLOGIES,	22,	2,	,	,	,	,	Oncology,	,	 Head & Neck ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2001,	INGN 201,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Non-Small Cell Lung,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2001,	INGN 201,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Prostate  ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2001,	INGN 201,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	3,	,	,	,	,	Oncology,	,	Bladder ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2001,	INGN 201,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Ovarian ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2001,	INGN 241,	Preclinical,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Solid Tumors,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2001,	INGN 251,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	0.3158,	Oncology,	,	 Colorectal ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2001,	INGN 251,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	22,	40,	,	,	,	,	Oncology,	,	  Brain (glioblastoma),	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2001,	 BAK PROGRAM      ,	Research,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	0,	Oncology,	,	Various Cancers,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2001,	P16 PROGRAM     ,	Research,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	-1,	Oncology,	,	 Pancreatic ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2002,	INGN 201,	Phase III,	INTROGEN ENABLING TECHNOLOGIES,	22,	2,	,	,	,	,	Oncology,	,	 Head & Neck ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2002,	INGN 201,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Non-Small Cell Lung,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2002,	INGN 201,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Prostate  ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2002,	INGN 201,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	3,	,	,	,	,	Oncology,	,	Bladder ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2002,	INGN 201,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Breast,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2002,	INGN 201,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Ovarian ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2002,	INGN 241,	Phase I,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Solid Tumors,	,	Preclinical,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2002,	INGN 251,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	0.3158,	Oncology,	,	 Colorectal ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2002,	INGN 251,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	22,	40,	,	,	,	,	Oncology,	,	  Brain (glioblastoma),	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2002,	 BAK PROGRAM      ,	Research,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	0,	Oncology,	,	Various Cancers,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2002,	P16 PROGRAM     ,	Research,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	-1,	Oncology,	,	 Pancreatic ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2003,	ADVEXIN® Gene Therapy ,	Phase III,	INTROGEN ENABLING TECHNOLOGIES,	22,	2,	,	INGN 201,	,	,	Oncology,	,	 Head & Neck ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2003,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	INGN 201,	,	,	Oncology,	,	Non-Small Cell Lung,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2003,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	INGN 201,	,	,	Oncology,	,	  Prostate  ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2003,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	3,	,	INGN 201,	,	,	Oncology,	,	Bladder ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2003,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	INGN 201,	,	,	Oncology,	,	Breast,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2003,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	INGN 201,	,	,	Oncology,	,	  Ovarian ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2003,	INGN 241,	Phase II,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Solid Tumors,	,	Phase I,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2003,	INGN 241,	Preclinical,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Pancreatic,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2003,	INGN 251,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	-0.6429,	Oncology,	,	 Colorectal ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2003,	INGN 251,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	22,	40,	,	,	,	,	Oncology,	,	  Brain (glioblastoma),	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2003,	 BAK PROGRAM      ,	Research,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	-1,	Oncology,	,	Various Cancers,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2003,	P16 PROGRAM     ,	Research,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	-1,	Oncology,	,	 Pancreatic ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2003,	FUS-1 Program,	Research,	3p21.3 family of genes.,	22,	,	,	,	,	,	Oncology,	,	Various,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2003,	Mebendazole ( INGN 601),	Research,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	2005,	-0.8,	Oncology,	,	Gastro-intestinal,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	ADVEXIN® Gene Therapy ,	Phase III,	INTROGEN ENABLING TECHNOLOGIES,	22,	2,	,	,	,	,	Oncology,	,	 Head & Neck ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Non-Small Cell Lung,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Prostate  ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	3,	,	,	,	,	Oncology,	,	Bladder ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Breast,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Ovarian ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Perioperative (and surgery),	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	40,	,	,	,	,	Oncology,	,	Brain (glioblastoma),	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	ADVEXIN® Gene Therapy ,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	5,	20,	,	,	,	,	Inflammation,	,	Rheumatoid Arthritis,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	INGN 225 ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Small Cell Lung,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	INGN 225 ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Breast,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	INGN 241,	Phase II,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Solid Tumors,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	INGN 241,	Preclinical,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Pancreatic,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	INGN 241,	Phase II,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Melanoma,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	INGN 401,	Phase I,	3p21.3 family of genes.,	22,	,	,	FUS-1 Program,	,	,	Oncology,	,	Various,	,	Research,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2004,	INGN 007,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Solid Tumors,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	ADVEXIN® Gene Therapy ,	Phase III,	INTROGEN ENABLING TECHNOLOGIES,	22,	2,	,	,	,	,	Oncology,	,	 Head & Neck ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Non-Small Cell Lung,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Prostate  ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	3,	,	,	,	,	Oncology,	,	Bladder ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Breast,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Ovarian ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Perioperative (and surgery),	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	40,	,	,	,	,	Oncology,	,	Brain (glioblastoma),	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	ADVEXIN® Gene Therapy ,	Preclinical,	INTROGEN ENABLING TECHNOLOGIES,	5,	20,	,	,	,	,	Inflammation,	,	Rheumatoid Arthritis,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	INGN 225 ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Small Cell Lung,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	INGN 225 ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Breast,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	INGN 234 (p53 topical),	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Oral Cancer Prevention,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	INGN 241,	Phase II,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Solid Tumors,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	INGN 241,	Preclinical,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Pancreatic,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	INGN 241,	Phase II,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Melanoma,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	INGN 401,	Phase I,	3p21.3 family of genes.,	22,	,	,	,	,	,	Oncology,	,	Lung cancer,	Various,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	INGN 007,	Preclinical,	Replication Competent Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Solid Tumors,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2005,	INGN 402 nanoparticle formulation (p53),	Preclinical,	Nanoparticle Systemic Delivery Platform,	22,	,	,	,	,	,	Oncology,	,	Various Cancers,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	ADVEXIN® Gene Therapy ,	Phase III,	INTROGEN ENABLING TECHNOLOGIES,	22,	2,	,	,	,	,	Oncology,	,	 Head & Neck ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Non-Small Cell Lung,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Prostate  ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	3,	,	,	,	,	Oncology,	,	Bladder ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Breast,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Ovarian ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Perioperative (and surgery),	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	40,	,	,	,	,	Oncology,	,	Brain (glioblastoma),	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	INGN 225 ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Small Cell Lung,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	INGN 225 ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Breast,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	INGN 234 (p53 topical),	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Oral Cancer Prevention,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	INGN 241,	Phase II,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Solid Tumors,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	INGN 241,	Preclinical,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Pancreatic,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	INGN 241,	Phase II,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Melanoma,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	INGN 241,	Phase III,	Nanoscale Viral Delivery Systems,	22,	2,	,	,	,	,	Oncology,	,	Head and Neck,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	INGN 401,	Phase I,	3p21.3 family of genes.,	22,	,	,	,	,	,	Oncology,	,	Lung cancer,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	INGN 007,	Preclinical,	Replication Competent Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Solid Tumors,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2006,	INGN 402 nanoparticle formulation (p53),	Preclinical,	Nanoparticle Systemic Delivery Platform,	22,	,	,	,	,	,	Oncology,	,	Various Cancers,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	ADVEXIN® Gene Therapy ,	Phase III,	INTROGEN ENABLING TECHNOLOGIES,	22,	2,	,	,	,	,	Oncology,	,	 Head & Neck ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Non-Small Cell Lung,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Prostate  ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	3,	,	,	,	,	Oncology,	,	Bladder ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Breast,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Ovarian ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Perioperative (and surgery),	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	40,	,	,	,	,	Oncology,	,	Brain (glioblastoma),	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	INGN 225 ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Small Cell Lung,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	INGN 225 ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Breast,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	INGN 234 (p53 topical),	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Oral Cancer Prevention,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	INGN 241,	Phase II,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Solid Tumors,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	INGN 241,	Preclinical,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Pancreatic,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	INGN 241,	Phase II,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Melanoma,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	INGN 241,	Phase III,	Nanoscale Viral Delivery Systems,	22,	2,	,	,	,	,	Oncology,	,	Head and Neck,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	INGN 401,	Phase I,	3p21.3 family of genes.,	22,	,	,	,	,	,	Oncology,	,	Lung cancer,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	INGN 007,	Preclinical,	Replication Competent Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Solid Tumors,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	INGN 402 nanoparticle formulation (p53),	Preclinical,	Nanoparticle Systemic Delivery Platform,	22,	,	,	,	,	,	Oncology,	,	Various Cancers,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2007,	INGN 225,,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	,	,	,	,	,	,	,	,	,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	ADVEXIN® Gene Therapy ,	Phase III,	INTROGEN ENABLING TECHNOLOGIES,	22,	2,	,	,	,	,	Oncology,	,	 Head & Neck ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Non-Small Cell Lung,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Prostate  ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	3,	,	,	,	,	Oncology,	,	Bladder ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Breast,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	  Ovarian ,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	ADVEXIN® Gene Therapy ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Perioperative (and surgery),	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	ADVEXIN® Gene Therapy ,	Phase I,	INTROGEN ENABLING TECHNOLOGIES,	22,	40,	,	,	,	,	Oncology,	,	Brain (glioblastoma),	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	INGN 225 ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Small Cell Lung,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	INGN 225 ,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Breast,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	INGN 234 (p53 topical),	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Oral Cancer Prevention,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	INGN 241,	Phase II,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Solid Tumors,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	INGN 241,	Preclinical,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Pancreatic,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	INGN 241,	Phase II,	Nanoscale Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Melanoma,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	INGN 241,	Phase III,	Nanoscale Viral Delivery Systems,	22,	2,	,	,	,	,	Oncology,	,	Head and Neck,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	INGN 401,	Phase I,	3p21.3 family of genes.,	22,	,	,	,	,	,	Oncology,	,	Lung cancer,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	INGN 007,	Preclinical,	Replication Competent Viral Delivery Systems,	22,	,	,	,	,	,	Oncology,	,	Solid Tumors,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	INGN 402 nanoparticle formulation (p53),	Preclinical,	Nanoparticle Systemic Delivery Platform,	22,	,	,	,	,	,	Oncology,	,	Various Cancers,	,	,
wvcs20000001018710,	INTROGEN THERAPEUTICS INC ,	10-K,	2000,	2008,	INGN 225,,	Phase II,	INTROGEN ENABLING TECHNOLOGIES,	22,	,	,	,	,	,	Oncology,	,	Various Cancers,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	S-1,	2000,	2000,	GENEWARE Technology ,	Research,	GENEWARE Technology ,	,	,	,	,	2005,	0.6667,	Therapuetics,	,	Manufacturing therapeutic proteins,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	S-1,	2000,	2000,	GENEWARE Technology ,	Research,	GENEWARE Technology ,	30,	,	,	,	,	,	Therapuetics,	,	Identifying the function of plant genes,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	S-1,	2000,	2000,	GENEWARE Technology ,	Research,	GENEWARE Technology ,	30,	,	,	,	,	,	Therapuetics,	,	Identifying the function of human genes,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	S-1,	2000,	2000,	ProGEx System,	Research,	ProGEx System ,	,	,	,	,	2002,	4.3333,	Therapuetics,	,	drug targets and diagnostics,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	S-1,	2000,	2000,	ProGEx System,	Research,	ProGEx System ,	,	,	,	,	,	,	Therapuetics,	,	proteomics databases,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	S-1,	2000,	2000,	ProGEx System,	Research,	ProGEx System ,	70,	,	,	,	,	,	Therapuetics,	,	Monitoring and predicting specific drug effects,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	S-1,	2000,	2000,	ProGEx System,	Research,	ProGEx System ,	,	,	,	,	,	,	Therapuetics,	,	Toxicology,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	424B,	2000,	2000,	GENEWARE Technology ,	Research,	GENEWARE Technology ,	,	,	,	,	2005,	0.6667,	Therapuetics,	,	Manufacturing therapeutic proteins,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	424B,	2000,	2000,	GENEWARE Technology ,	Research,	GENEWARE Technology ,	30,	,	,	,	,	,	Therapuetics,	,	Identifying the function of plant genes,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	424B,	2000,	2000,	GENEWARE Technology ,	Research,	GENEWARE Technology ,	30,	,	,	,	,	,	Therapuetics,	,	Identifying the function of human genes,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	424B,	2000,	2000,	ProGEx System,	Research,	ProGEx System ,	,	,	,	,	2002,	4.3333,	Therapuetics,	,	drug targets and diagnostics,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	424B,	2000,	2000,	ProGEx System,	Research,	ProGEx System ,	,	,	,	,	,	,	Therapuetics,	,	proteomics databases,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	424B,	2000,	2000,	ProGEx System,	Research,	ProGEx System ,	70,	,	,	,	,	,	Therapuetics,	,	Monitoring and predicting specific drug effects,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	424B,	2000,	2000,	ProGEx System,	Research,	ProGEx System ,	,	,	,	,	,	,	Therapuetics,	,	Toxicology,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2001,	Marker Proteins ,	Research,	ProGEx System ,	,	,	,	,	2005,	-0.375,	Therapuetics Production,	,	drug targets and diagnostics,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2001,	Human Protein Index, or HPI, databas,	Research,	ProGEx System ,	,	,	,	,	,	,	Therapuetics Production,	,	proteomics databases,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2001,	Protein Chips,	Research,	ProGEx System ,	70,	,	,	,	2003,	-0.375,	Therapuetics Production,	,	Monitoring and predicting specific drug effects,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2001,	Molecular Anatomy and Pathology, or MAP, database,	Research,	ProGEx System ,	,	,	,	,	,	,	Therapuetics Production,	,	Protein Analysis,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2001,	Molecular Effects of Drugs, or MED, database,	Research,	ProGEx System ,	,	,	,	,	,	,	Therapuetics Production,	,	Protein Analysis,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2001,	GENEWARE Technology ,	FDA Pending,	GENEWARE Technology ,	,	,	,	,	2005,	0.6667,	Therapuetics,	,	Manufacturing therapeutic proteins,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2001,	GENEWARE Technology ,	Research,	GENEWARE Technology ,	30,	,	,	,	,	,	Therapuetics,	,	Identifying the function of plant genes,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2001,	GENEWARE Technology ,	Research,	GENEWARE Technology ,	30,	,	,	,	,	,	Therapuetics,	,	Identifying the function of human genes,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2002,	NHL vaccines,	Phase I,	GENEWARE Technology ,	27,	,	,	,	,	,	Therapuetics,	,	non-Hodgkin’s lymphoma,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2002,	PLURIGEN CM,	Preclinical,	GENEWARE Technology ,	,	,	,	,	2005,	-1,	Therapuetics,	,	Endothelial Cell-Derived Growth Factor. ,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2002,	Rapid and Cost-Effective Protein and Vaccine Manufacturing.,	FDA Pending,	GENEWARE Technology ,	,	,	,	GENEWARE Technology ,	2005,	0.6667,	Therapuetics,	,	Manufacturing therapeutic proteins,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2002,	Protein BioChips,	Research,	ProGEx System ,	70,	,	,	GENEWARE Technology ,	2004,	6.6667,	Therapuetics Production,	,	Monitoring and predicting specific drug effects,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2002,	Marker Proteins ,	Marketed,	ProGEx System ,	,	,	,	,	2005,	-0.375,	Therapuetics Production,	,	drug targets and diagnostics,	,	Research,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2002,	Plant Functional Genomics, Forestry and Agriculture,	Research,	GENEWARE Technology ,	30,	,	,	,	,	,	Plant Functional Genomics, Forestry and Agriculture,	Therapuetics,	Identifying the function of plant genes,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2003,	Alpha-Galactosidase A.,	Preclinical,	GENEWARE system,	30,	,	,	,	,	,	Genetic Disorders,	,	 Fabry disease,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2003,	Aprotinin,	Preclinical,	GENEWARE Technology ,	,	,	,	,	,	,	Surgery ,	,	systemic inflammatory response,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2003,	NHL vaccines,	Phase I,	GENEWARE Technology ,	27,	,	,	,	,	,	Therapuetics,	,	non-Hodgkin’s lymphoma,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2003,	PLURIGEN CM,	Preclinical,	GENEWARE Technology ,	,	,	,	,	2005,	-1,	Therapuetics,	,	Endothelial Cell-Derived Growth Factor. ,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2003,	Rapid and Cost-Effective Protein and Vaccine Manufacturing.,	Marketed,	GENEWARE Technology ,	,	,	,	,	2005,	4,	Therapuetics,	,	Manufacturing therapeutic proteins,	,	FDA Pending,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2003,	Marker Proteins ,	Marketed,	GENEWARE Technology ,	,	,	,	,	2005,	4,	Therapuetics Production,	,	drug targets and diagnostics,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2003,	Plant Functional Genomics, Forestry and Agriculture,	Research,	GENEWARE Technology ,	30,	,	,	,	,	,	Plant Functional Genomics, Forestry and Agriculture,	,	Identifying the function of plant genes,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2004,	Alpha-Galactosidase A.,	Preclinical,	GENEWARE system,	30,	,	,	,	,	,	Genetic Disorders,	,	 Fabry disease,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2004,	Aprotinin,	Preclinical,	GENEWARE Technology ,	,	,	,	,	,	,	Surgery ,	,	systemic inflammatory response,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2004,	NHL vaccines,	Phase I,	GENEWARE Technology ,	27,	,	,	,	,	,	Therapuetics,	,	non-Hodgkin’s lymphoma,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2004,	Human lysosomal acid lipase,	Preclinical,	GENEWARE Technology ,	24,	,	,	,	,	,	lipid metabolism,	,	Wolman disease and cholesterol ester storage disorder,,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2004,	BAMF Diagnostics,	Marketed,	BAMF Diagnostics,	22,	,	,	,	,	,	Oncology,	,	ovarian cancer,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2004,	GRAMMR Gene Shuffling—,	Marketed,	GRAMMR Gene Shuffling,	30,	70,	,	,	,	,	Protein Manufacturing/Research,	,	gene expression to protein manufacturing,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2005,	Alpha-Galactosidase A.,	IND,	GENEWARE system,	30,	,	,	,	,	,	Genetic Disorders,	,	 Fabry disease,	,	Preclinical,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2005,	Aprotinin,	Marketed,	GENEWARE Technology ,	,	,	,	,	,	,	Surgery ,	,	systemic inflammatory response,	,	Preclinical,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2005,	NHL vaccines,	Phase I,	GENEWARE Technology ,	27,	,	,	,	,	,	Therapuetics,	,	non-Hodgkin’s lymphoma,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2005,	Human lysosomal acid lipase,	Preclinical,	GENEWARE Technology ,	24,	,	,	,	,	,	lipid metabolism,	Cardiovascular,	Wolman disease and cholesterol ester storage disorder,,	heart disease,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2005,	BAMF Diagnostics,	Marketed,	BAMF Diagnostics,	22,	,	,	,	,	,	Oncology,	,	ovarian cancer,	,	,
wvcs20000001108951,	LARGE SCALE BIOLOGY CORP,	10-K,	2000,	2005,	GRAMMR Gene Shuffling—,	Marketed,	GRAMMR Gene Shuffling,	30,	70,	,	,	,	,	Protein Manufacturing/Research,	,	gene expression to protein manufacturing,	,	,
wvcs20000001113481,	MEDICINES CO,	S-1,	2000,	2000,	Angiomax,	 NDA,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular Surgery,	,	Angioplasty,	,	,
wvcs20000001113481,	MEDICINES CO,	S-1,	2000,	2000,	Angiomax,	Phase II,	inhibits thrombin,	9,	21,	,	,	,	,	Cardiovascular,	,	Acute Myocardial Infarction,	,	,
wvcs20000001113481,	MEDICINES CO,	S-1,	2000,	2000,	Angiomax,	Phase II,	inhibits thrombin,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Unstable Angina,	,	,
wvcs20000001113481,	MEDICINES CO,	S-1,	2000,	2000,	Angiomax,	Phase I,	inhibits thrombin,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	HIT/HITTS,	,	,
wvcs20000001113481,	MEDICINES CO,	S-1,	2000,	2000,	Angiomax,	PreMarket,	inhibits thrombin,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Deep Venous Thrombosis,	,	,
wvcs20000001113481,	MEDICINES CO,	S-1,	2000,	2000,	CTV-05,	Phase II,	GyneLogix, Inc,	23,	70,	3,	,	2005,	-0.5556,	sexually transmitted diseases,	,	Bacterial Vaginosis,	,	,
wvcs20000001113481,	MEDICINES CO,	424B3,	2000,	2000,	Angiomax,	 NDA,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular Surgery,	,	Angioplasty,	,	,
wvcs20000001113481,	MEDICINES CO,	424B3,	2000,	2000,	Angiomax,	Phase II,	inhibits thrombin,	9,	21,	,	,	,	,	Cardiovascular,	,	Acute Myocardial Infarction,	,	,
wvcs20000001113481,	MEDICINES CO,	424B3,	2000,	2000,	Angiomax,	Phase II,	inhibits thrombin,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Unstable Angina,	,	,
wvcs20000001113481,	MEDICINES CO,	424B3,	2000,	2000,	Angiomax,	Phase I,	inhibits thrombin,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	HIT/HITTS,	,	,
wvcs20000001113481,	MEDICINES CO,	424B3,	2000,	2000,	Angiomax,	PreMarket,	inhibits thrombin,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Deep Venous Thrombosis,	,	,
wvcs20000001113481,	MEDICINES CO,	424B3,	2000,	2000,	CTV-05,	Phase II,	GyneLogix, Inc,	23,	70,	3,	,	2005,	-0.5556,	sexually transmitted diseases,	,	Bacterial Vaginosis,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2001,	Angiomax,	Phase IIIB,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular Surgery,	,	Angioplasty,	,	NDA,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2001,	Angiomax,	Phase III,	inhibits thrombin,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	HIT/HITTS,	,	Phase I,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2001,	Angiomax,	Phase II,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular Surgery,	,	CABG,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2001,	Angiomax,	Marketed,	inhibits thrombin,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Unstable Angina,	,	Phase II,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2001,	Angiomax,	Phase II,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular disease,	,	thrombosis in infants,	Deep Venous Thrombosis,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2001,	Angiomax,	Phase II,	inhibits thrombin,	9,	21,	,	,	,	,	Cardiovascular,	,	Acute Myocardial Infarction,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2001,	CTV-05,	Phase II,	GyneLogix, Inc,	23,	70,	3,	,	2005,	-0.5556,	sexually transmitted diseases,	,	Bacterial Vaginosis,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2001,	CLEVIDIPINE,	Phase III,	calcium channel inhibitors,	21,	,	,	,	,	,	Cardiovascular,	,	Blood pressure control,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2001,	IS-159,	N/a,	 Immunotech S.A. ,	21,	,	,	,	2005,	-1,	Cardiovascular,	,	Cardiovascular,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2003,	Angiomax,	mARKETED,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular Surgery,	,	Angioplasty,	,	Phase IIIB,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2003,	Angiomax,	Phase III,	inhibits thrombin,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	HIT/HITTS,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2003,	Angiomax,	Phase II,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular Surgery,	,	CABG,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2003,	Angiomax,	Marketed,	inhibits thrombin,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	Unstable Angina,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2003,	Angiomax,	Phase II,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular disease,	,	thrombosis in infants,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2003,	Angiomax,	Phase II,	inhibits thrombin,	9,	21,	,	,	,	,	Cardiovascular,	,	Acute Myocardial Infarction,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2003,	CTV-05,	Phase II,	GyneLogix, Inc,	23,	70,	3,	,	2005,	-0.9898,	sexually transmitted diseases,	,	Bacterial Vaginosis,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2003,	CLEVIDIPINE,	Phase III,	calcium channel inhibitors,	21,	,	,	,	,	,	Cardiovascular,	,	Blood pressure control,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2003,	IS-159,	N/a,	 Immunotech S.A. ,	21,	,	,	,	2005,	-1,	Cardiovascular,	,	Cardiovascular,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2004,	Angiomax,	mARKETED,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular Surgery,	,	Angioplasty,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2004,	Angiomax,	Phase II,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular Surgery,	,	CABG,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2004,	Angiomax,	Phase II,	inhibits thrombin,	9,	21,	,	,	,	,	Cardiovascular,	,	Acute Myocardial Infarction,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2004,	Angiomax,	Phase III,	inhibits thrombin,	9,	21,	,	,	,	,	Acute Coronary Syndrome,	,	HIT/HITTS,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2004,	Angiomax,	Phase II,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular disease,	,	thrombosis in infants,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2004,	Clevelox,	Phase III,	calcium channel inhibitors,	21,	,	,	CLEVIDIPINE,	,	,	Cardiovascular,	,	Blood pressure control,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2004,	cangrelor,	Preclinical,	AstraZeneca,	9,	21,	25,	,	,	,	Cardiovascular Surgery,	,	 platelet activation inhibition (Emergency Room/Surgery),	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2005,	Angiomax,	Marketed,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular Surgery,	,	arterial thrombosis CABG,	CABG,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2005,	Angiomax,	Phase III,	inhibits thrombin,	9,	21,	25,	,	,	,	Cardiovascular Surgery,	,	arterial thrombosis Emergency Room ,	Acute Myocardial Infarction,	Phase II,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2005,	Angiomax,	Phase II,	inhibits thrombin,	21,	70,	,	,	,	,	Cardiovascular Surgery,	,	arterial thrombosis cardiac catheterization laboratory,	Angioplasty,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2005,	Clevelox,	Phase III,	calcium channel inhibitors,	21,	,	,	,	,	,	Cardiovascular,	,	Blood pressure control,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2005,	cangrelor,	Phase II,	AstraZeneca,	9,	21,	25,	,	,	,	vascular disease,	,	 acute care setting of the cardiac catheterization laboratory. ,	 platelet activation inhibition (Emergency Room/Surgery),	Preclinical,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2006,	Angiomax,	Marketed,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular Surgery,	,	arterial thrombosis CABG,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2006,	Angiomax,	Phase III,	inhibits thrombin,	9,	21,	25,	,	,	,	Cardiovascular Surgery,	,	arterial thrombosis Emergency Room ,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2006,	Angiomax,	Phase II,	inhibits thrombin,	21,	70,	,	,	,	,	Cardiovascular Surgery,	,	arterial thrombosis cardiac catheterization laboratory,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2006,	Clevidipine,	Phase III,	calcium channel inhibitors,	21,	,	,	Clevelox,	,	,	Cardiovascular,	,	Blood pressure control,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2006,	cangrelor,	Phase III,	AstraZeneca,	9,	21,	25,	,	,	,	vascular disease,	,	 acute care setting of the cardiac catheterization laboratory. ,	,	Phase II,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2007,	Angiomax,	Marketed,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular Surgery,	,	anticoagulant in patients undergoing PCI,	arterial thrombosis CABG,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2007,	Cleviprex™ ,	Phase III,	calcium channel inhibitors,	21,	,	,	Clevidipine,	,	,	Cardiovascular,	,	Blood pressure control,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2007,	cangrelor,	Phase III,	AstraZeneca,	9,	21,	25,	,	,	,	vascular disease,	,	 acute care setting of the cardiac catheterization laboratory. ,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2008,	Angiomax,	Marketed,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular Surgery,	,	anticoagulant in patients undergoing PCI,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2008,	Cleviprex™ ,	Phase III,	calcium channel inhibitors,	21,	,	,	,	,	,	Cardiovascular,	,	Blood pressure control,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2008,	cangrelor,	Phase III,	AstraZeneca,	9,	21,	25,	,	,	,	vascular disease,	,	 acute care setting of the cardiac catheterization laboratory. ,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2009,	Angiomax,	Marketed,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular Surgery,	,	anticoagulant in patients undergoing PCI,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2009,	Cleviprex™ ,	Phase III,	calcium channel inhibitors,	21,	,	,	,	,	,	Cardiovascular,	,	Blood pressure control,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2009,	cangrelor,	Phase III,	AstraZeneca,	9,	21,	25,	,	,	,	vascular disease,	,	 acute care setting of the cardiac catheterization laboratory. ,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2009,	oritavancin,	Phase III,	 novel semi-synthetic lipoglycopeptide ,	23,	,	,	,	,	,	Infectious Diseases,	,	gram-positive bacterial infections,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2009,	 CU-2010,,	Preclinical,	 small molecule serine protease inhibitor,	,	,	,	,	,	,	Surgery ,	,	 blood loss,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2010,	Angiomax,	Marketed,	inhibits thrombin,	21,	,	,	,	,	,	Cardiovascular Surgery,	,	anticoagulant in patients undergoing PCI,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2010,	Cleviprex™ ,	Marketed,	calcium channel inhibitors,	21,	,	,	,	,	,	Cardiovascular,	,	Blood pressure control,	,	Phase III,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2010,	cangrelor,	Phase III,	AstraZeneca,	9,	21,	25,	,	,	,	vascular disease,	,	 acute care setting of the cardiac catheterization laboratory. ,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2010,	oritavancin,	Phase III,	 novel semi-synthetic lipoglycopeptide ,	23,	,	,	,	,	,	Infectious Diseases,	,	gram-positive bacterial infections,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2010,	 CU-2010,,	Phase I,	 small molecule serine protease inhibitor,	,	,	,	,	,	,	Surgery ,	,	 blood loss,	,	Preclinical,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2010,	ApoA-I Milano,	Phase I,	Naturally occurring variant of a protein found in HDL,	21,	,	,	,	,	,	Cardiovascular Diseases,	,	ACS,	,	,
wvcs20000001113481,	MEDICINES CO,	10-K,	2000,	2010,	Argatroban,	Phase III,	Direct thrombin inhibitor,	21,	,	,	,	,	,	vascular disease,	,	thrombosis in patients with or at risk for HIT,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	S-1,	1999,	1999,	Minocycline Periodontal Therapeutic System. MPTS,	Phase III,	American Home Products, or AHP,	2,	,	,	,	,	,	oral diseases and disorders,	,	 adult periodontitis,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	S-1,	1999,	1999,	OC-1012,	Preclinical,	protein osteopontin,	2,	,	,	,	,	,	oral diseases and disorders,	,	Oral Mucositis,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	S-1,	1999,	1999,	OC-1016,	Preclinical,	Brigham and Women's Hospital of Boston,	20,	2,	,	,	,	,	oral diseases and disorders,	,	dental implants and bone augmentation,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	S-1,	1999,	1999,	Minocycline Periodontal Therapeutic System. MPTS,	Preclinical,	American Home Products, or AHP,	25,	2,	,	,	,	,	oral diseases and disorders,	,	Traumatic Tooth Injury,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	424B,	1999,	2000,	Minocycline Periodontal Therapeutic System. MPTS,	Phase III,	American Home Products, or AHP,	2,	,	,	,	,	,	oral diseases and disorders,	,	 adult periodontitis,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	424B,	1999,	2000,	OC-1012,	Preclinical,	protein osteopontin,	2,	,	,	,	,	,	oral diseases and disorders,	,	Oral Mucositis,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	424B,	1999,	2000,	OC-1016,	Preclinical,	Brigham and Women's Hospital of Boston,	20,	2,	,	,	,	,	oral diseases and disorders,	,	dental implants and bone augmentation,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	424B,	1999,	2000,	Minocycline Periodontal Therapeutic System. MPTS,	Preclinical,	American Home Products, or AHP,	25,	2,	,	,	,	,	oral diseases and disorders,	,	Traumatic Tooth Injury,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	10-K,	1999,	2001,	Arestin(TM),	Marketed ,	American Home Products, or AHP,	2,	,	,	Minocycline Periodontal Therapeutic System. MPTS,	,	,	oral diseases and disorders,	,	 adult periodontitis,	,	Phase III,
wvcs20000001028065,	ORAPHARMA INC ,	10-K,	1999,	2001,	OC-1012,	Preclinical,	protein osteopontin,	2,	,	,	,	,	,	oral diseases and disorders,	,	Oral Mucositis,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	10-K,	1999,	2001,	OC-1016,	Preclinical,	Brigham and Women's Hospital of Boston,	20,	2,	,	,	,	,	oral diseases and disorders,	,	dental implants and bone augmentation,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	10-K,	1999,	2001,	Minocycline Periodontal Therapeutic System. MPTS,	Preclinical,	American Home Products, or AHP,	25,	2,	,	,	,	,	oral diseases and disorders,	,	Traumatic Tooth Injury,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	10-K,	1999,	2002,	Arestin(TM),	Marketed ,	American Home Products, or AHP,	2,	,	,	,	,	,	oral diseases and disorders,	,	 adult periodontitis,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	10-K,	1999,	2002,	OC-1012,	Phase I,	protein osteopontin,	2,	,	,	,	,	,	oral diseases and disorders,	,	Oral Mucositis,	,	Preclinical,
wvcs20000001028065,	ORAPHARMA INC ,	10-K,	1999,	2002,	OC-1016,	Preclinical,	Brigham and Women's Hospital of Boston,	20,	2,	,	,	,	,	oral diseases and disorders,	,	dental implants and bone augmentation,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	10-K,	1999,	2002,	Drug Delivery System for Large and Small Molecule Drugs,	Research,	N/a,	22,	,	,	,	,	,	Oncology,	,	Oncology,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	10-K,	1999,	2002,	Drug Delivery System for Large and Small Molecule Drugs,	Research,	N/a,	42,	,	,	,	,	,	CNS,	,	CNS,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	10-K,	1999,	2002,	Drug Delivery System for Large and Small Molecule Drugs,	Research,	N/a,	62,	9,	,	,	,	,	Pain Management,	,	Pain Management,	,	,
wvcs20000001028065,	ORAPHARMA INC ,	10-K,	1999,	2002,	Minocycline Periodontal Therapeutic System. MPTS,	Preclinical,	American Home Products, or AHP,	25,	2,	,	,	,	,	oral diseases and disorders,	,	Traumatic Tooth Injury,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	S-1,	2000,	2000,	NATURA,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	S-1,	2000,	2000,	CONFORMA,	Marketed,	 patented digital signal processing,	2,	,	,	,	2005,	1.5,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	424B4,	2000,	2000,	NATURA,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	424B4,	2000,	2000,	CONFORMA,	Marketed,	 patented digital signal processing,	2,	,	,	,	2005,	1.5,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2001,	NATURA,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2001,	CONFORMA,	Marketed,	 patented digital signal processing,	2,	,	,	,	2005,	1.5,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2001,	ALTAIR(TM),	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2002,	NATURA,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2002,	TributeTM,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2002,	ALTAIR(TM),	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2002,	QuartetTM ,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2002,	CONFORMA,	Marketed,	 patented digital signal processing,	2,	,	,	,	2005,	1.5,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2002,	Adesso,	Marketed,	 patented digital signal processing,	2,	,	,	,	2005,	0,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2003,	NATURA,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2003,	TributeTM,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2003,	ALTAIR(TM),	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2003,	QuartetTM ,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2003,	CONFORMA,	Marketed,	 patented digital signal processing,	2,	,	,	,	2005,	0.25,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2003,	Adesso,	Marketed,	 patented digital signal processing,	2,	,	,	,	2005,	0,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2004,	NATURA,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2004,	TributeTM,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2004,	ALTAIR(TM),	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2004,	QuartetTM ,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2005,	NATURA,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2005,	TributeTM,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2005,	ALTAIR(TM),	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2005,	QuartetTM ,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2006,	 Innova,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2006,	Applause,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2006,	NATURA,	Marketed,	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2006,	TributeTM,	Marketed,	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2006,	QuartetTM ,	Marketed,	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2006,	Otogram,	Marketed,	 patented digital signal processing,	20,	2,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2007,	 Innova,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2007,	Applause,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2007,	NATURA,	Marketed,	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2007,	TributeTM,	Marketed,	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2007,	QuartetTM ,	Marketed,	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2007,	, Balance,,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2007,	Ion,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2008,	 Innova,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2008,	Applause,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2008,	NATURA,	Marketed,	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2008,	TributeTM,	Marketed,	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2008,	QuartetTM ,	Marketed,	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2008,	, Balance,,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2008,	Ion,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2008,	Velocity,	Marketed,	DIRECTIONALfocus® technology,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2009,	 Innova,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2009,	Applause,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2009,	NATURA,	Marketed,	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2009,	TributeTM,	Marketed,	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2009,	QuartetTM ,	Marketed,	 patented digital signal processing/Personalized Noise Reduction technology and Directionalplus system,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2009,	, Balance,,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2009,	Ion,	Marketed,	 patented digital signal processing,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2009,	Velocity,	Marketed,	DIRECTIONALfocus® technology,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001105982,	OTIX GLOBAL, INC.,	10-K,	2000,	2009,	Touch,	Marketed,	DIRECTIONALfocus® technology,	2,	,	,	,	,	,	Hearing Impairment,	,	hearing aid,	,	,
wvcs20000001059790,	POZEN INC ,	S-1,	2000,	2000,	 MT 100,	Phase III,	metoclopramide hydrochloride,	61,	62,	,	,	2007,	-0.5864,	Migraine Market,	,	migraine,	,	,
wvcs20000001059790,	POZEN INC ,	S-1,	2000,	2000,	MT 300 ,	Phase III,	dihydroergotamine mesylate, or DHE,	61,	62,	,	,	2008,	0,	Migraine Market,	,	Migraine    Severe,	,	,
wvcs20000001059790,	POZEN INC ,	S-1,	2000,	2000,	MT 500,	Phase II,	locks a type of serotonin brain receptor,	61,	62,	,	,	2003,	-0.7073,	Migraine Market,	,	Migraine   Prophylaxis  ,	,	,
wvcs20000001059790,	POZEN INC ,	S-1,	2000,	2000,	MT 400,	Phaes II,	triptan drug with that of a commercially approved long-acting, non-steroidal,	61,	62,	,	,	,	,	Migraine Market,	,	 Migraine ,	,	,
wvcs20000001059790,	POZEN INC ,	424B4,	2000,	2000,	 MT 100,	Phase III,	metoclopramide hydrochloride,	61,	62,	,	,	2007,	-0.5864,	Migraine Market,	,	migraine,	,	,
wvcs20000001059790,	POZEN INC ,	424B4,	2000,	2000,	MT 300 ,	Phase III,	dihydroergotamine mesylate, or DHE,	61,	62,	,	,	2008,	0,	Migraine Market,	,	Migraine    Severe,	,	,
wvcs20000001059790,	POZEN INC ,	424B4,	2000,	2000,	MT 500,	Phase II,	locks a type of serotonin brain receptor,	61,	62,	,	,	2003,	-0.7073,	Migraine Market,	,	Migraine   Prophylaxis  ,	,	,
wvcs20000001059790,	POZEN INC ,	424B4,	2000,	2000,	MT 400,	Phaes II,	triptan drug with that of a commercially approved long-acting, non-steroidal,	61,	62,	,	,	,	,	Migraine Market,	,	 Migraine ,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2001,	 MT 100,	Phase III,	metoclopramide hydrochloride,	61,	62,	,	,	2007,	-0.5864,	Migraine Market,	,	migraine,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2001,	MT 300 ,	Phase III,	dihydroergotamine mesylate, or DHE,	61,	62,	,	,	2008,	0,	Migraine Market,	,	Migraine    Severe,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2001,	MT 500,	Phase II,	locks a type of serotonin brain receptor,	61,	62,	,	,	2003,	-0.75,	Migraine Market,	,	Migraine   Prophylaxis  ,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2001,	MT 400,	Phaes II,	triptan drug with that of a commercially approved long-acting, non-steroidal,	61,	62,	,	,	,	,	Migraine Market,	,	 Migraine ,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2002,	 MT 100,	Phase III,	metoclopramide hydrochloride,	61,	62,	,	,	2007,	-0.5864,	Migraine Market,	,	migraine,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2002,	MT 300 ,	Phase III,	dihydroergotamine mesylate, or DHE,	61,	62,	,	,	2008,	0,	Migraine Market,	,	Migraine    Severe,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2002,	MT 400,	Phaes II,	triptan drug with that of a commercially approved long-acting, non-steroidal,	61,	62,	,	,	,	,	Migraine Market,	,	 Migraine ,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2003,	 MT 100,	Phase III,	metoclopramide hydrochloride,	61,	62,	,	,	2007,	-0.5864,	Migraine Market,	,	migraine,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2003,	MT 300 ,	Phase III,	dihydroergotamine mesylate, or DHE,	61,	62,	,	,	2008,	0,	Migraine Market,	,	Migraine    Severe,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2003,	MT 400,	Phase III,	triptan drug with that of a commercially approved long-acting, non-steroidal,	61,	62,	,	,	,	,	Migraine Market,	,	 Migraine ,	,	Phase II,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2004,	 MT 100,	Phase IIIB,	metoclopramide hydrochloride,	61,	62,	,	,	2007,	-0.5864,	Migraine Market,	,	migraine,	,	Phase III,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2004,	MT 300 ,	NDA ,	dihydroergotamine mesylate, or DHE,	61,	62,	,	,	2008,	0,	Migraine Market,	,	Migraine    Severe,	,	Phase III,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2004,	MT 400,	Phase III,	triptan drug with that of a commercially approved long-acting, non-steroidal,	61,	62,	,	,	,	,	Migraine Market,	,	 Migraine ,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2005,	 MT 100,	NDA ,	metoclopramide hydrochloride,	61,	62,	,	,	2007,	-0.5563,	Migraine Market,	,	migraine,	,	Phase IIIB,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2005,	MT 300 ,	NDA ,	dihydroergotamine mesylate, or DHE,	61,	62,	,	,	2008,	0,	Migraine Market,	,	Migraine    Severe,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2005,	MT 400,	Phase III,	 MT 400 technology,	61,	62,	,	,	,	,	Migraine Market,	,	 Migraine ,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2005,	Trexima,	Phase III,	 MT 400 technology,	61,	62,	,	,	,	,	Migraine Market,	,	 Migraine ,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2005,	Lornoxicam Program,	Phase I,	 NSAID,	61,	62,	,	,	2010,	-0.8571,	Migraine Market,	,	 Migraine ,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2005,	PN (PPI / NSAID) Program,	Phase I,	 PPI with an NSAID ,	5,	,	,	,	,	,	Inflammation,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2006,	MT 300 ,	NDA ,	dihydroergotamine mesylate, or DHE,	61,	62,	,	,	2008,	-0.6444,	Migraine Market,	,	Migraine    Severe,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2006,	Trexima,	Phase III,	 MT 400 technology,	61,	62,	,	MT 400,	,	,	Migraine Market,	,	 Migraine ,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2006,	Lornoxicam Program,	Phase I,	 NSAID,	61,	62,	,	,	2010,	-0.8571,	Migraine Market,	,	 Migraine ,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2006,	PN (PPI / NSAID) Program,	Phase III,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	Inflammation,	 arthritis or other chronic inflammatory conditions.,	,	Phase I,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2007,	Trexima,	Phase III,	 MT 400 technology,	61,	62,	,	,	,	,	Migraine Market,	,	 Migraine ,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2007,	Lornoxicam Program,	Phase II,	 NSAID,	61,	62,	,	,	2010,	-0.8571,	Migraine Market,	,	 Migraine ,	,	Phase I,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2007,	PN 400,	Phase III,	 PPI with an NSAID ,	62,	,	,	PN (PPI / NSAID) Program,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2007,	PN 200,	Phase I,	 PPI with an NSAID ,	62,	,	,	PN (PPI / NSAID) Program,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2007,	PA 325,	Phase I,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2008,	Trexima,	Phase III,	 MT 400 technology,	61,	62,	,	,	,	,	Migraine Market,	,	 Migraine ,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2008,	Lornoxicam Program,	Phase II,	 NSAID,	61,	62,	,	,	2010,	-0.9934,	Migraine Market,	,	 Migraine ,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2008,	PN 400,	Phase III,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2008,	PN 200,	Phase III,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	Phase I,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2008,	PA32540,	Phase I,	 PPI with an NSAID ,	62,	,	,	PA 325,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2008,	PN 100,	Phase I,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2009,	Trexima,	Marketed,	 MT 400 technology,	61,	62,	,	,	,	,	Migraine Market,	,	 Migraine ,	,	Phase III,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2009,	PN 400,	Phase III,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2009,	PN 200,	Phase III,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2009,	PA32540,	Phase III,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	Phase I,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2009,	PN 100,	Phase I,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2010,	Trexima,	Marketed,	 MT 400 technology,	61,	62,	,	,	,	,	Migraine Market,	,	 Migraine ,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2010,	 VIMOVO,	Phase III,	 PPI with an NSAID ,	62,	,	,	PN 400,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2010,	PN 200,	Phase III,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2010,	PA32540,	Phase III,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2010,	PN 100,	Phase I,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2011,	Trexima,	Marketed,	 MT 400 technology,	61,	62,	,	,	,	,	Migraine Market,	,	 Migraine ,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2011,	 VIMOVO,	Marketed,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	Phase III,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2011,	PN 200,	Phase III,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2011,	PA32540,	Phase III,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001059790,	POZEN INC ,	10-K,	2000,	2011,	PN 100,	Phase I,	 PPI with an NSAID ,	62,	,	,	,	,	,	Pain Market,	,	 arthritis or other chronic inflammatory conditions.,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	S-1,	2000,	2000,	abarelix-depot-M,	Phase III,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	,	,	,	Oncology,	,	hormonally responsive prostate cancer,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	S-1,	2000,	2000,	abarelix-depot-F,	Phase II,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	,	,	,	,	,	Chronic Pain,	,	endometriosis,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	S-1,	2000,	2000,	Latranal,	Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	20,	,	,	2003,	-0.875,	Chronic Pain,	,	acute and chronic muscle and tendon related pain,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	S-1,	2000,	2000,	Apan,	Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	40,	,	,	,	,	,	brain disorder/ neurodegenerative disease,	,	Alzheimer's Disease,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	424b4,	2000,	2000,	abarelix-depot-M,	Phase III,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	,	,	,	Oncology,	,	hormonally responsive prostate cancer,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	424b4,	2000,	2000,	abarelix-depot-F,	Phase III,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	,	,	,	,	,	Chronic Pain,	,	endometriosis,	,	Phase II,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	424b4,	2000,	2000,	Latranal,	Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	20,	,	,	2003,	-0.875,	Chronic Pain,	,	acute and chronic muscle and tendon related pain,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	424b4,	2000,	2000,	Apan,	Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	40,	,	,	,	,	,	brain disorder/ neurodegenerative disease,	,	Alzheimer's Disease,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2001,	abarelix-depot-M,	Phase III,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	,	,	,	Oncology,	,	hormonally responsive prostate cancer,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2001,	abarelix-depot-F,	Phase III,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	,	,	,	,	,	Chronic Pain,	,	endometriosis,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2001,	abarelix-depot-M,	Phase III,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	,	,	,	Oncology,	,	hormonally responsive prostate cancer,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2001,	abarelix-depot-F,	Phase III,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	,	,	,	,	,	Chronic Pain,	,	endometriosis,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2001,	Latranal,	Phase II,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	20,	,	,	,	,	Chronic Pain,	,	acute and chronic muscle and tendon related pain,	,	Preclinical,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2001,	Apan,	Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	40,	,	,	,	,	,	brain disorder/ neurodegenerative disease,	,	Alzheimer's Disease,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2001,	CCR5 Antagonist,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	23,	,	,	,	,	,	Infectious Diseases,	,	AIDS,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2001,	PPI 3088  ,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	5,	20,	,	,	,	,	Inflammation,	,	Inflammation,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2001,	Androgen ReceptorHormone-Independent Antagonist,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	,	,	,	Oncology,	,	Hormone Independent Prostate Cancer,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2001,	Endometriosis Diagnostic,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	70,	,	,	,	,	Chronic Pain,	,	endometriosis,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2002,	Plenaxis  ,	NDA ,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	abarelix-depot-M,	,	,	Oncology,	,	hormonally responsive prostate cancer,	,	Phase III,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2002,	Plenaxis  ,	Phase III,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	,	,	abarelix-depot-F,	,	,	Chronic Pain,	,	endometriosis,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2002,	Plenaxis  ,	Phase III,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	abarelix-depot-M,	,	,	Oncology,	,	hormonally responsive prostate cancer,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2002,	Plenaxis  ,	Phase III,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	,	,	abarelix-depot-F,	,	,	Chronic Pain,	,	endometriosis,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2002,	Apan,	Phase I,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	40,	,	,	,	,	,	brain disorder/ neurodegenerative disease,	,	Alzheimer's Disease,	,	Preclinical,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2002,	CCR5 Antagonist,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	23,	,	,	,	,	,	Infectious Diseases,	,	AIDS,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2002,	PPI 3088  ,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	20,	,	,	,	,	Oncology,	,	Cancer,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2002,	PPI 3088  ,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	5,	20,	,	,	,	,	Inflammation,	,	Rheumatoid Arthritis,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2002,	Androgen ReceptorHormone-Independent Antagonist,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	,	,	,	Oncology,	,	Hormone Independent Prostate Cancer,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2002,	Endometriosis Diagnostic,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	70,	,	,	,	,	Chronic Pain,	,	endometriosis,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2003,	Plenaxis  ,	NDA ,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	,	,	,	Oncology,	,	hormonally responsive prostate cancer,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2003,	Plenaxis  ,	Phase II,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	,	,	,	,	,	Chronic Pain,	,	endometriosis,	,	Phase III,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2003,	Plenaxis  ,	NDA ,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	,	,	,	Oncology,	,	hormonally responsive prostate cancer,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2003,	Plenaxis  ,	Phase II,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	,	,	,	,	,	Chronic Pain,	,	endometriosis,	,	Phase III,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2003,	Apan,	Phase I,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	40,	,	,	,	,	,	brain disorder/ neurodegenerative disease,	,	Alzheimer's Disease,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2003,	Antiviral Antagonist,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	23,	,	,	CCR5 Antagonist,	,	,	Infectious Diseases,	,	AIDS,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2003,	PPI-2458,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	27,	,	PPI 3088  ,	,	,	Oncology,	,	B-Cell Non-Hodgkin's Lymphoma,	Cancer,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2003,	PPI-2458,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	5,	27,	20,	PPI 3088  ,	,	,	Inflammation,	,	Rheumatoid Arthritis,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2003,	Androgen ReceptorHormone-Independent Antagonist,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	,	,	,	Oncology,	,	Hormone Independent Prostate Cancer,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2003,	Endometriosis Diagnostic,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	70,	,	,	,	,	Chronic Pain,	,	endometriosis,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2004,	Plenaxis  ,	NDA ,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	,	,	,	Oncology,	,	hormonally responsive prostate cancer,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2004,	Plenaxis  ,	Phase II,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	,	,	,	,	,	Chronic Pain,	,	endometriosis,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2004,	Plenaxis  ,	NDA ,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	,	,	,	Oncology,	,	hormonally responsive prostate cancer,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2004,	Plenaxis  ,	Phase II,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	,	,	,	,	,	Chronic Pain,	,	endometriosis,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2004,	Apan,	Phase I,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	40,	,	,	,	,	,	brain disorder/ neurodegenerative disease,	,	Alzheimer's Disease,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2004,	Antiviral Antagonist,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	23,	,	,	,	,	,	Infectious Diseases,	,	AIDS,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2004,	PPI-2458,	Phase I,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	27,	,	,	,	,	Oncology,	,	B-Cell Non-Hodgkin's Lymphoma,	,	Research/Preclinical,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2004,	PPI-2458,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	5,	27,	20,	,	,	,	Inflammation,	,	Rheumatoid Arthritis,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2004,	Androgen ReceptorHormone-Independent Antagonist,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	,	,	,	Oncology,	,	Hormone Independent Prostate Cancer,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2004,	Endometriosis Diagnostic,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	62,	70,	,	,	,	,	Chronic Pain,	,	endometriosis,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2005,	Plenaxis  ,	Approved,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	,	,	,	Oncology,	,	hormonally responsive prostate cancer,	,	NDA,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2005,	Plenaxis  ,	Approved,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	,	,	,	Oncology,	,	hormonally responsive prostate cancer,	,	NDA,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2005,	Apan,	Phase I,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	40,	,	,	,	,	,	brain disorder/ neurodegenerative disease,	,	Alzheimer's Disease,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2005,	PPI-2458,	Phase I,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	27,	,	,	,	,	Oncology,	,	B-Cell Non-Hodgkin's Lymphoma,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2005,	PPI-2458,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	5,	27,	20,	,	,	,	Inflammation,	,	Rheumatoid Arthritis,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2005,	Plenaxis,	Phase I,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	,	,	Androgen ReceptorHormone-Independent Antagonist,	,	,	Oncology,	,	Hormone Independent Prostate Cancer,	,	Research/Preclinical,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2006,	PPI-2458,	Phase I,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	22,	27,	,	,	,	,	Oncology,	,	B-Cell Non-Hodgkin's Lymphoma,	,	,
wvcs20000001033025,	PRAECIS PHARMACEUTICALS INC,	10K,	2000,	2006,	PPI-2458,	Research/Preclinical,	Ligand Evolution to Active Pharmaceuticals, or LEAP.,	5,	27,	20,	,	,	,	Inflammation,	,	Rheumatoid Arthritis,	,	,
wvcs20000001099414,	TANOX INC,	S-1,	2000,	2000,	 E25,	Phase III,	monoclonal antibody,	5,	29,	,	,	,	,	Immunology,	,	allergic asthma,	,	,
wvcs20000001099414,	TANOX INC,	S-1,	2000,	2000,	 E25,	Phase III,	monoclonal antibody,	5,	29,	,	,	,	,	Immunology,	,	allergic rhinitis,	,	,
wvcs20000001099414,	TANOX INC,	S-1,	2000,	2000,	HU-901,	Phase II,	monoclonal antibody,	5,	,	,	,	,	,	Immunology,	,	allergic reactions to peanuts,	,	,
wvcs20000001099414,	TANOX INC,	S-1,	2000,	2000,	5D12,	Phase II,	monoclonal antibody,	5,	,	,	,	2005,	0,	Autoimmune Diseases,	,	Crohn's disease,	,	,
wvcs20000001099414,	TANOX INC,	S-1,	2000,	2000,	 5A8 ,	Preclinical,	monoclonal antibody,	23,	,	,	,	,	,	Infectious Diseases,	,	HIV,	,	,
wvcs20000001099414,	TANOX INC,	S-1,	2000,	2000,	166-32 ,	Research,	monoclonal antibody,	5,	9,	,	,	2005,	-1,	Inflammation,	,	acute inflammation.,	,	,
wvcs20000001099414,	TANOX INC,	S-1,	2000,	2000,	163-93,	Research,	monoclonal antibody,	23,	,	,	,	2003,	-1,	Infectious Diseases,	,	neutropenia,	,	,
wvcs20000001099414,	TANOX INC,	424B4,	2000,	2000,	 E25,	Phase III,	monoclonal antibody,	5,	29,	,	,	,	,	Immunology,	,	allergic asthma,	,	,
wvcs20000001099414,	TANOX INC,	424B4,	2000,	2000,	 E25,	Phase III,	monoclonal antibody,	5,	29,	,	,	,	,	Immunology,	,	allergic rhinitis,	,	,
wvcs20000001099414,	TANOX INC,	424B4,	2000,	2000,	HU-901,	Phase II,	monoclonal antibody,	5,	,	,	,	,	,	Immunology,	,	allergic reactions to peanuts,	,	,
wvcs20000001099414,	TANOX INC,	424B4,	2000,	2000,	5D12,	Phase II,	monoclonal antibody,	5,	,	,	,	2005,	0,	Autoimmune Diseases,	,	Crohn's disease,	,	,
wvcs20000001099414,	TANOX INC,	424B4,	2000,	2000,	 5A8 ,	Preclinical,	monoclonal antibody,	23,	,	,	,	,	,	Infectious Diseases,	,	HIV,	,	,
wvcs20000001099414,	TANOX INC,	424B4,	2000,	2000,	166-32 ,	Research,	monoclonal antibody,	5,	9,	,	,	2005,	-1,	Inflammation,	,	acute inflammation.,	,	,
wvcs20000001099414,	TANOX INC,	424B4,	2000,	2000,	163-93,	Research,	monoclonal antibody,	23,	,	,	,	2003,	-1,	Infectious Diseases,	,	neutropenia,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2001,	Xolair,	Bilogics License Application (BLA),	monoclonal antibody,	5,	29,	,	 E25,	,	,	Immunology,	,	allergic asthma,	,	Phase III,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2001,	Xolair,	Bilogics License Application (BLA),	monoclonal antibody,	5,	29,	,	 E25,	,	,	Immunology,	,	allergic rhinitis,	,	Phase III,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2001,	HU-901,	Phase II,	monoclonal antibody,	5,	,	,	,	,	,	Immunology,	,	allergic reactions to peanuts,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2001,	5D12,	Phase II,	monoclonal antibody,	5,	,	,	,	,	,	Autoimmune Diseases,	,	Crohn's disease,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2001,	 5A8 ,	Preclinical,	monoclonal antibody,	23,	,	,	,	,	,	Infectious Diseases,	,	HIV,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2001,	166-32 ,	Preclinical,	monoclonal antibody,	5,	9,	,	,	,	,	Inflammation,	,	acute inflammation.,	,	Research,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2001,	163-93,	Research,	monoclonal antibody,	23,	,	,	,	,	,	Infectious Diseases,	,	neutropenia,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2002,	Xolair,	Bilogics License Application (BLA),	monoclonal antibody,	5,	29,	,	,	,	,	Immunology,	,	allergic asthma,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2002,	Xolair,	Phase III,	monoclonal antibody,	5,	29,	,	,	,	,	Immunology,	,	allergic rhinitis,	,	Bilogics License Application (BLA),
wvcs20000001099414,	TANOX INC,	10K,	2000,	2002,	TNX-901,	Phase II,	monoclonal antibody,	5,	,	,	HU-901,	,	,	Immunology,	,	allergic reactions to peanuts,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2002,	TNX-100,	Phase II,	monoclonal antibody,	5,	,	,	5D12,	,	,	Autoimmune Diseases,	,	Crohn's disease,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2002,	TNX-335 ,	Phase I,	monoclonal antibody,	23,	,	,	 5A8 ,	,	,	Infectious Diseases,	,	HIV,	,	Preclinical,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2002,	TNX-224 ,	Preclinical,	monoclonal antibody,	5,	9,	,	166-32 ,	,	,	Inflammation,	,	acute inflammation.,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2003,	Xolair,	Bilogics License Application (BLA),	monoclonal antibody,	5,	29,	,	,	,	,	Immunology,	,	allergic asthma,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2003,	Xolair,	Phase III,	monoclonal antibody,	5,	29,	,	,	,	,	Immunology,	,	allergic rhinitis,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2003,	TNX-901,	Phase II,	monoclonal antibody,	5,	,	,	,	,	,	Immunology,	,	allergic reactions to peanuts,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2003,	TNX-100,	Phase II,	monoclonal antibody,	5,	,	,	,	,	,	Autoimmune Diseases,	,	Crohn's disease,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2003,	TNX-335 ,	Phase IB,	monoclonal antibody,	23,	,	,	,	,	,	Infectious Diseases,	,	HIV,	,	phase I,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2003,	TNX-224 ,	Preclinical,	monoclonal antibody,	5,	9,	,	,	,	,	Inflammation,	,	acute inflammation.,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2004,	Xolair,	Marketed,	monoclonal antibody,	5,	29,	,	,	,	,	Immunology,	,	allergic asthma,	,	Bilogics License Application (BLA),
wvcs20000001099414,	TANOX INC,	10K,	2000,	2004,	Xolair,	Phase II,	monoclonal antibody,	5,	29,	,	TNX-901,	,	,	Immunology,	,	allergic reactions to peanuts,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2004,	TNX-355,	Phase II,	monoclonal antibody,	23,	70,	,	TNX-335 ,	,	,	Infectious Diseases,	,	HIV,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2004,	Allergic mediator,	Preclinical,	MADP,	8,	,	,	,	,	,	Skin Diseases,	,	Atopic dermatitis,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2004,	Complement Factor D,	Preclinical,	MADP,	5,	,	,	,	,	,	Inflammation,	,	Accute inflammatory disease,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2004,	Complement C5a,	Research,	MADP,	5,	,	,	,	,	,	Inflammation,	,	Inflammatory disease,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2004,	Osteoblast signaling pathway,	Research,	MADP,	20,	,	,	,	,	,	Bone Diseases,	,	Osteoporosis/bone fracture,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2005,	Xolair,	Marketed,	monoclonal antibody,	5,	29,	,	,	,	,	Immunology,	,	allergic asthma,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2005,	Xolair,	Phase II,	monoclonal antibody,	5,	29,	,	,	,	,	Immunology,	,	allergic reactions to peanuts,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2005,	TNX-355,	Phase II,	monoclonal antibody,	23,	70,	,	,	,	,	Infectious Diseases,	,	HIV,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2005,	TNX-650,	Preclinical,	monoclonal antibody,	5,	,	,	,	,	,	Inflammatory Diseases,	,	Inflammatory Diseases,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2005,	TNX-717,	Research,	monoclonal antibody,	20,	,	,	Osteoblast signaling pathway,	,	,	Bone Diseases,	,	Osteoporosis/bone fracture,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2005,	TNX-558,	Research,	monoclonal antibody,	5,	,	,	Complement C5a,	,	,	Inflammation,	,	Inflammatory disease,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2005,	TNX-668,	Research,	monoclonal antibody,	5,	,	,	,	,	,	Autoimmune Diseases,	,	Systemic Lupus Erythematosus,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2005,	TNX-336,	Research,	monoclonal antibody,	5,	,	,	,	,	,	Autoimmune Diseases,	,	Autoimmune Diseases,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2006,	Xolair,	Marketed,	monoclonal antibody,	5,	29,	,	,	,	,	Immunology,	,	allergic asthma,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2006,	TNX-355,	Phase II,	monoclonal antibody,	23,	70,	,	,	,	,	Infectious Diseases,	,	HIV,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2006,	TNX-832,	Phase II,	monoclonal antibody,	5,	9,	25,	,	,	,	Inflammatory Diseases,	,	acute lung injury (ALI) and acute respiratory distress syndrome (ARDS),	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2006,	TNX-650,	IND,	monoclonal antibody,	5,	27,	,	,	,	,	Inflammatory Diseases,	,	" 
Hodgkin’s Lymphoma,"	,	Preclinical,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2006,	TNX-650,	Preclinical,	monoclonal antibody,	5,	,	,	,	,	,	Inflammatory Diseases,	,	Inflammatory Diseases,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2006,	TNX-717,	Preclinical,	monoclonal antibody,	20,	,	,	,	,	,	Bone Diseases,	,	Osteoporosis/bone fracture,	,	Research,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2006,	TNX-833,	Preclinical,	monoclonal antibody,	22,	,	,	,	,	,	Oncology,	,	Cancer,	,	,
wvcs20000001099414,	TANOX INC,	10K,	2000,	2006,	TNX-234,	Preclinical,	monoclonal antibody,	1,	,	,	,	,	,	Eye-Diseases,	,	Age-Related Macular Degeneration,	,	,
wvcu20020001139665,	XCEL PHARMACEUTICALS INC,	S-1,	2003,	2003,	Diastat,	marketed,	rectally administered gel ,	9,	43,	,	,	,	,	CNS(neurology),	,	epilepsy,	,	,
wvcu20020001139665,	XCEL PHARMACEUTICALS INC,	S-1,	2003,	2003,	Mysoline,	marketed,	Oral tablets,	43,	,	,	,	,	,	CNS(neurology),	,	epilepsy,	,	,
wvcu20020001139665,	XCEL PHARMACEUTICALS INC,	S-1,	2003,	2003,	Migranal ,	marketed,	Nasal spray ,	40,	,	,	,	,	,	CNS(neurology),	,	 migraine,	,	,
wvcu20020001139665,	XCEL PHARMACEUTICALS INC,	S-1,	2003,	2003,	D.H.E. 45,	marketed,	Intravenous, intramuscular or subcutaneous injection ,	9,	25,	40,	,	,	,	CNS(neurology),	,	 migraine,	,	,
wvcu20040001286517,	CELLDEX THERAPEUTICS INC,	S-1,	2004,	2004,	HCG-VAC,	IND,	APC targeting technology ,	22,	,	,	,	,	,	Oncology,	,	Colorectal,	,	,
wvcu20040001286517,	CELLDEX THERAPEUTICS INC,	S-1,	2004,	2004,	HCG-VAC,	IND,	APC targeting technology ,	22,	,	,	,	,	,	Oncology,	,	Pancreatic,	,	,
wvcu20040001286517,	CELLDEX THERAPEUTICS INC,	S-1,	2004,	2004,	HCG-VAC,	IND,	APC targeting technology ,	22,	,	,	,	,	,	Oncology,	,	Breast Cancer,	,	,
wvcu20040001286517,	CELLDEX THERAPEUTICS INC,	S-1,	2004,	2004,	COL-VAC,	Preclinical,	APC targeting technology ,	22,	,	,	,	,	,	Oncology,	,	Colorectal Cancer,	,	,
wvcu20040001286517,	CELLDEX THERAPEUTICS INC,	S-1,	2004,	2004,	AFP-VAC,	Preclinical,	APC targeting technology ,	22,	28,	,	,	,	,	Oncology,	,	Liver Cancer,	,	,
wvcu20040001286517,	CELLDEX THERAPEUTICS INC,	S-1,	2004,	2004,	MEL-VAC,	Preclinical,	APC targeting technology ,	22,	,	,		,	,	Oncology		Melanoma		
wvcu20040001286517,	CELLDEX THERAPEUTICS INC,	S-1,	2004,	2004,	PSA-VAC,	Research,	APC targeting technology ,	22,	,	,		,	,	Oncology		Prostate Cancer		
wvcu20040001286517,	CELLDEX THERAPEUTICS INC,	S-1,	2004,	2004,	GVHD-TOX,	Research,	APC targeting technology ,	27,	20,	,		,	,	bone marrow transplants		GVHD		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	Carbopol[nc_cad,176],	Marketed,	,	,	,	,		,	,	Personal Care and Pharmaceuticals		Acrylic thickener which imparts stability and improves aesthetics. Used as a controlled release agent.		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	Pemulen[nc_cad,176],	Marketed,	,	,	,	,		,	,	Personal Care and Pharmaceuticals		Polymeric emulsifier reducing formulation irritancy and providing water resistance.		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	Avalure[nc_cad,176],	Marketed,	,	,	,	,		,	,	Personal Care and Pharmaceuticals		Polymers for color cosmetics.		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	Specialty silicones,	Marketed,	,	,	,	,		,	,	Personal Care and Pharmaceuticals		Polymers affecting "slip-and-feel."		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	Colorants,	Marketed,	,	,	,	,		,	,	Personal Care and Pharmaceuticals		Imparts color in personal care products.		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	Polycarbophil,	Marketed,	,	,	,	,		,	,	Personal Care and Pharmaceuticals		Active agent for bulk laxatives.		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	Benzoates,	Marketed,	,	,	,	,		,	,	Food and Beverage		Improves shelf life for certain consumable goods.		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	Colors,	Marketed,	,	,	,	,		,	,	Food and Beverage		Preservative for manufacturers of soft drinks, bottled beverages, fruit-based products and prepared salads.		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	Flavors and Fragrances,	Marketed,	,	,	,	,		,	,	Food and Beverage		Food, personal care and soap products.		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	TempRite[nc_cad,176],	Marketed,	CPVC,	,	,	,		,	,	Specialty Plastics		Residential plumbing.		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	FlowGuard[nc_cad,176],	Marketed,	CPVC,	,	,	,		,	,	Specialty Plastics		Residential and commercial plumbing.		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	 Corzan[nc_cad,176],	Marketed,	CPVC,	,	,	,		,	,	Specialty Plastics		Industrial piping.		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	 TempRite™ PEX,	Marketed,	PEX,	,	,	,		,	,	Specialty Plastics		Flexible piping systems.		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	Estane[nc_cad,176],	Marketed,	TPU,	,	,	,		,	,	Specialty Plastics		Film and sheet, wire and cable insulation, athletic equipment, medical applications, automotive molded parts a		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	 Estaloc[nc_cad,176],	Marketed,	TPU,	,	,	,		,	,	Specialty Plastics		Automotive trim, sporting goods, agricultural equipment and o		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	Hycar[nc_cad,176],	Marketed,	Reactive Liquid Polymers,	,	,	,		,	,	Polymer Additives		Used as strengtheners and modifiers in epoxy resins (construction composites, coatings and structural adhesives		
nvcu20020001177317,	NOVEON INTERNATIONAL INC,	S-1,	2002,	2002,	  Good-Rite[nc_cad,176],	Marketed,	Antioxidants,	,	,	,		,	,	Polymer Additives		Primarily used by rubber manufacturers to prevent oxidative degradations, impart durability and prevent loss of flexibility		

wvcs20040001070494,	ACADIA PHARMACEUTICALS INC,	S-1,	2004,	2004,	ACP-103,	Phase II,	proprietary target-based and chemistry-based technologies,	40,	,	,	,	,	,	central nervous system disorders,	,	 Parkinson’s disease,	,	,40,July 9, 2004,phase 2,neuro